0001178879-18-000027.txt : 20181105 0001178879-18-000027.hdr.sgml : 20181105 20181105145636 ACCESSION NUMBER: 0001178879-18-000027 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181105 DATE AS OF CHANGE: 20181105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 181159708 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 10-Q 1 amicus-09302018x10q.htm 10-Q Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
 
ý       QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2018
OR
o       TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from             to
Commission file number 001-33497
Amicus Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
 
71-0869350
(State or Other Jurisdiction of
 
(I.R.S. Employer
Incorporation or Organization)
 
Identification Number)
 
 
 
1 Cedar Brook Drive, Cranbury, NJ
 
08512
(Address of Principal Executive Offices)
 
(Zip Code)
 
 
 
(609) 662-2000
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ý No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x
 
Accelerated filer o
Non-accelerated filer o
 
Smaller reporting company o
 
 
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o No ý
The number of shares outstanding of the registrant’s common stock, $0.01 par value per share, as of October 29, 2018 was 189,289,881 shares.
 



AMICUS THERAPEUTICS, INC.
 
Form 10-Q for the Quarterly Period Ended September 30, 2018
 
 
Page
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
 
 
 
 
Item 4.
 
 
 
 
 
Item 1.
 
 
 
 
 
Item 1A.
 
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
 
 
 
 
Item 4.
 
 
 
 
 
Item 5.
 
 
 
 
 
Item 6.
 
 
 
 
 
 
 
We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS AND DESIGN, AMICUS ASSIST AND DESIGN, CHART AND DESIGN, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF and Galafold® and design.

i


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks, uncertainties and assumptions.  Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negatives or plurals thereof and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.
 
We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:
 
•
the progress and results of our preclinical and clinical trials of our drug candidates;
•
the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy (“ERT”);
•
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates including those testing the use of pharmacological chaperones co-formulated and co-administered with ERT and for the treatment of lysosomal storage disorders;
•
the future results of on-going preclinical research and subsequent clinical trials for cyclin-dependent kinase-like 5 (“CDKL5”) deficiency, including our ability to obtain regulatory approvals and commercialize CDKL5 therapies and obtain market acceptance for such therapies;
•
the costs, timing and outcome of regulatory review of our product candidates;
•
the number and development requirements of other product candidates that we pursue;
•
the costs of commercialization activities, including product marketing, sales and distribution;
•
the emergence of competing technologies and other adverse market developments;
•
our ability to successfully commercialize migalastat HCl ;
•
our ability to manufacture or supply sufficient clinical or commercial products;
•
our ability to obtain reimbursement for migalastat HCl;
•
our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of migalastat HCl;
•
our ability to obtain market acceptance of migalastat HCl;
•
the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;
•
the extent to which we acquire or invest in businesses, products and technologies;
•
our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;
•
our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators;
•
fluctuations in foreign currency exchange rates; and
•
changes in accounting standards.
 
In light of these risks and uncertainties, we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in Part I Item 1A — Risk Factors of the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Those factors and the other risk factors described therein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations or investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.
 

1


You should read this Quarterly Report on Form 10-Q in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law. 

2


PART I.          FINANCIAL INFORMATION
 
Item 1.             Consolidated Financial Statements and Notes (unaudited)
 
Amicus Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
 
September 30,
 
December 31,
 
2018
 
2017
Assets
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
201,827

 
$
49,060

Investments in marketable securities
362,556

 
309,502

Accounts receivable
14,189

 
9,464

Inventories
6,311

 
4,623

Prepaid expenses and other current assets
16,151

 
19,316

Total current assets
601,034

 
391,965

Property and equipment, less accumulated depreciation of $15,483 and $12,515 at September 30, 2018 and December 31, 2017, respectively
10,659

 
9,062

In-process research & development
23,000

 
23,000

Goodwill
197,797

 
197,797

Other non-current assets
6,099

 
5,200

Total Assets
$
838,589

 
$
627,024

Liabilities and Stockholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable, accrued expenses, and other current liabilities
$
54,330

 
$
53,890

Deferred reimbursements
2,750

 
7,750

Contingent consideration payable
8,800

 
8,400

Total current liabilities
65,880

 
70,040

Deferred reimbursements
14,156

 
14,156

Convertible notes
172,186

 
164,167

Senior secured term loan
146,622

 
—

Contingent consideration payable
19,300

 
17,000

Deferred income taxes
6,465

 
6,465

Other non-current liabilities
3,029

 
2,346

Total liabilities
427,638

 
274,174

Commitments and contingencies


 


Stockholders’ equity:
 
 
 
Common stock, $0.01 par value, 500,000,000 and 250,000,000 shares authorized, 189,254,341 and 166,989,790 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
1,941

 
1,721

Additional paid-in capital
1,731,174

 
1,400,758

Accumulated other comprehensive loss:
 
 
 
Foreign currency translation adjustment
(875
)
 
(1,659
)
Unrealized gain on available-for-sale securities
(211
)
 
(436
)
Warrants
13,063

 
16,076

Accumulated deficit
(1,334,141
)
 
(1,063,610
)
Total stockholders’ equity
410,951

 
352,850

Total Liabilities and Stockholders’ Equity
$
838,589

 
$
627,024


 See accompanying notes to consolidated financial statements

3


Amicus Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Revenue:
 

 
 

 
 

 
 

Net product sales
$
20,596

 
$
10,874

 
$
58,601

 
$
22,201

Cost of goods sold
4,310

 
1,790

 
10,060

 
3,626

Gross profit
16,286

 
9,084

 
48,541

 
18,575

Operating expenses:
 
 
 
 
 
 
 
Research and development
138,227

 
40,641

 
213,685

 
103,502

Selling, general and administrative
31,867

 
21,647

 
88,435

 
60,090

Changes in fair value of contingent consideration payable
1,300

 
(244,250
)
 
2,700

 
(238,622
)
Loss on impairment of assets
—

 
465,427

 
—

 
465,427

Depreciation
1,073

 
851

 
3,015

 
2,486

Total operating expenses
172,467

 
284,316

 
307,835

 
392,883

Loss from operations
(156,181
)
 
(275,232
)
 
(259,294
)
 
(374,308
)
Other income (expense):
 
 
 
 
 
 
 
Interest income
2,721

 
1,190

 
7,371

 
2,702

Interest expense
(4,715
)
 
(4,351
)
 
(13,763
)
 
(12,820
)
Change in fair value of derivatives
—

 
—

 
(2,739
)
 
163

Other (expense) income
(1,039
)
 
2,044

 
(3,593
)
 
4,891

Loss before income tax
(159,214
)
 
(276,349
)
 
(272,018
)
 
(379,372
)
Income tax benefit
51

 
164,683

 
1,104

 
164,578

Net loss attributable to common stockholders
$
(159,163
)
 
$
(111,666
)
 
$
(270,914
)
 
$
(214,794
)
Net loss attributable to common stockholders per common share — basic and diluted
$
(0.84
)
 
$
(0.69
)
 
$
(1.47
)
 
$
(1.44
)
Weighted-average common shares outstanding — basic and diluted
189,162,841

 
160,796,841

 
184,606,790

 
148,963,864

 
See accompanying notes to consolidated financial statements


4


Amicus Therapeutics, Inc.
Consolidated Statements of Comprehensive Loss
(Unaudited)
(in thousands)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Net loss
$
(159,163
)
 
$
(111,666
)
 
$
(270,914
)
 
$
(214,794
)
Other comprehensive (loss) gain:
 
 
 
 
 
 
 
Foreign currency translation adjustment gain (loss), net of tax impact of $59, $0, $168, $0, respectively
665

 
(1,176
)
 
1,167

 
(3,312
)
Unrealized gain (loss) on available-for-sale securities
244

 
(131
)
 
225

 
(203
)
Other comprehensive income (loss)
$
909

 
$
(1,307
)
 
$
1,392

 
$
(3,515
)
Comprehensive loss
$
(158,254
)
 
$
(112,973
)
 
$
(269,522
)
 
$
(218,309
)
 
See accompanying notes to consolidated financial statements


5


Amicus Therapeutics, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
 
Nine Months Ended September 30,
 
2018
 
2017
Operating activities
 

 
 

Net loss
$
(270,914
)
 
$
(214,794
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Amortization of debt discount and deferred financing
7,868

 
7,179

Depreciation
3,015

 
2,486

Stock-based compensation
20,873

 
17,067

Loss on impairment
—

 
465,427

Gain on disposal of asset
—

 
(8
)
Change in fair value of derivatives
2,739

 
(265
)
Non-cash changes in the fair value of contingent consideration payable
2,700

 
(238,622
)
Foreign currency remeasurement (gain)/ loss
775

 
(4,932
)
Non-cash deferred taxes
—

 
(164,585
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(5,182
)
 
(4,288
)
Inventories
(2,049
)
 
(3,386
)
Prepaid expenses and other current assets
2,633

 
(3,358
)
Other non-current assets
(1,101
)
 
344

Account payable and accrued expenses
3,684

 
13,037

Non-current liabilities
681

 
637

Deferred reimbursement
(5,000
)
 
(12,600
)
Net cash used in operating activities
$
(239,278
)
 
$
(140,661
)
Investing activities
 
 
 
Sale and redemption of marketable securities
388,135

 
230,981

Purchases of marketable securities
(440,963
)
 
(450,358
)
Capital expenditures
(4,571
)
 
(3,398
)
Net cash used in investing activities
$
(57,399
)
 
$
(222,775
)
Financing activities
 
 
 
Proceeds from issuance of common stock, net of issuance costs
294,584

 
243,036

Proceeds from senior secured term loan, net of issuance costs

146,622

 
—

Payment of capital leases
(218
)
 
(212
)
Payment of contingent consideration
—

 
(10,000
)
Purchase of vested restricted stock units
(2,681
)
 
(1,067
)
Proceeds from exercise of stock options
8,492

 
8,841

Payment of deferred financing fees
—

 
(28
)
Proceeds from exercise of warrants
3,617

 
—

Net cash provided by financing activities
$
450,416

 
$
240,570

Effect of exchange rate changes on cash, cash equivalents and restricted cash
$
(1,146
)
 
$
1,030

Net increase (decrease) in cash and cash equivalents and restricted cash
152,593

 
(121,836
)
Cash and cash equivalents and restricted cash at beginning of period
$
51,237

 
$
187,413

Cash and cash equivalents and restricted cash at end of period
$
203,830

 
$
65,577

Supplemental disclosures of cash flow information
 
 
 
Cash paid during the period for interest
$
3,787

 
$
3,662

Capital expenditures, unpaid
$
538

 
$
—

Capital expenditures funded by capital lease
$
80

 
$
—

 
See accompanying notes to consolidated financial statements

6


Amicus Therapeutics, Inc. 
Notes to the Consolidated Financial Statements
(Unaudited)
 
Note 1. Description of Business
 
Amicus Therapeutics, Inc. (the “Company”) is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases. With one medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic and the recent addition of fourteen new gene therapy programs into the pipeline, including two clinical stage gene therapies for Batten disease, the Company has a leading portfolio of medicines for lysosomal storage disorders (“LSDs”).

The cornerstone of the Company’s portfolio is migalastat HCl (also referred to as “migalastat”), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold® in the United States (“U.S.”), European Union (“EU”) and Japan, with additional approvals granted and applications pending in several other geographies. During the third quarter of 2018, the Company initiated the commercial launch of Galafold® in the U.S. for the treatment of adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant.

The lead biologics program of the Company’s pipeline is Amicus Therapeutics GAA (“AT-GAA”, also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. The Company’s Chaperone-Advanced Replacement Therapy (“CHART®”) platform technology is leveraged to develop novel products for Pompe disease and potentially future other LSDs.

During the second half of 2018, the Company has expanded its portfolio to include fourteen new gene therapy programs. In September 2018, the Company acquired worldwide development and commercial rights for ten gene therapy programs for neurologic LSDs developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and The Ohio State University through the acquisition of Celenex, Inc., (“Celenex”) a private, clinical stage gene therapy company, for cash consideration of $100.0 million and additional consideration payable upon the achievement of certain development and approval milestones. The acquisition establishes Amicus as a leading company in neurologic LSDs. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. For additional information see "—Note 3. Acquisitions."

In October 2018, the Company further expanded its gene therapy portfolio through a collaboration agreement with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (“Penn”) to pursue the research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDKL5 deficiency disorder (“CDD”) and one additional undisclosed rare metabolic disorder. This relationship will combine the Company's protein engineering and glycobiology expertise with Penn’s adeno associated virus (“AAV”) gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability.
The Company believes that its platform technologies and its product pipeline uniquely positions it and drives its commitment to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
 
During the third quarter of 2018, the Company entered into a loan agreement with BioPharma Credit PLC, as the lender, for a $150.0 million non-dilutive senior secured term loan (the “Senior Secured Term Loan”) with an interest rate equal to 3-month LIBOR plus 7.50% per annum, subject to a floor and ceiling on the rate, which matures in five years. The Company received net proceeds of $146.6 million in September 2018, after deducting fees and estimated expenses payable by the Company. There are no warrants or any equity conversion features associated with the Senior Secured Term Loan. The proceeds from this financing will be used to support the cost of the Celenex acquisition, its related development costs and other general corporate purposes. For additional information, see " —Note 6. Debt."

During the first quarter of 2018, the Company issued 20,239,839 shares of its common stock through an underwritten offering resulting in net proceeds of $294.6 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for the ERT ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes. For additional information, see “—Note 7. Stockholders’ Equity.”


7


The Company had an accumulated deficit of approximately $1.3 billion as of September 30, 2018 and anticipates incurring losses through the fiscal year ending December 31, 2018 and beyond. The Company has been able to fund its operating losses to date through stock offerings, debt issuances, payments from partners during the terms of the collaboration agreements, and other financing arrangements.
    
The current cash position, including expected Galafold® revenues, is sufficient to fund ongoing Fabry, Pompe and gene therapy program operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company’s future capital requirements.
 
Note 2. Summary of Significant Accounting Policies
 
Basis of Presentation
 
The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information.
 
The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
 
Consolidation
 
The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
 
Foreign Currency Transactions
 
The functional currency for most of the Company’s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders’ equity.
 
Use of Estimates
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
 
Reclassification

Certain prior year amounts have been reclassified for comparative purposes. The reclassifications did not affect results of operations, net assets or cash flows.

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive income (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.

8



Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company’s consolidated balance sheet.

Concentration of Credit Risk
 
The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.
 
The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold®. The Company’s accounts receivable at September 30, 2018 have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.
  
Revenue Recognition
 
The Company’s net product sales consist of sales of Galafold® for the treatment of Fabry disease primarily in the EU. The Company has recorded revenue on sales where Galafold® is available either on a commercial basis or through a reimbursed early access program (“EAP”). Orders for Galafold® are generally received from pharmacies and the ultimate payor is typically a government authority.
 
The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold®. The transaction price is determined based on fixed consideration in the Company’s customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

The Company elected the portfolio approach practical expedient in applying ASC Topic 606 to its identified revenue streams. Contracts within each revenue stream have similar characteristics and the Company believes this approach would not differ materially from applying ASC Topic 606 to each individual contract.

 
Recent Accounting Developments - Guidance Adopted in 2018
 
ASU 2018-07 — In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”).These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 in the second quarter of 2018 and there was no material impact on its consolidated financial statements from the adoption.


9


ASU 2018-02 — In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”). Prior to ASU 2018-02, U.S. GAAP required the remeasurement of deferred tax assets and liabilities as a result of a change in tax laws or rates to be presented in net income from continuing operations, even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income. As a result, such items, referred to as stranded tax effects, did not reflect the appropriate tax rate. Under ASU 2018-02, entities are permitted, but not required, to reclassify from accumulated other comprehensive income to retained earnings those stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new standard effective January 1, 2018. As a result of the adoption, the Company reclassified a gain of $383,000 from the foreign currency translation adjustment in accumulated other comprehensive loss to accumulated deficit in the consolidated balance sheet as of September 30, 2018.
 
ASU 2017-09 — In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). The amendments in ASU 2017-09 provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASU 2017-09. An entity should account for the effects of a modification unless all the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The Company adopted this standard on January 1, 2018 and as the Company did not have any modification of awards, the adoption of the standard did not have a material impact on its consolidated financial statements.
 
ASU 2017-01 — In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). This ASU clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in ASU 2017-01 are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of the standard did not have a material impact on its consolidated financial statements. For additional information see "—Note 3. Acquisitions."
 
ASU 2016-18 — In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). The amendments of ASU 2016-18 require an entity to include amounts generally described as restricted cash and restricted cash equivalents with cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the statement of cash flows. The amendments of ASU 2016-18 are effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the guidance in ASU 2016-18 effective January 1, 2018. In connection with the adoption of the standard, the Company applied the guidance retrospectively which resulted in an increase in cash flows from operations of $1.1 million on the statement of cash flows for the nine months ended September 30, 2017.

ASU 2016-16 — In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). ASU 2016-16 requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in ASU 2016-16 are effective for public business entities for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The Company adopted ASU 2016-16 on January 1, 2018 and there was no material impact from the adoption.


10


ASU 2016-01 — In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income. Companies have the option to measure equity investments without readily determinable fair values at either fair value or at cost adjusted for changes in observable prices minus impairment. Companies that elect the fair value option for financial liabilities must recognize changes in fair value related to instrument-specific credit risk in other comprehensive income. Companies must assess valuation allowances for deferred tax assets related to available-for-sale debt securities in combination with their other deferred tax assets. ASU 2016-01 is effective beginning in the first quarter of 2018 and the Company adopted it in the first quarter of 2018. There was no impact on the Company’s consolidated financial statements and related disclosures upon adoption, as the Company does not have equity investments or liabilities with credit risk. In addition, the guidance relating to deferred tax assets did not result in a change in accounting treatment for the Company.

ASU 2014-09 — In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which along with amendments issued in 2015 and 2016, replaced substantially all current U.S. GAAP guidance on this topic and eliminated industry-specific guidance. The new revenue recognition standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Effective January 1, 2018, the Company adopted the new revenue recognition standard using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under the new revenue recognition standard. As such, the adoption of the new revenue recognition standard did not have a material impact on the Company's consolidated financial statements. The information presented for the periods prior to January 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods.

Recent Accounting Developments - Guidance Not Yet Adopted

In August 2018, the Securities Exchange Commission (“SEC”) issued Final Rule 33-10532, Disclosure Update and Simplification, which amends certain disclosure requirements that were redundant, duplicative, overlapping or superseded by other SEC disclosure requirements. The amendments generally eliminated or otherwise reduced certain disclosure requirements of various SEC rules and regulations. However, in some cases, the amendments require additional information to be disclosed, including changes in stockholders’ equity in interim periods. The rule is effective 30 days after its publication in the Federal Register. The rule was posted on October 4, 2018. On September 25, 2018, the SEC released guidance advising it will not object to a registrant adopting the requirement to include changes in stockholders’ equity in the Form 10-Q for the first quarter beginning after the effective date of the rule. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption and expects to adopt the guidance in it's Form 10-Q for the period ended March 31, 2019.
ASU 2018-13 — In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption.


11


ASU 2017-12 — In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The amendments in this ASU 2017-12 better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments in ASU 2017-12 also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. For public business entities, the amendment is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption, including adoption in an interim period, is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-11 — In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Part I of ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. Part II of ASU 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. For public business entities, the amendments in Part I of ASU 2017-11 are effective for fiscal years beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-08 — In March 2017, the FASB issued ASU 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities (“ASU 2017-08”). The amendments in ASU 2017-08 shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. ASU 2017-08 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-04 — In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 

12


ASU 2016-02 — In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, (“ASU 2018-11”). ASU 2018-11 provide entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will adopt these standards effective January 1, 2019, and expects to elect certain of the practical expedients permitted, including the expedient that permits the Company to retain its existing lease assessment and classification. The Company also expects to elect the transition method in ASU 2018-11. The Company is currently working through an adoption plan which includes the evaluation of lease contracts compared to the new standard. While the Company is currently assessing the impact that this standard will have on its consolidated financial statements, the Company expects to recognize lease liabilities and right of use assets.
  
Note 3. Acquisitions

In September 2018, the Company expanded its pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through its acquisition of Celenex. Celenex is a private, clinical stage gene therapy company whose lead programs are ten gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, the Company acquired Celenex for cash consideration of $100 million. The Company has also agreed to pay up to an additional $15 million in connection with the achievement of certain development milestones, $262 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children’s Hospital (“NCH”). Under this license agreement, NCH is eligible to receive development and sales based milestones of up to $7.8 million for each product.
 
The Company evaluated the Celenex transaction based on the guidance in Business Combinations (Topic 805) and concluded that the transaction did not meet the definition of a business and was an asset acquisition. Given the fact that the license has no alternative future use, the $100.0 million upfront payment was expensed to research and development expense in the Consolidated Statements of Operations for the three and nine months ended September 30, 2018 in accordance with ASC Topic 730, Research and Development.



Note 4.  Cash, Cash Equivalents, Marketable Securities and Restricted Cash
 
As of September 30, 2018, the Company held $201.8 million in cash and cash equivalents and $362.6 million of available-for-sale debt securities which are reported at fair value on the Company’s consolidated balance sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive loss in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.
 
The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current, while investments that have maturities greater than one year are classified as long-term.
  

13


Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:
 
 
As of September 30, 2018
(in thousands)
Cost
 
Gross
unrealized
Gain
 
Gross
unrealized
Loss
 
Fair
Value
Cash and cash equivalents
$
201,827

 
$
—

 
$
—

 
$
201,827

Corporate debt securities, current portion
227,517

 
5

 
(123
)
 
227,399

Commercial paper
82,704

 
—

 
(49
)
 
82,655

Asset-backed securities
52,145

 
—

 
(44
)
 
52,101

Money market
350

 
—

 
—

 
350

Certificates of deposit
51

 
—

 
—

 
51

 
$
564,594

 
$
5

 
$
(216
)
 
$
564,383

Included in cash and cash equivalents
$
201,827

 
$
—

 
$
—

 
$
201,827

Included in marketable securities, current and non-current
362,767

 
5

 
(216
)
 
362,556

Total cash, cash equivalents and marketable securities
$
564,594

 
$
5

 
$
(216
)
 
$
564,383

 
 
As of December 31, 2017
(in thousands)
Cost
 
Gross
unrealized
Gain
 
Gross
unrealized
Loss
 
Fair
Value
Cash and cash equivalents
$
49,060

 
$
—

 
$
—

 
$
49,060

Corporate debt securities, current portion
199,314

 
1

 
(303
)
 
199,012

Commercial paper
79,878

 
—

 
(75
)
 
79,803

Asset-backed securities
30,346

 
—

 
(59
)
 
30,287

Money market
350

 
—

 
—

 
350

Certificates of deposit
50

 
—

 
—

 
50

 
$
358,998

 
$
1

 
$
(437
)
 
$
358,562

Included in cash and cash equivalents
$
49,060

 
$
—

 
$
—

 
$
49,060

Included in marketable securities
309,938

 
1

 
(437
)
 
309,502

Total cash, cash equivalents and marketable securities
$
358,998

 
$
1

 
$
(437
)
 
$
358,562

 
For the nine months ended September 30, 2018 there were nominal realized gains. For the fiscal year ended December 31, 2017, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.
 
Unrealized loss positions in the available-for-sale debt securities as of September 30, 2018 and December 31, 2017 reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain (loss). The fair value of these available-for-sale debt securities in unrealized loss positions was $315.3 million and $295.1 million as of September 30, 2018 and December 31, 2017, respectively.
 
The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.

(in thousands)
September 30, 2018
 
December 31, 2017
 
September 30, 2017
 
December 31, 2016
Cash and cash equivalents
$
201,827

 
$
49,060

 
$
64,133

 
$
187,026

Restricted cash
2,003

 
2,177

 
1,444

 
387

Cash and cash equivalents and restricted cash shown in the statement of cash flows
$
203,830

 
$
51,237

 
$
65,577

 
$
187,413



Note 5.   Inventories

14


 
Inventories consist of raw materials, work-in-process and finished goods related to the manufacture of Galafold®. The following table summarizes the components of inventories:
 
(in thousands)
September 30, 2018
 
December 31, 2017
Raw materials
$
2,954

 
$
2,394

Work-in-process
$
1,458

 
$
1,449

Finished goods
1,899

 
780

Total inventories
$
6,311

 
$
4,623

 
 
Note 6.   Debt
 
Senior Secured Term Loan due 2023
 
In September 2018, the Company entered into a loan agreement with BioPharma Credit PLC as the lender. The loan agreement provides for a $150 million senior secured term loan (“Senior Secured Term Loan”) with an interest rate equal to the 3-month LIBOR plus 7.50% per annum and matures five years from the maturity date. The Senior Secured Term Loan will be repaid in four quarterly payments equal to 12.50% thereof starting on the forty-eight month anniversary of the date of the first credit extension with the balance due on the Maturity Date. Interest is payable quarterly in arrears. The Senior Secured Term Loan contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, but does not include any financial covenants relating to the achievement or maintenance of revenue or cash flow. If an event of default occurs and is continuing, the lender may declare all amounts outstanding under the Senior Secured Term Loan to be immediately due and payable. The Company received net proceeds of $146.6 million in September 2018, after deducting fees and estimated expenses payable by the Company.

Convertible Notes due 2023
 
In December 2016, the Company issued at par value $250 million aggregate principal amount of unsecured Convertible Senior Notes due 2023 (the “Convertible Notes”), which included the exercise in full of the $25 million over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the “Note Offering”). Interest is payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company’s common stock or a combination thereof. The net proceeds from the Note Offering were $243.0 million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5 million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions (“Capped Call Confirmations”) that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes are initially convertible into approximately 40,849,675 shares of the Company’s common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $6.12 per share of the Company's common stock, subject to adjustment under certain conditions. The last reported sale price of the Company’s common stock was equal to or more than 130% of the conversion price of the Convertible Notes for at least 20 trading days of the 30 consecutive trading days ending on the last day of the second quarter. As a result, the Convertible Notes are currently convertible into the Company’s common stock.

As further described in “—Note 7. Stockholders’ Equity,” on February 15, 2018, the Company entered into an underwriting agreement relating to an underwritten public offering of 19,354,839 shares of the Company’s common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for 30 days after February 16, 2018, to purchase up to an additional 2,903,225 shares of the Company’s common stock, which was exercised with respect to 885,000 shares of the Company’s common stock.


15


Subsequent to the underwritten public offering on February 15, 2018, the Company did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the Company accounted for the portion of the bifurcated conversion feature and of the Capped Call Confirmations that would not be able to be net share settled as a current derivative liability and as a derivative asset, respectively. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be $507.4 million and $13.6 million, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded in the second quarter of 2018 through earnings on the Company’s consolidated statements of operations resulting in a change in fair value of derivatives for the nine months ended September 30, 2018 of $2.7 million. 

Following the approval by the stockholders of the Company on June 7, 2018, to increase the authorized shares of common stock to 500,000,000, the Company has sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at June 7, 2018 was determined to be $88.3 million and $2.4 million, respectively.

The Convertible Notes and Senior Secured Term Loan consist of the following (in thousands):
 
Liability component
 
September 30, 2018
 
December 31, 2017
Principal
 
$
400,000

 
$
250,000

Less: debt discount (1)
 
(76,946
)
 
(81,566
)
Less: deferred financing (1)
 
(4,246
)
 
(4,267
)
Net carrying value of the debt
 
$
318,808

 
$
164,167

 
______________________________________
(1) Included in the consolidated balance sheets within convertible notes and senior secured term loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.
 
The following table sets forth total interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the three and nine months ended September 30, 2018, respectively:
 
Components (In thousands)
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Contractual interest expense
 
$
1,969

 
$
5,744

Amortization of debt discount
 
2,609

 
7,620

Amortization of deferred financing
 
137

 
399

Total
 
$
4,715

 
$
13,763

  
Note 7.   Stockholders’ Equity

Common Stock and Warrants
 
On February 15, 2018, the Company announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share, resulting in gross proceeds of $300.0 million. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for 30 days after February 16, 2018, to purchase up to an additional 2,903,225 shares of the Company’s common stock, which was exercised with respect to 885,000 shares of the Company’s common stock at a purchase price of $15.50 per share. The Company received net proceeds of $294.6 million from these offerings, after deducting underwriting discounts and commissions and offering expenses payable by the Company.
  
In April 2018, 453,214 warrants were exercised at $7.98 per share of common stock resulting in gross cash proceeds of $3.6 million.

On June 7, 2018, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that the Company is authorized to issue from 250,000,000 shares to 500,000,000 shares.


16



Note 8.   Share based Compensation
 
The Company’s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) and the 2007 Director Option Plan (the “2007 Director Plan”). The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company’s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company’s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.
 
Stock Option Grants
 
The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Expected stock price volatility
75.5
%
 
82.5
%
 
80.7
%
 
83.1
%
Risk free interest rate
2.7
%
 
1.8
%
 
2.4
%
 
2.0
%
Expected life of options (years)
5.62

 
5.89

 
5.62

 
6.21

Expected annual dividend per share
$
—

 
$
—

 
$
—

 
$
—

 
Beginning in the third quarter of 2017, the average expected life was determined using our actual historical data versus a “simplified” method used in prior quarters. The “simplified” method of estimating the expected exercise term uses the mid-point between the vesting date and the end of the contractual term. In earlier quarters, we did not have sufficient reliable exercise data to justify a change from the use of the “simplified” method of estimating the expected exercise term of employee stock option grants. The impact from this change was not material.
 
A summary of the Company’s stock options for the nine months ended September 30, 2018 were as follows:
 
 
Number of
Shares
 
Weighted
Average
Exercise Price
 
Weighted
Average
Remaining
Contractual Life
 
Aggregate
Intrinsic
Value
 
(in thousands)
 
 
 
 
 
(in millions)
Options outstanding, December 31, 2017
15,181

 
$
7.48

 
 
 
 

Granted
2,077

 
$
15.36

 
 
 
 

Exercised
(1,282
)
 
$
6.62

 
 
 
 

Forfeited
(200
)
 
$
9.75

 
 
 
 

Expired
(7
)
 
10.45

 
 
 
 
Options outstanding, September 30, 2018
15,769

 
$
8.56

 
7.0 years
 
$
65.8

Vested and unvested expected to vest, September 30, 2018
15,003

 
$
8.43

 
6.9 years
 
$
63.9

Exercisable at September 30, 2018
9,406

 
$
7.26

 
6.0 years
 
$
47.4

 
As of September 30, 2018, the total unrecognized compensation cost related to non-vested stock options granted was $36.0 million and is expected to be recognized over a weighted average period of three years.
 

17


Restricted Stock Units (“RSUs”) and Performance-Based Restricted Stock Units
 
RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee’s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2018 is as follows:
 
 
Number of Shares

 
Weighted
Average Grant Date
Fair Value
 
Weighted Average
Remaining Years
 
Aggregate Intrinsic
Value 
 
(in thousands)
 
 
 
 
 
(in millions)
Non-vested units as of December 31, 2017
2,575

 
$
5.85

 
 
 
 

Granted
1,635

 
$
16.57

 
 
 
 

Vested
(517
)
 
$
5.91

 
 
 
 

Forfeited
(58
)
 
$
10.23

 
 
 
 

Non-vested units as of September 30, 2018
3,635

 
$
10.49

 
2.7 years
 
$
44.0

 
On December 30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the “Performance-Based RSU Agreement”), to be used for performance-based RSUs granted to participants under the Amended and Restated 2007 Equity Incentive Plan, including named executive officers. Certain awards under the Performance-Based RSU Agreement were granted in January 2017 and 2018. The 2018 grants include 187,222 market performance-based restricted stock units (“MPRSUs”) granted to executives.  Vesting of these awards is contingent upon the Company meeting certain total shareholder return (“TSR”) levels as compared to a select peer group over the next three years. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (374,444 shares) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized on a straight-line basis over the vesting term.  The estimated fair value per share of the MPRSUs was $25.44 and was calculated using a Monte Carlo simulation model.  The awards also include 187,211 performance based awards that will vest over the next three years based on the Company achieving certain clinical milestones. During the nine months ended September 30, 2018, none of the clinical milestones for the performance based RSUs awarded in 2017 or 2018 were reached.
 
For the nine months ended September 30, 2018, 516,940 RSUs have vested and all non-vested units are expected to vest over their normal term. As of September 30, 2018, there was $25.6 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of three years.
 
Compensation Expense Related to Equity Awards
 
The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
Equity compensation expense recognized in:
 
 

 
 

 
 

 
 

Research and development expense
 
$
2,905

 
$
2,390

 
$
8,603

 
$
7,456

Selling, general and administrative expense
 
4,149

 
3,110

 
12,270

 
9,611

Total equity compensation expense
 
$
7,054

 
$
5,500

 
$
20,873

 
$
17,067

 

18


Note 9.  Assets and Liabilities Measured at Fair Value
 
The Company’s financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:
 
Level 1 — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
 
Level 2 — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.
 
Level 3 — Inputs that are unobservable for the asset or liability.

A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2018 are identified in the following table:
 
(in thousands)
 
Level 2
 
Total
Assets:
 
 

 
 

Commercial paper
 
$
82,655

 
$
82,655

Asset-backed securities
 
52,101

 
52,101

Corporate debt securities
 
227,399

 
227,399

Money market funds
 
3,335

 
3,335

 
 
$
365,490

 
$
365,490

 
 
 
Level 2
 
Level 3
 
Total
Liabilities:
 
 

 
 

 
 

Contingent consideration payable
 
$
—

 
$
28,100

 
$
28,100

Deferred compensation plan liability
 
2,996

 
—

 
2,996

 
 
$
2,996

 
$
28,100

 
$
31,096

 
A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2017 are identified in the following table:
 
(in thousands)
Level 2
 
Total
Assets:
 

 
 

Commercial paper
$
79,803

 
$
79,803

Asset-backed securities
30,287

 
30,287

Corporate debt securities
199,012

 
199,012

Money market funds
2,598

 
2,598

 
$
311,700

 
$
311,700

 
 
Level 2
 
Level 3
 
Total
Liabilities:
 

 
 

 
 

Contingent consideration payable
$
—

 
$
25,400

 
$
25,400

Deferred compensation plan liability
2,258

 
—

 
2,258

 
$
2,258

 
$
25,400

 
$
27,658

 

19


The Company’s Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the debt at September 30, 2018 was approximately $531.2 million.

The Company’s Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.

The Company did not have any Level 3 assets as of September 30, 2018 or December 31, 2017.

 Cash, Money Market Funds and Marketable Securities
 
The Company classifies its cash within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale debt securities and classifies these assets and the money market funds within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the nine months ended September 30, 2018. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine months ended September 30, 2018.

Contingent Consideration Payable
 
The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. (“Callidus”) in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of operations.
 
The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods.
  
The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program:
 
Contingent Consideration
Liability
 
Fair Value as of
September 30, 2018
 
Valuation Technique
 
Unobservable Input
 
Range
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discount rate
 
10.0%
 
 
 

 
 
 
 
 
 
Clinical and regulatory milestones
 
$
27.6
 million
 
Probability weighted discounted cash flow
 
Probability of achievement of milestones
 
71.0%-100.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Projected year of payments
 
2018-2022
 
Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.


20


The following table shows the change in the balance of contingent consideration payable for the three and nine months ended September 30, 2018 and 2017, respectively:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
Balance, beginning of the period
 
$
26,800

 
$
265,350

 
25,400

 
269,722

Payment of contingent consideration in cash
 
—

 
—

 
—

 
(10,000
)
Changes in fair value during the period, included in statement of operations
 
1,300

 
(244,250
)
 
2,700

 
(238,622
)
Balance, end of the period
 
$
28,100

 
$
21,100

 
28,100

 
$
21,100

 
Deferred Compensation Plan - Investment and Liability
 
The Deferred Compensation Plan (the “Deferral Plan”) provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant’s base salary, bonus and director’s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment’s fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.
 
Note 10.  Basic and Diluted Net Loss per Common Share
 
The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands, except per share amounts) 
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 

 
 

 
 

 
 

Net loss attributable to common stockholders
 
$
(159,163
)
 
$
(111,666
)
 
$
(270,914
)
 
$
(214,794
)
Denominator:
 
 
 
 
 
 
 
 
Weighted average common shares outstanding — basic and diluted
 
189,162,841

 
160,796,841

 
184,606,790

 
148,963,864

 
Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.

The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:
 
 
 
As of September 30,
(in thousands) 
 
2018
 
2017
Options to purchase common stock
 
15,769

 
16,212

Convertible notes
 
40,850

 
40,850

Outstanding warrants, convertible to common stock
 
2,657

 
3,110

Unvested restricted stock units
 
3,635

 
2,690

Vested restricted stock units, unissued
 
103

 
50

Total number of potentially issuable shares
 
63,014

 
62,912

 

21


Note 11.  Collaborations

In October 2018, the Company further expanded its gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. This relationship will combine the Company's protein engineering and glycobiology expertise with Penn’s AAV gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability. In connection with the collaboration agreement, the Company made an upfront payment of $7 million in cash to Penn in October 2018 and agreed to certain milestone payments following the achievement of certain developmental and commercial milestone events by a licensed product in each indication up to an aggregate of $86.5 million per indication.



22



 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Overview
 
We are a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases. With one medicine for Fabry disease achieving widespread global approval, a differentiated biologic for Pompe disease in the clinic and the recent addition of fourteen new gene therapy programs into our pipeline, including two clinical stage gene therapies for Batten disease, we have a leading portfolio of medicines for lysosomal storage disorders (“LSDs”).

The cornerstone of our portfolio is migalastat HCl, (also referred to as “migalastat”), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold® in the United States (“U.S.”), European Union (“EU”) and Japan, with additional approvals granted and applications pending in several geographies. During the third quarter of 2018, we initiated the commercial launch of Galafold® in the U.S. for the treatment of adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant.
 
The lead biologics program of our pipeline is Amicus Therapeutics GAA (“AT-GAA”, also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. Our Chaperone-Advanced Replacement Therapy (“CHART®”) platform technology is leveraged to develop novel products for Pompe disease and potentially future other LSDs.

During the second half of 2018, we have expanded our portfolio to include fourteen new gene therapy programs. During the third quarter of 2018, we acquired worldwide development and commercial rights for ten gene therapy programs for neurologic LSDs developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital ("NCH") and The Ohio State University through the acquisition of Celenex, Inc. (“Celenex”), a private, clinical stage gene therapy company, for cash consideration of $100.0 million and additional consideration payable upon the achievement of certain development and approval milestones. The acquisition establishes Amicus as a leading company in neurologic LSDs. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases.

In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (“Penn”) to pursue the research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDKL5 deficiency disorder (“CDD”) and one additional undisclosed rare metabolic disorder. This relationship will combine our protein engineering and glycobiology expertise with Penn’s adeno associated virus (“AAV”) gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability.
We believe that our platform technologies and our product pipeline uniquely position us and drive our commitment to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.

During the third quarter of 2018, we entered into a loan agreement with BioPharma Credit PLC, as the lender, for a $150.0 million non-dilutive senior secured term loan (the “Senior Secured Term Loan”) with an interest rate equal to 3-month LIBOR plus 7.50% per annum, subject to a floor and ceiling on the rate, which matures in five years. We received net proceeds of $146.6 million in September 2018, after deducting fees and estimated expenses payable by us. There are no warrants or any equity conversion features associated with the Senior Secured Term Loan. The proceeds from this financing will be used to support the cost of the Celenex acquisition, its related development costs and other general corporate purposes.
 
Our Strategy
 
Our strategy is to create, manufacture, test and deliver the highest quality medicines for people living with rare metabolic diseases through internally developed, acquired or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. In addition to our lead programs in Fabry and Pompe, we have begun to leverage our global capabilities to develop and expand our robust pipeline through our recent entry into genomic medicine. Since the beginning of the year, we made significant progress toward fulfilling our vision to build a leading global biotechnology company focused on rare metabolic diseases.


23


Highlights of our progress in 2018 include:

•
Commercial success. In the nine months ended September 30, 2018, Galafold® revenue totaled approximately $58.6 million. Revenue has been generated primarily in the EU.
•
Regulatory progress. We received approval for migalastat in the U.S. and Japan.
•
Pompe clinical study. We have reported positive data from a Phase 1/2 clinical study to evaluate Pompe disease patients treated with our novel treatment paradigm AT-GAA.
•
Pipeline Growth: With 14 new gene therapy programs for LSDs, we have established a leading portfolio of medicines for people living with rare metabolic disorders. We acquired worldwide development and commercial rights for ten gene therapy programs in rare, neurologic LSDs with lead programs in CLN6, CLN3, and CLN8 Batten disease. An additional four programs were added to the pipeline through the collaboration with Penn to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder.
•
Manufacturing. We successfully scaled manufacture of Pompe biologic engineering batches to commercial scale (1,000L) with capacity plans to enable us to produce sufficient quantities to serve the entire Pompe population as quickly as possible after receipt of applicable regulatory approvals. Through our collaborations with NCH and Penn, we also gain access to their preclinical manufacturing capabilities, clinical supply and CMO relationships for those programs.
•
Financial strength. Total cash, cash equivalents and marketable securities of $564.4 million at September 30, 2018 compared to $358.6 million at December 31, 2017. The current cash position, including expected Galafold® revenues, is sufficient to fund ongoing Fabry, Pompe and gene therapy program operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.

 Our Commercial Product and Product Candidates
 
Migalastat for Fabry Disease
 
Migalastat was granted accelerated approval by the U.S. Food and Drug Administration (“FDA”) in August 2018 under the brand name Galafold® for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA approved Galafold® for 348 amenable GLA variants. Migalastat was approved in the EU in May 2016 under the brand name Galafold® as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable variant. The approved EU label includes 367 Fabry-causing variants, which represent up to half of all patients with Fabry disease. Approvals have also been granted in Australia, Canada, Israel, Japan, South Korea, and Switzerland, with additional applications pending in other geographies.
 
We have been granted pricing and reimbursement in 22 countries. We plan to continue to launch Galafold® in additional countries during the remainder of 2018 and 2019.
 
As an orally administered monotherapy, migalastat is designed to bind to and stabilize an endogenous alpha-galactosidase A (“alpha-Gal A”) enzyme in those patients with genetic variants identified as amenable in a GLP cell-based amenability assay. Migalastat is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants and, at this time, it is not intended for concomitant use with ERT.

Patients with Fabry disease have an inherited deficiency of the alpha-Gal A enzyme that would normally degrade the lipid substrate globotriaosylceramide in the lysosome. Genetic variants that cause changes in the amino acid sequence of alpha-Gal A result in an unstable enzyme that does not efficiently fold into its correct three-dimensional shape and cannot be trafficked properly in the cell, even if it has the potential for biological activity. Migalastat is an oral small molecule pharmacological chaperone that is designed to bind to and stabilize a patient’s own endogenous target protein. This is considered a precision medicine because migalastat targets only patients with GLA variants (mutations) amenable to migalastat.


24


Next-Generation Gene Therapy for Fabry Disease

We are committed to continued innovation for all people living with Fabry disease. For people living with Fabry disease who have non-amenable variants (mutations), which are not suitable for migalastat as a monotherapy, our strategy is to develop a Fabry gene therapy. In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for Fabry disease. For additional information, see above “—Overview.”

Novel ERT for Pompe Disease
 
We are leveraging our biologics capabilities and CHART® platform to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with a pharmacological chaperone, AT2221, to improve activity and stability. We acquired ATB200 as well as our enzyme targeting technology through our purchase of Callidus Biopharma, Inc. (“Callidus”). ATB200 is our first biologic to enter clinical development.
 
The pharmacological chaperone, AT2221 is not an active ingredient that contributes directly to GAA substrate reduction but instead acts to stabilize ATB200. The small molecule pharmacological chaperone AT2221 binds and stabilizes ATB200 to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, glycogen.

In preclinical studies, AT-GAA demonstrated greater tissue enzyme levels and further substrate reduction compared to the currently approved ERT for Pompe disease (alglucosidase alfa).
 
We have been engaged in collaborative discussions with U.S. and EU regulators regarding a registration-directed study for approval, manufacturing activities, and the best and fastest pathway forward for AT-GAA. Following feedback from the FDA and the scientific advice received from the European Medicines Agency (“EMA”), we plan to initiate a pivotal study in the second half of 2018. Both regulatory agencies indicated that the current clinical package is not sufficient to support accelerated approval or conditional approval. We continue to generate data to support further discussions on a potential pathway for accelerated approval with the FDA and conditional approval with the EMA authorities in 2019.
 
On October 5, 2018 we reported additional interim data from our clinical study ATB200-02 at the 23rd International Annual Congress of the World Muscle Society. Highlights included safety and tolerability data in all 20 patients (maximum of 28+ months of treatment) as well as PD data (muscle damage biomarker and disease substrate biomarker) for all 20 patients (15 ERT-switch patients and 5 ERT-naive patients). To date, adverse events have been generally mild and transient. AT-GAA has resulted in a low rate of infusion-associated reactions (“IARs”) following 890+ infusions (seven events of IARs in five patients; < 1% of all 890+ infusions with an IAR). The clinical pharmacokinetic profile has been consistent with previously reported preclinical data. Treatment with AT-GAA resulted in persistent and durable reductions in creatine kinase and urine hexose tetrasaccharide across all patient cohorts out to month 18.
 
As of the last interim analysis in October 2018, data on functional outcomes are available for 19 of the 20 patients enrolled (one patient dropped out of the extension study due to travel burden and family considerations). Muscle function improved in 17 of 19 patients at month 12. Muscle function improved in 17 out of 18 patients with available data at month 18. Mean 6MWT improved in both ERT-naïve and ERT-switch patients with continued benefit observed out to month 18. All 5 ERT-naïve patients showed increases in 6MWT distance at all-time points out to month 18. The ERT-naïve patients showed mean increases of 42 meters at month 6 (n=5), 63 meters at month 12 (n=5), and 49 meters at month 18 (n=5). 6MWT increased in 7/10, 9/10, and 9/9 ERT-switch patients at Months 6,12 and 18, respectively. The ERT-switch patients showed mean increases of 24 meters at month 6 (n=10), 42 meters at month 12 (n=10), and 52 meters at month 18 (n=9). Other motor function tests generally showed mean improvements consistent with 6MWT distance out to month 18 in both ambulatory cohorts. Three of the four non-ambulatory ERT-switch patients showed improvements in upper extremity strength (which includes elbow and shoulder) from baseline to month 18, as measured by quantitative muscle testing and manual muscle testing. Pulmonary function improved in ERT-naïve patients and was generally stable in ERT-switch patients. In ERT-naïve patients, mean absolute change in forced vital capacity ("FVC") one of the main measures of pulmonary function in Pompe disease, was +4.2% at month 6 (n=5), +4.4% at month 12 (n=5), and +5.0% at month 18 (n=5). In ERT-switch patients mean absolute change in FVC was -1.3% at month 6 (n=9), -3.3% at month 12 (n=9), and -3.7% at month 18 (n=8). Overall, other pulmonary tests of maximal inspiratory pressure, a measure of inhalation, and maximal expiratory pressure, a measure of exhalation, were stable or increased in both ERT-naïve and ERT-switch patients.


25


     Next-Generation Gene Therapy for Pompe Disease

We are committed to continued innovation for people living with Pompe disease. In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for, among other indications, Pompe disease. For additional information, see above “—Overview.”

CDKL5 Deficiency Disorder
 
We are researching a potential first-in-class protein replacement therapy approach for CDD in addition to a gene therapy in preclinical studies. CDKL5 is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. Genetic mutations in the CDKL5 gene result in CDKL5 protein deficiency and the disorder manifests clinically as persistent seizures starting in infancy, followed by severe impairment in neurological development. Most children affected by CDD cannot walk or care for themselves and may also suffer from scoliosis, visual impairment, sensory issues, and gastrointestinal complications.
        
In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for, among other indications, CDD. For additional information, see above “—Overview.”

Strategic Alliances and Arrangements
 
In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. For additional information, see above “—Overview.”
We will continue to evaluate business development opportunities as appropriate that build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market pharmacological chaperone therapeutics, ERTs, gene therapies and other technologies or products with a focus on rare metabolic diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include the acquisition of preclinical-stage, clinical-stage or marketed products so long as such transactions are consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.

26


Consolidated Results of Operations
 
Three Months Ended September 30, 2018 compared to September 30, 2017

The following table provides selected financial information for the Company:
 
 
Three Months Ended September 30,
(in thousands)
 
2018
 
2017
 
Change
Net product sales
 
$
20,596

 
$
10,874

 
$
9,722

Cost of goods sold
 
4,310

 
1,790

 
2,520

Cost of goods sold as a percentage of net product sales
 
20.9
%
 
16.5
%
 
4.4
%
Operating expenses:
 
 
 
 
 

Research and development
 
138,227

 
40,641

 
97,586

Selling, general and administrative
 
31,867

 
21,647

 
10,220

Changes in fair value of contingent consideration payable
 
1,300

 
(244,250
)
 
245,550

Loss on impairment of asset
 
—

 
465,427

 
(465,427
)
Depreciation
 
1,073

 
851

 
222

Other income (expense):
 
 
 
 
 

Interest income
 
2,721

 
1,190

 
1,531

Interest expense
 
(4,715
)
 
(4,351
)
 
(364
)
Change in fair value of derivatives
 
—

 
—

 
—

Other (expense) income
 
(1,039
)
 
2,044

 
(3,083
)
Income tax benefit
 
51

 
164,683

 
(164,632
)
Net loss attributable to common stockholders
 
$
(159,163
)
 
$
(111,666
)
 
$
(47,497
)

     Net Product Sales. Net product sales increased $9.7 million during the three months ended September 30, 2018 compared to the same period in the prior year. Galafold® was approved for sale in the EU in May 2016 and has been approved for pricing and reimbursement in 22 countries, including U.S. and Japan, as well as in select other European markets through reimbursed EAPs. The increase in revenue was related to the increase in the number of markets where we had obtained pricing and reimbursements and the corresponding increase in the number of patients being treated with Galafold®.
 
Cost of Goods Sold. Cost of goods sold includes manufacturing costs as well as royalties associated with sales of our product. Cost of goods sold as a percentage of net product sales was 20.9% during the three months ended September 30, 2018 compared to 16.5% during the same period in the prior year primarily due to the proportion of sales in countries subject to a higher royalty burden.
 

27


Research and Development Expense.  The following table summarizes our principal product development programs for each product candidate in development, and the out-of-pocket, third party expenses incurred with respect to each product candidate:
(in thousands)
 
Three Months Ended September 30,
Projects
 
2018
 
2017
Third party direct project expenses
 
 

 
 

Migalastat (Fabry Disease)
 
$
2,610

 
$
3,265

AT-GAA (Pompe Disease)
 
12,312

 
10,456

SD-101 (EB-Epidermolysis Bullosa)
 
—

 
9,660

Pre-clinical programs
 
254

 
192

Total third party direct project expenses
 
15,176

 
23,573

Other project costs
 
 

 
 

Personnel costs
 
15,584

 
11,410

Other costs
 
7,467

 
5,658

Total other project costs
 
23,051

 
17,068

Business development transactions
 
100,000

 
—

Total research and development costs
 
$
138,227

 
$
40,641


The increase in research and development costs was primarily due to $100 million in expense associated with the acquisition of ten gene therapy assets with the Celenex transaction. There were also increases in personnel and other costs with the advancement and enrollment of clinical studies and investments in manufacturing. The decrease in the EB program was due to the discontinuation of the program after the results of a Phase 3 study that did not meet the primary endpoint in September 2017.

Selling, General and Administrative Expense.  Selling, general and administrative increased $10.2 million primarily due to the expanded geographic scope of the ongoing commercial launch of Galafold® and related operational costs of our global business.
 
Changes in Fair Value of Contingent Consideration Payable. The change in the fair value of the contingent consideration payable of $245.6 million resulted from a decrease in the Scioderm, Inc. (“Scioderm”) contingent consideration of $254.7 million, partially offset by an increase in the Callidus contingent consideration of $9.1 million. The fair value and change in fair value are impacted by updates to the estimated probability of achievement, assumed timing of milestones and adjustments to the discount periods and rates. The decrease in Scioderm contingent consideration was due to the results announced in September 2017 that the study did not meet the primary or secondary endpoints, and, as a result, the contingent consideration is no longer payable.
 
Loss on Impairment of Assets. For the three months ended September 30, 2017, we recorded $465.4 million as impairment charges to assets, which primarily included $463.7 million in In-Process Research and Development (“IPR&D”). The impairment was assessed after the announcement of the results from the Phase 3 Scioderm ESSENCE study. There was no similar event in 2018.

Other Expense. The $3.1 million increase in other expense was primarily due to unrealized losses on foreign exchange transactions.
 
Income Tax Benefit. The income tax benefit is related to the provision for the three months ended September 30, 2018. We are subject to income taxes in the United States, although currently not a tax payer, and in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions. The income tax benefit for the three months ended September 30, 2017 was $164.7 million and was primarily due to the reduction of the deferred tax liability related to Scioderm IPR&D as a result of announcement of the Phase 3 Scioderm ESSENCE Study in 2017.


28


Nine Months Ended September 30, 2018 compared to September 30, 2017

The following table provides selected financial information for the Company:
 
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
Change
Net product sales
 
$
58,601

 
$
22,201

 
36,400

Cost of goods sold
 
10,060

 
3,626

 
6,434

Cost of goods sold as a percentage of net product sales
 
17.2
%
 
16.3
%
 
0.9
%
Operating expenses:
 
 
 
 
 
 
Research and development
 
213,685

 
103,502

 
110,183

Selling, general and administrative
 
88,435

 
60,090

 
28,345

Changes in fair value of contingent consideration payable
 
2,700

 
(238,622
)
 
241,322

Loss on impairment of assets
 
—

 
465,427

 
(465,427
)
Depreciation
 
3,015

 
2,486

 
529

Other income (expense):
 
 
 
 
 
 
Interest income
 
7,371

 
2,702

 
4,669

Interest expense
 
(13,763
)
 
(12,820
)
 
(943
)
Change in fair value of derivatives
 
(2,739
)
 
163

 
(2,902
)
Other (expense) income
 
(3,593
)
 
4,891

 
(8,484
)
Income tax benefit
 
1,104

 
164,578

 
(163,474
)
Net loss attributable to common stockholders
 
$
(270,914
)
 
$
(214,794
)
 
$
(56,120
)

     Net Product Sales. Net product sales increased $36.4 million during the nine months ended September 30, 2018 compared to the same period in the prior year. Galafold® was approved for sale in the EU in May 2016 and has been approved for pricing and reimbursement in 22 countries, including U.S. and Japan, as well as in select other European markets through reimbursed EAPs. The increase in revenue was related to the increase in the number of markets where we had obtained pricing and reimbursements and the corresponding increase in the number of patients being treated with Galafold®.
 
Cost of Goods Sold. Cost of goods sold includes manufacturing costs as well as royalties associated with sales of our product. Cost of goods sold as a percentage of net product sales increased to 17.2% during the nine months ended September 30, 2018 compared to 16.3% during the same period in the prior year primarily due to the proportion of sales in countries subject to a higher royalty burden.
 
Research and Development Expense.  The following table summarizes our principal product development programs for each product candidate in development, and the out-of-pocket, third party expenses incurred with respect to each product candidate:
(in thousands)
 
Nine Months Ended September 30,
Projects
 
2018
 
2017
Third party direct project expenses
 
 

 
 

Migalastat (Fabry Disease)
 
$
10,044

 
$
8,644

AT-GAA (Pompe Disease)
 
37,364

 
29,594

SD-101 (EB-Epidermolysis Bullosa)
 
—

 
15,424

Pre-clinical programs
 
1,054

 
430

Total third party direct project expenses
 
48,462

 
54,092

Other project costs
 
 

 
 

Personnel costs
 
44,501

 
34,162

Other costs
 
20,722

 
15,248

Total other project costs
 
65,223

 
49,410

Business development transactions
 
100,000

 
—

Total research and development costs
 
$
213,685

 
$
103,502


29



The increase in research and development costs was primarily due to $100 million in expenses associated with the acquisition of ten gene therapy assets with the Celenex transaction. There were also increases in personnel and other costs with the advancement and enrollment of clinical studies and investments in manufacturing. The decrease in the EB program was due to the discontinuation of the program after the results of a Phase 3 study that did not meet the primary endpoint in September 2017.

Selling, General and Administrative Expense.  Selling, general and administrative increased $28.3 million primarily due to the expanded geographic scope of the ongoing commercial launch of Galafold®and related operational costs of our global business.
 
Changes in Fair Value of Contingent Consideration Payable. The change in the fair value of the contingent consideration payable of $241.3 million resulted from a decrease in the Scioderm contingent consideration of $250.0 million, partially offset by an increase in the Callidus contingent consideration of $8.7 million. The fair value and change in fair value are impacted by updates to the estimated probability of achievement, assumed timing of milestones and adjustments to the discount periods and rates. The decrease in Scioderm contingent consideration was due to the results announced in September 2017 that the study did not meet the primary or secondary endpoints, and, as a result, the contingent consideration is no longer payable.
 
Loss on Impairment of Assets. For the nine months ended September 30, 2017, we recorded $465.4 million as impairment charges to assets, which primarily included $463.7 million in IPR&D. The impairment was assessed after the announcement of the results from the Phase 3 ESSENCE Scioderm study. There was no similar event in 2018.

Interest Income. Interest income increased $4.7 million due to the overall higher average cash and investment balances as a result of our financing transactions.

Change in Fair Value of Derivatives. Subsequent to the underwritten public offering on February 15, 2018, we did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be $507.4 million and $13.6 million, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Following the approval by the Company's stockholders on June 7, 2018, to increase the authorized shares of common stock to 500,000,000, we now have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded through earnings on our consolidated statements of operations resulting in a change in fair value of derivatives for the nine months ended September 30, 2018 of $2.7 million.
 
Other Expense.  The $8.5 million increase in other expense was primarily due to unrealized losses on foreign exchange transactions.
 
Income Tax Benefit. The income tax benefit recorded during the nine months ended September 30, 2018 related to a discrete tax item. We are subject to income taxes in the United States, although currently not a tax payer, and in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions. The income tax benefit for the nine months ended September 30, 2017 was $164.6 million and was primarily due to the reduction of the deferred tax liability related to Scioderm IPR&D as a result of announcement of the Phase 3 ESSENCE Study in 2017.

Liquidity and Capital Resources
  
As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold®, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations principally through the issuance and sale of stock, collaborations, debt financings, grants and non-refundable license fees.
 
Source of Liquidity

During the third quarter of 2018, we entered into a loan agreement with BioPharma Credit PLC, as the lender, for a $150.0 million non-dilutive senior secured term loan (the "Senior Secured Term Loan") with an interest rate equal to 3-month LIBOR plus 7.50% per annum, subject to a floor and ceiling on the rate, which matures in five years. We received net proceeds of $146.6 million in September 2018, after deducting fees and estimated expenses payable by us.


30


During the first quarter of 2018, we issued, through an underwritten offering, 20,239,839 shares of our common stock resulting in net proceeds of $294.6 million after deducting underwriting discounts and commissions and offering expenses payable by us. We expect to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for ATB200, the continued clinical development of our product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes.

Cash flow discussion
 
As of September 30, 2018, we had cash, cash equivalents and marketable securities of $564.4 million. We invest cash in excess of our immediate requirements with regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents and marketable securities, refer to “—Note 4.  Cash, Cash Equivalents, Marketable Securities and Restricted Cash,” in our Notes to Consolidated Financial Statements.

Net Cash Used in Operating Activities
 
Net cash used in operations for the nine months ended September 30, 2018 was $239.3 million. The components of net cash used in operations included the net loss for the nine months ended September 30, 2018 of $270.9 million and the net increase in operating assets of $5.7 million. The change in operating assets was primarily due to increases in accounts receivable by $5.2 million and inventory of $2.0 million due to commercial sales of Galafold®, partially offset by a decrease in prepaid and other current assets of $2.6 million for spending to support commercial activities for Galafold® launch. The net cash used in operations was also impacted by an increase in accounts payable and accrued expenses of $3.7 million, mainly related to program expenses and support for the commercial launch of Galafold®, and a decrease in deferred reimbursement of $5.0 million due to payment of a milestone.
 
Net cash used in operations for the nine months ended September 30, 2017 was $140.7 million. The components of net cash used in operations included the net loss for the nine months ended September 30, 2017 of $214.8 million and the decrease in operating assets of $10.7 million and deferred reimbursement of $12.6 million. The decrease in operating assets was primarily due to increases in accounts receivable of $4.3 million, inventories by $3.4 million, and prepaid expenses and other current assets of $3.4 million due to an increase in commercial sales. The net cash used in operations was partially offset by an increase of $13.0 million in accounts payable and accrued expenses related to program expenses and support for the commercial launch of Galafold®.
 
Net Cash Used in Investing Activities
 
Net cash used in investing activities for the nine months ended September 30, 2018 was $57.4 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash used in investing activities reflects $441.0 million for the purchase of marketable securities, and $4.6 million for the acquisition of property and equipment, partially offset by $388.1 million for the sale and redemption of marketable securities.
 
Net cash used in investing activities for the nine months ended September 30, 2017 was $222.8 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash used in investing activities reflects $450.4 million for the purchase of marketable securities, and $3.4 million for the acquisition of property and equipment, partially offset by $231.0 million for the sale and redemption of marketable securities.
 
Net Cash Provided by Financing Activities
 
Net cash provided by financing activities for the nine months ended September 30, 2018 was $450.4 million. Net cash provided by financing activities primarily reflects $294.6 million from the issuance of common stock, net of issuance costs, $146.6 million in proceeds from the Senior Secured Term Loan, net of issuance costs and estimated fees payable by the company, and $12.1 million from the exercise of stock options and warrants, partially offset by $2.7 million from the purchase of vested restricted stock units. 

31


Net cash provided by financing activities for the nine months ended September 30, 2017 was $240.6 million. Net cash provided by financing activities primarily reflects $243.0 million from the issuance of common stock, net of issuance costs, $8.8 million from the exercise of stock options partially offset by $10.0 million in payment for contingent consideration, and $1.1 million from the purchase of vested of restricted stock units.
 
Funding Requirements
 
We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials. Our future capital requirements will depend on a number of factors, including:
 
•
the progress and results of our clinical trials of our drug candidates;
•
the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe ERT;
•
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates;
•
the costs, timing and outcome of regulatory review of our product candidates;
•
the number and development requirements of other product candidates that we pursue;
•
the costs of commercialization activities, including product marketing, sales and distribution;
•
the emergence of competing technologies and other adverse market developments;
•
our ability to obtain reimbursement for migalastat HCl;
•
our ability to obtain market acceptance of migalastat HCl;
•
the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;
•
the extent to which we acquire or invest in businesses, products and technologies;
•
our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected; and
•
our ability to establish collaborations and obtain milestone, royalty or other payments from any such collaborators.
 
While we have generated revenue from product sales in 2018, in the absence of additional funding, we expect our continuing operating losses to result in increases in our cash used in operations over the next several quarters and years. We may seek additional funding through public or private financings of debt or equity. We believe that our current cash position, including expected Galafold® revenues, is sufficient to fund ongoing Fabry, Pompe and gene therapy program operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.
 
Financial Uncertainties Related to Potential Future Payments
 
Milestone Payments / Royalties
 
In September 2018, we expanded our pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through our acquisition of Celenex. Celenex is a private, clinical stage gene therapy company whose lead programs are ten gene therapy programs including CLN6 and CLN3 which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, we acquired Celenex for cash consideration of $100 million. We also agreed to pay up to an additional $15 million in connection with the achievement of certain development milestones, $262 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments.


32


Celenex has an exclusive license agreement with NCH). Under this license agreement, NCH is eligible to receive development and sales based milestones of up to $7.8 million from us for each product.

In October 2018, we further expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. Under this collaboration agreement, Penn is eligible to receive certain milestone and royalty payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $86.5 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis.

We acquired exclusive worldwide patent rights to develop and commercialize migalastat and other pharmacological chaperones for the prevention or treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes pursuant to a license agreement with Mount Sinai School of Medicine (“MSSM”). This agreement expires upon expiration of the last of the licensed patent rights, which occurred in 2018 in the U.S. and will be in 2019 in Europe and Japan for monotherapy. If we develop a product for combination therapy of specific pharmacological chaperone such as migalastat plus an ERT for certain LSDs such as Fabry disease and a patent issues from the pending MSSM applications covering such a combination therapy(ies), expiration for the combination product(s) will be 2024.
 
In November 2013, we entered into the Revised Agreement (the “Revised Agreement”) with GlaxoSmithKline (“GSK”), pursuant to which we have obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between us and GSK in July 2012 (the "Original Collaboration Agreement"). Under the terms of the Revised Agreement, there was no upfront payment from us to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the United States. In addition, because we reacquired worldwide rights to migalastat, we are no longer eligible to receive any milestones or royalties we would have been eligible to receive under the Original Collaboration Agreement.
 
Under our license agreements, if we owe royalties on net sales for one of our products to more than one of the above licensors, we have the right to reduce the royalties owed to one licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and can vary under each agreement. For the nine months ended September 30, 2018, under the license agreements we paid $7.1 million in royalties and $5.0 million in sales-based milestones.

Critical Accounting Policies and Significant Judgments
 
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
 
There were no significant changes during the nine months ended September 30, 2018 to the items that we disclosed as our significant accounting policies and estimates described in “—Note 2. Summary of Significant Accounting Policies” to the Company’s financial statements as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, except as it relates to the adoption of ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is described below. 
 
Revenue Recognition
 
Our net product sales consist of sales of Galafold® for the treatment of Fabry disease primarily in the EU. We have recorded revenue on sales where Galafold® is available either on a commercial basis or through a reimbursed EAP. Orders for Galafold® are generally received from pharmacies and the ultimate payor is typically a government authority.


33


We recognize revenue when our performance obligation with our customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold®. The transaction price is determined based on fixed consideration in our customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold® are recognized. We recognize revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration amount received and we evaluate these estimates each reporting period to reflect known changes in factors.

We elected the portfolio approach practical expedient in applying ASC Topic 606 to our identified revenue streams. Contracts within each revenue stream have similar characteristics and we believe the results of this approach would not differ materially than if we applied ASC Topic 606 to each individual contract.

     Recent Accounting Pronouncements
 
Please refer to “—Note 2. Summary of Significant Accounting Policies,” in our Notes to Consolidated Financial Statements.

 
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk
 
Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents and marketable securities. We place our investments in high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities and U.S. government agency notes with maturities of less than one year, which we believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are subject to minimal interest rate risk. We believe that a 1% (100 basis points) change in average interest rates would either increase or decrease the market value of our investment portfolio by $1.6 million as of September 30, 2018. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. Our outstanding debt has a fixed interest rate and therefore, we have no exposure to interest rate fluctuations.
 
We have operated primarily in the U.S. with international operations increasing since the last quarter of 2015. We do conduct some clinical activities with vendors outside the U.S. While most expenses are paid in U.S. dollars, we now have increased transactions of expenses and cash flows in foreign currencies that are exposed to changes in foreign currency rates.
 
For information regarding our exposure to certain market risks, see Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017. There have been no material changes in our financial instrument portfolio or market risk exposures since our fiscal year ended December 31, 2017.

ITEM 4. CONTROLS AND PROCEDURES
 
As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation of the effectiveness of our disclosure controls and procedures (pursuant to Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) was carried out under the supervision of our Principal Executive Officer and Principal Financial Officer, with the participation of our management. Based on that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
 
During the fiscal quarter covered by this report, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

34



 
PART II.  OTHER INFORMATION
 
ITEM 1. LEGAL PROCEEDINGS
 
None.

ITEM 1A.  RISK FACTORS
 
 
The following risk factor should be considered in addition to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

It is difficult to predict the time and cost of development and subsequent regulatory approval of gene therapy product candidates. 

The regulatory approval process for gene therapy products is also extensive, lengthy, expensive, and uncertain.  In addition, regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future.  The FDA has established the Office of Tissue and Advanced Therapies within the Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.  Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the National Institute of Health, or NIH, also potentially are subject to review by the Regulatory Affairs Certification, or RAC; however, NIH announced in 2014 that the RAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks.  Although the FDA decides whether individual gene therapy protocols may proceed, the RAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and approved its initiation.  Conversely, the FDA can put an IND on a clinical hold even if the RAC has provided a favorable review or an exemption from in-depth, public review.  If we were to engage an NIH-funded institution to conduct a clinical trial, that institution’s institutional biosafety committee as well as its institutional review board would need to review the proposed clinical trial to assess the safety of the trial.  In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our gene therapy product candidates.  Similarly, the European Commission may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines.
These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions.  As we advance our gene therapy product candidates, we will be required to consult with these regulatory and advisory groups, and comply with applicable guidelines.  If we fail to do so, we may be required to delay or discontinue development of certain of our gene therapy product candidates.  These additional processes may result in a review and approval process that is longer than we otherwise would have expected.  Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business would be materially harmed.

 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
Recent Sales of Unregistered Securities
 
None.
 
Issuer Purchases of Equity Securities
 
None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES
 
None.
 
ITEM 4. MINE SAFETY DISCLOSURES
 
Not applicable.
 

35


ITEM 5. OTHER INFORMATION
 
None.


36


ITEM 6. EXHIBITS
 
Exhibit
Number
 
Description
 
 
 
2.1
 

 
 
 
10.1
 

 
 
 
31.1
 
 
 
 
31.2
 
 
 
 
32.1
 
 
 
 
101
 
The following financial information from this Quarterly Report on Form 10-Q for the nine months ended September 30, 2018, formatted in XBRL (Extensible Business Reporting Language) and filed electronically herewith: (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Operations; (iii) the Consolidated Statements of Comprehensive Loss; (iv) the Consolidated Statements of Cash Flows; (v) and the Notes to the Consolidated Financial Statements
 



37


SIGNATURES
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
AMICUS THERAPEUTICS, INC.
 
 
Date: November 5, 2018
By:
/s/ John F. Crowley
 
 
John F. Crowley
 
 
Chairman and Chief Executive Officer
 
 
(Principal Executive Officer)
 
 
Date: November 5, 2018
By:
/s/ William D. Baird III
 
 
William D. Baird III
 
 
Chief Financial Officer
 
 
(Principal Financial Officer)


38
 EX-31.1 2 fold-09302018xex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER
 
I, John F. Crowley, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Amicus Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 5, 2018
/s/ John F. Crowley
 
John F. Crowley
 
Chairman and Chief Executive Officer
 




 EX-31.2 3 fold-09302018xex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
CERTIFICATIONS PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER
 
I, William D. Baird III, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of Amicus Therapeutics, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: November 5, 2018
/s/ William D. Baird III
 
William D. Baird III
 
Chief Financial Officer
 



 EX-32.1 4 fold-09302018xex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND
PRINCIPAL FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Amicus Therapeutics, Inc. (the “Company”), that, to his knowledge, the Quarterly Report of the Company on Form 10-Q for the period ended September 30, 2018, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to such Form 10-Q. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 
Date: November 5, 2018
By:
/s/ John F. Crowley
 
 
John F. Crowley
 
 
Chairman and Chief Executive Officer
 
 
 
Date: November 5, 2018
By:
/s/ William D. Baird III
 
 
William D. Baird III
 
 
Chief Financial Officer
 



 EX-101.INS 5 fold-20180930.xml XBRL INSTANCE DOCUMENT 0001178879 2018-01-01 2018-09-30 0001178879 fold:CallidusBiopharmaIncMember 2018-01-01 2018-09-30 0001178879 2018-10-29 0001178879 2018-09-30 0001178879 2017-12-31 0001178879 2017-01-01 2017-09-30 0001178879 2018-07-01 2018-09-30 0001178879 2017-07-01 2017-09-30 0001178879 2016-12-31 0001178879 2017-09-30 0001178879 2018-01-01 2018-03-31 0001178879 us-gaap:LineOfCreditMember 2018-09-30 0001178879 us-gaap:LineOfCreditMember 2018-09-01 2018-09-30 0001178879 fold:CelenexMember 2018-09-01 2018-09-30 0001178879 us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-07-01 2018-09-30 0001178879 2018-09-01 2018-09-30 0001178879 us-gaap:LineOfCreditMember 2018-07-01 2018-09-30 0001178879 us-gaap:SubsequentEventMember 2018-10-08 0001178879 us-gaap:AccountingStandardsUpdate201618Member 2017-01-01 2017-09-30 0001178879 fold:AccountingStandardsUpdate201802Member us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0001178879 fold:AccountingStandardsUpdate201802Member 2018-09-30 0001178879 fold:CelenexMember 2018-09-30 0001178879 fold:NationwideChildrensHospitalMember fold:CelenexMember 2018-09-30 0001178879 2017-01-01 2017-12-31 0001178879 us-gaap:CertificatesOfDepositMember 2017-12-31 0001178879 us-gaap:MoneyMarketFundsMember 2017-12-31 0001178879 us-gaap:AssetBackedSecuritiesMember 2017-12-31 0001178879 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2017-12-31 0001178879 fold:ShortTermCorporateDebtSecuritiesMember 2017-12-31 0001178879 us-gaap:CertificatesOfDepositMember 2018-09-30 0001178879 us-gaap:AssetBackedSecuritiesMember 2018-09-30 0001178879 us-gaap:MoneyMarketFundsMember 2018-09-30 0001178879 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2018-09-30 0001178879 fold:ShortTermCorporateDebtSecuritiesMember 2018-09-30 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2017-12-31 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2018-09-30 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2018-07-01 2018-09-30 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2016-12-31 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2016-12-01 2016-12-31 0001178879 fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember us-gaap:OverAllotmentOptionMember fold:PrivatePlacementPurchaseAgreementMember 2016-12-31 0001178879 srt:MinimumMember fold:ConvertibleSeniorNotes2016Due2023Member us-gaap:ConvertibleDebtMember 2016-12-01 2016-12-31 0001178879 fold:CommonStockCappedCallConfirmationMember 2018-02-15 0001178879 us-gaap:ConvertibleDebtMember 2018-01-01 2018-09-30 0001178879 2018-02-15 0001178879 2018-06-07 0001178879 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2018-02-15 2018-02-15 0001178879 fold:CommonStockCappedCallConfirmationMember us-gaap:ConvertibleDebtMember 2018-06-07 0001178879 us-gaap:CommonStockMember 2018-02-16 2018-02-16 0001178879 us-gaap:CommonStockMember 2018-02-15 2018-02-15 0001178879 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2018-02-16 2018-02-16 0001178879 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001178879 us-gaap:WarrantMember us-gaap:CommonStockMember 2018-04-30 0001178879 us-gaap:WarrantMember 2018-04-01 2018-04-30 0001178879 us-gaap:CommonStockMember 2018-02-16 0001178879 us-gaap:CommonStockMember 2018-02-15 0001178879 us-gaap:CommonStockMember 2018-02-15 2018-02-15 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2018-01-01 2018-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2018-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2017-12-31 0001178879 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001178879 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0001178879 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-07-01 2018-09-30 0001178879 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-09-30 0001178879 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001178879 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2017-09-30 0001178879 us-gaap:ResearchAndDevelopmentExpenseMember 2017-07-01 2017-09-30 0001178879 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2017-07-01 2017-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2018-07-01 2018-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2017-01-01 2017-09-30 0001178879 fold:MarketPerformanceBasedRestrictedStockUnitsMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember us-gaap:ExecutiveOfficerMember fold:CliffVestingMember 2018-01-01 2018-09-30 0001178879 us-gaap:RestrictedStockUnitsRSUMember fold:ContingentConsiderationLiabilityClinicalMilestoneMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember 2018-01-01 2018-09-30 0001178879 us-gaap:RestrictedStockUnitsRSUMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember 2018-01-01 2018-09-30 0001178879 fold:MarketPerformanceBasedRestrictedStockUnitsMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember us-gaap:ExecutiveOfficerMember 2018-01-01 2018-09-30 0001178879 us-gaap:RestrictedStockUnitsRSUMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember 2018-09-30 0001178879 srt:MaximumMember fold:MarketPerformanceBasedRestrictedStockUnitsMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember us-gaap:ExecutiveOfficerMember 2018-01-01 2018-09-30 0001178879 srt:MaximumMember fold:MarketPerformanceBasedRestrictedStockUnitsMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember us-gaap:ExecutiveOfficerMember 2018-09-30 0001178879 us-gaap:RestrictedStockUnitsRSUMember fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember 2017-12-31 0001178879 fold:CallidusBiopharmaIncMember fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember fold:TB200PompeProgramMember 2018-09-30 0001178879 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001178879 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2018-09-30 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2018-09-30 0001178879 us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2018-09-30 0001178879 us-gaap:FairValueInputsLevel2Member 2018-09-30 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2018-09-30 0001178879 us-gaap:FairValueInputsLevel3Member 2018-09-30 0001178879 2017-06-30 0001178879 2018-06-30 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2017-12-31 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:AssetBackedSecuritiesMember 2017-12-31 0001178879 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2017-12-31 0001178879 us-gaap:CorporateDebtSecuritiesMember 2017-12-31 0001178879 fold:CallidusBiopharmaIncMember fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember fold:TB200PompeProgramMember fold:ProbabilityWeightedDiscountedCashFlowMember 2018-09-30 0001178879 srt:MaximumMember fold:CallidusBiopharmaIncMember fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember fold:MeasurementInputProbabilityOfMilestoneAchievementMember fold:TB200PompeProgramMember 2018-09-30 0001178879 srt:MinimumMember fold:CallidusBiopharmaIncMember fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember fold:MeasurementInputProbabilityOfMilestoneAchievementMember fold:TB200PompeProgramMember 2018-09-30 0001178879 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2017-01-01 2017-09-30 0001178879 fold:VestedRestrictedStockUnitsUnissuedMember 2017-01-01 2017-09-30 0001178879 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-09-30 0001178879 fold:EmployeeAndDirectorsStockOptionsMember 2018-01-01 2018-09-30 0001178879 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001178879 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001178879 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001178879 fold:VestedRestrictedStockUnitsUnissuedMember 2018-01-01 2018-09-30 0001178879 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0001178879 us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2018-10-31 0001178879 us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2018-10-01 2018-10-31 iso4217:USD xbrli:shares fold:day fold:medicine iso4217:USD xbrli:shares xbrli:pure fold:program false --12-31 Q3 2018 2018-09-30 10-Q 0001178879 189289881 Yes false Large Accelerated Filer AMICUS THERAPEUTICS INC false 137000 399000 100000000 0 80000 358998000 564594000 1000 5000 437000 216000 358562000 564383000 86500000 1.000 0.710 0.10 0.125 P20D 4932000 -775000 -12600000 -5000000 637000 681000 2903225 -164585000 0 1 P30D 14 4 2 10 40849675 0 10000000 0 0 7000000 1067000 2681000 13500000 7800000 15000000 262000000 75000000 0 0 0 0 53890000 54330000 9464000 14189000 12515000 15483000 -436000 -211000 -1659000 -875000 1400758000 1731174000 5500000 2390000 3110000 17067000 7456000 9611000 7054000 2905000 4149000 20873000 8603000 12270000 2609000 7620000 7179000 7868000 62912000 16212000 50000 40850000 2690000 3110000 63014000 15769000 103000 40850000 3635000 2657000 465427000 465427000 0 0 627024000 838589000 391965000 601034000 311700000 311700000 30287000 79803000 199012000 2598000 30287000 79803000 199012000 2598000 365490000 365490000 52101000 82655000 227399000 3335000 52101000 82655000 227399000 3335000 1000 1000 0 0 0 0 5000 5000 0 0 0 0 437000 303000 59000 0 75000 0 216000 123000 44000 0 49000 0 309938000 199314000 30346000 50000 79878000 350000 362767000 227517000 52145000 51000 82704000 350000 309502000 199012000 30287000 50000 79803000 350000 362556000 362600000 227399000 52101000 51000 82655000 350000 -238622000 2700000 25400000 0 25400000 28100000 27600000 0 28100000 8400000 8800000 17000000 19300000 0 538000 187026000 64133000 49060000 201827000 201800000 49060000 201827000 187413000 65577000 51237000 203830000 -121836000 152593000 7.98 0.01 0.01 250000000 500000000 500000000 166989790 189254341 166989790 189254341 1721000 1941000 -112973000 -218309000 -158254000 -269522000 531200000 164167000 172186000 1790000 3626000 4310000 10060000 0.075 250000000 400000000 6.12 0.1633987 30 1.3 250000000 25000000 P5Y 81566000 76946000 295100000 315300000 0 0 2258000 2258000 0 2996000 2996000 0 7750000 2750000 14156000 14156000 6465000 6465000 4267000 4246000 851000 2486000 1073000 3015000 13600000 88300000 507400000 -0.69 -1.44 -0.84 -1.47 1030000 -1146000 P3Y P3Y 25600000 36000000 244250000 238622000 -1300000 -2700000 269722000 265350000 21100000 25400000 26800000 28100000 265000 -2739000 0 163000 0 -2739000 -2700000 8000 0 197797000 197797000 9084000 18575000 16286000 48541000 -276349000 -379372000 -159214000 -272018000 -164683000 -164578000 -51000 -1104000 13037000 3684000 4288000 5182000 3386000 2049000 -344000 1101000 3358000 -2633000 23000000 23000000 4351000 12820000 4715000 13763000 4715000 13763000 1969000 5744000 3662000 3787000 780000 1899000 4623000 6311000 2394000 2954000 1449000 1458000 1190000 2702000 2721000 7371000 274174000 427638000 627024000 838589000 70040000 65880000 27658000 2258000 25400000 31096000 2996000 28100000 150000000 164167000 318808000 309502000 362556000 240570000 450416000 -222775000 -57399000 -140661000 1100000 -239278000 -111666000 -214794000 -159163000 -270914000 284316000 392883000 172467000 307835000 -275232000 -374308000 -156181000 -259294000 2400000 5200000 6099000 -131000 -203000 244000 225000 -1176000 -3312000 665000 1167000 0 0 59000 168000 -1307000 -3515000 909000 1392000 2346000 3029000 2044000 4891000 -1039000 -3593000 28000 0 450358000 440963000 3398000 4571000 19316000 16151000 243000000 243036000 294600000 294584000 294600000 146600000 0 146622000 230981000 388135000 8841000 8492000 3600000 0 3617000 -214794000 -270914000 9062000 10659000 212000 218000 100000000 40641000 103502000 138227000 213685000 387000 1444000 2177000 2003000 -1063610000 -1334141000 383000 10874000 22201000 20596000 58601000 0 146622000 21647000 60090000 31867000 88435000 17067000 20873000 P3Y P3Y P3Y 58000 10.23 187222 187211 1635000 25.44 16.57 2575000 3635000 5.85 10.49 P2Y8M1D 516940 517000 5.91 0.825 0.831 0.755 0.807 0.018 0.020 0.027 0.024 374444 9406000 7.26 7000 200000 2077000 65800000 15181000 15769000 7.48 8.56 47400000 63900000 15003000 8.43 6.62 10.45 9.75 15.36 15.50 15.50 2 44000000 P5Y10M20D P6Y2M16D P5Y7M15D P5Y7M15D P6Y0M0D P7Y0M0D P6Y11M6D 19354839 885000 453214 20239839 1282000 300000000 352850000 410951000 -383000 16076000 13063000 160796841 148963864 189162841 184606790 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements.&#160;In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company&#8217;s interim financial information. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company&#8217;s financial statements and related notes as contained in the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;For a complete description of the Company&#8217;s accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Company expanded its pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through its acquisition of Celenex. Celenex is a private, clinical stage gene therapy company whose lead programs are ten gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, the Company acquired Celenex for cash consideration of </font><font style="font-family:inherit;font-size:10pt;">$100 million</font><font style="font-family:inherit;font-size:10pt;">. The Company has also agreed to pay up to an additional </font><font style="font-family:inherit;font-size:10pt;">$15 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain development milestones, </font><font style="font-family:inherit;font-size:10pt;">$262 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with the achievement of certain regulatory approval milestones across multiple programs and up to </font><font style="font-family:inherit;font-size:10pt;">$75 million</font><font style="font-family:inherit;font-size:10pt;"> in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children&#8217;s Hospital (&#8220;NCH&#8221;). Under this license agreement, NCH is eligible to receive development and sales based milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> for each product.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company evaluated the Celenex transaction based on the guidance in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations</font><font style="font-family:inherit;font-size:10pt;"> (Topic 805) and concluded that the transaction did not meet the definition of a business and was an asset acquisition. Given the fact that the license has no alternative future use, the </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment was expensed to research and development expense in the Consolidated Statements of Operations for the three and nine months ended September 30, 2018 in accordance with ASC Topic 730,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#8217;s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive income (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#8217;s consolidated balance sheet. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company held </font><font style="font-family:inherit;font-size:10pt;">$201.8 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and cash equivalents and </font><font style="font-family:inherit;font-size:10pt;">$362.6 million</font><font style="font-family:inherit;font-size:10pt;"> of available-for-sale debt securities which are reported at fair value on the Company&#8217;s consolidated balance sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive loss in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current, while investments that have maturities greater than one year are classified as long-term.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,517</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in marketable securities, current and non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,556</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,314</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,938</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">minal realized gains. For the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> realized gains or losses. The cost of securities sold is based on the specific identification method.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss positions in the available-for-sale debt securities as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain (loss). The fair value of these available-for-sale debt securities in unrealized loss positions was </font><font style="font-family:inherit;font-size:10pt;">$315.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$295.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,237</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company further expanded its gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. This relationship will combine the Company's protein engineering and glycobiology expertise with Penn&#8217;s AAV gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability. In connection with the collaboration agreement, the Company made an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash to Penn in October 2018 and agreed to certain milestone payments following the achievement of certain developmental and commercial milestone events by a licensed product in each indication up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$86.5 million</font><font style="font-family:inherit;font-size:10pt;"> per indication.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Convertible Notes and Senior Secured Term Loan consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability&#160;component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt discount (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,946</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81,566</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: deferred financing (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">318,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________________________</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Included in the consolidated balance sheets within convertible notes and senior secured term loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Senior Secured Term Loan due 2023</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a loan agreement with BioPharma Credit PLC as the lender. The loan agreement provides for a </font><font style="font-family:inherit;font-size:10pt;">$150 million</font><font style="font-family:inherit;font-size:10pt;"> senior secured term loan (&#8220;Senior Secured Term Loan&#8221;) with an interest rate equal to the 3-month LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">7.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum and matures </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years from the maturity date. The Senior Secured Term Loan will be repaid in four quarterly payments equal to </font><font style="font-family:inherit;font-size:10pt;">12.50%</font><font style="font-family:inherit;font-size:10pt;"> thereof starting on the forty-eight month anniversary of the date of the first credit extension with the balance due on the Maturity Date. Interest is payable quarterly in arrears. The Senior Secured Term Loan contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, but does not include any financial covenants relating to the achievement or maintenance of revenue or cash flow. If an event of default occurs and is continuing, the lender may declare all amounts outstanding under the Senior Secured Term Loan to be immediately due and payable. The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$146.6 million</font><font style="font-family:inherit;font-size:10pt;"> in September 2018, after deducting fees and estimated expenses payable by the Company</font><font style="font-family:inherit;font-size:10pt;color:#661de8;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Notes due 2023</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2016, the Company issued at par value </font><font style="font-family:inherit;font-size:10pt;">$250 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of unsecured Convertible Senior Notes due 2023 (the &#8220;Convertible Notes&#8221;), which included the exercise in full of the </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;"> over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule&#160;144A under the Securities Act (the &#8220;Note Offering&#8221;). Interest is payable semiannually on June&#160;15 and December&#160;15 of each year, beginning on June&#160;15, 2017.&#160;The Convertible Notes will mature on December&#160;15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms.&#160;The Convertible Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company&#8217;s common stock or a combination thereof. The net proceeds from the Note Offering were </font><font style="font-family:inherit;font-size:10pt;">$243.0 million</font><font style="font-family:inherit;font-size:10pt;">, after deducting fees and estimated expenses payable by the Company.&#160;In addition, the Company used approximately </font><font style="font-family:inherit;font-size:10pt;">$13.5 million</font><font style="font-family:inherit;font-size:10pt;"> of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions (&#8220;Capped Call Confirmations&#8221;) that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes are initially convertible into approximately </font><font style="font-family:inherit;font-size:10pt;">40,849,675</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock under certain circumstances prior to maturity at a conversion rate of </font><font style="font-family:inherit;font-size:10pt;">163.3987</font><font style="font-family:inherit;font-size:10pt;"> shares per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of Convertible Notes, which represents a conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.12</font><font style="font-family:inherit;font-size:10pt;"> per share of the Company's common stock, subject to adjustment under certain conditions. The last reported sale price of the Company&#8217;s common stock was equal to or more than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price of the Convertible Notes for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days of the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last day of the second quarter. As a result, the Convertible Notes are currently convertible into the Company&#8217;s common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As further described in &#8220;&#8212;Note&#160;7. Stockholders&#8217; Equity,&#8221; on February&#160;15, 2018, the Company entered into an underwriting agreement relating to an underwritten public offering of </font><font style="font-family:inherit;font-size:10pt;">19,354,839</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days after February&#160;16, 2018, to purchase up to an additional </font><font style="font-family:inherit;font-size:10pt;">2,903,225</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, which was exercised with respect to </font><font style="font-family:inherit;font-size:10pt;">885,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to the underwritten public offering on February 15, 2018, the Company did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the Company accounted for the portion of the bifurcated conversion feature and of the Capped Call Confirmations that would not be able to be net share settled as a current derivative liability and as a derivative asset, respectively.&#160;The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be </font><font style="font-family:inherit;font-size:10pt;">$507.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$13.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded in the second quarter of 2018 through earnings on the Company&#8217;s consolidated statements of operations resulting in a change in fair value of derivatives for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the approval by the stockholders of the Company on June 7, 2018, to increase the authorized shares of common stock to </font><font style="font-family:inherit;font-size:10pt;">500,000,000</font><font style="font-family:inherit;font-size:10pt;">, the Company has sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at June 7, 2018 was determined to be </font><font style="font-family:inherit;font-size:10pt;">$88.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Convertible Notes and Senior Secured Term Loan consist of the following (in thousands): </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability&#160;component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: debt discount (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,946</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81,566</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: deferred financing (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,267</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net carrying value of the debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">318,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________________________</font></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Included in the consolidated balance sheets within convertible notes and senior secured term loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Components&#160;(In&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of deferred financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share based Compensation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the &#8220;Plan&#8221;) and the 2007 Director Option Plan (the &#8220;2007 Director Plan&#8221;). The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company&#8217;s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company&#8217;s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Option Grants</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life of options (years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected annual dividend per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in the third quarter of 2017, the average expected life was determined using our actual historical data versus a &#8220;simplified&#8221; method used in prior quarters. The &#8220;simplified&#8221; method of estimating the expected exercise term uses the mid-point between the vesting date and the end of the contractual term. In earlier quarters, we did not have sufficient reliable exercise data to justify a change from the use of the &#8220;simplified&#8221; method of estimating the expected exercise term of employee stock option grants.&#160;The impact from this change was not material.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock options for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160;Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">10.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and unvested expected to vest, September 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation cost related to non-vested stock options granted was </font><font style="font-family:inherit;font-size:10pt;">$36.0 million</font><font style="font-family:inherit;font-size:10pt;"> and is expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">(&#8220;RSUs&#8221;)</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">and Performance-Based Restricted Stock Units</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee&#8217;s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of&#160;Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average&#160;Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining&#160;Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate&#160;Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested units as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested units as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,635</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the &#8220;Performance-Based RSU Agreement&#8221;), to be used for performance-based RSUs granted to participants under the Amended and Restated 2007 Equity Incentive Plan, including named executive officers. Certain awards under the Performance-Based RSU Agreement were granted in January&#160;2017 and 2018. The 2018 grants include </font><font style="font-family:inherit;font-size:10pt;">187,222</font><font style="font-family:inherit;font-size:10pt;"> market performance-based restricted stock units (&#8220;MPRSUs&#8221;) granted to executives.&#160; Vesting of these awards is contingent upon the Company meeting certain total shareholder return (&#8220;TSR&#8221;) levels as compared to a select peer group over the next </font><font style="font-family:inherit;font-size:10pt;">three years</font><font style="font-family:inherit;font-size:10pt;">. The MPRSUs cliff vest at the end of the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year period and have a maximum potential to vest at </font><font style="font-family:inherit;font-size:10pt;">200%</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">374,444</font><font style="font-family:inherit;font-size:10pt;"> shares) based on TSR performance.&#160;The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized on a straight-line basis over the vesting term.&#160; The estimated fair value per share of the MPRSUs was </font><font style="font-family:inherit;font-size:10pt;">$25.44</font><font style="font-family:inherit;font-size:10pt;"> and was calculated using a Monte Carlo simulation model.&#160; The awards also include </font><font style="font-family:inherit;font-size:10pt;">187,211</font><font style="font-family:inherit;font-size:10pt;"> performance based awards that will vest over the next </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years based on the Company achieving certain clinical milestones. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, none of the clinical milestones for the performance based RSUs awarded in 2017 or 2018 were reached.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">516,940</font><font style="font-family:inherit;font-size:10pt;"> RSUs have vested and all non-vested units are expected to vest over their normal term. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$25.6</font><font style="font-family:inherit;font-size:10pt;"> million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation Expense Related to Equity Awards</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation expense recognized in:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,270</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basic and Diluted Net Loss per Common Share</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Numerator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,666</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(270,914</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,794</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Denominator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Weighted average common shares outstanding&#160;&#8212; basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,162,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,796,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,606,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,963,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Outstanding warrants, convertible to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested restricted stock units, unissued</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total number of potentially issuable shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company&#8217;s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are identified in the following table:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company&#8217;s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are identified in the following table:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent&#160;Consideration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value as of<br clear="none"/> September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation&#160;Technique</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Clinical and regulatory milestones</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.6</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;million</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Probability weighted discounted cash flow</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Probability of achievement of milestones</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">71.0%-100.0%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Projected year of payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2018-2022</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets and Liabilities Measured at Fair Value</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3</font><font style="font-family:inherit;font-size:10pt;"> &#8212; Inputs that are unobservable for the asset or liability.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company&#8217;s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> are identified in the following table:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,655</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">365,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,096</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the fair value of the Company&#8217;s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are identified in the following table:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred compensation plan liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,658</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the debt at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> was approximately </font><font style="font-family:inherit;font-size:10pt;">$531.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not have any Level 3 assets as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Money Market Funds and Marketable Securities</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale debt securities and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> changes in valuation techniques or inputs occurred during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy occurred during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Consideration Payable</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. (&#8220;Callidus&#8221;) in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent&#160;Consideration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value as of<br clear="none"/> September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Valuation&#160;Technique</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable&#160;Input</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Range</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Discount rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.0%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Clinical and regulatory milestones</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.6</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;million</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Probability weighted discounted cash flow</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Probability of achievement of milestones</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">71.0%-100.0%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Projected year of payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">2018-2022</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the change in the balance of contingent consideration payable for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent consideration in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in fair value during the period, included in statement of operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Compensation Plan - Investment and Liability</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Deferred Compensation Plan (the &#8220;Deferral Plan&#8221;) provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant&#8217;s base salary, bonus and director&#8217;s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment&#8217;s fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Transactions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency for most of the Company&#8217;s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders&#8217; equity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth total interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Components&#160;(In&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Three Months Ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,609</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of deferred financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,715</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of raw materials, work-in-process and finished goods related to the manufacture of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The following table summarizes the components of inventories: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Adopted in 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2018-07 &#8212; In June 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2018-07&#8221;).These amendments expand the scope of Topic 718, Compensation&#8212;Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity&#8212;Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 in the second quarter of 2018 and there was no material impact on its consolidated financial statements from the adoption.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2018-02</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">&#8212; In February 2018, the FASB issued ASU 2018-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income (Topic 220)</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2018-02&#8221;). Prior to ASU 2018-02, U.S. GAAP required the remeasurement of deferred tax assets and liabilities as a result of a change in tax laws or rates to be presented in net income from continuing operations, even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income. As a result, such items, referred to as stranded tax effects, did not reflect the appropriate tax rate. Under ASU 2018-02, entities are permitted, but not required, to reclassify from accumulated other comprehensive income to retained earnings those stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new standard effective January 1, 2018. As a result of the adoption, the Company reclassified a gain of </font><font style="font-family:inherit;font-size:10pt;">$383,000</font><font style="font-family:inherit;font-size:10pt;"> from the foreign currency translation adjustment in accumulated other comprehensive loss to accumulated deficit in the consolidated balance sheet as of September 30, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-09 &#8212; In May&#160;2017, the FASB issued ASU 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-09&#8221;). The amendments in ASU 2017-09 provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASU 2017-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> An entity should account for the effects of a modification unless all the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December&#160;15, 2017. The Company adopted this standard on January 1, 2018 and as the Company did not have any modification of awards, the adoption of the standard did not have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-01 &#8212; In January&#160;2017, the FASB issued ASU 2017-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-01&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> This ASU clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in ASU 2017-01 are effective for public companies for annual periods beginning after December&#160;15, 2017, including interim periods within those periods. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of the standard did not have a material impact on its consolidated financial statements. For additional information see "&#8212;Note 3. Acquisitions."</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">&#8212; In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230)</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-18&#8221;). The amendments of ASU 2016-18 require an entity to include amounts generally described as restricted cash and restricted cash equivalents with cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the statement of cash flows. The amendments of ASU 2016-18 are effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the guidance in ASU 2016-18 effective January 1, 2018. In connection with the adoption of the standard, the Company applied the guidance retrospectively which resulted in an increase in cash flows from operations of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> on the statement of cash flows for the nine months ended September 30, 2017.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-16 &#8212; In October&#160;2016, the FASB issued ASU 2016-16,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-16&#8221;). ASU 2016-16 requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in ASU 2016-16 are effective for public business entities for annual periods beginning after December&#160;15, 2017, including interim reporting periods within those annual reporting periods. The Company adopted ASU 2016-16 on January 1, 2018 and there was no material impact from the adoption.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-01 &#8212; In January 2016, the FASB issued ASU No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-01&#8221;). ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income. Companies have the option to measure equity investments without readily determinable fair values at either fair value or at cost adjusted for changes in observable prices minus impairment. Companies that elect the fair value option for financial liabilities must recognize changes in fair value related to instrument-specific credit risk in other comprehensive income. Companies must assess valuation allowances for deferred tax assets related to available-for-sale debt securities in combination with their other deferred tax assets. ASU 2016-01 is effective beginning in the first quarter of 2018 and the Company adopted it in the first quarter of 2018. There was no impact on the Company&#8217;s consolidated financial statements and related disclosures upon adoption, as the Company does not have equity investments or liabilities with credit risk. In addition, the guidance relating to deferred tax assets did not result in a change in accounting treatment for the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2014-09 &#8212; In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606) which along with amendments issued in 2015 and 2016, replaced substantially all current U.S. GAAP guidance on this topic and eliminated industry-specific guidance. The new revenue recognition standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Effective January 1, 2018, the Company adopted the new revenue recognition standard using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under the new revenue recognition standard. As such, the adoption of the new revenue recognition standard did not have a material impact on the Company's consolidated financial statements. The information presented for the periods prior to January 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Not Yet Adopted</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Securities Exchange Commission (&#8220;SEC&#8221;) issued Final Rule 33-10532, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements that were redundant, duplicative, overlapping or superseded by other SEC disclosure requirements. The amendments generally eliminated or otherwise reduced certain disclosure requirements of various SEC rules and regulations. However, in some cases, the amendments require additional information to be disclosed, including changes in stockholders&#8217; equity in interim periods. The rule is effective 30 days after its publication in the Federal Register. The rule was posted on October 4, 2018. On September 25, 2018, the SEC released guidance advising it will not object to a registrant adopting the requirement to include changes in stockholders&#8217; equity in the Form 10-Q for the first quarter beginning after the effective date of the rule. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption and expects to adopt the guidance in it's Form 10-Q for the period ended March 31, 2019.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2018-13 &#8212; In August 2018, the FASB issued ASU 2018-03, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2018-13&#8221;). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-12 &#8212; In August&#160;2017, the FASB issued ASU 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-12&#8221;). The amendments in this ASU 2017-12 better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments in ASU 2017-12 also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. For public business entities, the amendment is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years. Early adoption, including adoption in an interim period, is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-11 &#8212; In July&#160;2017, the FASB issued ASU 2017-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part&#160;I) Accounting for Certain Financial Instruments with Down Round Features, (Part&#160;II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-11&#8221;). Part&#160;I of ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock.&#160;Part&#160;II of ASU 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification&#174;. For public business entities, the amendments in Part&#160;I of ASU 2017-11 are effective for fiscal years beginning after December&#160;15, 2018.&#160;Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-08 &#8212; In March&#160;2017, the FASB issued ASU 2017-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-08&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The amendments in ASU 2017-08 shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. ASU 2017-08 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-04 &#8212; In January&#160;2017, the FASB issued ASU 2017-04,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-04&#8221;). To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&#160;15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&#160;1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-02 &#8212; In February&#160;2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842) </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 will be effective for the Company for all annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In August 2018, the FASB issued ASU 2018-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:inherit;font-size:10pt;">, (&#8220;ASU 2018-11&#8221;). ASU 2018-11 provide entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.&#160;The Company will adopt these standards effective January 1, 2019, and expects to elect certain of the practical expedients permitted, including the expedient that permits the Company to retain its existing lease assessment and classification. The Company also expects to elect the transition method in ASU 2018-11. The Company is currently working through an adoption plan which includes the evaluation of lease contracts compared to the new standard. While the Company is currently assessing the impact that this standard will have on its consolidated financial statements, the Company expects to recognize lease liabilities and right of use assets. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amicus Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases. With </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic and the recent addition of </font><font style="font-family:inherit;font-size:10pt;">fourteen</font><font style="font-family:inherit;font-size:10pt;"> new gene therapy programs into the pipeline, including </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> clinical stage gene therapies for Batten disease, the Company has a leading portfolio of medicines for lysosomal storage disorders (&#8220;LSDs&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cornerstone of the Company&#8217;s portfolio is migalastat HCl (also referred to as &#8220;migalastat&#8221;), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in the United States (&#8220;U.S.&#8221;), European Union (&#8220;EU&#8221;) and Japan, with additional approvals granted and applications pending in several other geographies. During the third quarter of 2018, the Company initiated the commercial launch of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> in the U.S. for the treatment of adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. </font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The lead biologics program of the Company&#8217;s pipeline is Amicus Therapeutics GAA (&#8220;AT-GAA&#8221;, also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. The Company&#8217;s Chaperone-Advanced Replacement Therapy (&#8220;CHART&#174;&#8221;) platform technology is leveraged to develop novel products for Pompe disease and potentially future other LSDs. </font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second half of 2018, the Company has expanded its portfolio to include </font><font style="font-family:inherit;font-size:10pt;">fourteen</font><font style="font-family:inherit;font-size:10pt;"> new gene therapy programs. In September 2018, the Company acquired worldwide development and commercial rights for </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> gene therapy programs for neurologic LSDs developed at&#160;The Center for Gene Therapy&#160;at&#160;The Research Institute&#160;at Nationwide Children&#8217;s Hospital and&#160;The Ohio State University through the acquisition of Celenex, Inc., (&#8220;Celenex&#8221;) a private, clinical stage gene therapy company, for cash consideration of </font><font style="font-family:inherit;font-size:10pt;">$100.0</font><font style="font-family:inherit;font-size:10pt;"> million and additional consideration payable upon the achievement of certain development and approval milestones. The acquisition establishes Amicus as a leading company in neurologic LSDs. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. For additional information see "&#8212;Note 3. Acquisitions."</font></div><div style="line-height:120%;text-align:justify;padding-left:2px;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company further expanded its gene therapy portfolio through a collaboration agreement with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (&#8220;Penn&#8221;) to pursue the research and development of novel gene therapies for </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> additional indications, including Pompe disease, Fabry disease, CDKL5 deficiency disorder (&#8220;CDD&#8221;) and one additional undisclosed rare metabolic disorder. This relationship will combine the Company's protein engineering and glycobiology expertise with Penn&#8217;s adeno associated virus (&#8220;AAV&#8221;) gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability. </font></div><div style="line-height:120%;text-align:justify;text-indent:26px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that its platform technologies and its product pipeline uniquely positions it and drives its commitment to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the third quarter of 2018, the Company entered into a loan agreement with BioPharma Credit PLC, as the lender, for a </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> non-dilutive senior secured term loan (the &#8220;Senior Secured Term Loan&#8221;) with an interest rate equal to 3-month LIBOR plus </font><font style="font-family:inherit;font-size:10pt;">7.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum, subject to a floor and ceiling on the rate, which matures in </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$146.6 million</font><font style="font-family:inherit;font-size:10pt;"> in September 2018, after deducting fees and estimated expenses payable by the Company. There are no warrants or any equity conversion features associated with the Senior Secured Term Loan. The proceeds from this financing will be used to support the cost of the Celenex acquisition, its related development costs and other general corporate purposes. For additional information, see " &#8212;Note 6. Debt."</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2018, the Company issued </font><font style="font-family:inherit;font-size:10pt;">20,239,839</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock through an underwritten offering resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$294.6 million</font><font style="font-family:inherit;font-size:10pt;"> after deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for the ERT ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes. For additional information, see &#8220;&#8212;Note&#160;7. Stockholders&#8217; Equity.&#8221;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3</font><font style="font-family:inherit;font-size:10pt;"> billion as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and anticipates incurring losses through the fiscal year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and beyond. The Company has been able to fund its operating losses to date through stock offerings, debt issuances, payments from partners during the terms of the collaboration agreements, and other financing arrangements. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The current cash position, including expected Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> revenues, is sufficient to fund ongoing Fabry, Pompe and gene therapy program operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company&#8217;s future capital requirements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease primarily in the EU. The Company has recorded revenue on sales where Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> is available either on a commercial basis or through a reimbursed early access program (&#8220;EAP&#8221;). Orders for Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> are generally received from pharmacies and the ultimate payor is typically a government authority.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The transaction price is determined based on fixed consideration in the Company&#8217;s customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company elected the portfolio approach practical expedient in applying ASC Topic 606 to its identified revenue streams. Contracts within each revenue stream have similar characteristics and the Company believes this approach would not differ materially from applying ASC Topic 606 to each individual contract.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Outstanding warrants, convertible to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unvested restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,690</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Vested restricted stock units, unissued</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total number of potentially issuable shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,912</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the change in the balance of contingent consideration payable for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, beginning of the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269,722</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of contingent consideration in cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in fair value during the period, included in statement of operations</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,700</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238,622</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, end of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September&#160;30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,517</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,399</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,101</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in marketable securities, current and non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,767</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">362,556</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">564,383</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities, current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,314</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199,012</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,803</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Asset-backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,287</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificates of deposit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,938</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309,502</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(437</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">358,562</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Numerator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,163</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,666</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(270,914</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,794</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Denominator:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Weighted average common shares outstanding&#160;&#8212; basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189,162,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,796,841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,606,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,963,864</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity compensation expense recognized in:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,603</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,110</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,270</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,611</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total equity compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,054</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,873</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,067</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the components of inventories: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,899</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">780</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,311</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">201,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,003</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,237</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65,577</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,413</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the Company&#8217;s stock options for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual&#160;Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in&#160;millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,181</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15.36</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">10.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and unvested expected to vest, September 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected stock price volatility</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life of options (years)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected annual dividend per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of non-vested RSU activity under the Plan for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of&#160;Shares</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average&#160;Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining&#160;Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate&#160;Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested units as of December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.91</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested units as of September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,635</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements.&#160;In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company&#8217;s interim financial information. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company&#8217;s financial statements and related notes as contained in the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;For a complete description of the Company&#8217;s accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Transactions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional currency for most of the Company&#8217;s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders&#8217; equity.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassification</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified for comparative purposes. The reclassifications did not affect results of operations, net assets or cash flows.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company&#8217;s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive income (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company&#8217;s consolidated balance sheet. </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2018</font><font style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> for the treatment of Fabry disease primarily in the EU. The Company has recorded revenue on sales where Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> is available either on a commercial basis or through a reimbursed early access program (&#8220;EAP&#8221;). Orders for Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> are generally received from pharmacies and the ultimate payor is typically a government authority.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. The transaction price is determined based on fixed consideration in the Company&#8217;s customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company elected the portfolio approach practical expedient in applying ASC Topic 606 to its identified revenue streams. Contracts within each revenue stream have similar characteristics and the Company believes this approach would not differ materially from applying ASC Topic 606 to each individual contract.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Adopted in 2018</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2018-07 &#8212; In June 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2018-07&#8221;).These amendments expand the scope of Topic 718, Compensation&#8212;Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity&#8212;Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 in the second quarter of 2018 and there was no material impact on its consolidated financial statements from the adoption.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2018-02</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">&#8212; In February 2018, the FASB issued ASU 2018-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income (Topic 220)</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2018-02&#8221;). Prior to ASU 2018-02, U.S. GAAP required the remeasurement of deferred tax assets and liabilities as a result of a change in tax laws or rates to be presented in net income from continuing operations, even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income. As a result, such items, referred to as stranded tax effects, did not reflect the appropriate tax rate. Under ASU 2018-02, entities are permitted, but not required, to reclassify from accumulated other comprehensive income to retained earnings those stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new standard effective January 1, 2018. As a result of the adoption, the Company reclassified a gain of </font><font style="font-family:inherit;font-size:10pt;">$383,000</font><font style="font-family:inherit;font-size:10pt;"> from the foreign currency translation adjustment in accumulated other comprehensive loss to accumulated deficit in the consolidated balance sheet as of September 30, 2018.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-09 &#8212; In May&#160;2017, the FASB issued ASU 2017-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-09&#8221;). The amendments in ASU 2017-09 provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASU 2017-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> An entity should account for the effects of a modification unless all the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December&#160;15, 2017. The Company adopted this standard on January 1, 2018 and as the Company did not have any modification of awards, the adoption of the standard did not have a material impact on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-01 &#8212; In January&#160;2017, the FASB issued ASU 2017-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-01&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> This ASU clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in ASU 2017-01 are effective for public companies for annual periods beginning after December&#160;15, 2017, including interim periods within those periods. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of the standard did not have a material impact on its consolidated financial statements. For additional information see "&#8212;Note 3. Acquisitions."</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">&#8212; In November 2016, the FASB issued ASU No. 2016-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230)</font><font style="font-family:inherit;font-size:10pt;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2016-18&#8221;). The amendments of ASU 2016-18 require an entity to include amounts generally described as restricted cash and restricted cash equivalents with cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the statement of cash flows. The amendments of ASU 2016-18 are effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the guidance in ASU 2016-18 effective January 1, 2018. In connection with the adoption of the standard, the Company applied the guidance retrospectively which resulted in an increase in cash flows from operations of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> on the statement of cash flows for the nine months ended September 30, 2017.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-16 &#8212; In October&#160;2016, the FASB issued ASU 2016-16,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-16&#8221;). ASU 2016-16 requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in ASU 2016-16 are effective for public business entities for annual periods beginning after December&#160;15, 2017, including interim reporting periods within those annual reporting periods. The Company adopted ASU 2016-16 on January 1, 2018 and there was no material impact from the adoption.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-01 &#8212; In January 2016, the FASB issued ASU No. 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-01&#8221;). ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income. Companies have the option to measure equity investments without readily determinable fair values at either fair value or at cost adjusted for changes in observable prices minus impairment. Companies that elect the fair value option for financial liabilities must recognize changes in fair value related to instrument-specific credit risk in other comprehensive income. Companies must assess valuation allowances for deferred tax assets related to available-for-sale debt securities in combination with their other deferred tax assets. ASU 2016-01 is effective beginning in the first quarter of 2018 and the Company adopted it in the first quarter of 2018. There was no impact on the Company&#8217;s consolidated financial statements and related disclosures upon adoption, as the Company does not have equity investments or liabilities with credit risk. In addition, the guidance relating to deferred tax assets did not result in a change in accounting treatment for the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2014-09 &#8212; In May 2014, the FASB issued ASU 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;"> (Topic 606) which along with amendments issued in 2015 and 2016, replaced substantially all current U.S. GAAP guidance on this topic and eliminated industry-specific guidance. The new revenue recognition standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Effective January 1, 2018, the Company adopted the new revenue recognition standard using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under the new revenue recognition standard. As such, the adoption of the new revenue recognition standard did not have a material impact on the Company's consolidated financial statements. The information presented for the periods prior to January 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Developments - Guidance Not Yet Adopted</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Securities Exchange Commission (&#8220;SEC&#8221;) issued Final Rule 33-10532, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements that were redundant, duplicative, overlapping or superseded by other SEC disclosure requirements. The amendments generally eliminated or otherwise reduced certain disclosure requirements of various SEC rules and regulations. However, in some cases, the amendments require additional information to be disclosed, including changes in stockholders&#8217; equity in interim periods. The rule is effective 30 days after its publication in the Federal Register. The rule was posted on October 4, 2018. On September 25, 2018, the SEC released guidance advising it will not object to a registrant adopting the requirement to include changes in stockholders&#8217; equity in the Form 10-Q for the first quarter beginning after the effective date of the rule. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption and expects to adopt the guidance in it's Form 10-Q for the period ended March 31, 2019.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2018-13 &#8212; In August 2018, the FASB issued ASU 2018-03, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820):</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASU 2018-13&#8221;). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-12 &#8212; In August&#160;2017, the FASB issued ASU 2017-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-12&#8221;). The amendments in this ASU 2017-12 better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments in ASU 2017-12 also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. For public business entities, the amendment is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years. Early adoption, including adoption in an interim period, is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-11 &#8212; In July&#160;2017, the FASB issued ASU 2017-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part&#160;I) Accounting for Certain Financial Instruments with Down Round Features, (Part&#160;II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-11&#8221;). Part&#160;I of ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock.&#160;Part&#160;II of ASU 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification&#174;. For public business entities, the amendments in Part&#160;I of ASU 2017-11 are effective for fiscal years beginning after December&#160;15, 2018.&#160;Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-08 &#8212; In March&#160;2017, the FASB issued ASU 2017-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-08&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The amendments in ASU 2017-08 shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. ASU 2017-08 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2017-04 &#8212; In January&#160;2017, the FASB issued ASU 2017-04,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2017-04&#8221;). To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December&#160;15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January&#160;1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASU 2016-02 &#8212; In February&#160;2016, the FASB issued ASU 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842) </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 will be effective for the Company for all annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In August 2018, the FASB issued ASU 2018-11, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:inherit;font-size:10pt;">, (&#8220;ASU 2018-11&#8221;). ASU 2018-11 provide entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.&#160;The Company will adopt these standards effective January 1, 2019, and expects to elect certain of the practical expedients permitted, including the expedient that permits the Company to retain its existing lease assessment and classification. The Company also expects to elect the transition method in ASU 2018-11. The Company is currently working through an adoption plan which includes the evaluation of lease contracts compared to the new standard. While the Company is currently assessing the impact that this standard will have on its consolidated financial statements, the Company expects to recognize lease liabilities and right of use assets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock and Warrants</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 15, 2018, the Company announced the pricing of an underwritten offering of </font><font style="font-family:inherit;font-size:10pt;">19,354,839</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at&#160;</font><font style="font-family:inherit;font-size:10pt;">$15.50</font><font style="font-family:inherit;font-size:10pt;"> per share, resulting in gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;">. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> days after February&#160;16, 2018, to purchase up to an additional </font><font style="font-family:inherit;font-size:10pt;">2,903,225</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock, which was exercised with respect to </font><font style="font-family:inherit;font-size:10pt;">885,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$15.50</font><font style="font-family:inherit;font-size:10pt;"> per share. The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$294.6 million</font><font style="font-family:inherit;font-size:10pt;"> from these offerings, after deducting underwriting discounts and commissions and offering expenses payable by the Company.</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, </font><font style="font-family:inherit;font-size:10pt;">453,214</font><font style="font-family:inherit;font-size:10pt;"> warrants were exercised at </font><font style="font-family:inherit;font-size:10pt;">$7.98</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock resulting in gross cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 7, 2018, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of shares of common stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, that the Company is authorized to issue from </font><font style="font-family:inherit;font-size:10pt;">250,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares to </font><font style="font-family:inherit;font-size:10pt;">500,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div> EX-101.SCH 6 fold-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Assets and Liabilities Measured at Fair Value link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Basic and Diluted Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Basic and Diluted Net Loss per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Collaborations link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Collaborations (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Debt - Convertible Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Share based Compensation link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Share based Compensation - Expense Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Share based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Share based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Share based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fold-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 fold-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 fold-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Schedule of Debt Instruments Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Line of Credit Line of Credit [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Notes Convertible Debt [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Convertible Senior Notes 2016, Due 2023 Convertible Senior Notes2016 Due2023 [Member] Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes). Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Over-allotment Option Over-Allotment Option [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Private Placement Purchase Agreement Private Placement Purchase Agreement [Member] Represents information related to private placement purchase agreements. Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Common Stock Capped Call Confirmation Common Stock Capped Call Confirmation [Member] Common Stock Capped Call Confirmation [Member] Debt Instruments Debt Instrument [Line Items] New credit facility borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt instrument term Debt Instrument, Term Periodic payment, percentage Debt Instrument, Periodic Payment, Principal Percentage Debt Instrument, Periodic Payment, Principal Percentage Proceeds from issuance of debt Proceeds from Issuance of Debt Convertible Debt Convertible Debt [Abstract] Aggregate principle amount Debt Instrument, Face Amount Net proceeds after deducting fees and estimated expenses Proceeds from Debt, Net of Issuance Costs Proceeds for capped call confirmations Premiums Paid for Capped Call Confirmations The cash outflow for premiums paid for capped call confirmations. shares issued per increment of convertible debt Number Of Shares Issued Per Increment Of Convertible Debt Represents the number of shares per increment of convertible debt that will be issued upon conversion. For example, X number of shares may be issued for every $1,000 of convertible debt principal. Debt conversion ratio (in shares) Debt Instrument, Convertible, Conversion Ratio Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Threshold percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Threshold trading days Debt Instruments, Convertible, Threshold Trading Days Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Common stock issued from underwriting agreement (in shares) Stock Issued During Period, Shares, New Issues Number of days granted underwriters for purchase of shares Number Of Days Granted Underwriters For Purchase Of Shares Number Of Days Granted Underwriters For Purchase Of Shares Maximum number of additional shares granted to underwriters Maximum Number Of Additional Shares Granted To Underwriters Maximum Number Of Additional Shares Granted To Underwriters Derivative liability, noncurrent Derivative Liability, Noncurrent Derivative asset, noncurrent Derivative Asset, Noncurrent Change in fair value of derivatives Foreign Currency Transaction Gain (Loss), before Tax Common stock, shares authorized Common Stock, Shares Authorized Derivative liabilities Derivative Liability, Current Other assets, current Other Assets, Current Debt Instruments [Abstract] Debt Instruments [Abstract] Principal Long-term Debt, Gross Debt discount Debt Instrument, Unamortized Discount Less: deferred financing Deferred Offering Costs Net carrying value of the debt Long-term Debt Interest expense Interest Expense, Debt [Abstract] Contractual interest expense Interest Expense, Debt, Excluding Amortization Amortization of debt discount Amortization of Debt Discount (Premium) Amortization of deferred financing Amortization Deferred Financing Costs Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period. Total Interest Expense, Debt Accounting Policies [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Foreign Currency Adjustment Attributable Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2018-02 Accounting Standards Update 2018-02 [Member] Accounting Standards Update 2018-02 [Member] Accounting Standards Update 2016-18 Accounting Standards Update 2016-18 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Total stockholders’ equity Stockholders' Equity Attributable to Parent Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Business Combinations [Abstract] Acquisitions Business Combination Disclosure [Text Block] Fair Value Disclosures [Abstract] Assets and Liabilities Measured at Fair Value Fair Value Disclosures [Text Block] Statement of Comprehensive Income [Abstract] Net loss Net Income (Loss) Attributable to Parent Other comprehensive (loss) gain: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Foreign currency translation adjustment gain (loss), net of tax impact of $59, $0, $168, $0, respectively Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gain (loss) on available-for-sale securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Asset-backed securities Asset-backed Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Money market funds Money Market Funds [Member] T B200 Pompe Program T B200 Pompe Program [Member] Represents the information pertaining to ATB-200 Pompe program. Maximum Maximum [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Contingent Consideration Liability Clinical and Regulatory Milestones Contingent Consideration Liability Clinical And Regulatory Milestones [Member] Represents information pertaining to clinical and regulatory contingent consideration milestones. Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Probability Weighted Discounted Cash Flow Probability Weighted Discounted Cash Flow [Member] Represents information pertaining to valuation technique of probability weighted discounted cash flow. Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Discount Rate Measurement Input, Discount Rate [Member] Probability of Milestone Achievement Measurement Input, Probability Of Milestone Achievement [Member] Measurement Input, Probability Of Milestone Achievement [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Callidus Biopharma Inc Callidus Biopharma Inc [Member] Represents information pertaining to Callidus Biopharma, Inc. Financial assets and liabilities subject to fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Fair value of assets Assets, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Contingent consideration payable Business Combination, Contingent Consideration, Liability Deferred compensation plan liability Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Fair value of liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Convertible debt, fair value Convertible Debt, Fair Value Disclosures Discount rate Contingent Consideration, Measurement Input Contingent Consideration, Measurement Input Foreign currency translation adjustment gain (loss), tax (benefit) expense Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Options to purchase common stock Employee And Directors Stock Options [Member] An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected stock price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected life of options (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected annual dividend per share (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term. Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of debt discount and deferred financing Amortization of Debt Issuance Costs and Discounts Depreciation Depreciation Stock-based compensation Share-based Compensation Loss on impairment Asset Impairment Charges Gain on disposal of asset Gain (Loss) on Disposition of Assets Change in fair value of derivatives Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss) Non-cash changes in the fair value of contingent consideration payable Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Foreign currency remeasurement (gain)/ loss Foreign Currency Remeasurement Gain (Loss), Before Tax Foreign Currency Remeasurement Gain (Loss), Before Tax Non-cash deferred taxes Non Cash Deferred Taxes And Other Tax Benefits The portion of the non-cash component of deferred taxes and other tax benefits for the period. Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other non-current assets Increase (Decrease) in Other Operating Assets Account payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Non-current liabilities Increase (Decrease) In Noncurrent Operating Liabilities The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income. Deferred reimbursement Increase (Decrease) In Deferred Reimbursements The increase (decrease) during the reporting period in the amount of deferred reimbursements. Net cash used in operating activities Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Sale and redemption of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Purchases of marketable securities Payments to Acquire Marketable Securities Capital expenditures Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from senior secured term loan, net of issuance costs Proceeds from Issuance of Secured Debt Payment of capital leases Repayments of Debt and Capital Lease Obligations Payment of contingent consideration Payment Of Contingent Consideration The cash outflow associated with the payment of contingent consideration liabilities. Purchase of vested restricted stock units Payments For Repurchase Of Restricted Stock Units The cash outflow to reacquire restricted stock units during the period. Proceeds from exercise of stock options Proceeds from Stock Options Exercised Payment of deferred financing fees Payments of Financing Costs Proceeds from exercise of warrants Proceeds from Warrant Exercises Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase (decrease) in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents and restricted cash at end of period Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Capital expenditures, unpaid Capital Lease Obligations Incurred Capital expenditures funded by capital lease Capital Lease Obligations Incurred, Funded By Capital Lease Borrowings Capital Lease Obligations Incurred, Funded By Capital Lease Borrowings Earnings Per Share [Abstract] Basic and Diluted Net Loss per Common Share Earnings Per Share [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development expense Research and Development Expense [Member] Selling, general and administrative expense Selling, General and Administrative Expenses [Member] Total equity compensation expense Allocated Share-based Compensation Expense Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Equity [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Outstanding warrants, convertible to common stock Warrant [Member] Collaborative Agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Common stock issued from underwriting agreement Price per share of common stock issued (in dollars per share) Share Price Gross proceeds from issue of common stock before deducting underwriting discounts and commissions Stock Issued During Period, Value, New Issues Net proceeds from the issuance of common stock Warrants exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investments in marketable securities Marketable Securities, Current Accounts receivable Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, less accumulated depreciation of $15,483 and $12,515 at September 30, 2018 and December 31, 2017, respectively Property, Plant and Equipment, Net In-process research & development Intangible Assets, Net (Excluding Goodwill) Goodwill Goodwill Other non-current assets Other Assets, Noncurrent Total Assets Assets Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable, accrued expenses, and other current liabilities Accounts Payable and Accrued Liabilities, Current Deferred reimbursements Deferred Credits and Other Liabilities, Current Contingent consideration payable Business Combination, Contingent Consideration, Liability, Current Total current liabilities Liabilities, Current Deferred reimbursements Deferred Credits and Other Liabilities, Noncurrent Convertible notes Convertible Notes Payable, Noncurrent Senior secured term loan Secured Long-term Debt, Noncurrent Contingent consideration payable Business Combination, Contingent Consideration, Liability, Noncurrent Deferred income taxes Deferred Income Tax Liabilities, Net Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.01 par value, 500,000,000 and 250,000,000 shares authorized, 189,254,341 and 166,989,790 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive loss: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustment Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Unrealized gain on available-for-sale securities Accumulated Other Comprehensive Income (Loss), Debt Securities, Available-for-sale, Adjustment, after Tax Warrants Warrants and Rights Outstanding Accumulated deficit Total stockholders’ equity Total Liabilities and Stockholders’ Equity Liabilities and Equity Income Statement [Abstract] Revenue: Revenues [Abstract] Net product sales Revenue from Contract with Customer, Including Assessed Tax Cost of goods sold Cost of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense (Excluding Acquired in Process Cost) Selling, general and administrative Selling, General and Administrative Expense Changes in fair value of contingent consideration payable Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Loss on impairment of assets Depreciation Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Interest income Investment Income, Interest Interest expense Interest Expense Other (expense) income Other Nonoperating Income (Expense) Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss attributable to common stockholders Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Weighted-average common shares outstanding - basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Inventory Disclosure [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total inventories Cash, Cash Equivalents, and Short-term Investments [Abstract] Cash, Cash Equivalents, Marketable Securities and Restricted Cash Cash, Cash Equivalents, and Short-term Investments [Text Block] Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Realized gain (loss) on debt securities Debt Securities, Realized Gain (Loss) Fair value of available-for-sale debt securities in unrealized loss positions Debt Securities, Available-for-sale, Unrealized Loss Position Restricted cash Restricted Cash and Cash Equivalents Cash and cash equivalents and restricted cash shown in the statement of cash flows Schedule of Fair Value of Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Stock Options Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Non-Vested RSU Activity under the Plan Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Equity Compensation Expenses Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] [Domain] for Asset Acquisition [Axis] Celenex Celenex [Member] Celenex [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Nationwide Children's Hospital Nationwide Children's Hospital [Member] Nationwide Children's Hospital [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Upfront cash payment to acquire assets Asset Acquisition, Consideration Transferred Asset Acquisition, Consideration Transferred Development milestones Revenue Recognition, Milestone Method, Contingent On Development Revenue Recognition, Milestone Method, Contingent On Development Submission and approval milestones Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones Revenue Recognition, Milestone Method, Contingent On Submission And Approval Milestones Maximum expected payment over next four years Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years Revenue Recognition, Milestone Method, Maximum Expected Payment Over Next Four Years Research and development expense Research and Development Expense Schedule of cash and available-for-sale securities Cash, Cash Equivalents and Investments [Table Text Block] Schedule of restricted cash and cash equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Balance, beginning of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Payment of contingent consideration in cash Changes in fair value during the period, included in statement of operations Balance, end of the period Accumulated depreciation of property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Convertible notes Convertible Debt Securities [Member] Unvested restricted stock units Restricted Stock Units (RSUs) [Member] Vested restricted stock units, unissued Vested Restricted Stock Units Unissued [Member] Represent the information pertaining to vested restricted stock units, unissued. Antidilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Net loss attributable to common stockholders Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Antidilutive securities excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Corporate debt securities, current portion Short Term Corporate Debt Securities [Member] Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment. Money market Certificates of deposit Certificates of Deposit [Member] Cash, Money Market Funds, and Marketable Securities Debt Securities, Available-for-sale [Line Items] Cash and cash equivalents Available-for-sale debt securities Debt Securities, Available-for-sale Cash balances, Fair Value Cash and Cash Equivalents, Fair Value Disclosure Cost, available-for-sale securities Debt Securities, Available-for-sale, Amortized Cost Gross unrealized gain, available-for-sale securities Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross unrealized loss, available-for-sale securities Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Cost, Cash balances and available-for-sale securities Cash, Cash Equivalents And Available-for-sale Debt Securities Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. Gross unrealized gain, Cash balances and available-for-sale securities Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax Gross unrealized loss, Cash balances and available-for-sale securities Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax Fair value, Cash balances and available-for-sale securities Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities. Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Summary of assets and liabilities subject to fair value measurements Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of changes in contingent consideration payable Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Collaborative Arrangement [Abstract] Collaborative Arrangement [Abstract] Collaborative Arrangement Collaborative Arrangement [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Payments for collaborative arrangement Payments For Collaborative Arrangement Payments For Collaborative Arrangement Conditional aggregate payments per indication Collaborative Agreement, Conditional Aggregate Payments Per Indication Collaborative Agreement, Conditional Aggregate Payments Per Indication Collaboratives Collaborative Arrangement Disclosure [Text Block] Market Performance Based Restricted Stock Units Market Performance Based Restricted Stock Units [Member] Share instrument which is convertible to stock or an equivalent amount of cash, that is contingent upon achieving certain market based performance measures. Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Option Plan Amended Restated 2007 Equity Incentive Plan Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member] Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan. Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Executive Officer Executive Officer [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Cliff Vesting Cliff Vesting [Member] Share-based compensation award differentiated by a cliff vesting feature. Contingent Consideration Liability Clinical Milestone Contingent Consideration Liability Clinical Milestone [Member] Represents information pertaining to clinical based contingent consideration milestones. Total unrecognized compensation costs Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unrecognized compensation costs, period for recognition (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Market performance-based restricted stock units granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award vesting rights Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage MPRSUs, Exercisable at period end (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number MPRSUs granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value RSUs vested and non-vested units expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Share based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Debt Debt Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Consolidation Consolidation, Policy [Policy Text Block] Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash, Cash Equivalents, Restricted Cash and Marketable Securities Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Recent Accounting Developments New Accounting Pronouncements, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options outstanding, December 31, 2017 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited, Options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options, Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options outstanding, September 30, 2018 (in shares) Options, Vested and unvested expected to vest, September 30, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options, Exercisable at September 30, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Option outstanding, December 31, 2017 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options, Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options, Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Option outstanding, September 30, 2018 (in dollars per share) Options, Vested and unvested expected to vest, September 30, 2018 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options, Exercisable at September 30, 2018 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual life, options outstanding, September 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual life, options vested and unvested expected to vest, September 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted average remaining contractual life, options exercisable at September 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate intrinsic value, options outstanding, September 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, vested and unvested expected to vest, September 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate intrinsic value, exercisable at September 30, 2018 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Organization, Consolidation and Presentation of Financial Statements [Abstract] Number of approved medicines for Fabry disease Number Of Approved Medicines For Fabry Disease Number Of Approved Medicines For Fabry Disease Number of gene therapy programs Number Of Gene Therapy Programs Number Of Gene Therapy Programs Number of gene therapy programs for Batten disease Number Of Gene Therapy Programs For Batten Disease Number Of Gene Therapy Programs For Batten Disease Number of gene therapy programs for neurologic LSDs developed Number Of Gene Therapy Programs For Neurologic LSDs Developed Number Of Gene Therapy Programs For Neurologic LSDs Developed Retained earnings (accumulated deficit) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Non-vested units as of December 31, 2017 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Vested (in shares) Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Non-vested units as of September 30, 2018 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Non-vested units as of December 31, 2017 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Non-vested units as of September 30, 2018 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Non-vested units, weighted average remaining years Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Non-vested units, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of inventories for the period Schedule of Inventory, Current [Table Text Block] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Inventories Inventory Disclosure [Text Block] Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of liability components of the Convertible Notes Convertible Debt [Table Text Block] Components of total interest expense recognized related to the Convertible Notes Interest Income and Interest Expense Disclosure [Table Text Block] EX-101.PRE 10 fold-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2018
Oct. 29, 2018
Document And Entity Information [Abstract]    
Entity Registrant Name AMICUS THERAPEUTICS INC  
Entity Central Index Key 0001178879  
Document Type 10-Q  
Document Period End Date Sep. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   189,289,881
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q3  
Entity Emerging Growth Company false  
Entity Small Business false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 201,827 $ 49,060
Investments in marketable securities 362,556 309,502
Accounts receivable 14,189 9,464
Inventories 6,311 4,623
Prepaid expenses and other current assets 16,151 19,316
Total current assets 601,034 391,965
Property and equipment, less accumulated depreciation of $15,483 and $12,515 at September 30, 2018 and December 31, 2017, respectively 10,659 9,062
In-process research & development 23,000 23,000
Goodwill 197,797 197,797
Other non-current assets 6,099 5,200
Total Assets 838,589 627,024
Current liabilities:    
Accounts payable, accrued expenses, and other current liabilities 54,330 53,890
Deferred reimbursements 2,750 7,750
Contingent consideration payable 8,800 8,400
Total current liabilities 65,880 70,040
Deferred reimbursements 14,156 14,156
Convertible notes 172,186 164,167
Senior secured term loan 146,622 0
Contingent consideration payable 19,300 17,000
Deferred income taxes 6,465 6,465
Other non-current liabilities 3,029 2,346
Total liabilities 427,638 274,174
Commitments and contingencies
Stockholders’ equity:    
Common stock, $0.01 par value, 500,000,000 and 250,000,000 shares authorized, 189,254,341 and 166,989,790 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively 1,941 1,721
Additional paid-in capital 1,731,174 1,400,758
Accumulated other comprehensive loss:    
Foreign currency translation adjustment (875) (1,659)
Unrealized gain on available-for-sale securities (211) (436)
Warrants 13,063 16,076
Accumulated deficit (1,334,141) (1,063,610)
Total stockholders’ equity 410,951 352,850
Total Liabilities and Stockholders’ Equity $ 838,589 $ 627,024
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Accumulated depreciation of property and equipment $ 15,483 $ 12,515
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 250,000,000
Common stock, shares issued 189,254,341 166,989,790
Common stock, shares outstanding 189,254,341 166,989,790
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue:        
Net product sales $ 20,596 $ 10,874 $ 58,601 $ 22,201
Cost of goods sold 4,310 1,790 10,060 3,626
Gross profit 16,286 9,084 48,541 18,575
Operating expenses:        
Research and development 138,227 40,641 213,685 103,502
Selling, general and administrative 31,867 21,647 88,435 60,090
Changes in fair value of contingent consideration payable 1,300 (244,250) 2,700 (238,622)
Loss on impairment of assets 0 465,427 0 465,427
Depreciation 1,073 851 3,015 2,486
Total operating expenses 172,467 284,316 307,835 392,883
Loss from operations (156,181) (275,232) (259,294) (374,308)
Other income (expense):        
Interest income 2,721 1,190 7,371 2,702
Interest expense (4,715) (4,351) (13,763) (12,820)
Change in fair value of derivatives 0 0 (2,739) 163
Other (expense) income (1,039) 2,044 (3,593) 4,891
Loss before income tax (159,214) (276,349) (272,018) (379,372)
Income tax benefit 51 164,683 1,104 164,578
Net loss attributable to common stockholders $ (159,163) $ (111,666) $ (270,914) $ (214,794)
Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share) $ (0.84) $ (0.69) $ (1.47) $ (1.44)
Weighted-average common shares outstanding - basic and diluted (in shares) 189,162,841 160,796,841 184,606,790 148,963,864
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Net loss $ (159,163) $ (111,666) $ (270,914) $ (214,794)
Other comprehensive (loss) gain:        
Foreign currency translation adjustment gain (loss), net of tax impact of $59, $0, $168, $0, respectively 665 (1,176) 1,167 (3,312)
Unrealized gain (loss) on available-for-sale securities 244 (131) 225 (203)
Other comprehensive income (loss) 909 (1,307) 1,392 (3,515)
Comprehensive loss $ (158,254) $ (112,973) $ (269,522) $ (218,309)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]        
Foreign currency translation adjustment gain (loss), tax (benefit) expense $ 59 $ 0 $ 168 $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating activities    
Net loss $ (270,914) $ (214,794)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of debt discount and deferred financing 7,868 7,179
Depreciation 3,015 2,486
Stock-based compensation 20,873 17,067
Loss on impairment 0 465,427
Gain on disposal of asset 0 (8)
Change in fair value of derivatives 2,739 (265)
Non-cash changes in the fair value of contingent consideration payable 2,700 (238,622)
Foreign currency remeasurement (gain)/ loss 775 (4,932)
Non-cash deferred taxes 0 (164,585)
Changes in operating assets and liabilities:    
Accounts receivable (5,182) (4,288)
Inventories (2,049) (3,386)
Prepaid expenses and other current assets 2,633 (3,358)
Other non-current assets (1,101) 344
Account payable and accrued expenses 3,684 13,037
Non-current liabilities 681 637
Deferred reimbursement (5,000) (12,600)
Net cash used in operating activities (239,278) (140,661)
Investing activities    
Sale and redemption of marketable securities 388,135 230,981
Purchases of marketable securities (440,963) (450,358)
Capital expenditures (4,571) (3,398)
Net cash used in investing activities (57,399) (222,775)
Financing activities    
Proceeds from issuance of common stock, net of issuance costs 294,584 243,036
Proceeds from senior secured term loan, net of issuance costs 146,622 0
Payment of capital leases (218) (212)
Payment of contingent consideration 0 (10,000)
Purchase of vested restricted stock units (2,681) (1,067)
Proceeds from exercise of stock options 8,492 8,841
Payment of deferred financing fees 0 (28)
Proceeds from exercise of warrants 3,617 0
Net cash provided by financing activities 450,416 240,570
Effect of exchange rate changes on cash, cash equivalents and restricted cash (1,146) 1,030
Net increase (decrease) in cash and cash equivalents and restricted cash 152,593 (121,836)
Cash and cash equivalents and restricted cash at beginning of period 51,237 187,413
Cash and cash equivalents and restricted cash at end of period 203,830 65,577
Supplemental disclosures of cash flow information    
Cash paid during the period for interest 3,787 3,662
Capital expenditures, unpaid 538 0
Capital expenditures funded by capital lease $ 80 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business
 9 Months Ended
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business
Description of Business
 
Amicus Therapeutics, Inc. (the “Company”) is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases. With one medicine for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic and the recent addition of fourteen new gene therapy programs into the pipeline, including two clinical stage gene therapies for Batten disease, the Company has a leading portfolio of medicines for lysosomal storage disorders (“LSDs”).

The cornerstone of the Company’s portfolio is migalastat HCl (also referred to as “migalastat”), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold® in the United States (“U.S.”), European Union (“EU”) and Japan, with additional approvals granted and applications pending in several other geographies. During the third quarter of 2018, the Company initiated the commercial launch of Galafold® in the U.S. for the treatment of adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant.

The lead biologics program of the Company’s pipeline is Amicus Therapeutics GAA (“AT-GAA”, also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. The Company’s Chaperone-Advanced Replacement Therapy (“CHART®”) platform technology is leveraged to develop novel products for Pompe disease and potentially future other LSDs.

During the second half of 2018, the Company has expanded its portfolio to include fourteen new gene therapy programs. In September 2018, the Company acquired worldwide development and commercial rights for ten gene therapy programs for neurologic LSDs developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and The Ohio State University through the acquisition of Celenex, Inc., (“Celenex”) a private, clinical stage gene therapy company, for cash consideration of $100.0 million and additional consideration payable upon the achievement of certain development and approval milestones. The acquisition establishes Amicus as a leading company in neurologic LSDs. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. For additional information see "—Note 3. Acquisitions."

In October 2018, the Company further expanded its gene therapy portfolio through a collaboration agreement with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (“Penn”) to pursue the research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDKL5 deficiency disorder (“CDD”) and one additional undisclosed rare metabolic disorder. This relationship will combine the Company's protein engineering and glycobiology expertise with Penn’s adeno associated virus (“AAV”) gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability.
The Company believes that its platform technologies and its product pipeline uniquely positions it and drives its commitment to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
 
During the third quarter of 2018, the Company entered into a loan agreement with BioPharma Credit PLC, as the lender, for a $150.0 million non-dilutive senior secured term loan (the “Senior Secured Term Loan”) with an interest rate equal to 3-month LIBOR plus 7.50% per annum, subject to a floor and ceiling on the rate, which matures in five years. The Company received net proceeds of $146.6 million in September 2018, after deducting fees and estimated expenses payable by the Company. There are no warrants or any equity conversion features associated with the Senior Secured Term Loan. The proceeds from this financing will be used to support the cost of the Celenex acquisition, its related development costs and other general corporate purposes. For additional information, see " —Note 6. Debt."

During the first quarter of 2018, the Company issued 20,239,839 shares of its common stock through an underwritten offering resulting in net proceeds of $294.6 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company expects to use the net proceeds of the offering for investment in the U.S. and international commercial infrastructure for migalastat HCl, investment in manufacturing capabilities for the ERT ATB200, the continued clinical development of its product candidates, research and development expenditures, clinical and pre-clinical trial expenditures, commercialization expenditures and for other general corporate purposes. For additional information, see “—Note 7. Stockholders’ Equity.”

The Company had an accumulated deficit of approximately $1.3 billion as of September 30, 2018 and anticipates incurring losses through the fiscal year ending December 31, 2018 and beyond. The Company has been able to fund its operating losses to date through stock offerings, debt issuances, payments from partners during the terms of the collaboration agreements, and other financing arrangements.
    
The current cash position, including expected Galafold® revenues, is sufficient to fund ongoing Fabry, Pompe and gene therapy program operations into at least 2021. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company’s future capital requirements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
 
Basis of Presentation
 
The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information.
 
The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
 
Consolidation
 
The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
 
Foreign Currency Transactions
 
The functional currency for most of the Company’s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders’ equity.
 
Use of Estimates
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
 
Reclassification

Certain prior year amounts have been reclassified for comparative purposes. The reclassifications did not affect results of operations, net assets or cash flows.

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive income (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.

Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company’s consolidated balance sheet.

Concentration of Credit Risk
 
The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.
 
The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold®. The Company’s accounts receivable at September 30, 2018 have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis. To date, the Company has not incurred any credit losses.
  
Revenue Recognition
 
The Company’s net product sales consist of sales of Galafold® for the treatment of Fabry disease primarily in the EU. The Company has recorded revenue on sales where Galafold® is available either on a commercial basis or through a reimbursed early access program (“EAP”). Orders for Galafold® are generally received from pharmacies and the ultimate payor is typically a government authority.
 
The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold®. The transaction price is determined based on fixed consideration in the Company’s customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

The Company elected the portfolio approach practical expedient in applying ASC Topic 606 to its identified revenue streams. Contracts within each revenue stream have similar characteristics and the Company believes this approach would not differ materially from applying ASC Topic 606 to each individual contract.

 
Recent Accounting Developments - Guidance Adopted in 2018
 
ASU 2018-07 — In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”).These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 in the second quarter of 2018 and there was no material impact on its consolidated financial statements from the adoption.

ASU 2018-02 — In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”). Prior to ASU 2018-02, U.S. GAAP required the remeasurement of deferred tax assets and liabilities as a result of a change in tax laws or rates to be presented in net income from continuing operations, even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income. As a result, such items, referred to as stranded tax effects, did not reflect the appropriate tax rate. Under ASU 2018-02, entities are permitted, but not required, to reclassify from accumulated other comprehensive income to retained earnings those stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new standard effective January 1, 2018. As a result of the adoption, the Company reclassified a gain of $383,000 from the foreign currency translation adjustment in accumulated other comprehensive loss to accumulated deficit in the consolidated balance sheet as of September 30, 2018.
 
ASU 2017-09 — In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). The amendments in ASU 2017-09 provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASU 2017-09. An entity should account for the effects of a modification unless all the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The Company adopted this standard on January 1, 2018 and as the Company did not have any modification of awards, the adoption of the standard did not have a material impact on its consolidated financial statements.
 
ASU 2017-01 — In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). This ASU clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in ASU 2017-01 are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of the standard did not have a material impact on its consolidated financial statements. For additional information see "—Note 3. Acquisitions."
 
ASU 2016-18 — In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). The amendments of ASU 2016-18 require an entity to include amounts generally described as restricted cash and restricted cash equivalents with cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the statement of cash flows. The amendments of ASU 2016-18 are effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the guidance in ASU 2016-18 effective January 1, 2018. In connection with the adoption of the standard, the Company applied the guidance retrospectively which resulted in an increase in cash flows from operations of $1.1 million on the statement of cash flows for the nine months ended September 30, 2017.

ASU 2016-16 — In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). ASU 2016-16 requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in ASU 2016-16 are effective for public business entities for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The Company adopted ASU 2016-16 on January 1, 2018 and there was no material impact from the adoption.

ASU 2016-01 — In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income. Companies have the option to measure equity investments without readily determinable fair values at either fair value or at cost adjusted for changes in observable prices minus impairment. Companies that elect the fair value option for financial liabilities must recognize changes in fair value related to instrument-specific credit risk in other comprehensive income. Companies must assess valuation allowances for deferred tax assets related to available-for-sale debt securities in combination with their other deferred tax assets. ASU 2016-01 is effective beginning in the first quarter of 2018 and the Company adopted it in the first quarter of 2018. There was no impact on the Company’s consolidated financial statements and related disclosures upon adoption, as the Company does not have equity investments or liabilities with credit risk. In addition, the guidance relating to deferred tax assets did not result in a change in accounting treatment for the Company.

ASU 2014-09 — In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which along with amendments issued in 2015 and 2016, replaced substantially all current U.S. GAAP guidance on this topic and eliminated industry-specific guidance. The new revenue recognition standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Effective January 1, 2018, the Company adopted the new revenue recognition standard using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under the new revenue recognition standard. As such, the adoption of the new revenue recognition standard did not have a material impact on the Company's consolidated financial statements. The information presented for the periods prior to January 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods.

Recent Accounting Developments - Guidance Not Yet Adopted

In August 2018, the Securities Exchange Commission (“SEC”) issued Final Rule 33-10532, Disclosure Update and Simplification, which amends certain disclosure requirements that were redundant, duplicative, overlapping or superseded by other SEC disclosure requirements. The amendments generally eliminated or otherwise reduced certain disclosure requirements of various SEC rules and regulations. However, in some cases, the amendments require additional information to be disclosed, including changes in stockholders’ equity in interim periods. The rule is effective 30 days after its publication in the Federal Register. The rule was posted on October 4, 2018. On September 25, 2018, the SEC released guidance advising it will not object to a registrant adopting the requirement to include changes in stockholders’ equity in the Form 10-Q for the first quarter beginning after the effective date of the rule. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption and expects to adopt the guidance in it's Form 10-Q for the period ended March 31, 2019.
ASU 2018-13 — In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption.

ASU 2017-12 — In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The amendments in this ASU 2017-12 better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments in ASU 2017-12 also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. For public business entities, the amendment is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption, including adoption in an interim period, is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-11 — In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Part I of ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. Part II of ASU 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. For public business entities, the amendments in Part I of ASU 2017-11 are effective for fiscal years beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-08 — In March 2017, the FASB issued ASU 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities (“ASU 2017-08”). The amendments in ASU 2017-08 shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. ASU 2017-08 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-04 — In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
ASU 2016-02 — In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, (“ASU 2018-11”). ASU 2018-11 provide entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will adopt these standards effective January 1, 2019, and expects to elect certain of the practical expedients permitted, including the expedient that permits the Company to retain its existing lease assessment and classification. The Company also expects to elect the transition method in ASU 2018-11. The Company is currently working through an adoption plan which includes the evaluation of lease contracts compared to the new standard. While the Company is currently assessing the impact that this standard will have on its consolidated financial statements, the Company expects to recognize lease liabilities and right of use assets.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions
 9 Months Ended
Sep. 30, 2018
Business Combinations [Abstract]  
Acquisitions
Acquisitions

In September 2018, the Company expanded its pipeline by acquiring the rights and related intellectual property of ten gene therapy programs through its acquisition of Celenex. Celenex is a private, clinical stage gene therapy company whose lead programs are ten gene therapy programs including CLN6 and CLN3, which are in clinical stage, and several programs in pre-clinical stage. Pursuant to the terms of the agreement, the Company acquired Celenex for cash consideration of $100 million. The Company has also agreed to pay up to an additional $15 million in connection with the achievement of certain development milestones, $262 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments. Celenex has an exclusive license agreement with Nationwide Children’s Hospital (“NCH”). Under this license agreement, NCH is eligible to receive development and sales based milestones of up to $7.8 million for each product.
 
The Company evaluated the Celenex transaction based on the guidance in Business Combinations (Topic 805) and concluded that the transaction did not meet the definition of a business and was an asset acquisition. Given the fact that the license has no alternative future use, the $100.0 million upfront payment was expensed to research and development expense in the Consolidated Statements of Operations for the three and nine months ended September 30, 2018 in accordance with ASC Topic 730, Research and Development.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, Marketable Securities and Restricted Cash
 9 Months Ended
Sep. 30, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]  
Cash, Cash Equivalents, Marketable Securities and Restricted Cash
Cash, Cash Equivalents, Marketable Securities and Restricted Cash
 
As of September 30, 2018, the Company held $201.8 million in cash and cash equivalents and $362.6 million of available-for-sale debt securities which are reported at fair value on the Company’s consolidated balance sheets. Unrealized holding gains and losses are reported within accumulated other comprehensive loss in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company’s cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge.
 
The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current, while investments that have maturities greater than one year are classified as long-term.
  
Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:
 
 
As of September 30, 2018
(in thousands)
Cost
 
Gross
unrealized
Gain
 
Gross
unrealized
Loss
 
Fair
Value
Cash and cash equivalents
$
201,827

 
$
—

 
$
—

 
$
201,827

Corporate debt securities, current portion
227,517

 
5

 
(123
)
 
227,399

Commercial paper
82,704

 
—

 
(49
)
 
82,655

Asset-backed securities
52,145

 
—

 
(44
)
 
52,101

Money market
350

 
—

 
—

 
350

Certificates of deposit
51

 
—

 
—

 
51

 
$
564,594

 
$
5

 
$
(216
)
 
$
564,383

Included in cash and cash equivalents
$
201,827

 
$
—

 
$
—

 
$
201,827

Included in marketable securities, current and non-current
362,767

 
5

 
(216
)
 
362,556

Total cash, cash equivalents and marketable securities
$
564,594

 
$
5

 
$
(216
)
 
$
564,383

 
 
As of December 31, 2017
(in thousands)
Cost
 
Gross
unrealized
Gain
 
Gross
unrealized
Loss
 
Fair
Value
Cash and cash equivalents
$
49,060

 
$
—

 
$
—

 
$
49,060

Corporate debt securities, current portion
199,314

 
1

 
(303
)
 
199,012

Commercial paper
79,878

 
—

 
(75
)
 
79,803

Asset-backed securities
30,346

 
—

 
(59
)
 
30,287

Money market
350

 
—

 
—

 
350

Certificates of deposit
50

 
—

 
—

 
50

 
$
358,998

 
$
1

 
$
(437
)
 
$
358,562

Included in cash and cash equivalents
$
49,060

 
$
—

 
$
—

 
$
49,060

Included in marketable securities
309,938

 
1

 
(437
)
 
309,502

Total cash, cash equivalents and marketable securities
$
358,998

 
$
1

 
$
(437
)
 
$
358,562


 
For the nine months ended September 30, 2018 there were nominal realized gains. For the fiscal year ended December 31, 2017, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.
 
Unrealized loss positions in the available-for-sale debt securities as of September 30, 2018 and December 31, 2017 reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain (loss). The fair value of these available-for-sale debt securities in unrealized loss positions was $315.3 million and $295.1 million as of September 30, 2018 and December 31, 2017, respectively.
 
The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.

(in thousands)
September 30, 2018
 
December 31, 2017
 
September 30, 2017
 
December 31, 2016
Cash and cash equivalents
$
201,827

 
$
49,060

 
$
64,133

 
$
187,026

Restricted cash
2,003

 
2,177

 
1,444

 
387

Cash and cash equivalents and restricted cash shown in the statement of cash flows
$
203,830

 
$
51,237

 
$
65,577

 
$
187,413
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
Inventories
Inventories
 
Inventories consist of raw materials, work-in-process and finished goods related to the manufacture of Galafold®. The following table summarizes the components of inventories:
 
(in thousands)
September 30, 2018
 
December 31, 2017
Raw materials
$
2,954

 
$
2,394

Work-in-process
$
1,458

 
$
1,449

Finished goods
1,899

 
780

Total inventories
$
6,311

 
$
4,623
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Debt
Debt
 
Senior Secured Term Loan due 2023
 
In September 2018, the Company entered into a loan agreement with BioPharma Credit PLC as the lender. The loan agreement provides for a $150 million senior secured term loan (“Senior Secured Term Loan”) with an interest rate equal to the 3-month LIBOR plus 7.50% per annum and matures five years from the maturity date. The Senior Secured Term Loan will be repaid in four quarterly payments equal to 12.50% thereof starting on the forty-eight month anniversary of the date of the first credit extension with the balance due on the Maturity Date. Interest is payable quarterly in arrears. The Senior Secured Term Loan contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to the Company and certain of its subsidiaries, but does not include any financial covenants relating to the achievement or maintenance of revenue or cash flow. If an event of default occurs and is continuing, the lender may declare all amounts outstanding under the Senior Secured Term Loan to be immediately due and payable. The Company received net proceeds of $146.6 million in September 2018, after deducting fees and estimated expenses payable by the Company.

Convertible Notes due 2023
 
In December 2016, the Company issued at par value $250 million aggregate principal amount of unsecured Convertible Senior Notes due 2023 (the “Convertible Notes”), which included the exercise in full of the $25 million over-allotment option granted to the initial purchasers of the Convertible Notes in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act (the “Note Offering”). Interest is payable semiannually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2023, unless earlier repurchased, redeemed, or converted in accordance with their terms. The Convertible Notes are convertible at the option of the holders, under certain circumstances and during certain periods, into cash, shares of the Company’s common stock or a combination thereof. The net proceeds from the Note Offering were $243.0 million, after deducting fees and estimated expenses payable by the Company. In addition, the Company used approximately $13.5 million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the capped call transactions (“Capped Call Confirmations”) that the Company entered into in connection with the issuance of the Convertible Notes. In accounting for the issuance of the Convertible Notes, the Company separated the Convertible Notes into liability and equity components based on their relative values. The Convertible Notes are initially convertible into approximately 40,849,675 shares of the Company’s common stock under certain circumstances prior to maturity at a conversion rate of 163.3987 shares per $1,000 principal amount of Convertible Notes, which represents a conversion price of approximately $6.12 per share of the Company's common stock, subject to adjustment under certain conditions. The last reported sale price of the Company’s common stock was equal to or more than 130% of the conversion price of the Convertible Notes for at least 20 trading days of the 30 consecutive trading days ending on the last day of the second quarter. As a result, the Convertible Notes are currently convertible into the Company’s common stock.

As further described in “—Note 7. Stockholders’ Equity,” on February 15, 2018, the Company entered into an underwriting agreement relating to an underwritten public offering of 19,354,839 shares of the Company’s common stock. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for 30 days after February 16, 2018, to purchase up to an additional 2,903,225 shares of the Company’s common stock, which was exercised with respect to 885,000 shares of the Company’s common stock.

Subsequent to the underwritten public offering on February 15, 2018, the Company did not have sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the Company accounted for the portion of the bifurcated conversion feature and of the Capped Call Confirmations that would not be able to be net share settled as a current derivative liability and as a derivative asset, respectively. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at February 15, 2018 was determined to be $507.4 million and $13.6 million, respectively, of which the portion that was determined to not be able to be net share settled was recorded with a corresponding impact to additional-paid-in-capital. Subsequent changes to fair value of the derivatives were recorded in the second quarter of 2018 through earnings on the Company’s consolidated statements of operations resulting in a change in fair value of derivatives for the nine months ended September 30, 2018 of $2.7 million. 

Following the approval by the stockholders of the Company on June 7, 2018, to increase the authorized shares of common stock to 500,000,000, the Company has sufficient unissued authorized shares to cover a conversion of the Convertible Notes. As a result, the derivative liability and derivative asset were reclassified into additional-paid-in-capital. The fair value of the derivative liability for the conversion feature and derivative asset for the Capped Call Confirmations at June 7, 2018 was determined to be $88.3 million and $2.4 million, respectively.

The Convertible Notes and Senior Secured Term Loan consist of the following (in thousands):
 
Liability component
 
September 30, 2018
 
December 31, 2017
Principal
 
$
400,000

 
$
250,000

Less: debt discount (1)
 
(76,946
)
 
(81,566
)
Less: deferred financing (1)
 
(4,246
)
 
(4,267
)
Net carrying value of the debt
 
$
318,808

 
$
164,167

 
______________________________________
(1) Included in the consolidated balance sheets within convertible notes and senior secured term loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.
 
The following table sets forth total interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the three and nine months ended September 30, 2018, respectively:
 
Components (In thousands)
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Contractual interest expense
 
$
1,969

 
$
5,744

Amortization of debt discount
 
2,609

 
7,620

Amortization of deferred financing
 
137

 
399

Total
 
$
4,715

 
$
13,763
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
 9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stockholders' Equity
Stockholders’ Equity

Common Stock and Warrants
 
On February 15, 2018, the Company announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share, resulting in gross proceeds of $300.0 million. Under the terms of the underwriting agreement, the Company granted the underwriters an option, exercisable for 30 days after February 16, 2018, to purchase up to an additional 2,903,225 shares of the Company’s common stock, which was exercised with respect to 885,000 shares of the Company’s common stock at a purchase price of $15.50 per share. The Company received net proceeds of $294.6 million from these offerings, after deducting underwriting discounts and commissions and offering expenses payable by the Company.
  
In April 2018, 453,214 warrants were exercised at $7.98 per share of common stock resulting in gross cash proceeds of $3.6 million.

On June 7, 2018, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that the Company is authorized to issue from 250,000,000 shares to 500,000,000 shares.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share based Compensation
Share based Compensation
 
The Company’s Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the “Plan”) and the 2007 Director Option Plan (the “2007 Director Plan”). The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company’s Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company’s business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option.
 
Stock Option Grants
 
The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Expected stock price volatility
75.5
%
 
82.5
%
 
80.7
%
 
83.1
%
Risk free interest rate
2.7
%
 
1.8
%
 
2.4
%
 
2.0
%
Expected life of options (years)
5.62

 
5.89

 
5.62

 
6.21

Expected annual dividend per share
$
—

 
$
—

 
$
—

 
$
—


 
Beginning in the third quarter of 2017, the average expected life was determined using our actual historical data versus a “simplified” method used in prior quarters. The “simplified” method of estimating the expected exercise term uses the mid-point between the vesting date and the end of the contractual term. In earlier quarters, we did not have sufficient reliable exercise data to justify a change from the use of the “simplified” method of estimating the expected exercise term of employee stock option grants. The impact from this change was not material.
 
A summary of the Company’s stock options for the nine months ended September 30, 2018 were as follows:
 
 
Number of
Shares
 
Weighted
Average
Exercise Price
 
Weighted
Average
Remaining
Contractual Life
 
Aggregate
Intrinsic
Value
 
(in thousands)
 
 
 
 
 
(in millions)
Options outstanding, December 31, 2017
15,181

 
$
7.48

 
 
 
 

Granted
2,077

 
$
15.36

 
 
 
 

Exercised
(1,282
)
 
$
6.62

 
 
 
 

Forfeited
(200
)
 
$
9.75

 
 
 
 

Expired
(7
)
 
10.45

 
 
 
 
Options outstanding, September 30, 2018
15,769

 
$
8.56

 
7.0 years
 
$
65.8

Vested and unvested expected to vest, September 30, 2018
15,003

 
$
8.43

 
6.9 years
 
$
63.9

Exercisable at September 30, 2018
9,406

 
$
7.26

 
6.0 years
 
$
47.4


 
As of September 30, 2018, the total unrecognized compensation cost related to non-vested stock options granted was $36.0 million and is expected to be recognized over a weighted average period of three years.
 
Restricted Stock Units (“RSUs”) and Performance-Based Restricted Stock Units
 
RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee’s continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2018 is as follows:
 
 
Number of Shares

 
Weighted
Average Grant Date
Fair Value
 
Weighted Average
Remaining Years
 
Aggregate Intrinsic
Value 
 
(in thousands)
 
 
 
 
 
(in millions)
Non-vested units as of December 31, 2017
2,575

 
$
5.85

 
 
 
 

Granted
1,635

 
$
16.57

 
 
 
 

Vested
(517
)
 
$
5.91

 
 
 
 

Forfeited
(58
)
 
$
10.23

 
 
 
 

Non-vested units as of September 30, 2018
3,635

 
$
10.49

 
2.7 years
 
$
44.0


 
On December 30, 2016, the Compensation Committee approved a form of Performance-Based Restricted Stock Unit Award Agreement (the “Performance-Based RSU Agreement”), to be used for performance-based RSUs granted to participants under the Amended and Restated 2007 Equity Incentive Plan, including named executive officers. Certain awards under the Performance-Based RSU Agreement were granted in January 2017 and 2018. The 2018 grants include 187,222 market performance-based restricted stock units (“MPRSUs”) granted to executives.  Vesting of these awards is contingent upon the Company meeting certain total shareholder return (“TSR”) levels as compared to a select peer group over the next three years. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (374,444 shares) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized on a straight-line basis over the vesting term.  The estimated fair value per share of the MPRSUs was $25.44 and was calculated using a Monte Carlo simulation model.  The awards also include 187,211 performance based awards that will vest over the next three years based on the Company achieving certain clinical milestones. During the nine months ended September 30, 2018, none of the clinical milestones for the performance based RSUs awarded in 2017 or 2018 were reached.
 
For the nine months ended September 30, 2018, 516,940 RSUs have vested and all non-vested units are expected to vest over their normal term. As of September 30, 2018, there was $25.6 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of three years.
 
Compensation Expense Related to Equity Awards
 
The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
Equity compensation expense recognized in:
 
 

 
 

 
 

 
 

Research and development expense
 
$
2,905

 
$
2,390

 
$
8,603

 
$
7,456

Selling, general and administrative expense
 
4,149

 
3,110

 
12,270

 
9,611

Total equity compensation expense
 
$
7,054

 
$
5,500

 
$
20,873

 
$
17,067
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Assets and Liabilities Measured at Fair Value
 9 Months Ended
Sep. 30, 2018
Fair Value Disclosures [Abstract]  
Assets and Liabilities Measured at Fair Value
Assets and Liabilities Measured at Fair Value
 
The Company’s financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:
 
Level 1 — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
 
Level 2 — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.
 
Level 3 — Inputs that are unobservable for the asset or liability.

A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2018 are identified in the following table:
 
(in thousands)
 
Level 2
 
Total
Assets:
 
 

 
 

Commercial paper
 
$
82,655

 
$
82,655

Asset-backed securities
 
52,101

 
52,101

Corporate debt securities
 
227,399

 
227,399

Money market funds
 
3,335

 
3,335

 
 
$
365,490

 
$
365,490

 
 
 
Level 2
 
Level 3
 
Total
Liabilities:
 
 

 
 

 
 

Contingent consideration payable
 
$
—

 
$
28,100

 
$
28,100

Deferred compensation plan liability
 
2,996

 
—

 
2,996

 
 
$
2,996

 
$
28,100

 
$
31,096

 
A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2017 are identified in the following table:
 
(in thousands)
Level 2
 
Total
Assets:
 

 
 

Commercial paper
$
79,803

 
$
79,803

Asset-backed securities
30,287

 
30,287

Corporate debt securities
199,012

 
199,012

Money market funds
2,598

 
2,598

 
$
311,700

 
$
311,700

 
 
Level 2
 
Level 3
 
Total
Liabilities:
 

 
 

 
 

Contingent consideration payable
$
—

 
$
25,400

 
$
25,400

Deferred compensation plan liability
2,258

 
—

 
2,258

 
$
2,258

 
$
25,400

 
$
27,658


 
The Company’s Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the debt at September 30, 2018 was approximately $531.2 million.

The Company’s Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.

The Company did not have any Level 3 assets as of September 30, 2018 or December 31, 2017.

 Cash, Money Market Funds and Marketable Securities
 
The Company classifies its cash within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale debt securities and classifies these assets and the money market funds within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the nine months ended September 30, 2018. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine months ended September 30, 2018.

Contingent Consideration Payable
 
The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. (“Callidus”) in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Using this approach, expected future cash flows are calculated over the expected life of the agreement, are discounted, and then exercise scenario probabilities are applied. The valuation is performed quarterly. Gains and losses are included in the statement of operations.
 
The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. The Company may be required to record losses in future periods.
  
The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program:
 
Contingent Consideration
Liability
 
Fair Value as of
September 30, 2018
 
Valuation Technique
 
Unobservable Input
 
Range
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discount rate
 
10.0%
 
 
 

 
 
 
 
 
 
Clinical and regulatory milestones
 
$
27.6
 million
 
Probability weighted discounted cash flow
 
Probability of achievement of milestones
 
71.0%-100.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Projected year of payments
 
2018-2022

 
Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.

The following table shows the change in the balance of contingent consideration payable for the three and nine months ended September 30, 2018 and 2017, respectively:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
Balance, beginning of the period
 
$
26,800

 
$
265,350

 
25,400

 
269,722

Payment of contingent consideration in cash
 
—

 
—

 
—

 
(10,000
)
Changes in fair value during the period, included in statement of operations
 
1,300

 
(244,250
)
 
2,700

 
(238,622
)
Balance, end of the period
 
$
28,100

 
$
21,100

 
28,100

 
$
21,100


 
Deferred Compensation Plan - Investment and Liability
 
The Deferred Compensation Plan (the “Deferral Plan”) provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant’s base salary, bonus and director’s fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment’s fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basic and Diluted Net Loss per Common Share
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Basic and Diluted Net Loss per Common Share
Basic and Diluted Net Loss per Common Share
 
The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands, except per share amounts) 
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 

 
 

 
 

 
 

Net loss attributable to common stockholders
 
$
(159,163
)
 
$
(111,666
)
 
$
(270,914
)
 
$
(214,794
)
Denominator:
 
 
 
 
 
 
 
 
Weighted average common shares outstanding — basic and diluted
 
189,162,841

 
160,796,841

 
184,606,790

 
148,963,864


 
Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs and warrants for common stock equivalents. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.

The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:
 
 
 
As of September 30,
(in thousands) 
 
2018
 
2017
Options to purchase common stock
 
15,769

 
16,212

Convertible notes
 
40,850

 
40,850

Outstanding warrants, convertible to common stock
 
2,657

 
3,110

Unvested restricted stock units
 
3,635

 
2,690

Vested restricted stock units, unissued
 
103

 
50

Total number of potentially issuable shares
 
63,014

 
62,912
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborations
 9 Months Ended
Sep. 30, 2018
Collaborative Arrangement [Abstract]  
Collaboratives
Collaborations

In October 2018, the Company further expanded its gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for four additional indications, including Pompe disease, Fabry disease, CDD and one additional undisclosed rare metabolic disorder. This relationship will combine the Company's protein engineering and glycobiology expertise with Penn’s AAV gene transfer technologies to develop AAV gene therapies designed for optimal cellular uptake, targeting, dosing, safety and manufacturability. In connection with the collaboration agreement, the Company made an upfront payment of $7 million in cash to Penn in October 2018 and agreed to certain milestone payments following the achievement of certain developmental and commercial milestone events by a licensed product in each indication up to an aggregate of $86.5 million per indication.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
 
The Company has prepared the accompanying unaudited consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information.
 
The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s financial statements and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. For a complete description of the Company’s accounting policies, please refer to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
Consolidation
Consolidation
 
The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
Foreign Currency Transactions
Foreign Currency Transactions
 
The functional currency for most of the Company’s foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company’s foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders’ equity.
Use of Estimates
Use of Estimates
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
Cash, Cash Equivalents, Restricted Cash and Marketable Securities

The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheet. Unrealized holding gains and losses are reported within comprehensive income (loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs.

Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company’s consolidated balance sheet.
Concentration of Credit Risk
Concentration of Credit Risk
 
The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.
 
The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold®. The Company’s accounts receivable at September 30, 2018 have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis.
Revenue Recognition
Revenue Recognition
 
The Company’s net product sales consist of sales of Galafold® for the treatment of Fabry disease primarily in the EU. The Company has recorded revenue on sales where Galafold® is available either on a commercial basis or through a reimbursed early access program (“EAP”). Orders for Galafold® are generally received from pharmacies and the ultimate payor is typically a government authority.
 
The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold®. The transaction price is determined based on fixed consideration in the Company’s customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Galafold® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.

The Company elected the portfolio approach practical expedient in applying ASC Topic 606 to its identified revenue streams. Contracts within each revenue stream have similar characteristics and the Company believes this approach would not differ materially from applying ASC Topic 606 to each individual contract.
Recent Accounting Developments
Recent Accounting Developments - Guidance Adopted in 2018
 
ASU 2018-07 — In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”).These amendments expand the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. ASU 2018-07 supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees, and is effective for all public entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted ASU 2018-07 in the second quarter of 2018 and there was no material impact on its consolidated financial statements from the adoption.

ASU 2018-02 — In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (“ASU 2018-02”). Prior to ASU 2018-02, U.S. GAAP required the remeasurement of deferred tax assets and liabilities as a result of a change in tax laws or rates to be presented in net income from continuing operations, even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income. As a result, such items, referred to as stranded tax effects, did not reflect the appropriate tax rate. Under ASU 2018-02, entities are permitted, but not required, to reclassify from accumulated other comprehensive income to retained earnings those stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017. ASU 2018-02 is effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted the new standard effective January 1, 2018. As a result of the adoption, the Company reclassified a gain of $383,000 from the foreign currency translation adjustment in accumulated other comprehensive loss to accumulated deficit in the consolidated balance sheet as of September 30, 2018.
 
ASU 2017-09 — In May 2017, the FASB issued ASU 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (“ASU 2017-09”). The amendments in ASU 2017-09 provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under ASU 2017-09. An entity should account for the effects of a modification unless all the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification; (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The Company adopted this standard on January 1, 2018 and as the Company did not have any modification of awards, the adoption of the standard did not have a material impact on its consolidated financial statements.
 
ASU 2017-01 — In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”). This ASU clarifies the definition of a business. The amendments affect all companies and other reporting organizations that must determine whether they have acquired or sold a business. The amendments in ASU 2017-01 are effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The amendments should be applied prospectively as of the beginning of the period of adoption. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of the standard did not have a material impact on its consolidated financial statements. For additional information see "—Note 3. Acquisitions."
 
ASU 2016-18 — In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). The amendments of ASU 2016-18 require an entity to include amounts generally described as restricted cash and restricted cash equivalents with cash and cash equivalents when reconciling the beginning of period and end of period total amounts on the statement of cash flows. The amendments of ASU 2016-18 are effective for annual reporting periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted the guidance in ASU 2016-18 effective January 1, 2018. In connection with the adoption of the standard, the Company applied the guidance retrospectively which resulted in an increase in cash flows from operations of $1.1 million on the statement of cash flows for the nine months ended September 30, 2017.

ASU 2016-16 — In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). ASU 2016-16 requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The amendments eliminate the exception for an intra-entity transfer of an asset other than inventory. The amendments in ASU 2016-16 are effective for public business entities for annual periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods. The Company adopted ASU 2016-16 on January 1, 2018 and there was no material impact from the adoption.

ASU 2016-01 — In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option, and presentation and disclosure requirements for financial instruments. ASU 2016-01 does not apply to equity investments in consolidated subsidiaries or those accounted for under the equity method of accounting. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. Equity investments with readily determinable fair values will be measured at fair value with changes in fair value recognized in net income. Companies have the option to measure equity investments without readily determinable fair values at either fair value or at cost adjusted for changes in observable prices minus impairment. Companies that elect the fair value option for financial liabilities must recognize changes in fair value related to instrument-specific credit risk in other comprehensive income. Companies must assess valuation allowances for deferred tax assets related to available-for-sale debt securities in combination with their other deferred tax assets. ASU 2016-01 is effective beginning in the first quarter of 2018 and the Company adopted it in the first quarter of 2018. There was no impact on the Company’s consolidated financial statements and related disclosures upon adoption, as the Company does not have equity investments or liabilities with credit risk. In addition, the guidance relating to deferred tax assets did not result in a change in accounting treatment for the Company.

ASU 2014-09 — In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) which along with amendments issued in 2015 and 2016, replaced substantially all current U.S. GAAP guidance on this topic and eliminated industry-specific guidance. The new revenue recognition standard requires entities to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Effective January 1, 2018, the Company adopted the new revenue recognition standard using the modified retrospective approach and applied this approach only to contracts that were not completed as of January 1, 2018. The timing of revenue recognition and treatment of contract costs remains unchanged under the new revenue recognition standard. As such, the adoption of the new revenue recognition standard did not have a material impact on the Company's consolidated financial statements. The information presented for the periods prior to January 1, 2018 has not been restated and is reported under the accounting standard in effect for those periods.

Recent Accounting Developments - Guidance Not Yet Adopted

In August 2018, the Securities Exchange Commission (“SEC”) issued Final Rule 33-10532, Disclosure Update and Simplification, which amends certain disclosure requirements that were redundant, duplicative, overlapping or superseded by other SEC disclosure requirements. The amendments generally eliminated or otherwise reduced certain disclosure requirements of various SEC rules and regulations. However, in some cases, the amendments require additional information to be disclosed, including changes in stockholders’ equity in interim periods. The rule is effective 30 days after its publication in the Federal Register. The rule was posted on October 4, 2018. On September 25, 2018, the SEC released guidance advising it will not object to a registrant adopting the requirement to include changes in stockholders’ equity in the Form 10-Q for the first quarter beginning after the effective date of the rule. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption and expects to adopt the guidance in it's Form 10-Q for the period ended March 31, 2019.
ASU 2018-13 — In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is currently assessing the impact that this standard will have on its consolidated financial statements upon adoption.

ASU 2017-12 — In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). The amendments in this ASU 2017-12 better align an entity’s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. To meet that objective, the amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments in ASU 2017-12 also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. For public business entities, the amendment is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption, including adoption in an interim period, is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-11 — In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). Part I of ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. Part II of ASU 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. For public business entities, the amendments in Part I of ASU 2017-11 are effective for fiscal years beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-08 — In March 2017, the FASB issued ASU 2017-08, Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities (“ASU 2017-08”). The amendments in ASU 2017-08 shorten the amortization period for certain callable debt securities held at a premium. Specifically, the amendments require the premium to be amortized to the earliest call date. The amendments do not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. ASU 2017-08 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments should be applied on a modified retrospective basis, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

ASU 2017-04 — In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (“ASU 2017-04”). To simplify the subsequent measurement of goodwill, ASU 2017-04 eliminates Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. ASU 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 should be applied on a prospective basis. The nature of and reason for the change in accounting principle should be disclosed upon transition. A public business entity that is a U.S. SEC filer should adopt ASU 2017-04 for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
ASU 2016-02 — In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 will be effective for the Company for all annual and interim periods beginning after December 15, 2018, including interim periods within those fiscal years. In August 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, (“ASU 2018-11”). ASU 2018-11 provide entities with an additional transition method for adoption, whereby, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company will adopt these standards effective January 1, 2019, and expects to elect certain of the practical expedients permitted, including the expedient that permits the Company to retain its existing lease assessment and classification. The Company also expects to elect the transition method in ASU 2018-11. The Company is currently working through an adoption plan which includes the evaluation of lease contracts compared to the new standard. While the Company is currently assessing the impact that this standard will have on its consolidated financial statements, the Company expects to recognize lease liabilities and right of use assets.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Tables)
 9 Months Ended
Sep. 30, 2018
Cash, Cash Equivalents, and Short-term Investments [Abstract]  
Schedule of cash and available-for-sale securities
Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following:
 
 
As of September 30, 2018
(in thousands)
Cost
 
Gross
unrealized
Gain
 
Gross
unrealized
Loss
 
Fair
Value
Cash and cash equivalents
$
201,827

 
$
—

 
$
—

 
$
201,827

Corporate debt securities, current portion
227,517

 
5

 
(123
)
 
227,399

Commercial paper
82,704

 
—

 
(49
)
 
82,655

Asset-backed securities
52,145

 
—

 
(44
)
 
52,101

Money market
350

 
—

 
—

 
350

Certificates of deposit
51

 
—

 
—

 
51

 
$
564,594

 
$
5

 
$
(216
)
 
$
564,383

Included in cash and cash equivalents
$
201,827

 
$
—

 
$
—

 
$
201,827

Included in marketable securities, current and non-current
362,767

 
5

 
(216
)
 
362,556

Total cash, cash equivalents and marketable securities
$
564,594

 
$
5

 
$
(216
)
 
$
564,383

 
 
As of December 31, 2017
(in thousands)
Cost
 
Gross
unrealized
Gain
 
Gross
unrealized
Loss
 
Fair
Value
Cash and cash equivalents
$
49,060

 
$
—

 
$
—

 
$
49,060

Corporate debt securities, current portion
199,314

 
1

 
(303
)
 
199,012

Commercial paper
79,878

 
—

 
(75
)
 
79,803

Asset-backed securities
30,346

 
—

 
(59
)
 
30,287

Money market
350

 
—

 
—

 
350

Certificates of deposit
50

 
—

 
—

 
50

 
$
358,998

 
$
1

 
$
(437
)
 
$
358,562

Included in cash and cash equivalents
$
49,060

 
$
—

 
$
—

 
$
49,060

Included in marketable securities
309,938

 
1

 
(437
)
 
309,502

Total cash, cash equivalents and marketable securities
$
358,998

 
$
1

 
$
(437
)
 
$
358,562
Schedule of restricted cash and cash equivalents
The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same such amounts shown in the statement of cash flows.

(in thousands)
September 30, 2018
 
December 31, 2017
 
September 30, 2017
 
December 31, 2016
Cash and cash equivalents
$
201,827

 
$
49,060

 
$
64,133

 
$
187,026

Restricted cash
2,003

 
2,177

 
1,444

 
387

Cash and cash equivalents and restricted cash shown in the statement of cash flows
$
203,830

 
$
51,237

 
$
65,577

 
$
187,413
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Tables)
 9 Months Ended
Sep. 30, 2018
Inventory Disclosure [Abstract]  
Schedule of inventories for the period
The following table summarizes the components of inventories:
 
(in thousands)
September 30, 2018
 
December 31, 2017
Raw materials
$
2,954

 
$
2,394

Work-in-process
$
1,458

 
$
1,449

Finished goods
1,899

 
780

Total inventories
$
6,311

 
$
4,623
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Tables)
 9 Months Ended
Sep. 30, 2018
Debt Disclosure [Abstract]  
Schedule of liability components of the Convertible Notes
The Convertible Notes and Senior Secured Term Loan consist of the following (in thousands):
 
Liability component
 
September 30, 2018
 
December 31, 2017
Principal
 
$
400,000

 
$
250,000

Less: debt discount (1)
 
(76,946
)
 
(81,566
)
Less: deferred financing (1)
 
(4,246
)
 
(4,267
)
Net carrying value of the debt
 
$
318,808

 
$
164,167

 
______________________________________
(1) Included in the consolidated balance sheets within convertible notes and senior secured term loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.
Components of total interest expense recognized related to the Convertible Notes
The following table sets forth total interest expense recognized related to the Convertible Notes and Senior Secured Term Loan for the three and nine months ended September 30, 2018, respectively:
 
Components (In thousands)
 
Three Months Ended September 30, 2018
 
Nine Months Ended September 30, 2018
Contractual interest expense
 
$
1,969

 
$
5,744

Amortization of debt discount
 
2,609

 
7,620

Amortization of deferred financing
 
137

 
399

Total
 
$
4,715

 
$
13,763
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation (Tables)
 9 Months Ended
Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Fair Value of Options
The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Expected stock price volatility
75.5
%
 
82.5
%
 
80.7
%
 
83.1
%
Risk free interest rate
2.7
%
 
1.8
%
 
2.4
%
 
2.0
%
Expected life of options (years)
5.62

 
5.89

 
5.62

 
6.21

Expected annual dividend per share
$
—

 
$
—

 
$
—

 
$
—
Schedule of Stock Options Activity
A summary of the Company’s stock options for the nine months ended September 30, 2018 were as follows:
 
 
Number of
Shares
 
Weighted
Average
Exercise Price
 
Weighted
Average
Remaining
Contractual Life
 
Aggregate
Intrinsic
Value
 
(in thousands)
 
 
 
 
 
(in millions)
Options outstanding, December 31, 2017
15,181

 
$
7.48

 
 
 
 

Granted
2,077

 
$
15.36

 
 
 
 

Exercised
(1,282
)
 
$
6.62

 
 
 
 

Forfeited
(200
)
 
$
9.75

 
 
 
 

Expired
(7
)
 
10.45

 
 
 
 
Options outstanding, September 30, 2018
15,769

 
$
8.56

 
7.0 years
 
$
65.8

Vested and unvested expected to vest, September 30, 2018
15,003

 
$
8.43

 
6.9 years
 
$
63.9

Exercisable at September 30, 2018
9,406

 
$
7.26

 
6.0 years
 
$
47.4
Schedule of Non-Vested RSU Activity under the Plan
A summary of non-vested RSU activity under the Plan for the nine months ended September 30, 2018 is as follows:
 
 
Number of Shares

 
Weighted
Average Grant Date
Fair Value
 
Weighted Average
Remaining Years
 
Aggregate Intrinsic
Value 
 
(in thousands)
 
 
 
 
 
(in millions)
Non-vested units as of December 31, 2017
2,575

 
$
5.85

 
 
 
 

Granted
1,635

 
$
16.57

 
 
 
 

Vested
(517
)
 
$
5.91

 
 
 
 

Forfeited
(58
)
 
$
10.23

 
 
 
 

Non-vested units as of September 30, 2018
3,635

 
$
10.49

 
2.7 years
 
$
44.0
Schedule of Equity Compensation Expenses
The following table summarizes information related to compensation expense recognized in the statements of operations related to the equity awards:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
Equity compensation expense recognized in:
 
 

 
 

 
 

 
 

Research and development expense
 
$
2,905

 
$
2,390

 
$
8,603

 
$
7,456

Selling, general and administrative expense
 
4,149

 
3,110

 
12,270

 
9,611

Total equity compensation expense
 
$
7,054

 
$
5,500

 
$
20,873

 
$
17,067
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Assets and Liabilities Measured at Fair Value (Tables)
 9 Months Ended
Sep. 30, 2018
Summary of assets and liabilities subject to fair value measurements
A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of September 30, 2018 are identified in the following table:
 
(in thousands)
 
Level 2
 
Total
Assets:
 
 

 
 

Commercial paper
 
$
82,655

 
$
82,655

Asset-backed securities
 
52,101

 
52,101

Corporate debt securities
 
227,399

 
227,399

Money market funds
 
3,335

 
3,335

 
 
$
365,490

 
$
365,490

 
 
 
Level 2
 
Level 3
 
Total
Liabilities:
 
 

 
 

 
 

Contingent consideration payable
 
$
—

 
$
28,100

 
$
28,100

Deferred compensation plan liability
 
2,996

 
—

 
2,996

 
 
$
2,996

 
$
28,100

 
$
31,096

 
A summary of the fair value of the Company’s recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2017 are identified in the following table:
 
(in thousands)
Level 2
 
Total
Assets:
 

 
 

Commercial paper
$
79,803

 
$
79,803

Asset-backed securities
30,287

 
30,287

Corporate debt securities
199,012

 
199,012

Money market funds
2,598

 
2,598

 
$
311,700

 
$
311,700

 
 
Level 2
 
Level 3
 
Total
Liabilities:
 

 
 

 
 

Contingent consideration payable
$
—

 
$
25,400

 
$
25,400

Deferred compensation plan liability
2,258

 
—

 
2,258

 
$
2,258

 
$
25,400

 
$
27,658
Schedule of changes in contingent consideration payable
The following table shows the change in the balance of contingent consideration payable for the three and nine months ended September 30, 2018 and 2017, respectively:
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands)
 
2018
 
2017
 
2018
 
2017
Balance, beginning of the period
 
$
26,800

 
$
265,350

 
25,400

 
269,722

Payment of contingent consideration in cash
 
—

 
—

 
—

 
(10,000
)
Changes in fair value during the period, included in statement of operations
 
1,300

 
(244,250
)
 
2,700

 
(238,622
)
Balance, end of the period
 
$
28,100

 
$
21,100

 
28,100

 
$
21,100
Callidus Biopharma Inc  
Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable
The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB200 Pompe program:
 
Contingent Consideration
Liability
 
Fair Value as of
September 30, 2018
 
Valuation Technique
 
Unobservable Input
 
Range
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discount rate
 
10.0%
 
 
 

 
 
 
 
 
 
Clinical and regulatory milestones
 
$
27.6
 million
 
Probability weighted discounted cash flow
 
Probability of achievement of milestones
 
71.0%-100.0%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Projected year of payments
 
2018-2022
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basic and Diluted Net Loss per Common Share (Tables)
 9 Months Ended
Sep. 30, 2018
Earnings Per Share [Abstract]  
Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share
The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in thousands, except per share amounts) 
 
2018
 
2017
 
2018
 
2017
Numerator:
 
 

 
 

 
 

 
 

Net loss attributable to common stockholders
 
$
(159,163
)
 
$
(111,666
)
 
$
(270,914
)
 
$
(214,794
)
Denominator:
 
 
 
 
 
 
 
 
Weighted average common shares outstanding — basic and diluted
 
189,162,841

 
160,796,841

 
184,606,790

 
148,963,864
Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method
The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:
 
 
 
As of September 30,
(in thousands) 
 
2018
 
2017
Options to purchase common stock
 
15,769

 
16,212

Convertible notes
 
40,850

 
40,850

Outstanding warrants, convertible to common stock
 
2,657

 
3,110

Unvested restricted stock units
 
3,635

 
2,690

Vested restricted stock units, unissued
 
103

 
50

Total number of potentially issuable shares
 
63,014

 
62,912
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2018
USD ($)
medicine
program
Sep. 30, 2018
USD ($)
medicine
program
Mar. 31, 2018
USD ($)
shares
Sep. 30, 2018
USD ($)
medicine
program
Sep. 30, 2017
USD ($)
Oct. 08, 2018
program
Dec. 31, 2017
USD ($)
Business Acquisition [Line Items]              
Number of approved medicines for Fabry disease | medicine 1 1   1      
Number of gene therapy programs | program 14 14   14      
Number of gene therapy programs for Batten disease | program 2 2   2      
Number of gene therapy programs for neurologic LSDs developed | program 10            
Common stock issued from underwriting agreement (in shares) | shares     20,239,839        
Proceeds from issuance of common stock, net of issuance costs     $ 294,600,000 $ 294,584,000 $ 243,036,000    
Retained earnings (accumulated deficit) $ 1,334,141,000 $ 1,334,141,000   1,334,141,000     $ 1,063,610,000
Line of Credit              
Business Acquisition [Line Items]              
New credit facility borrowing capacity 150,000,000 $ 150,000,000   $ 150,000,000      
Debt instrument term   5 years          
Proceeds from issuance of debt 146,600,000            
Line of Credit | LIBOR              
Business Acquisition [Line Items]              
Basis spread on variable rate   7.50%          
Subsequent Event              
Business Acquisition [Line Items]              
Number of gene therapy programs | program           4  
Celenex              
Business Acquisition [Line Items]              
Research and development expense $ 100,000,000            
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Foreign Currency Transactions (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total stockholders’ equity $ 410,951   $ 352,850
Retained earnings (accumulated deficit) (1,334,141)   $ (1,063,610)
Net cash used in operating activities (239,278) $ (140,661)  
Accounting Standards Update 2018-02      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Retained earnings (accumulated deficit) 383    
Accounting Standards Update 2016-18      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Net cash used in operating activities   $ 1,100  
Accumulated Foreign Currency Adjustment Attributable | Accounting Standards Update 2018-02      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total stockholders’ equity $ (383)    
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions (Details) - Celenex
$ in Millions
 1 Months Ended
Sep. 30, 2018
USD ($)
Business Acquisition [Line Items]  
Upfront cash payment to acquire assets $ 100.0
Development milestones 15.0
Submission and approval milestones 262.0
Maximum expected payment over next four years 75.0
Research and development expense 100.0
Nationwide Children's Hospital  
Business Acquisition [Line Items]  
Development milestones $ 7.8
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Dec. 31, 2016
Cash, Money Market Funds, and Marketable Securities        
Cash and cash equivalents $ 201,827 $ 49,060 $ 64,133 $ 187,026
Available-for-sale debt securities 362,556 309,502    
Cash balances, Fair Value 201,827 49,060    
Cost, available-for-sale securities 362,767 309,938    
Gross unrealized gain, available-for-sale securities 5 1    
Gross unrealized loss, available-for-sale securities (216) (437)    
Cost, Cash balances and available-for-sale securities 564,594 358,998    
Gross unrealized gain, Cash balances and available-for-sale securities 5 1    
Gross unrealized loss, Cash balances and available-for-sale securities (216) (437)    
Fair value, Cash balances and available-for-sale securities 564,383 358,562    
Corporate debt securities, current portion        
Cash, Money Market Funds, and Marketable Securities        
Available-for-sale debt securities 227,399 199,012    
Cost, available-for-sale securities 227,517 199,314    
Gross unrealized gain, available-for-sale securities 5 1    
Gross unrealized loss, available-for-sale securities (123) (303)    
Commercial paper        
Cash, Money Market Funds, and Marketable Securities        
Available-for-sale debt securities 82,655 79,803    
Cost, available-for-sale securities 82,704 79,878    
Gross unrealized gain, available-for-sale securities 0 0    
Gross unrealized loss, available-for-sale securities (49) (75)    
Asset-backed securities        
Cash, Money Market Funds, and Marketable Securities        
Available-for-sale debt securities 52,101 30,287    
Cost, available-for-sale securities 52,145 30,346    
Gross unrealized gain, available-for-sale securities 0 0    
Gross unrealized loss, available-for-sale securities (44) (59)    
Money market        
Cash, Money Market Funds, and Marketable Securities        
Available-for-sale debt securities 350 350    
Cost, available-for-sale securities 350 350    
Gross unrealized gain, available-for-sale securities 0 0    
Gross unrealized loss, available-for-sale securities 0 0    
Certificates of deposit        
Cash, Money Market Funds, and Marketable Securities        
Available-for-sale debt securities 51 50    
Cost, available-for-sale securities 51 50    
Gross unrealized gain, available-for-sale securities 0 0    
Gross unrealized loss, available-for-sale securities $ 0 $ 0    
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash, Cash Equivalents, Marketable Securities and Restricted Cash - Additional Information (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Dec. 31, 2016
Cash, Cash Equivalents, and Short-term Investments [Abstract]        
Realized gain (loss) on debt securities $ 0 $ 0    
Fair value of available-for-sale debt securities in unrealized loss positions 315,300,000 295,100,000    
Cash and cash equivalents 201,827,000 49,060,000 $ 64,133,000 $ 187,026,000
Restricted cash 2,003,000 2,177,000 1,444,000 387,000
Cash and cash equivalents and restricted cash shown in the statement of cash flows $ 203,830,000 $ 51,237,000 $ 65,577,000 $ 187,413,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Inventory Disclosure [Abstract]    
Raw materials $ 2,954 $ 2,394
Work-in-process 1,458 1,449
Finished goods 1,899 780
Total inventories $ 6,311 $ 4,623
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt - Convertible Debt (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 16, 2018
shares
Feb. 15, 2018
USD ($)
shares
Sep. 30, 2018
USD ($)
shares
Dec. 31, 2016
USD ($)
day
$ / shares
shares
Sep. 30, 2018
USD ($)
shares
Mar. 31, 2018
shares
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
shares
Sep. 30, 2017
USD ($)
Jun. 07, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
shares
Convertible Debt                      
Common stock issued from underwriting agreement (in shares) | shares           20,239,839          
Derivative liability, noncurrent   $ 507,400,000                  
Change in fair value of derivatives         $ 0   $ 0 $ (2,739,000) $ 163,000    
Common stock, shares authorized | shares     500,000,000   500,000,000     500,000,000   500,000,000 250,000,000
Derivative liabilities                   $ 88,300,000  
Common Stock Capped Call Confirmation                      
Convertible Debt                      
Derivative asset, noncurrent   $ 13,600,000                  
Common Stock                      
Convertible Debt                      
Common stock issued from underwriting agreement (in shares) | shares 885,000 19,354,839                  
Over-allotment Option | Common Stock                      
Convertible Debt                      
Number of days granted underwriters for purchase of shares   30 days                  
Maximum number of additional shares granted to underwriters | shares 2,903,225                    
Convertible Notes                      
Convertible Debt                      
Threshold percentage               130.00%      
Convertible Notes | Common Stock Capped Call Confirmation                      
Convertible Debt                      
Other assets, current                   $ 2,400,000  
Convertible Notes | Convertible Senior Notes 2016, Due 2023                      
Convertible Debt                      
Aggregate principle amount       $ 250,000,000              
Net proceeds after deducting fees and estimated expenses       243,000,000              
Proceeds for capped call confirmations       $ 13,500,000              
shares issued per increment of convertible debt | shares       40,849,675              
Debt conversion ratio (in shares)       0.1633987              
Conversion price (in dollars per share) | $ / shares       $ 6.12              
Threshold consecutive trading days | day       30              
Debt Instruments [Abstract]                      
Principal     $ 400,000,000   $ 400,000,000     $ 400,000,000     $ 250,000,000
Debt discount     (76,946,000)   (76,946,000)     (76,946,000)     (81,566,000)
Less: deferred financing     (4,246,000)   (4,246,000)     (4,246,000)     (4,267,000)
Net carrying value of the debt     318,808,000   318,808,000     318,808,000     $ 164,167,000
Interest expense                      
Contractual interest expense         1,969,000     5,744,000      
Amortization of debt discount         2,609,000     7,620,000      
Amortization of deferred financing         137,000     399,000      
Total         4,715,000     13,763,000      
Convertible Notes | Convertible Senior Notes 2016, Due 2023 | Minimum                      
Convertible Debt                      
Threshold trading days       20 days              
Convertible Notes | Convertible Senior Notes 2016, Due 2023 | Over-allotment Option | Private Placement Purchase Agreement                      
Convertible Debt                      
Aggregate principle amount       $ 25,000,000              
Line of Credit                      
Debt Instruments                      
New credit facility borrowing capacity     $ 150,000,000   $ 150,000,000     $ 150,000,000      
Debt instrument term         5 years            
Periodic payment, percentage     12.50%                
Proceeds from issuance of debt     $ 146,600,000                
Line of Credit | LIBOR                      
Debt Instruments                      
Basis spread on variable rate         7.50%            
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity - Common Stock and Warrants (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 16, 2018
Feb. 15, 2018
Apr. 30, 2018
Mar. 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Jun. 07, 2018
Dec. 31, 2017
Collaborative Agreements                
Common stock issued from underwriting agreement       20,239,839        
Net proceeds from the issuance of common stock       $ 294,600 $ 294,584 $ 243,036    
Proceeds from exercise of warrants         $ 3,617 $ 0    
Common stock, par value (in dollars per share)         $ 0.01     $ 0.01
Common stock, shares authorized         500,000,000   500,000,000 250,000,000
Outstanding warrants, convertible to common stock                
Collaborative Agreements                
Common stock issued from underwriting agreement     453,214          
Proceeds from exercise of warrants     $ 3,600          
Common Stock                
Collaborative Agreements                
Price per share of common stock issued (in dollars per share) $ 15.50 $ 15.50            
Gross proceeds from issue of common stock before deducting underwriting discounts and commissions   $ 300,000            
Net proceeds from the issuance of common stock         $ 294,600      
Common Stock | Outstanding warrants, convertible to common stock                
Collaborative Agreements                
Warrants exercise price (in dollars per share)     $ 7.98          
Common Stock                
Collaborative Agreements                
Common stock issued from underwriting agreement 885,000 19,354,839            
Common Stock | Over-allotment Option                
Collaborative Agreements                
Number of days granted underwriters for purchase of shares   30 days            
Maximum number of additional shares granted to underwriters 2,903,225              
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected stock price volatility 75.50% 82.50% 80.70% 83.10%
Risk free interest rate 2.70% 1.80% 2.40% 2.00%
Expected life of options (years) 5 years 7 months 15 days 5 years 10 months 20 days 5 years 7 months 15 days 6 years 2 months 16 days
Expected annual dividend per share (in dollars per share) $ 0 $ 0 $ 0 $ 0
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation - Stock Option Activity (Details) - Options to purchase common stock
$ / shares in Units, shares in Thousands, $ in Millions
 9 Months Ended
Sep. 30, 2018
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Options outstanding, December 31, 2017 (in shares) | shares 15,181
Options, Granted (in shares) | shares 2,077
Options, Exercised (in shares) | shares (1,282)
Forfeited, Options (in shares) | shares (200)
Options, Expired (in shares) | shares (7)
Options outstanding, September 30, 2018 (in shares) | shares 15,769
Options, Vested and unvested expected to vest, September 30, 2018 (in shares) | shares 15,003
Options, Exercisable at September 30, 2018 (in shares) | shares 9,406
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]  
Option outstanding, December 31, 2017 (in dollars per share) | $ / shares $ 7.48
Options, Granted (in dollars per share) | $ / shares 15.36
Options, Exercised (in dollars per share) | $ / shares 6.62
Options, Forfeited (in dollars per share) | $ / shares 9.75
Options, Expired (in dollars per share) | $ / shares 10.45
Option outstanding, September 30, 2018 (in dollars per share) | $ / shares 8.56
Options, Vested and unvested expected to vest, September 30, 2018 (in dollars per share) | $ / shares 8.43
Options, Exercisable at September 30, 2018 (in dollars per share) | $ / shares $ 7.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Weighted average remaining contractual life, options outstanding, September 30, 2018 7 years
Weighted average remaining contractual life, options vested and unvested expected to vest, September 30, 2018 6 years 11 months 6 days
Weighted average remaining contractual life, options exercisable at September 30, 2018 6 years
Aggregate intrinsic value, options outstanding, September 30, 2018 | $ $ 65.8
Aggregate intrinsic value, vested and unvested expected to vest, September 30, 2018 | $ 63.9
Aggregate intrinsic value, exercisable at September 30, 2018 | $ $ 47.4
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation - RSUs and PBRSUs Summary (Details) - Stock Option Plan Amended Restated 2007 Equity Incentive Plan - Unvested restricted stock units
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2018
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Non-vested units as of December 31, 2017 (in shares) | shares 2,575,000
Granted (in shares) | shares 1,635,000
Vested (in shares) | shares (516,940)
Forfeited (in shares) | shares (58,000)
Non-vested units as of September 30, 2018 (in shares) | shares 3,635,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Non-vested units as of December 31, 2017 (in dollars per share) | $ / shares $ 5.85
Granted (in dollars per share) | $ / shares 16.57
Vested (in dollars per share) | $ / shares 5.91
Forfeited (in dollars per share) | $ / shares 10.23
Non-vested units as of September 30, 2018 (in dollars per share) | $ / shares $ 10.49
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]  
Non-vested units, weighted average remaining years 2 years 8 months 1 day
Non-vested units, aggregate intrinsic value | $ $ 44.0
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation - Narrative (Details)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2018
USD ($)
$ / shares
shares
Options to purchase common stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Total unrecognized compensation costs | $ $ 36.0
Unrecognized compensation costs, period for recognition (in years) 3 years
MPRSUs, Exercisable at period end (in shares) 9,406,000
Market Performance Based Restricted Stock Units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan | Executive Officer  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Market performance-based restricted stock units granted (in shares) 187,222
Award vesting period (in years) 3 years
MPRSUs granted, weighted average exercise price (in dollars per share) | $ / shares $ 25.44
Market Performance Based Restricted Stock Units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan | Executive Officer | Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting rights 200.00%
MPRSUs, Exercisable at period end (in shares) 374,444
Market Performance Based Restricted Stock Units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan | Executive Officer | Cliff Vesting  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting period (in years) 3 years
Unvested restricted stock units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Unrecognized compensation costs, period for recognition (in years) 3 years
Market performance-based restricted stock units granted (in shares) 1,635,000
MPRSUs granted, weighted average exercise price (in dollars per share) | $ / shares $ 16.57
RSUs vested and non-vested units expected to vest (in shares) 516,940
Unrecognized compensation cost | $ $ 25.6
Unvested restricted stock units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan | Contingent Consideration Liability Clinical Milestone  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Market performance-based restricted stock units granted (in shares) 187,211
Award vesting period (in years) 3 years
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share based Compensation - Expense Summary (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total equity compensation expense $ 7,054 $ 5,500 $ 20,873 $ 17,067
Research and development expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total equity compensation expense 2,905 2,390 8,603 7,456
Selling, general and administrative expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total equity compensation expense $ 4,149 $ 3,110 $ 12,270 $ 9,611
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Assets and Liabilities Measured at Fair Value (Details)
$ in Thousands
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Assets:    
Fair value of assets $ 365,490 $ 311,700
Liabilities:    
Contingent consideration payable 28,100 25,400
Deferred compensation plan liability 2,996 2,258
Fair value of liabilities 31,096 27,658
T B200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Callidus Biopharma Inc    
Liabilities:    
Contingent consideration payable $ 27,600  
T B200 Pompe Program | Minimum | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Callidus Biopharma Inc    
Liabilities:    
Discount rate 0.710  
T B200 Pompe Program | Maximum | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Callidus Biopharma Inc    
Liabilities:    
Discount rate 1.000  
Commercial paper    
Assets:    
Fair value of assets $ 82,655 79,803
Asset-backed securities    
Assets:    
Fair value of assets 52,101 30,287
Corporate debt securities    
Assets:    
Fair value of assets 227,399 199,012
Money market funds    
Assets:    
Fair value of assets 3,335 2,598
Level 2    
Assets:    
Fair value of assets 365,490 311,700
Liabilities:    
Contingent consideration payable 0 0
Deferred compensation plan liability 2,996 2,258
Fair value of liabilities 2,996 2,258
Convertible debt, fair value 531,200  
Level 2 | Commercial paper    
Assets:    
Fair value of assets 82,655 79,803
Level 2 | Asset-backed securities    
Assets:    
Fair value of assets 52,101 30,287
Level 2 | Corporate debt securities    
Assets:    
Fair value of assets 227,399 199,012
Level 2 | Money market funds    
Assets:    
Fair value of assets 3,335 2,598
Level 3    
Liabilities:    
Contingent consideration payable 28,100 25,400
Deferred compensation plan liability 0 0
Fair value of liabilities $ 28,100 $ 25,400
Level 3 | T B200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability Weighted Discounted Cash Flow | Discount Rate | Callidus Biopharma Inc    
Liabilities:    
Discount rate 0.10  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Balance, beginning of the period $ 26,800 $ 265,350 $ 25,400 $ 269,722
Payment of contingent consideration in cash 0 0 0 (10,000)
Changes in fair value during the period, included in statement of operations 1,300 (244,250) 2,700 (238,622)
Balance, end of the period $ 28,100 $ 21,100 $ 28,100 $ 21,100
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basic and Diluted Net Loss per Common Share (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Numerator:        
Net loss attributable to common stockholders $ (159,163) $ (111,666) $ (270,914) $ (214,794)
Denominator:        
Weighted-average common shares outstanding - basic and diluted (in shares) 189,162,841 160,796,841 184,606,790 148,963,864
Antidilutive securities excluded from computation of diluted earnings per share (in shares)     63,014,000 62,912,000
Options to purchase common stock        
Denominator:        
Antidilutive securities excluded from computation of diluted earnings per share (in shares)     15,769,000 16,212,000
Convertible notes        
Denominator:        
Antidilutive securities excluded from computation of diluted earnings per share (in shares)     40,850,000 40,850,000
Outstanding warrants, convertible to common stock        
Denominator:        
Antidilutive securities excluded from computation of diluted earnings per share (in shares)     2,657,000 3,110,000
Unvested restricted stock units        
Denominator:        
Antidilutive securities excluded from computation of diluted earnings per share (in shares)     3,635,000 2,690,000
Vested restricted stock units, unissued        
Denominator:        
Antidilutive securities excluded from computation of diluted earnings per share (in shares)     103,000 50,000
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborations (Details) - Collaborative Arrangement - Subsequent Event
$ in Millions
 1 Months Ended
Oct. 31, 2018
USD ($)
Collaborative Agreements  
Payments for collaborative arrangement $ 7.0
Conditional aggregate payments per indication $ 86.5
EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO=V]R:W-H M965T&UL4$L! M A0#% @ /'=E34!:-)71 0 .@0 !D ( !]GD 'AL M+W=OP >&PO&PO&PO7W)E;',O=V]R:V)O M;VLN>&UL+G)E;'-02P$"% ,4 " \=V5-,)0TP:\! ! &@ $P M @ 'O_@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ,P S -<- ( #/ $ ! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 111 247 1 false 47 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.amicustherapeutics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1003501 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) Sheet http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical Consolidated Statements of Comprehensive Loss (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.amicustherapeutics.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101100 - Disclosure - Description of Business Sheet http://www.amicustherapeutics.com/role/DescriptionOfBusiness Description of Business Notes 8 false false R9.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2105100 - Disclosure - Acquisitions Sheet http://www.amicustherapeutics.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 2106100 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash Sheet http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash Cash, Cash Equivalents, Marketable Securities and Restricted Cash Notes 11 false false R12.htm 2107100 - Disclosure - Inventories Sheet http://www.amicustherapeutics.com/role/Inventories Inventories Notes 12 false false R13.htm 2108100 - Disclosure - Debt Sheet http://www.amicustherapeutics.com/role/Debt Debt Notes 13 false false R14.htm 2109100 - Disclosure - Stockholders' Equity Sheet http://www.amicustherapeutics.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 2110100 - Disclosure - Share based Compensation Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensation Share based Compensation Notes 15 false false R16.htm 2111100 - Disclosure - Assets and Liabilities Measured at Fair Value Sheet http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue Assets and Liabilities Measured at Fair Value Notes 16 false false R17.htm 2112100 - Disclosure - Basic and Diluted Net Loss per Common Share Sheet http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare Basic and Diluted Net Loss per Common Share Notes 17 false false R18.htm 2113100 - Disclosure - Collaborations Sheet http://www.amicustherapeutics.com/role/Collaborations Collaborations Notes 18 false false R19.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 2306301 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Tables) Sheet http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Tables) Tables http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCash 20 false false R21.htm 2307301 - Disclosure - Inventories (Tables) Sheet http://www.amicustherapeutics.com/role/InventoriesTables Inventories (Tables) Tables http://www.amicustherapeutics.com/role/Inventories 21 false false R22.htm 2308301 - Disclosure - Debt (Tables) Sheet http://www.amicustherapeutics.com/role/DebtTables Debt (Tables) Tables http://www.amicustherapeutics.com/role/Debt 22 false false R23.htm 2310301 - Disclosure - Share based Compensation (Tables) Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensationTables Share based Compensation (Tables) Tables http://www.amicustherapeutics.com/role/ShareBasedCompensation 23 false false R24.htm 2311301 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables) Sheet http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables Assets and Liabilities Measured at Fair Value (Tables) Tables http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValue 24 false false R25.htm 2312301 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables) Sheet http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables Basic and Diluted Net Loss per Common Share (Tables) Tables http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShare 25 false false R26.htm 2401401 - Disclosure - Description of Business (Details) Sheet http://www.amicustherapeutics.com/role/DescriptionOfBusinessDetails Description of Business (Details) Details http://www.amicustherapeutics.com/role/DescriptionOfBusiness 26 false false R27.htm 2402402 - Disclosure - Summary of Significant Accounting Policies - Foreign Currency Transactions (Details) Sheet http://www.amicustherapeutics.com/role/SummaryOfSignificantAccountingPoliciesForeignCurrencyTransactionsDetails Summary of Significant Accounting Policies - Foreign Currency Transactions (Details) Details 27 false false R28.htm 2405401 - Disclosure - Acquisitions (Details) Sheet http://www.amicustherapeutics.com/role/AcquisitionsDetails Acquisitions (Details) Details http://www.amicustherapeutics.com/role/Acquisitions 28 false false R29.htm 2406402 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Details) Sheet http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashDetails Cash, Cash Equivalents, Marketable Securities and Restricted Cash (Details) Details http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashTables 29 false false R30.htm 2406403 - Disclosure - Cash, Cash Equivalents, Marketable Securities and Restricted Cash - Additional Information (Details) Sheet http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesAndRestrictedCashAdditionalInformationDetails Cash, Cash Equivalents, Marketable Securities and Restricted Cash - Additional Information (Details) Details 30 false false R31.htm 2407402 - Disclosure - Inventories (Details) Sheet http://www.amicustherapeutics.com/role/InventoriesDetails Inventories (Details) Details http://www.amicustherapeutics.com/role/InventoriesTables 31 false false R32.htm 2408402 - Disclosure - Debt - Convertible Debt (Details) Sheet http://www.amicustherapeutics.com/role/DebtConvertibleDebtDetails Debt - Convertible Debt (Details) Details 32 false false R33.htm 2409401 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details) Sheet http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockAndWarrantsDetails Stockholders' Equity - Common Stock and Warrants (Details) Details 33 false false R34.htm 2410402 - Disclosure - Share based Compensation - Weighted-average Assumptions (Details) Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails Share based Compensation - Weighted-average Assumptions (Details) Details 34 false false R35.htm 2410403 - Disclosure - Share based Compensation - Stock Option Activity (Details) Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails Share based Compensation - Stock Option Activity (Details) Details 35 false false R36.htm 2410404 - Disclosure - Share based Compensation - RSUs and PBRSUs Summary (Details) Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensationRsusAndPbrsusSummaryDetails Share based Compensation - RSUs and PBRSUs Summary (Details) Details 36 false false R37.htm 2410405 - Disclosure - Share based Compensation - Narrative (Details) Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails Share based Compensation - Narrative (Details) Details 37 false false R38.htm 2410406 - Disclosure - Share based Compensation - Expense Summary (Details) Sheet http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails Share based Compensation - Expense Summary (Details) Details 38 false false R39.htm 2411402 - Disclosure - Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueDetails Assets and Liabilities Measured at Fair Value (Details) Details http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueTables 39 false false R40.htm 2411403 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details) Sheet http://www.amicustherapeutics.com/role/AssetsAndLiabilitiesMeasuredAtFairValueLevel3RollforwardDetails Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details) Details 40 false false R41.htm 2412402 - Disclosure - Basic and Diluted Net Loss per Common Share (Details) Sheet http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareDetails Basic and Diluted Net Loss per Common Share (Details) Details http://www.amicustherapeutics.com/role/BasicAndDilutedNetLossPerCommonShareTables 41 false false R42.htm 2413401 - Disclosure - Collaborations (Details) Sheet http://www.amicustherapeutics.com/role/CollaborationsDetails Collaborations (Details) Details http://www.amicustherapeutics.com/role/Collaborations 42 false false All Reports Book All Reports fold-20180930.xml fold-20180930.xsd fold-20180930_cal.xml fold-20180930_def.xml fold-20180930_lab.xml fold-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 59 0001178879-18-000027-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001178879-18-000027-xbrl.zip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

.(F#GQ7,]0H9#6'9C&VG:PBW'-F1DKVY8G([A&9)< MD5R17)%CPHF46&TH"A>MD$NS*]1MA:GPL0AS6S MC7Q7 49CF'K'<,35GQU,M+;P#Z5IS^=&D#HC==82H!-29*3(2)&1(CO;,6-5 M,=M#L=L^H4R:CC0=:;IC1J":+0R0BQRW6S_-\"'M#B<]UI.2M&IYT[;>-VTA ME#!%=4GJ1C#ZN2@]0?3/I M(%I M(%Y N(%U NH#B \%) MA19E34^5;:@*UV/,-JWKTH)Y"*#\7?UY#Q83=K[NBNJ;3+5CF>*Z*!U*N+;P MX;$-?8O$N74> (GGJ0YBD&"28))@OH:.QSM8< #5Z%P!22Y)[AX>KV&<7WC; M(H>G#VFO*W+]DI7QD&^,=U:VQWFLNC:Y%A[?>/OQKR&2,WLP54NJD5P[@3YAFS;[ EL-X7+!WTS_>+[/B?%#-W-^< MGB!Y7-J:DI' M4F5EYU-O!W'F,:A[+,X53OFW22J5@VQ2Q&FOV"=LG)G$Y0[[:[DCYG M(Z$VPNVT_B"KN'VM:\ #TYV.;%+OLI/QQ V;<5(UMZUJCM$4I^T<0/J&] WI M&](WI&](WY"^N6Y]0Z$4%83ND[W)\G&6QR63>NRA7 MA!+^72;;/7M#.A=P7 M5X^M.$Y'4X25,[:%"XYML,DN7[-,D#20-) T3 O$-%E870;5?Y&X7+FXH$,E M*RJ9D->&)2W*B1PW7AF-6-Y-XJ$TCL?LY5,'A\)+70U\E.5T;,NF9 #E'=MC MHJY'NBBU3R)&(G;<:,H2A^I#P*0D>"1X>WB.XA(95V_6;GT;R2T*5M[A,K/> M8<"AUYOBT.2.I@L#C6K+BA_;$22S<\4B0,=4W8L>#JF!JU(#5-Y,NH!T >D"T@6D"T@7 MD"Z@\$!L2J%%.=-3Y1JJLO481+/4YVV(,$DP23!? T=CW=ZX "JT>$!DER2W#T\7D,^TF[X#1K6 M6]\,_Y*5\9#O?G=6]L#YQOAKH];3'P!J"VE/=\[GDA)HIRXH:0LW'#L"('>! M5 VIFC,5>[2%#TC)D)(A)7,EJ907"'/;*1/20J2%2 N=M4BB+=P@,/WS'4]R MK+O^9 -K$&V8I.QNP+BV4E3YF_<-*OYK4I1)__D<6FC/$?*ODA14)N@9'01& MY)"C+)?* 9-6!GS(PU*8C9 '22/X^9F-2S9Z8/E\D32Y(ZFR MLII&.6C(0,6<24_XCQAB9D(>,TK2>"CE#'CJ?X"6CW&2%O?2=-G[20%Z2WH& M 1-)[(!UEVFM<%JO>GF'/+[35F(OT5D"*@^SHF! \2] [6Y6E C].L\!XTY! M3TH*Z2$NX*XLY:M2C%D7H6*E!(6^ HU-X+<1*P=9[Y[4G[ A_Y;.5@P72N*0 MO$#J L^:X5+$7^-DB#;MKI_E=T4,YKO''LKF$L8L M6TI CG&6Q_FSE(S&<9*/^)Y*.8A+:1!_9=(#8RFN5;RX?E(?18\5_%)8R2TPY$\"3,M0M(*JC<[BAV8A5XRF0CQSW!F(00[R^:8MQK$EPWA >WC''^HCK& MO2)X<"2!1["Q.4,[5 +_#Y_)Y@C<+4;]D0V'V1,$PE*U*SS.LZ]@[$$W<6V4 M=I-A4ME\8.R-]=4=_BVL4YDGW9+5%^0,-"9^>DK*06W&X)'\3$*,WS_$PSCM M@ILQ8*RL=&DQ&4EEQB\M^69VI=6D(AZQ6E&.L@FJWF*0/:53ZUB4\$!4R;-A M8H*G$,HM1UV+4T28.T^@\=R%Y)(,]S0?@I^;+TZS?!0/%U(M"EXS>W#%8UTV M'-;7?/]&?L,_%^.X._V\AG1?DA'PY"_L2?J4C>*5E-U3TBL'[QSS7K=US3*^ MF:8\NL#=\;A@[Z9_O%].7\R'UCPO,D^!F&O/!^U^Y*0:F69]LSW)LC:C4]VO MO/)V[;ROI\G3Y*]_\OL=/MOQR-Z"_E7.?$#-/LS*X6W\TU-E)AZR8:_>;N/F M.YL4X#X4^^PHS6:@G0&"? MY7R9I%PPGRX])U%GD(&T,&&BK;G>/G1AO5\:; M!H+2QOB/^([X[@0*CQB/&.\<"L_W(LC"+W9:%/K9A)OM[U1*A6,(R9% M' &XC(Z;QR#E,;;"M8ZMB=N?.IBB%\%YQ_9:6J206^?.D)8D+7DN+6DH';4- M#=HO@O%(29*2O!1>)24I\/B!T3'$I6Y)29*2)"79"EXE)2GVX(2NB#ND15IR MQZSH9CS(=7__];M)9'GYA>6C#^E75I0<"^H+ M$,(;9MT_?OC/__CK[';$G0!:QXA>X^9YG#[R9&&0%-UA5DQR-KL-H5&0F)]8 M__LW48!UNW_3_O$E>",E/?@B[I9W2F#YKAUZH6Z9>B [;JC9IBO[=N#[KFM$ M;WY86IPFH;= :*Q;VQ-BZ/"/*P56#?)EZGO]71? M&?DA9/F02K]VRPSKXY"9.5:BY&"C!VM?HBT4' M/F C6K" TD>@)Y-Z"W4-2T6VZF/^K0-BHDB6IQ-)'^!$F M!$/#%S\.G[O90P*FY_$9UQJM6,'FZ_7?TV;LUOM"#.N#RQMO8R-*V>KUV,%R M,")%P,HQS:3(NXS^ (&6D=-('13O)XX=DF)3/]Q(P,>CE%.''@./XN"L8J[6, MN,CCH[@'9$_AY?T<5W\6YFN'+ MIFEH@6('N2'KG(.-^18X&S51[S\70)LFG0W>BH-BB+#5125D*2M M]5N.#EDHTE/A]WV9J]<%T]%/TCCEBB-)BS*?--!9T;Z!Y>'&#M76\D)UJX7* M:]XOD@(T=0[F(X?!O(AZN+FC7H7-.K<#25IR&&9TNG:8 M^,8!+.;=ORIS"/H V3K(?^!'AOH(=ZBV]\8$,T)3@EQ*K&ES>6%AT CE$-?-5< MU2Q]@>C@+6RDSPV#C1Y35X OL3[_@JU#5T@Z?XPU+IOK9.G5TL#S MA$57"X*QH O7D0XTB)"W'AV5F&-I@^H%Z:^887&5YXJY/GX5_K:H(7B,4FD1 M7"ZX,$9M5-1-!J8Z#30:A"K@S /;<*4,(I"!ZN-1!BA-(%J"&@/]6(2HK:)# M4"Q)-QES)JRT'(1B?=1?52.#=92?(X0W9Y7&(_1BP0BA5\SG5L4.TQBA9/FH MX+8+5&&/X<>J%KR+IFAF'HG%M>->TH_LR, M:-(O&2IA7-3/+$W &'Q&-Q)6$+<)I)^R.)U%%S73S+,DBS"H[U9-=?MENS&J MA1W2ED.&*[(L#BS<$8(5;MJ$N7RIMU\;X/29B\Z% S;^E-2)_;DF0[NCTX3&/)WW,(29,QO%0E 2WB&ZM M$VWAJN^RC\:U H_J,LY!:=W5'$>P:OI=MV*D6279%>P[)I'PNP@V:6\P\)]O[!2ZL9Y_HS^ M"AY;9M.3<)B+H&#J-'GFHP"5%&P"=VQ/,HK5C4[(14=4:K/6%3PSYW^[^#1-Z5'GQ8C+,YF M00UQL'FA,9;RK?2AJAWJ3:L6%ZJ-'N(AEAA*Q8"QLN 8(U75SZRV))W5EA15 M;4E1UY9@6: TQ-H2CLTQRN"&_ZDK9/$\(2MX@31B9DAH._C+B$#Y,^ MFY/Y1J2JCN$[LFE'KJJ9BBO+5X>BA:2ZQ)JB%I:R5Q_Q\FFI9GVH>X.8 M]"#(567U9<"_JZ:^Z@C6IQ]2:7Z&?A58C)^CYIH648!JY;@(%.8EV<=!G(_B M*4C+QY]\*:XJJ("" (440Q:+)[310KR=@@2H\D9^ MG5VBO/^VHE6<+JEUAE@A:&"06MK=",8PD'[ZX/WZ21H/)X48LECWAOR-&'H@ MOE*\F*&_0)*"!R?!=BVJ:N%:KE^Q\]36@>< MUA^FS)X42#E>?#JG)5 WSG-A!;)+1")@%EAY6%[D"7UVO^R*P M2 7IP7 ]N"E '*9"')2?HIOWIG XOV5#&?>!CX%XB*B"9.JSVL\'CD]&/!JI MPX4Y]S\\-WGIM4.K-WY,4^DQNT:RN03'[_ HOR43V."YKH9]Y+(*YQMP6:?5 M=_/1@T2:BZYK4A03A/A!I-"\WB$3HUU4T5[F'%MS/"V"J_4PJL1).G4_F^Q5 M:^)%+I/>(@4:KND*0S9]TAH1;VJB*B@D]B="UA6,^SX3, BU,R"*=&(IAVF8 M.\25*BN#.>8XA(]H_JO$#0X]29,2C>YXDG<'<8&X5!O3-.B3X"I\K?R@?@6^ M"P_BH'[]A,="P.3EI$;_?9@\XP,Y3#)"Y<&EGR9#-N=,1=?=!0LZPPMTN^7* M@N$HI%_K]S87:[TS5;!1@OXXQ^:"F?^?2=I\M<'-T:JTP ]3+"MTEL%E88]) MFM;.XO)#J@+7^_E7Z]%:N.])D 7<.+JI>EU M) 3H O<'_D(GIWI+E>M#L)^\QUVAJ0^:Y!6VU];!H7O33 (B""1<6#-,S0Z# M; C+5'3JY9IYFTG>G8S0&^K6!KZ&6IQ>4.,L=JHP&1VSCE1 3,R6(8T6D.40 M'A)!'$M,M/$@N$*#KK T:R^^PZ#U(7)\\ZJ((L+>%C-A(5?7>3C1?#D.D+"G@#-C 7'VMN8#$K60WEO'3@' M :]ANS@?9/EN-RXN= $!>E[A5V[0XS#&X12@I&*T?T]J5-8*HJ1 Q#[6JT/7 M)*]#,8@-N;,P@V==ITIJDS)\7E J599,//?IT(9A* M7,!LGF5!D.":*CQ=D-<9!3%Y$E.[UYPU':M?0P=,:@G2$FOK"@_+M*WQ!-?( M1.7!S;(@Q2+MX2&51!U#)9KWBBHNJ\C78HDE_]6 M5I:A%N!AC,E6A@TP0-@1''1.EIW8_REN9/LP)9/E'(@T%<32FJC$W]0$K%G_ M]4J2I]Y+"0+P0A"BK2J(^\%T\*;IX\5*%*P]F:K8K*@[NY$VO=2Y]Q=>JHH[%Z4LA=E4[# M'4.&BMA##HS3@%NK8[,7-^W22C\^8=")\/"S';AFYKEY5L'_-+ 6 M9K^=CF;H'5MSSN')W$N_S>+P"A*ZOG$]A1:I.DLJ-*]G/+]>AY&=:?*$!R_" M&B")4EE1M8ZJGL6AG7I-W+#7Z:Y> M%<+ 4\:U@R%D9+9MB',)]V1V4OI'4OJ?)P\%.(2LRO8MZ(.UNG.NN:7U"KN7 M]/A>(<>L+B;]?M)-*L=VFL2>E(,LYX?1:B;@O5?P#-J"O[\YZ%[C:"P@:->M MOCAH/IY[FS_L(0$+U^6A=N--?58E^G@_M/JMF[(*52;A*9L,JVD^P&WUONI# ME0"IG/^"E>409\NCF,KE ;/*D['H9RV&\_RJQJ_8F:#L3"48OAD^+V4%^W&2 M+Y?*K'GXE X;9KO\RMGUF^2[L"/>A4UY\M[42J#,Y?C2K'+V$Q"E:50ZM9-W M>( $5-!=-Q[C%N&])#7T!IC7]+$2XY>XLJBRNK.WUP=>%Z,(O(USU+2S(^A5 M3.47TR!DO:5HG)EMX/+#LS((QVO&K10&GR+NBU2CYCM#"X-N#G@J#4*6-L7> MB/RL"@^L6$_: ?#UT-A94.[\7FP?P88.NQ@#>?$6/EILN8C)LZ^XUU?EVXM& MU+;/I.LACN=I-T<.XA6#ULQY=@4K9EO$N5[&A52HS#_<]%OP'9E)W)5 M-KH *Z9XJBV'\'&Z6;M%*Y_;,6ARRS%] MN^U]KJ$JB"O94E+["]I_5/K">I M;-2VA=JV7+!H"U=]EXU= M3ST/J&W+R?(NI,)(A9$*H[8M[>";UZJP6X=/I;8M)PM#KZ\)!;5MF=U'$D,2 M0VU;CB(QE'*BMBV7K:=NJ_4#M6UIB2M!LDNRNZ?L4MN6UCHUU^6[4-N6-N29 MJ9>"4"I=0B\%:MM";5M(U9"J.8&JH;8MU+9ESQ%2VY;;;=O2SEH64:69^A%* MCN9%0V6-@EKRPF/$(,S*>+BZ[EA!_9ARMN"P-W-PV#V77&AYW)2N;1DBE9,)*R:R+KJ;2+WKT5$K6IO2E M\'(*?X:E.]>.;S^D\P_S@E[*-XC?P[F1 I_-EF*I]#& M"Z5?% B*#P2OKHA%[9BR,,^F+6)Q; >&).**)<+JF&L:_MRX1%!F9F<+O%S M15%3B[31[12 *-KYJS_:(J24T"#1;)%H:HZX7.*MB^:M9P"^X-% BFM.DW^E ML@>A5+J$?*S>L935?GY4]$"*AA0-*1JA\5K',C72-,PAS)(BNXP*R8Y^P*3]899]X\?_O,__CJ[9/;SKWT\'LK2@F=\/E5E%WY6 ME,5G; SEQ07K?8R?>=^YV:.PY >)^(GUOW\3!7@DZF_:/[X$;Z2D!U_$W?). MM[7(4353TQ37,#S%]3W-=G5'=>PPTAWGS0]+B](D\)93[.O6=.^2%W$5+_SC M*GH^;T_X@/23FB1^D1&NKG+BZ%5&Z]HF5HVYL90-7HOE7A^'<5HL-S5R1U7Y M#5;V?&*\NV)/4F796G^_])97%,U;AN.7LX_*^V_Y@_ :_HP@R5FWS'+I5]YU M>OTC%J]=*L>D2B=DS0IJPJIJN5U ML= N>J&-7;+0?!*O8Z/Q,'MFK.A(<>]K4F1Y]2BDWF18QMA_,BZE&,:4=*?] M.!OMT.KV>^O6QBG4ZY:$PQ*?A)0+XD.(RTFTWR^)%)V5/*\F*0C/'. M:M3PCMDP5P:WU.N/KTHVI6"S1W8R7=\964?UE:.LK/H %I-NEQ4O=G-^P/I" MN*::RNJ*+D^L^7BX+)_4_-NZ6G9#A$"C-8X>J>ZLJ:<<=P-^]]V)D)[K3- M./Z69'PV_*'5?50?*LY:\LO?86_'I%N;2\Y9M;+\$5>\('J+K<==Z9]92W,M M/U,Q QD%A9&,N#VLFQ-C^3?>Q:^I*ZICR1O&W3_N/G=!@6"'U+ETX<^CK,>& M52?FQ1:"E:?$>GD! M&612A@+X\D9JI??A5"K+I[+\T[&:L'.?Q&K$:J35B-5:P6K4U/JU7!G^B7B$ MLUW/:EOG:S:,RP2WOPYAU:UGNJ_FS+9EW(L[!GB5W3*^.1EYR$C M21Y)WADD3[X75T-(DD>21Y*WJ^1I]PI)GA#)N_4"P4])\8?4Q^VYA28.QY"_ MBQ,S59Q]NPUAHC3>#4N+FD1!KEV&])" MNUS;=KFF+?"F]1IOGUF<[]6RY083#\:]J1X]\= 65L'["!:LY:;LFF3+IAX" M)%LD6V2W2+9(MBY&MLQ[]?B;4=^W30+O^(T150)#B_!TMXC\Q@8%1AEJHMZWELBTR&EW0!Z0+2!:0+2!>0+B!=0+J = 'I M@MO2!3LA'9]L8 VB70>VW%'Q!#WVF*0]NG"7I'' 5O_V*3X$G#>8<+F0^]( M3XC]VI/2K)0&0%6IF/3[23>!%99R-DPXMM]L7)QJ92;5_ "4ZP[B%-:AGV\G[0'JNITT,>)(TR#IE4(2P+>>0, M=VF^KIK6(^YIC8I*L*M'PDQ>%7BGZ M=NVB1T_(H?O%<0>J^(W0-$<^17![6#^_3!8]B:R_JRT]Z3!YOYJ7,?0 M3!#^U0JS_;WN =!*27"KA$4KQQ;64?:<(S\B[!6)[6GR[V<0U=T] Q+;UHKM M)S:*>8NC5H[.GZP$DD]_$Q9X_;0#S.-;H/(!Q)6B3=5H[N M=VSHM"L?4K1[VFCW"F7U;9+.:58.LDD1I[V]JE!;QFR7:RG.SUWM$$=BJ(NB M#S'4I3/4!6FHX]H_N'N(.^,[F[^#'+ 6E2\>\SS9K_4I@VQ2%B4X%3#*CA2P M;MT 2>'[[Z?#;SW!$LC4M$8BVALK79(64(Q[S20M0%K@W%K@ MA@(98I_VHJBWCEFN1:?2-M)+@'W5"6EA@D(IQ[RZ",*"F!ZW)XKV&3IL3;OA M1;[7A84>5Y_;(ZFC30 KA,2L?6$H_V+];@%LPX"TL;& 4)<70U< MW5XV07C[UP#$M28D4(R.93HGHU5;>(C2GY>7_FP+[]SD'HA];U"E#2F!LRL! M86[)*A2: (0.67H&7B)0_Q8S4%N4STU:$=.X%^:7MV4A7VM%:-=G,VU_9P6V M.L0.CI/T:_5AU@"QS'B?QZ/&?E>Y#00QGRQKE%9N(Y.0^7Z9/JWG-BHV6@P; M=5(TI&AH&^8T$:AY[XB-0%M$NW,9)VY?^+%'N=06S-5 & M;XT=ET>,6B\Z.'4ZNDP[#2=8<;+&E"ANK1:P[E52 J0$SJX$VAWLT79CZQFH M+MFCRE<@<>^1V.6%C&>X84/12GE;!C7^[G -7?U-F]19MT_I*P^ MZ_M88=]+3W$A9OY_T=!\UOWDA#R1[U(GQ<+^] .3&E-':R?%TE/=U%V*O_(& MZM(8GIGUA"UM.<@9V^ 9'/*\>Y)@$4.N/N+E[Q*0BJ1;/>D3L'N><(;YS%G^ MMS0IQ2S9Y:/XK3+[KRX M ++ON +$](<.&7E$BI_BO,?P'$\/M" :AX_#.)7BG$F/+ 5%.!P^2\7DX5^@ M/%%U@L;'R]$:@'O)E2M>VX7GPV<8IP3V Q[ 1N-A]LS8E D5ZWU17S5!,\+R MKTF7W4O5(#:]K5]A8DW@]Z1?/W.$+X&@;92D8)\*:0Q:.L>+BQZG4S MXX'7].,DET9Q_@SZUI1\IC= "?*[N$O]>&J#?)\>YJ6/C]NAE*PWA< %U=(.,(AO>,#V[8 M;WBO%,.E7Y/R>7G1^UGU08BR2(%>8K0.T+ <@ %/D?$NPLM"I@&/J)\-(8@N MWMV6SMHTPL9C%B)V&=1:4\_AY^9[4C0+PX4 5\%K9@_FX9+49<-A?.8 _89IU 16$EUR\WDW_>+\< M4LX'U=Q-FX>EVMJRQMTWY*HQ:=8WVP/?M4%T/2?]E?=?].W:18_>N.C1GY;V ME[^[?:"*G_K:*VW;CPS]L05^YC25X2^E]^W#"&IO).@ODT4_(NO/__[,/<%= M;>N1ADU[7&W#3;@](?E[G5H[LRBL'YQ;I?OFB\X;>LX_!A"=M7+@$42@\V'^ MCC$HR;,P>6Z;#+]B3_MX\CPC[%2(VB@GG]@H3E(@[7RX_Z#]>3)^I[(OCX\Y M>T0C,J/LA[3,D[1(NJV4E\J27"L$4GMEYQB PJNTJB60I]%6Q*]5@O,V2:5R MD$V*..T5U ;A#-KZ--JX=?0A_B'Z$'VN1O]_XRW_B> MX.D1W)7-^E+ NG6)E\)W?<7AKU\E,(G:,<1UVKGZDLH+$KW660;AUJ#UW$:U MV\W[C'N;% TIFG-G]]M#N(MJ^-0BNK6.X2ZO?U*/0+R: ?DX0_5@5% MYW096^,,*1U3HP:GE%X[>Q#5%MZYR6)IQ;PWA.6GVK*2I 4N3PO<4"!#[$-M MCF].I](^TC; ^U;F25KCJ+PU3KB/1GV*6R)UK3-U58,[&VK.2Q RO2 FVCST7YL<0^M$%U_ETT0AW'J[5_G)IX31L"]M1_OF*_*?6K9EU^ MLS,7?!@E9CMGA1CWXX11OL[]M"17.SY(KF/.6.\F/>A^F]\T9A4V79DL)_3[!9R8<4 7B2KU6SDHZ4I-WA!#68E,8CN);]R;H3 M_GO6[R==EA?WD@\:(4[2JLM-\VU;IB@],6Q)4P\:'O!_XG02Y\_S-4+4&#Y6 M3*I4;67PK^J>HAZ5 M:B[L; &*^SF=I-_K)C55=YR"3=.RE(>TO[O7$FJY8 ='+2KUH<39L(@?1,.Q")&[Z0)]TA#:9-C%!D!C$( M:0R<^&D%\@/N;8MT0PB]59RRN4OEMM<@O-'VLNV$M-;R:/9WS&(CRB#^%=[]: M:'O5Z&\U[8"5KG:WFG9C;+9?3%$BRSQ&*WR'%AE?"M?,9'+:YPH'U50M7S8- M":A0#6(ZN%IJQ+6I5(U[4>N(%,&!@>/:G51K-"EPNK'T,UP/*C'.AYE4@*P, MJY4:93TV7"9$K5;C89$=P?HHJV>J#YIL@S]KUJK'70Y Z)^2X;#2 ,?2QV)F MP97ZHFA,[5;<'23L:]-R@:I.,2I!9#^8&GC1X)@$52\WH=W6%ANE[;#U<\B+ M.MA,;B97:^8VZR*WNM0+#0>!,MR'@JNYX\0]KIP!_5B/6IL*/0Y)3?W$<+Z0 MQQ@0USGZ:G;C("IRB>+N5+WYR_MQ@A)-5_:#0;J:+9 7M"P8SJK+7F5BI4MK M: US$VK:34$\7D&YIZGZ_EM4"32W9!R)"KCWCY0AOFA4136$<#G^8\6>=A>/:(^C"+&S)Z[U6K M6.X2\FZF5?->N Y32=R-XJO2T!!K8[>&B">57\H3:9C2XBH] P&/JS[!C4?Q MT*Y:W,H;IXZURX]9V'.ZJ8ZUEI".M?IE=YR][(:W-'F:_ 5,_O)K%P\_^LT_ MB>G6VS)RM>YLR6RXUAEZU;6JW<@7OD/USAL1TQ'3B&V9CIOKU/+>? ML0#BM+MGZY(EH5YZ%R?8[>A\>CF]KD06(Q$?MHT/V\9JPI )B=7:QFJD\H@/ MB0^/I0\/\+/;4]=RS%/[]6[8]FV8ES=3J&#HM&@0A(UWLW4R)%\D7R1?)%\D M7R1?)%\D7R1?)%^O"W47>$*Y^)#V$RN =-T!/T7>P]K);,RK8>NXEG)7PO21 M?>?G,AD,864=Z9"G+XV%5Q]\;)6F"R#@< MU4QP$H:RQ2*RQ5M.%K4FF_QZ1,Z.HHM#FSZ4;&V1UV/[0R2<))Q[T%'K*(HX MO%P23A).$DYA=%34CFJ1=))TDG2V4#J=CKD&VY*$DXY0'$3 +QSGC6VN#:", MZ6DRIEM[JU%*=1\J74;.5396,9F/19FV\,*Q_2E2-*1H2-$LW&=T#/E( 1TI M&E(TI&A(T4P+M3NV)>PP"6D:TC2D:4C3K$U20_!D"@/)N1E-LU/KQ75___6[ M27'W&,?C=T%2=(=9,$ABFZ1BRH42>;3NJX_B.YBN!Z?O!FQ^6EJ5)XBVPU.M6]83(X?SC M"@@*D#/I\G,V03*<(!+Z+ZR4?LJ*@K>/PD:+62IQ.K[(#>>9TSZ:_XPC7 =M MCVTKDQ[P2\QQ4M)N,DRJ%&G=5"B=C!"E/LOK.K0T&R4I_\R[3&)+)9"3"6]_ M\3!;Q5Z]BBFLXA!7,2[+/'F85"^M /-Q17EOPZJ%8+72T^]QI0GX?ODQ"Z:> M@.\)^/Z21D^3I\E?P.0)^)Z [T]Y^N/F,<@)^)Z8[N1,=Q;@^R,2]UC&Y!C8 M]W/6G8'@=^;?L3^[L!+SS^-FM\JJCW0\RB9I67Q+ANGZ@7Q;I34(,YI8K86P MT,1JQ&JDU8C5+H+5S@YV?]'GVC<7+?"H9KI90S#WIQ1T@C$E&%.2+Y(ODB^2 M+Y(ODB^2+Y(ODB^2KZ,$N6W:'=J-?KL<2/UECX."E*L2IJ*$TZ>TO&&5IUC.B$1+X%PK2$6 M<1QQ''$<<1QQ7'L(1QQW".%HF[2Z_^_\0#7K23%,.7YD"W@IA91-RJ*,4YQ$ M@\;\+UM5U/>K""V4UA OV=N.>YSZ5,?K\5GK+)$+%"N\-) MCW%8T=[T'M;OLVZ):*,+=V=C!"$M.@B6RSD?CP/WV$,I3=*DA.\_??ZMX('L M4YSG,;ZDG^4;1W _)^O'K(1ODG@X?)Z/8O/(68[-GOG >U(_ST;SX<,7K ;Y MY=BE%3A-$R(5AP0OPE^3K%=(#ZP;3PI68ZLFB*E:)G=+M+B_F(4_A6P==0*( MB%N=-']@8 *E<0L+B;Y<_WL$2L'68_0;Y%\;SS*^_J-$3""F! MD)XRU#)N'0_2Y29^A@$YIR:!01Z1ZNO!( G7L=7MID^S_TP(:,1J5\IJ9T= M.[=O>+PSPK]6:2,L'!]/\NX@+A9S.Z*$O$5T;IWTGXYPK:F!4(R.93I'IU$+ MQ.\DFV D76T@7'NDR^RHBDK2=32OX?*<@UW.2OJ-G:,T*QGAQIQ("UVTLM'E MCFW0L142"1()$@D*SH4&Y_/JA-FIC<4#'DMX;ZUTBV]);5UG/*%V3$-<=_5K M#R=(N$BX]J"3UE$48;["U0L7Q>K5_;^!#U#@@OYJJ*]2@V.H=2TT H>]D$ET%85<@YE9>I=61QX.=;:=46.:.$ M PG5$85*[3@"C_+=BE#MA(ZQ[N^_?C/PNK)$*/K+\,UK)+S!=;PAA M_ __^1]_G5X4Q4G^>SR<,+^G)'Y(ADF9L.)G7J3.>K^FGUAWDN?P M-+C@ERS-IQ^]N$B*+SB^V=-Q>Q\I^XGUOW\3!5AH\S?M'U^"-U+2@R_B;GFG MF;H?&:HI:[9CR$;@6:IB1:IAN9YON+[QYH>EE=IWIP](OA?'VD^/$Q9X\Q)F@> MGOECANPK&TI)NOR60<+R..\.GJ6GI!S [T^#I#N J[*"2:-JG4<<"*&/\!4Q M+XY<8=9#YKZ^PE):6X!UR/,EA.!(<-V2?L)ZL[EG0[ 2#LN/H2ML/R8!:MR M2]@*SE5@*[SR]C.__I8F3T7B!Q2)2XW:<(I#1,4ANT.1WUZ9[D_H.2+Y*OE\G4+Y\Q?HI^?C48L[R*@ZS@>LYS<^=/L M9IUPLXJZ^8J8M(W%<72*GM0 J0%2 Z0&*.&RVXXV9E/N<+)8'(#[U'Q'FJ(_ MBOZ.<:Q8[2BRL(YK5Q_[D721=)%TM<W=8=Z;2 M)6S!:J;1T<7!M]U,K32I&E(UI&I(U;01EH$JR\>W4UFN:$)*RPV;JJLO]?;+ M'OU%3?Z@NOHK"(O+)$NE&V$U:*8K1F*5%'7<- MXW36S.>9TD1M2A/=3(V8VG$<4QCOW7J-& DG"6>[,P\DHB2B)*)D/]LIG!>^ M1].Z33W26?L('!4^WD#AXQ$5]A67/9*B(45#BN:,.6+2-*1I2-.0IEEWGZ9T M9/)I",IA[Q$V81E4'5A:Y)!=J9B,1G'^+&5]J1PPJ1\GN?0U'D[8]!L_&P'K M/,_2G-;[0LH133P'49-BWJ]5BM/>;)M+#,W_,$*L!)=XR M?.$M@X3E<=X=/$M/23F WY\&27> C<4+)HU87$QR-H*Y%W#3< COPW&MT/>P M#;\N&SVPO%&BJ'0D558L(8^7XIQ)"2Y;TD^ #M.I9T,P4T@ZSLXO5TY='3-O M&B'ADGS_QA8"2V)IMX0NT;+;"5IC+_=">.WO6ZYDLTD!]JCX=@]GBPJJ"3Z" MZOA;Q794QW^B.G[>)'"O$GZJY*-*/CK"T88C'"1?MRI?%WX*0T"E[&C$\FX2 M#Z5Q/&;Y.;W2MM#D)LL\+*=CR\+ Q=JRE,,7'0*@2D$)NEJNVF[+@LFHL'[SE)V<<*D M.$Y'5H3M5;5ET2DL;(_E(9FX#IF@&.D8#?M!6?MV\ZF@B&15+J$#0U-43H6U292B$NUB:1J2-6T4=50<>*F$5(] M%["S*J;/M'-+-4TMN_VR1W]1D[_X:K9V-(JFDB*J9*-*MC:S'35")K:C LH+ MV 2M/N+E1VF$?'E'W-J7%K_V?13:Y+RE(Z0D7R1?)%\D7]WV M]O-M"XUNLESQ"%UCVK*>Q[;)9'I)%UR5+E"-CDZ-*DD-D!H@-4!JX-411(MB M]@OJ5TLE 6M* E2#2@(HU79^0T_">8H FD241)1$E.QG.X7SPE/I[=M[H3H7 MD52ZB C[> KIBJM<*!%'BH84S1E3>:1I2-.0IB%-LU;36!V3?)KC5^Y.__[K M=Y/B[C&.Q^^B.,E_QQ:65?\<-^TUSH'_7#6N[/V:?IJVRH0+?LG26>=,+RZ2 MX@N^^@O0R1MFW3]^^,__^*O(I^/]?%?@"^L.TN3?$[;T0CR3A*OTB?6_?Q,% MJJS8?]/^\27X9SV*?WJ3(DE94;C=?T^2(L%GN7\FQ3_[V;#W3S\>0@ ^*;PD M&P_B?!1_2+L_\XZ:;Z2D!P^,N^6=;1N.J8:NK*BF(0>F;8>J9WMRY.B&K?K^ MFQ^6N*;) 5MJ=MDC[@Q)XSQ[ MS.,1=1I=?LSM5J8K0BK3E3-7IK_R=AK]Y;[>/D%M^1E*!G?WJ(Y?/C@_NCQ7 MT'[3 NVJK4];:WO T0>*.5^F#Q79;N8W]-,E[JA7K>DW!2;29S8NE]O-R[S= MO+#HC5BU=>S9)H4^"P?GE)T%AL2"Q((G8,'?&B'PG+@?,!8F#B0./ $'?HK! MI3T@2TAGCX_,ENTA7.OD>;O_?6K6(W:[8G9K!XN1=B-V:P_5B-V(W6Z6W:[5 M#6[?D>3VD*UU))(X(#[_/4U>/ MZX1]3+;;*\B-:%0?APH GBB@&M29BI#VDJ;\+<&JO/+^_A'@KTFU&W?#Y8#_0 MR$FE.OA4Z+J 2[W7BEV8&YVDXW%_TO);&#RHNB9#IK0*QW"48QQ;P%K1U,"S M9#1E%;DVF!I,#,N>NN))S+!\'3ZR=G=X1*TO/RTWD/,RG@[;YZV_G+5;'.BI M%W8R6;\*N*9G0C&Z-0K=&' ,. 8< XX!QX [#7V84[6;@H%'H TSLC4(V1AP M#+@Z *XYLK123_,_A(W1CX6P0O0NSZT%.IK9M\QX>5#?,O9T.^NT.IT=%.E# M=J-^M5_TV@;56)_C!?C\Z-7&TEICZ$Y_?'4Q[ VONNW;_LW58#2Z&/1OVJ/6 M1:M[T1Y?'J(Q=$G801]7.@_)@Z%\)^UHC/1L#"LV\F:"+V+.87;U%E[QQA46 M&G+WYN4WY+X*9L E%O^:S@PM;ONUB"EI^,IYV,E8HC)EV.A,\G2?9 MZA$NM3VXSYVX\..S&T]5_V[MHJDK0BNTIPO3>)ZZ]M1P(\,1\%I\7*2:A$J+RCEA_Q\D]N#*^TY9-^$4_",]HK.]@%($:&/IW/QG\E :H>\]"U M 57@\(&GN4^ ,%;X Y$).[&[N$N9Y"@Q#+[3$2R> E;%.7H:4RNBSVD /0[@ ML?#\R% 7*G2D<+ICQ>*7P,Q:.%'.)A08_Q M",E>T#E2G41J'O$TB K2 P24Y7FR9;51"JJ^I;_U3J2 *"\E*NEB_F#\3#@R0" M>1=]+,MKR\Y9'MCQTH 8U)QRJ&[MHV6T8[1[!]K=!V B[A /.*K$FG*M[9?< M["_; 1P#/-&.0\U)MJD!Q>WNDV'Z8OIB^MKW(.LM586CT0CHOJM@-A,AA7'G MUER$K,Z7QGY*AT]=<.;];4"6@-"$AA^CCCGH]\O:>5V.LFKUA-D LP%F T?/ M!MCALBFBC=Z4,]RL &A@G)HBTFS]L?57 7/J=\QV:S59CVT_IBZF+J:NNNL$ MQR7ZKX)P'N#,%<,1#W$%PI^YT/9 ;"_ M B@7J@3$F,!NV>ZN$_]Y+8OI>"R'KMGMEN8SW!EL=2%+-MN9.)DXCY0X&V[U MURX!AWG66PBN"P3G! G66+TG%[HNQ%A:A'5K*#4A!-L=],W>16MOL*D+-K#O MA%D-LQIF-0U@-6]NR,65Y?/3J2QO=TLI+>^/N+JZJ;_6-VOQ.=?5'8I33 MIY421[;2N7B9:^89[4X,[59;JC':,=IQJX;:)2_(CWCYRZT:M#;(W*^A5L'3 MN@1':Q?..OKX)],7TQ?3%],7TQ?35Q/IJ^'Y.R54[?@QK P'!-B!'[E@O-%( M%QR.1($LMJ'W$FSG6'K#&B-HG?;+VGY=SK-JG85Y ?."H^(%G9'9;I66-5.7 MHV0VP&R V0"S@;U;6#7R:50)V&LQ$2'."K2#V5SXD;*[/,O/AS&QFZA.;J*3 MJ1'KF!<7@])P[]1KQ)@XF3CK[7E@$F4291)E^5E/XFQXC*9V03WF66\A."Y\ M/('"QPH9]A&7/3*C84;#C.: /F+F-,QIF-,PIUEW7[=MMEBGX58.;UZAWI:A MTP.4+G/)8R-*9C,K7!C!Q(BGPIA8;F@\65XBTF^N@AF@SB)SN/<7!XI$P9L**DE#,8.\1W.1Y\#YUC*XPTK%(:+Q^9.7(!#NO7 S&%H"-T?KERZNB0>=,*N2_)WWX:E=*69-@] MI>X2-;N=6VN\2;THO?;W S'9((E 'D4?WZ!L<4$UMX_@.OY:H1W7\>^ICI^& M!+ZIA)\K^;B2CU,XZI#"P?1UJO35\"R,$BIE9S,1VJ[E&7-K+L)#:J5U@#;!=O"GPA4;O&6Y6.+L-QVV>DO[^ M&';+[(Q6HV.LHK,)S"8P4U?=1=MQ2; R!KQO366-(Z;VQ879:I<6JZK+H;-9 M6!_)PS1Q'#3!-E(5 \RY#'5-55/_8E2:?G?J9:AL7>W#NF+B9.(\/>.L?N%L M+A@J$TI-"&ATVVUSR+6);.)R;2*S&F8U=60U7)RX:85SV9J^^49MO?#5;/09%7LD@Y.:E MN-7/+7[L<10.<%2\H-,W>SRHDMD LP%F \P&WFU!U,AF;]"\6BX)6%,2T.ES M20"[V@XOZ)DX]V% ,XDRB3*)LORL)W$VW)5>O]@+U[F4":5&6-C5,:0CKG)A M1QPS&F8T!W3E,:=A3L.LTU13N;NWA1U=67"E,TOO-PPEO0I\ MPFK$UZ]!+-3$4->/ YJ\264X1L>PK5@\!F$V<'1I(*D<5)J-)3TW[HN_/UN1 MX8A8A#, A&,D$; &XR$,?HC0^".A]\)#+0/._LRR8_=)9"W4 OD,BM2L/%>- M6Z5FGE9?A1Q![/KS)([@=4"H..8W>(A$ M^$2M"?"!-.\XC<$:'P+XC%_"3@LO_V@:46)/Y0-AE2**#6SHN_[!%J:0SF:! M#T2F'D-WP58CR4QL*PP7N,4"0]D(=8UNHR7(,;$<@E@,QW5 ;,3&U *\PR\D M*72S*=OE#;^N7#( RI7RH(JG=#.F[V\#FU7--SY.?L3+7R[,O+*BJ6G(-K:_ M2AWL%MO8DJR07Q!KO=NN=SJKZ;LR-ML##N9.2+ "'[/A7#9(=4V>1\92X7P; MOX/K(Y$Q1!"1=-]ZX8Y"?$F.DWQV<<=H_6;/B6D=,V%%("1G6*[A@%B48C7; MA"K@D'MPP=B(8KR4WC/+L2GOQ(_KM9XL4"Y2S2"RO)5^_82-&H2*.U1:S6RE M%_,. .P@8. 9<'1&$H-V\L_=;!>E6D3Z7L_+8?=?@W+$CPW:UJ/<3K[L6-A3 MW_TC@>\1"Z02%]BP!=2,'-@)@ /A6.W+6H:68=ZJPYE!R^7D!JAB!(/M9Y)&,R(X5CV'XD;N:FHOK(\ MSW62R+AT@_G4"F>6:7SQ[7/C0^J>Z;0^IQ=E7[4_?T3I^35X(M)&:NY*A6@6 MH*-"8 <;3;BN=;98H'$$#ZDG1*(2,D/D HAZ'5VXEEX 8;O""+9+9X[R3PCUF,HB'^; M=%^^*#-5NWRX$8<,HZ8#VP7-*= V1+H;W @K\USA2.#DNX UST4(BM,,WOM' M8H4 &V]Q;OQLN;Y4[+P 1)%\ANO;7N*03X?6%L6P 9(ML-A@KLX\*I43,G&] M3ERH]V;T,[50;0"LR+1UAU3\S$\3HCI,+]N6($ M1.0Y "4C3#9M8"'ZZ@Z. 2 M >Q!F)$30$$Q!B ;-W :0335D\^@ O*9!!X<)N*[=M9&XA=PDA IQS2%I,O& MY.NDJ$NR%%W']Y>=5LOXAB50R)D?0VOV<@^N>ASW'E:H/>9T6S"W2VG!W#YP M"^9WWLZK;^[K1WMHHGR WIC;IPY5WR=6+H?T]-BQRR]VGDAU&0 M47 /*/B[9@)K?ABTA1D#&0/W@('?,?Z]+2RYR<[^T+(^@*L=/;^N?^\;]1C= MCAC=ZH%BS-T8W>H#-48W1K>31;=C58/KUWNG/F"K'=TV70EF9&L0LC'@&'!U M %QS9.E[H+:Y1R$^\%KEGU(-,*,BH^*K3N/WPZW=.F_]Y=35XSIA'Y/M]@IR M8^;.-0G!:D-3'O>R;A;F,. 8< PX!AP#[G@!QR; 6ZWZ*\_U9:L1WS%"\8B5 MJ=C4#)XHHAC4FI=[SC#25FSJ[P*N>,HZ=K!V=WA$K2\_+3>0 M\S*>#MOGK;^@#3.R-0C9&' ,N#H KCFRM%)/\S]D\^J%L$+T+L^M!0T>8;QDO#RD M;QE[NIUU6IW.#HHTCUUM6+MT;>Q#L3^S/C81VY/C3!0:C4*]N;7NWL*RI_#K M/ CQ0:H[MQH4X.C%3Y&YU&4_YWF41C7/.&+Z+4YKBLZ-G%5JW:2S.V?X@@A6 M((<#P.+L#$OS 0PDB[0WNNK$7MR.M7[$P2QPA'>.PQ=" )'L M55[<>3;P*79G E^1KA[;GLM)#WB3;*&^?AI-I+\@" U':&_##NK4<#N(1-[D M_5'@B$I33D4RW"CPZ&C-I;=:2RW=Y2K@)M7;??UZJ'T[CCB(##^@]O.AY=M" M];-/UT,-P!U7]J5/VWMG)Y")/./9]3SL_S[##O=-H9U]L*?*9R7DS=[5G+,I M3MR@DZ-A6VEG]P?+H_.%8]UJO$)I(Y+B:2@$$= I#TLB )3RI-*&;)K(0W MB_LDX-)]"&7M,05U[*2ZWP]*Z7[?ZS6Z?_R!7\^;W_WV3J-7WZBCVVEP +L' M&#[;1BV&!VBI7ZL&^O>DG?XJ]\Q!GZZ UIXP JCVOY0;=4QQ*CV;E1[ MM:'12:(::$?INK+R4P1_3>!"/KN]CM$B%]V1\M"Q:KA$X:T?D MI3/!$^AWL2U:-:+EQ< \^F:/)7D]D>3(J&M[)]31=-7N#"[,X?;)ZR=/7F]W>AR7;^.;2L5^*;'5 M]2G=FUV6^V=,C>,_$ARC3KM3FH2K"ZE4+>!;!,N ML+T$4VKARBBVXJSY;S!7UB W:*@37WLMI>5X'%MMLUNBUWA7L-6%H*O6+9@X MF3C?HJUT>CVS4V+,]+V0.VX]AZFWJHCKP2CVH!%9<\BBE45K#8B31>L:T=H= MF8,2([HL6LMU(1R7IR#+=1>^4TV6.[.YMQ!H%PC4"1+LSU-: ?=19)IN"Z5& M*& CLUV5!K8&-'5!AJHU+>8TS&F8TQ0Y39LY#7.:D^8T++Z9J)BH6'RS^#X9 M3L,M^M_&A-ZXPJJZ=,N/>/DG-X97VO*;E287UV(B0FS-?Q7,YL*/9-7"-\_R MC3/CB_\DHCAKL_^+:NR_X",J;GI8[+\NC7[/OVYX\X M ^')=41DV,"O+-1E8(?DIK]U0V'$08C/] M> J7&L$4U10E]M286\@<76!M<9:-.OP'%1^5WXL$#/A1'8\&8::2!7J3TPDK5 D9P ;X4_X%?QIWP_G$82)["_2>([ MD;P?CQ_G'Z051+#&."H\#]XOGR,;[FN;AG^>+-?#[\\F07@&L)>M[S-X46O^ M2&2P)##)R1?IQ(X%04AM4H/ U!6A%=K3!;[G%_$D/*.#(SE<6 P@N)'$PN 'H,H?21"K^1(&]P:C<:=]W;\>=6YOVC_]^Q+OT5G$*\W@ MURD-39 N"MY&"G!#ASA+D5*E"# 2@BOP%#L%-U+:+) ,*,XY3)'3J3.*D@?@ M.BY0-%(N<0M@ (#\V@//#3A1HNC?S^_.B[?0^)98G:\D_75+"G"R#%XLN0P] MQ\&!!J&ILZ;E(4*QHDW)T],9.W)$#FPN9:OXHSYS))H*(:_W M25!E\)!CFI3,Q*,#H39+)#CD@<&E\U!, 6K(R.6M)@X $J "P'5T >CP,N,Y MBH%G3H$-@!#3]F"(/Q*0,J7.Z2G;5GJ+V-E5FN@BZ0NVL0,!+[$3[DN_N)$X MFHNT>Q3N;Y%(_6&O<]5I70S;-ZU^Y_KZXO*B,[R D[CL7':Z-ZUCDD@Y&UR> M2H0-SO@;I-*X[X;M _'>HKL"U M]T!9QB\!\#,>7E3Z\*(#3 JJC\JP!.'[[X^0>>B, -G=_=T'FSY-E]\LYZ]85QDG&R.IQ\ M93#/FU"22[E?&%D=@F6Q\5PS&F8T^R?T_3-8:_'G*8RA?&X],+Q+( =_C.+CCGB(38<-[+AS&,V M!,LW!(^NY5C''+1*TVSJ0A95*S!,$4=,$4-ST"DMV_I8*((],UM+8)42JY)D M_$>VFFK$C4ZGA4B[6]ID6^[NPZ3)I%D>'+L7Y?D23YTT3]T#<(^I@6S7[,?_ MRL6WI4*I"?[8GCEL]_<&F;K@ CM0F-$PH]FSO68.!UWF-%54^;]<#;-K(4NQ M&.9)^'$0+K2+WU#PTAWU6X/AY55GW.OTAU>#46CRWZO,SI$P4M) MITP?5[+&4GBY@JLIRUNR!E6]@CNTGHV9!3CM6EYD&L]!^ .6<#8/ UM$LC1H MXOIN-!6.\1@$3K1<3@18E4PP_2P4^+R?+<^:P%&NP&57!A E\Q<,MA6PYH\9 MSF/]K(8]>3SPO+4\9)?UR0KWE>*L9(8EY/^4Q>EY#2'50;KY,7Q:K58Z:O3> M@O><;.7/J)S*GXM3JEZIV>UU+MVAH-LIU^U\H/X?.Y3FG%J:_UN ^I8Z678& M[.H,8 SV("KWW7#X)#DO!'>"M])[UM!]KJ L189 MS%5 JHITPXM^]>G-C<":]WJ^."FA(N<[,S!F8"\PL.X%,S!.W2@!?O]=],,> MDGW5!22E,:)&1?[,7K\T8[HN)UFU=L-*#'.!8^,"/2[$8L_-=H"]+<1K=_$T MQ31V8 (6^A8$/ M?]IR2HHCCN]8:WX_[M36L\@C][XVZO>SEHC5M7QS000W[$ MRU\>T?1=8.Z1D8/:N,8!7\%.A##\_N<'!0<0[BA_M@[MK&L#WZ^,GX,L,YAVI64AP87X&#J1F'QMW4"L79 MI17!9K]9BUD1K=^[>EKK,J!2X.@ .[^78_;@_8Y%"1'I[Q(&BZ&"!J# 0 NR0*%3AH2Z.?*)F+$)X-=]TE#S'!M-_JG_5; MIG%#LZ8T@,HOB@B2(M'93?IZDU;CPJE-)G+N#&T$UF#,0:3#"^ V.9<,OY^ M$ ,"70@CCF>KHS-3HLRH'90\@:L_0;] : MF,9W8/=^(N2PL+1#MAH%>@4,,9B)<&E I@W;U M7>"D76095X4)>^I2)?Q W*Q68NP"DS6%=.5L#=1(-6C6SIJX7:E)Q/?6G\8- M<5-%N&-MO.!O-%YP[>9+V?%ZB=TI2&SC6X@3W4 4%+" !BO^/!Y_,T(<7(CM MZ.0,Y)FPT&R9J6F'6;.Z&#:Z:88E_*/F0N(MEAI#3 P3[O*L9Q*ML1XL0??2$$P!\UP#L(DEML*:>;G[W!S6#S53'SCT,L5 M:1IG9VWB$L(4K1<2[%L"ANY$W(?+@,VC2A I^;YN1^L&AB+17"4*D_XS>(B M:F(E28>Z%M19KZS41$LI*@ZIRH ;],&2CI0AHJW_/RV?N+0L3AD54"6=CIJ^ MR=1GI>9G1;/!C4=D/7!#*5SD7[JCKMEJK0;1=K(BLD-.1[IFTW'U,;%6-E%V M&Y+T@H@8AWX=,";7=N-4*RNH5<4)N1;1_^K(F?J.:FVLX3\\:UTL&_Z_6HM\ M0WC-1OT$[]Z+*?Z*):H;Y7>I4?MKX.0*@.9OJ$J0(S"*@AR9C69Y ^+K4$?? M@0NF[V/JTD*+2(U&QG4J\YHD"P+$58Y-?PG<@ MI$(7&* MOS(-=R+5"32%/3@Z''G]A,_--39XQS0@$S^!L_N8"A6Y2!0=>(AJ M KH163@B6_Z]W_6D>E6ZGME,.*C= !(]"!0<:Z^*LGV<&U_TC2GH.X&(2,VQ MZ( ,%)SJA:X_3^(,[7']\I98V%/?_2,1:L0[GJX\>U@O72^W3Y(95V'JU[A1 M0:LB?Q0PVQGI:>H]8MWN:"XY*2C+F_AL?.A(#'G"1P'J%"ESS6E:"ESZ<6Z^ M^;V@_TR+_]"5BUPUC-8M,")N02XJ. G0$A-I7H VEQD2A5_6(.CZ-[T?D70> M^KJR:?D^#EA3>J.I'(X(Z1=5RN7;-JFIN:!4^NIPDX[I1KF"">!8TBPE@D4% M%3(U+*;6DR#2*- .\C)B\&9!"TWAG+VK^)2=G5RL>U6A>[57@BX2+;;7O]J5 MZ5^7202 N$(^/C@^LJ 5[K6J-4'7>O*LT* %K50@A5>"VPYE6&GD3VA0I6K MK:M<]593[I$'X,IM INK^DPY2U![4%!;T1]3(0DL3KK5716MD!98F#GO@O 1 M?ORG.C&2DS/ ZTR[%*!;"KH'_K50G,%6(A'C) 'J4)L74E!DVR3.BEQ8Q2;R M5:YRXC=PU*V9MOIR9;U**WP@OXR'8@YT[V@N%XR^@DS6YHM27\A'TL&DOOVU M_%V'QRIW5RNJFD4;MPAF1^H/E 0YP59;],Y(".,GC=E\#4#EZ8(TQ7./I,9Q M_M.)A-$[%]5P],'9FDR$&D1RZ57/ M=%'F;78_9SZ@7+32J=3.5AX=RCB@EB4#BCI M[)9!% O#.78HK(A6FH-=.I'SV$]YKN[V>=N JSQT I9"5B_C3^8R\E%-F@4T M EVL'X$^?*=-Q#']5Z7I8-D^^LV.@X*2N%ERJ2>8+Z@3Y7!_%2"^M_X4F8S1E(D+)DV1@5L:;[S%7)LM$KS(8J,_/9'2^,GX M+CF$#"$!$OU:3$?1TH;S7)3\RU^TK)3J^%[12Z3Q/8!Y&F!;RA7-G-_HF*J8[##!_U75( J 2-$&D%,O6G?& M^+(@B5]?-*Q1N"3\=!0-\7L[B&*5W*&P0%M]\(#9U?2X>8A)UJ"*^TE$(L$- M<1'ZXLG1*+(DR?6(F"WF=7R3U)AYT3-K#;8FE[GF#46:+P2Z443R'-PUMY'ZD.N!^1.2.U9A7SNUQ.DI>] I0%ES ]8YYPRBS)F MN13_2OD<4<4:_(>CT9%(TEZ.!6LX59$UD1LB6'N\>5(?I7JY?B%)4I,5,1"? M3(M*+4>U?,X!W[<*U5N?RT0_;301>U6F,&U5S5"2MS KHOBH'#>6%V 6$;Y+ M-V_D[F797)\H4ZJ78$9XEJTT!;W2Q4M+?+049#UGB4+;LMJ%?'>IE88O<6"3 MX2+GT>E]TD3!I,M0@2C4U,@L,)+9I)F-53!)TWN)AN']\9(9.<$XS\R-LA$X M6KD0WF2G1Z!\6]+%*.68RN9-1\& _'"4W, M GD/NIX$I*/IJ:_!@!)V,>5I?9+$JR!\/3*GG<[_W2I&=T]^E#PPER?6IP(D M-?;G:1W LJT^M:1]9N];O5U8?E'1'2PFSD,'? ^KPL M"ZT4W<5,%1;44H"'JD*M35Z27 "!S@Y,#E05TW 26)5-Z:RF@>U>/!!A,A%,K@ OIM>L.(1S@.DFFX3*-/M&=0+6@BJ3J\M'<3.DP4\%DQH7$ ( MYY@:1X^)++2 U_]'\ P4'II4.H7^=MN*1)KFER\K"^ZN3_B0FHA:"180Y?YE MS;R.,)M^"LP&%='7XIH0.KKQHDW9;AF,M(N7GQGP5Z2>7BU'VYJU M)0H0& S8"*[3'H;6YCP@)T20A7F,7JI&_.9K\;=.7]>-")+"$Y3[GBFFEO/D MDOX#QB#Y;%!@!@__(.]$0$4\N ;0%6.E%BA=23LP/5K^)IC17N$DC';K[+\R MN5ZTMI=# WF>.H(S+8V.%7R*/GV ?%YV+[T7Z?*59J*2H_6D4X("*3);%S87 M['.IW>=Z+GV_$KUV8U"#5O>N0ODRDOJK%0*YJXD_%\U1-[(RMW9WVL:CZP M\$3:]*3G&K_@?XVN[@K6*E;4]LFS%A=3LY!!NQY MFJV8OI=XMO0M%\7)*Y6Q>1&5_CU%E_+;#%G:.@,-BU2@S+&PXM5%UB<]1)," M:E/\2WC68L48U_28PM-@4=ZU>*#9'>!U+5M#PK-U9+WVW+IIH5V@TP;5/ MQ(,D5_P/X3PB%J9RN(UE$_=6^$@^L^4&4N-B##J]>8PX7VV,'('R6O%JG-8O MI*?P(&(4'X0#>=I0(39$T;B9Y0/KES6I^5;4B')%8'D6"^Y\JG8NPS1 DE-W MCI9?&"2/A9I8,/&GJHH"Q4H>8]=9?J:?XJ-!__94S7\#Z23@4I9TGBV4M@U\"5FWAHCV JJI0>6#:-!IT,D28A<*'\?B>P M:9/RL04U3%;>I>)"7IX)&EG_]0]O1'=LXU8_O#-"C4EXLO'97F;O%+R@_./F#P4CU;.@// (@_R!C,GX_=&I#G.^@*2V_] MF$:=TW036:,0NC]4ZA5(#JFJ2$^SBCP^6)&;B72\3L59)TFLY8P%((]")*ES MX[\QR:[89416@KX,D]P>U;L:187T&SUI,KL3I-@:6&)>$68GP'OGV"B)&H:J MFY?:!E!68"YZM,+5I?8#R#'_5 E9:U517 6Y;L]S+%HFS)>1"FQ=6!<<$"&5 M;SVYCS*)*&,UYI;<"7TPMI5$F8\74#6*A;*700"HA+4Y:!6J*T0L_0XY2U[; M0O=*:Q&@-C;L?7Z3!D.*W&O$MI(5OZ.6HYW%"]Z)%1_8UMI-\_495E_6=DX8 MK69ZA?9T^[X)U56S8L#>)8=FI"T1Y"K8?QBN).&=-AI.&TZBA/V0=0WNMEMG MG=9'T_@&1HJ;S(SQ#(WC?RJC",@S@>8TIIUJ$N3K!W"K4H%8$ MQ=)Z+FSN7#!"L1;&JOK(TD&LO+FZLF"G@%[.[9T*C[+ +91E>%KGQIW*=\.@ M\<:XK?(QT/G*8*U:0IXQ+YLI1S&]7/D\EW;D!'I'(\IBR^6"EGFV=L'H9\5K M/V=Q"DJ 4^T\L]Z?A77-4(*#"#LO0'+%ZGVQ2JJ2Z,4:X?)RQ^JM1!V L?18'M9J57:4**RO5^6&BYW$N/I1)CX43*Q:XOI6!8YJO^;$S3W"V\ MA[K@:N]6"T)Y+1\M\]6U]A;Z\5 5DIT7T)%[0%_$4GW+FB[:LDLTL%C\TD'7 M08Q8GK]"N1&6-YXF'A7!KSD!5#X\+(WL$H!0(1Y<33&@6%ZH52 "P=,: M72KI\Y2\U2]&'#;U9RE240#;3"A:B])82JYHJ&B> 8;5(?YLKZ@JC>D*X<*[%&ML")5XD<8M:Y6 M:@XH8KMS3R?-+$%1)2Y@\8:K,B/6*Y$+I09A)VZJ2,$$P(GKB3!K_TJI"OK. M<%DNQ7HH64.A4JI);3HV68"XDV/CXD7=4ZYG)8=D\SIRGDDM4&6K4(<(12YD M1:RVUW6C;**F5:IBU=A>D0-LK;^D2J4S1+9NAE+A,)%?,!";=X?L=3Y66**L]#S5'=BVH%*S=?Q[:?EI37S1 Z#7K:405(QNG<7_ELCXEOT@B_'Q MK;-T*XQMKI+)AFR@D@HKUF>NKN^&@3]D3>DS=XW4KWP].R^7T6F#"#K>+/'@ M&VGDLRLKO%!YFTD;U]"[."),*AM*CH]<<%D'YP/1NN1>9TF5I=09S."]EE6F>+]ASWJ AXXMY7:JT)'/? MJ3[1!>.>H" 6P+,G7:A8OZN!,2]C7F7HA.^H<^!&DXS]GZ^RI9>GV[YU:JT^ M\?8WK8GP5;9+^##VG6]:?MEODRP3(>OC&:V9IKO%1-Q^KW?5'W6&UZ/13;\W M&ERV;VZN1]VKR^[5\+(UNC[$1-R2=#GZN%+;>5U,4T_[99^N^MP9E*T^SUP; M]!K@0Z$U%PDPV$CS)W[Q[?.5F;5++4Y4^27.%^G 2Q!\C]9C7@9 L94G$8)4=/+R737(9383(=)/%N";4&SF":L6 M#6I<-S'\ (L@LCIYJ>FII6 >QI.;-GL(U>@24#[1>(8WDX@%'HB_EJ)8!+XH M)SR'PQ]L=%S($IZ'<)&N5W)?=)-8]M056&_P#(I)-,=F1^E14)N")W0^6I2< M(9"=NW*BE(OG ?O')W_#:4'9D],!5("%4KOI1)2>4UH'TTF0A+$0)74O M1:F&2CHN&3!Z@0K;8VC1H#PE^.;N7"#=Z2I#*2^/GX-R-B$A+\7DH]#WDP8( M+ZT8X[+JQ(HRE' "A2;M#'UA$T#T0-;Y2'22#_$641"!+,#W!%1\!,\+0BS; M+"C&O]Q=1P6-N#'<;=^!HM(W<$^I>B$8G7!$?I8-M:[+5'[0. T&+'!064'? M,/[CRC,^D(ZZ-*U1.^'\W@< A"T1A0!S,/[_0NW,XCW6M8-B3F ;/6XN".W$* MQ:I_QZQ81XZJ+=(N.H"+9WJ3A&#Y@04!-RTU5;@ISI*G6986(%H:_\Y-W%2P M1,8C5HBK[BI:94*4I>9A0;B@9IBJC.]1($>>3ZG/X'4>%@%+(ER90EUD;=), M3AO\Y(J!X5G8_09O.LWS1S=_ZE,J] JR',R7S?2@-(\!"VG(7>ZXUJ,?J"39 M(HW*LIR-%/J*L54G+GH48@ %>J:U1:E>\Z)$4(H.LL\U>CYV*BLZP.[/X"N- M!9C2M_'#Q]1@D!CC^\M.J_77\7T'?OV(2B5IW6:FL)R1PF*"+(I)T42O9X1@ M.2,'BH::54R@3N%<:G[ZEJ_\8 M?[_7"%!G;W!G+".*N74"D/*$K,0NE%A+ZP)@CB'B:(W.3%5EZ:ZQ,EHFF$N. MAPH4D\O^-J )E0@G:CB@:WB3]2(%M659@T@E?;H>I74WJ:&EL]G4(5>^U@UF MM4M>.LOJ.0@]!\W&%XQNZ6B3.%^.F506!-;;>1/*<@ E1YJW2'OI[J@;\9+? M&IL"A#(]"1^GF$A^T?(-WP40/+9GP:HB-TYBH5]K?"7MAT!Z-74]!W36 @_[ MCR":N[$,\10?_-L44(XT.-3,T+FF*H0SU M4U&;P_#4$SS>?,&^S/PSILSMQ;D?Q>:.Y0TN:;7.2YK0K>:?2(TE5U*+"Y]; M"U)CTOX/J=\DZZJ8]J9:HH14U<6W"++"TLI>[3BPQ^"#YT93D8G:@A5N9PKL M,F[*9Y%PUUP5QM4O7P6("@B+M4]<8R;=#I[W2N__F M4V'6B(()B"1440HBL,A8!H%'H\A3YX&*;FH,$'[])GP_6GB@\KE6@AVEB21BI M\<9ARJIE3Y64%]?7*Y8_NINTMR=^GHFVZD&G1Y[+"9YZMP@9$)2MW0OAQ?]+ M%DPLL!+4?X0?J0"37OSH+>Q &CHR( A&=Z0F!^@G3O+4 II!;U84V-(Q\.2& M2=$%,A[_O; Y>>AI$^1,^5?=DU.-'^Y:1@_90D-EIV$L%EVGMO"\Q+-"D"NQ M]0-=L92N )L!_DI9+Z8161,!J$QM-RP_F5@V& =J2'2#[ (]6/T EJ5XRDHN M4&]>,:?22"W]*DVGW"9-:$BYA_Q%"0Y,*R5*#:D,74:/9S,W2UJPR.I+T41R M+/IDA,$#YJUD#T=QGL1X"&?8KL)4PA%3"8L&:=$AOBDR=,+QQK*%T=O\?:2< M4Y"06E)Z@;4B;2[=X-O4 @7%N)*3#;[]3PO-_Z2SG F0N9_SLSL60C[T\Z M\0+*#,:NLG)BIM+K0[)Q9'[,3#4><$MJQ#"!$RIG6RKI3N>I(17&PE'B[!M@ MF+*XHCR#JS)6,FTS[;<8)7-4AE7L(4@;I6ACQM2HKO+95>>B M5S:[6N9-V=Z4 \26$Y13_Z=L.Z^(-=WY-LQK73ICHOJP+0.+,G'3A\NREW2 M4R&ZEZ6$RQY^Q#$R%RUPAM#"9B\V11WP,<4, '/IL;D90MXI:ZYU85%AQ)OO M]RK@8RJ.)XO>G=Q]N&13ZWJ^C;HY%>"8F^UP@B6P-]D%*GNLZM!WEGT1TTR1 MI:M7LL+TWV5WP+0'_;N8K*9Q+7';7/T>GAMW&YJ>RWXV>@R^,:RN\;Q:)\6I MY:CF#S(UGL0R>D5DF!R=O'^2?N*5-]KGW7+8UD/JWBZ/NV9:6X[#:FCW MJ"162\D#,5OUI#,E-U4TF;1\!G$CLIO M18UU#KH')H<9CF97@XJ;B98-GEK5541RQUSC+59@547GO5'9C"KW@[S\5Y,8 M5SI4CF)PJ9-,=_Q*Y0+XV&FE/*EY9!'U98V2B?1LQQF9!?YC@. A1[BIW./D M5UX3+DX)DMR/Y&22Y8A8 ]=IG\/=67A-)G1DI=9%FTXC,J31U ])/LHH&W2\ MM0YF4YEV5F:S/AU&K0ANI(!R843/BYB^6@=3=BV+7B>C9CQJ8["7BFJV*'SI M#2][UZ-^[_IRT.YWKH<7O8M>:S1JC4>]ZZO6H'>(PI?#SSV3<_DTP-;6Z&\F M!UY'=,I\(QL')QG+"C=7.H/D%R>7A+HV\;282SH/0;>F5KK*IKWY?55EPHJ_ MT*$67!*UT1]!(*6*V1.#*I94I8.ST^GDU&Y$L_M5>]M0"\V'PIT])#C.+>W$ M9F,ODTS@%?*]Q]\*=1W&;[+X@[*A3@K8Z&O.:_LS1[S4L2F\9*?13,1>]'W- MR(U@+=!E WK\8B[;&6(='!:R^3*!*(FG 74#9-YL?V9A+90/&$K?L\RC3!%6)3T15J76C60])ZI0 M6*'>DFXE2+I,\&DSV#_CK-^#*SOIA<&#=,%,B8#UP6KY6&L,(X(LS8=@(LE3 M9Z[4Q-(ZB8(NDV/3S%JHLEK520Z,N96\TU28+$4&9*\&V;FA\%"!8\7S'F:J M\P8U1*#>J*H<0\WXJ:]<.2;GL5!-:8G=9_F0V1#X-:U)"'_FVX]21U7*134[Z)D&:FO,7]<'M[,6A= M7HUZ-^U1'_^XN.RTAH/K]N7@MM_J=(_)_9#A?BRCF\(+GM-Y69&6;IY'CY@MT*>3(MY9RY/&S_AX?-6(O2TP':2^STK,'RW/'M%9US=]^:OU$GZ.Y9:>? MWX[HSZX33^%/V.8#I0N?D=MT'HE/Z1_Z_G$SVJ+"["_4$'$I_M]^&OYDA,&S M_+N=7?O7V,G_#-<^0:U>+FG8^?N#7-VKUKQSHDBHK MJRY6:TATY-<_JRH-_2LJ?J-O7EVF1I'+>*R1PHY<9F.+I"VYSMHCJ NXT%\R M 3GS:>HZP+0.P96+\,F6V__I95@I3I:6]\S_-"AV8OR?%OUO)UBN96KKDA.1%L%9*LBZM*A_L'UJO]FO:$13'PE.8))@DF"38.'^?<9[$-$"%>@ZH;@>F M:G @Q328[6RMUXAM':<]T3$'_:U]<"=O3C!Q,7&] 4Y=L]TN35N)B6UW> M_SM5C%***)854!*J3(;#V<9LN;.9L@WG&73[;*4P13!%Y(KN!=OM;+>_TV[_ M^TNBV<3_4/>W6NK%I\2K7LNF.4Z#H]U:;3^U;P#6@(39UF?2K!MIEAE)C*=RI$I4G_OU+=\MKK7^P^4'Y# M@?7M"BY5XTA]5-KE0ON$+1_@>2"\K_3^(6_I4] =75YTKRXZ _BG?WDQ'E]? M]-NM3N?BNGT][HZOC[)/P23P@(EA[D2L=!U ;=EO@%JDI"V$'BQ/=H*:J%;F MC[)UY[H9@6E'NQ4\W&61\304L@,IX$M)TT-H:DN$S9++FBZPEX[0I3QI;:70 M+@^BSO380Q<('BY]D>EPUX;2NC:T!Z6T;>CU&MTWX<"OY\TWI>5%S6[?[^L; MTN^C6:84PZ?00NA=#M9W6YTO6US5UUW?DW;ZJ]0G;TB?S$>ZO:')!R/=]D@W M.'6D^XK#$=Z/YKP>WD&%4:T +&4:U[5&-NQ4Q M5V.NU@2NQCF\&[#R4@9_3.-!/+H^QNW2 8FROWY9M%PC<-:.R$MG@K5/;ON7 MO:%5$W(<.@-SU.(22&8US&J8U53-:OIFM\0LZ[J?/O.:FO*:XZQ?Z/3-'DOR M>B+)D5'7]DZHRBAM_\+KPAQVN*]G=4Z/X_)M?+,6Z=#EC8FM.(34BJ;LLMP_ M8VH<__G7=,AJIS0)5Q=2J5J2,UTP73!=,%WL SZUL0:9+I@N6%ZLWO>AW3); MY;E)5L^].B91.B%MG6W($>P-$+R2\][1DIM8;FC@_'AA.$GHJF'),I!MP@5J M[K*+W:*M6*3&83!7UF!IC2!J!/KF\K7#M<#9-T-LF]T2O<:GWOF&B9.)LTQM MI=/KF9T:=*8Z#3V'J;>JB.M)=I3KF$,6K2Q::T"<+%K7B-;NR!R4&-%ET5JN M"^&X/ 59KKOPG6JRW)G-O85 #]NKKL:9IMM"J1$*V,AL5Z6!'7$#/^8TS&F8 MT[R-T[29TS"G.6E.P^*;B8J)BL4WB^^3X32E=OI^=R_N]2V^KZQHBO^_@><\ M61[<'8U]YVX:A/&]"&=?:)8G9F-$][B#-W7V[M_V6OVKR\[M]:A_?7TUOKFZ MOKWI#KO=X6UWT.HGUG;=H-*Q2 M7584N1-7.(85&?!3B*DOB>_!61L(>#A#^"V(X;W/;B2,!P&B@AY*Y1(TSDUY MS+*VXI]6NU97T!BZ0GE4T@JUQQ2D$K>N?GOKZOXI]?"MV>W-7CUOOBF;;TCK MZA>4OAWET\9.5N^+)[?[I]XU=QRA[S4"]"J*8 M/4VE>9H8U3:CVL]A$+U<]G"HE25^*.!=_WQE3OC! &>Y/M,HTRC3:'UI])?7 MX,8TRC1:#JK=6FY82QKX.Y9#5F/_G%*1*?K;R1V^Y'@_)'NI?;D!]]XL!#A; M;7/4*6T00^U/'^_C8I,:)ET.]VR$>6XNZ\PN9PPN:!"U;VX8!'R7K.D M1DZ1:NV5V4R$MFMYQMR:BY=3"TY^,-0(N_SUV!G CL?ZB*CCH2[V[3.),8E5 M:TWU2E,-3[S')1,>$][;-,=!OS3/WM&+M5,/(XVC2,1G>,S"T8)([.* ^_H= ML]UC)SE[_=CK5Z'EQ'3!=-%XNOC0*\U9QU8-4\N14PLJ5JTV"Y#WFB(U,OVK M!.RO ,J%Z@7(QO]+D.J6.-3MV"U_]JNQ7XUC1DQB3&),8DQB3&(G06*L(%9I MCQV7V76%&YS %F-!W4@=,0\BMQH+[+#]7"OP<)3FW7@--'7!EJH%&!3-:/J# MGMF_**_^;&>@U05_V$U[.#6"V1FSLYHT.F%&QHR,&1DSLH.E&7?:@_I [+0S ME)G3,:=C3E>E!=H=E=:0BQ6W4\]F^.+;7N((QW!].?*F;K-OZ@*HTAA5D]A- MR=V7ZW*655M[K.HP'S@J/L#USP+R >0'S K8/2G8JU,AKNB]O M@RQ^!876+!#E#CO *F7*;<-VB\_?[AB;W^4H":Y%K;=ZU)7;"A:@N U05F M-TR!7;0 [>DQK@^< M4'[6W^,'X I_PC85^@):>M8\$I_2/SXOHV*^*-WWEZ/S8*VO=WOWH5Q3 MK_^7UPEF+76J/;WS]O?>W^C;F[UZWGQ3-O^V0,+!--E*>E?1IV?)_Q\"SRDC MY-?NU[N+G W"3X0:($:[P6^T$7YC:L-\+6PQ>Q!A#LUNVS0ZK?;666\[8685 MT*T*0NK^RUTK#XV'/X=!]'( ^U K2_Q0P+O^*9Q:+N]GR_69@)F #XZ'3,"[ M+>^7U^#&!-Q@ JX5C=Y:;EA+&OB[Y26B&LMI#_5NVS/I0PX2JF.[G=HGLI87 MUSJ&?F"]"[,UX-EE>\.)$Q;CS&I.F]54,12G[AC _(;Y#?,;YC?,;YC?,+\Y M;G[#IA07A+[%>Q.$\R"T8F$XXB%>V\((?H_=X"VQH*T+N1M7C]V^N#"[[=+* M&>N"!54+;);+QTP33 U,#4P-:8%8MU5:70;7?S&Y'#FYH$+5:G=8A+S7+*F1 M3Z1:>V4V$Z'M6IXQM^;BY:R#7=M+'4W[J.&%.1J.V!G ?L?ZB*CCH2YV[3.) M,8E5:TT-R^OJPXU)F?"8\-Z@.9;GR#AZL7;J8:1Q%(GX#(]9.+LU#CU>%T>W M979[I36-JLN)5ZT(LM@Y8I+@X6M,%TP7:\R=_D79>'+:5@U3RQ%3"RA6G1%/ M[7NW*5(CT[]*P/X*H%RH 0=L_+](6'U.(&6_6HU$T_&0%L>,F,28Q)C$F,28 MQ)I+8JP@5FF/'9?9=84;G, 68T$=3ATQ#R+W()/0&T=G)9+9*Z"I"[94+KT@+M#TIK+\2*VZEG,WSQ;2]QA&.XOAQX4[?)-W4! M5&F,JDGLIMSFRW4YRJJ-/=9TF T<%1O@\F;F!P+R >0&;!^6Z M%&KD,]V7KT&6K5OH:ZJVO=9KF6)'5,34NC ONA5EI[P!<'5!MZK%>8VHMG9R MGLES7]D63)A,F$R8[X%C==D#.T"-DP>8>C#\/H@M MCZ+?YDH,G +C[[5:]Y\ 5!?0[B_/ITD.M'T7E-0%&ZJV %A=8%;#K.9 Q1YU MP0-F,LQDF,D9"!RV2J LVE.C^^2LY.=9>O^;O?_MK M$IT]6M;\TYT]%4[BB=\F5U8TQ?_?Y"Z4L>_<38,POA?A[(O_)*)XAE_?XZON M 2Z77F#_^/?__;_^;?5I-U;H [I%WT1X-[5"<6E%K@W/NW:])!9.\1%P!#[" M^;N8_.VGV^M.JSWZK^[_W%__9+@.?&'9\5F[U[L=#V[Z_=M>OS^\ZHZ&MZ-. MMW_3:=W<7,+W/_W[TKGI9W#OSD1D?!7/QO=@9FUF@-KMGNN+LZD@?MONM/[R M6<.#?R11[$X6Y7JRIL*8!!YP:8":(3U6\S!XTQ!++6 MO=)C7!^.17[6W^,'X)6=?GX[KC^[ M3CR%/V&;BDT"^_.L>20^I7]\7F9Y^:)T'W/.-H=K8PK;NZGEFGJ]O[S.F-=* M ;6GP]Y^X-?SYGGSQ[_YM\6[#F9P5=)'C3X]2_'Q %*Y3DG=1V:?9LL=UKOA MHPVJA0BU?8]V ]=H(WK=3T,AC%_AMVEDW/B8"WPGYK&8/8 ^V&V9C'2,=*4C MW5=0E$O N9V$117 K4J8E [X#ZZ?HVX\#9(([,7(S+\3?]IP$OEGL KS#V07 M&M8L2/PX^LB"J4H>T3T CW@%EH?F&N@U8E1C5-L/JI46-6-48U1CKL:H5@M4 MVYJK554RVSZT?^8]:+DYW9RLFC18\W+HA(LO]EQ\49?BBMT]@U4E8AQ[]033 M%],7TQ?3%],7TQ?3%],7TQ?3UZE5UVZ3&OGU#8F"[*LJC465#I^ZT.5)MM[[ MT.Y?F.U!M^R],)MX$YO@Y(8W)S=^\[J>'^;T!&&%3OFJ%=:P] :6)M[R8]BNCAFNABTS.'% M@.F"Z8+IHB O>N:@-0#:X#F03!=,%QE=]$;FQ:!KC@:E14N.A2Y*;3/ZIL:@ M&WJ+SN9>L!#B3H1/KBW2QPCG*IC-A1]1C\RQ!P^@OWZ;?!=V\.@#4!QXJQO M=5$D ^ M9:+,NG:D43*;62%<%QFN/\$&EM2+-!2>A5:OS ?.X&^(/_%O0:U+)?"Q(2FV M+04S.!;4218;F09S+(N%.R+]47@=#O.)%X;U;(5.Q U'EQ]38+'<<)0;CC9I M];QYWGP#-L\-1[GAZ#[-JI/O_<@-1QGI]HYT!VDX2GF#)]YMU,B:C'(.]R'2 M&/:"?NHM9'*NO*)6?(";[1TS'M8-U;B%Z-&B&K,\QD/&PZ8U'SVTJ^;=*'LC M R:OAV&X1J=.L7)N,76R+::8OIB^F+Z8OIB^F+Z8OIB^F+Z8ODJLK6MTQPFZ M[[N( '3V5$TX?Q)>,,?4P=2N9=]5:?RHVGQN;OWS)E;[[DUWS(M6OZR-U^4D MJU97F LP%S@R+M#E.B_F LP%3IH+C,Q!J[3&XW4Y2>8"S 68"[QATT.SUR^M MKWA=3G+_#I83Z/5)]]T)SX.5F<:C\$5H>>2!L9R9Z[M1C!6;3Z)L)PQ[B\OP M%K^2650;;_*[X=@SV[V+TG!O5[#5A5ZKUH>8.)DXWP#'KMENE^9Y8.)DXF3B M+ ^.[8[9&3)U,G4R==:0.B_,0;NTIH4G3YPGGT)Q'\1@O8O-M0'L,=V/Q[1( MBET@12=(L.M2:87TQ^!2W1I*S?"YMOJE]1-\%3)UP86J]2EF-,QHF-$4[NN; M_59%!ATS&F8TS&B8T:2%VN9H6%HR"7,:YC3,:9C3K'52@_$T**U)SLEPFG*[ MM9?;:GU]/_\!OT9[]MM<>MR[&-\/.L-/O7;='_5ZG M?3T8W=ZT.A>CSO6IM6?'YNGHZ /<44W6705B5T2?C!"UL)<1L$T(R"WLWEWO;ST;,PO.S[6\Z)#DO!'>V_=4/ J/PFMH M]Q((*X!4)87R)89H&XTU53LY:\3#:B=OF8$Q ]N5@74OF('5(5>P\=K7?P?A MCS/7/YN'@2VB@^I?=0')298*M\U>OS1CNBXG6;5VPTH,WQ.$E.A/G:DW'B"MG MV>!^-_S6AY9DL9Z6KE,-JG$"Y0DD4 [,;E5UQ$>9@X_)84[/9%;SP>C=N7 MU^-Q?]BZ&+6O;SOC?J_;ZHRO!\/.2:1@S\/@R75@*Q:-6_1MUW-EIX5@8M@ M7.JA2'^(',PF?1MFAR$O",4\"/'3LQM/*8T0<[I]L@\L_/[!\BS?%D8T%2*& MGZT84\"-.*!+8](CX;7X(;)FF!^.4S1F8$S$$=P4//N&>FP4PP-IJ$:Z3)0V MT?F+B%RGL]B)$JO:0$/SRB\&Y[U1KSOLEY==WAZ4DE[>'9Y2AG7-;N?--W;U MC=K\VQQ!NZ0>'[J1$Q<7-"&U.RLN,+BF@&L*#E!38+RUE(#QCO&N3(;'B,>( M=PB&M_5HDMU4Q8JG=C0B/?IJDPOJD"1?^QAW+4H1:N/K!THU1YWRVK+4_?1W M\BUR\E$]TXEKCVW,:PIQQ0NS-2@OV:KNA\^LAED-LYH#Y4KUS':WO!R&NA\^ MLQIF-.:8(IHC&4P26L)?6&XEF<95E*(UNT/:_@K83J#Q7JMK MCKK[F[K6;,RK6FNI$4.NG3K#7)*YY*&X9+]M=KK[&^/4;,1C)LE,LBFXRDRR MQ/2#OMDOSW7+3)*9)#/)6N J,\ER$R=Z[?TUFFDVYI7H%7U_>YJM6\VL[U2S M?N[H70PW_#;'/Z.Q';M/;KQX\^S0T>7XJC^Z&EQU>X/^96\X&EWT;B\'G7;_ M=M2[NNP?7>.:L9H4NDB[PR!(+7\AQ<&HTQY^CN"9"+U PM:8!"%=N8(ZN[S? M!P"4\B!C!E].(T, H)QRUO:6T7([+?E9A,*P(M4Y*/KT(C&^$6L.H!N4M,*& MMLPI=11KNUM*LYQ>_YUM.SJ-;EKRSMN;O?IFMZO9[^O?GU1ZZ)S2'5G\QGKL MP[8'/\("]Z])49,()MO*TOTV@$#=^J 5X$?F(N&F#YN1[;_I"^'4DA+&<$S6 MXZIQ4H>UW?PI0MN-1(Z1W\">?GFM3+85>39K-L6>R;:V9/M=S"S7AU.NY>JN MX-O0LN/$\G*2^<6=,%MA;6 OE/OX&(I'*ZXG[7X!XG#]R+5KN;J_6UZR-9VR MM;M?:_<(:?6#Z^]TJ;B5'[HV=&4U-&4R/ O41MNYLUQP^WVB'< M]LDL=9EEWQST.A:&WGQ/^KM!^'-H^:_%@BM6&6NC#'7,%G=<8T_:X8VHNN!. M:;92D[A NW_>+:V?;UU.DKE \[C "1DRC#[U;5)8.V0Y%I[*8:3-L$TSI$LS M3(XS4O2A;79&G;W!*,>3!BFQI64UU8CT:B>].(YTVG&DP?F@>C94EZ.OVIAB M1M-\P#5*HZX1W&J'1X*D>97HHRS=VPQ!C3*TT?CC0& M55&G^QW@=]HF4HV(MKERKS9>O/? :;/##1_8;IWW2C,]CMZWQU3'00<&7%, MMWV#KCT"L?: X_C%^KX%V00!8^/@@#H-UZF-2=#NF\/!Q=Y@51<<8O=G\]R? M=<&=DXR!C,[[7&G#3.#@3* TM62U%5H)'3I:Q@)PB9OZUQB!ZL)\3E**#/KG MI>GE=3G(]TH1COILANW?110+QP CSTC\)_E!_#D7.-#0B ,#OZK4]CO*,!#8 M?*U6>>,\V:U<&UH\?O%=>VSC8J.BV=AC1L.,AL,P^[% !^<7Y5J@-8)6"PS/.\P$F D-YC*;+1$/MKC+;(VNO7 M_/UO?TVBLT?+FG^ZLZ?"23SQV^1N:H7BTHJ$,8ZB9":_ M*SX93L9'\'\7D[_]='N-9M5_=?_G_OHGPW7@"\N.SZYN1KW^]7 \'%RT^S># M[NCV\O+VMGO1Z]VTA^/+_D__OG2<^M'I;]XPQ.+_ M(O(YQCQT;?QY%CC",Y[=>$I/F 0><'G\X5E--#^SGFAZN&'E)_GI11Q^(T0/ M($I*6J'VF(+$:0%:Z'B"G_7W^$$XL[P"@V[C-=F#B=P-6WB>NN9O/[5^HL_ MR^ST\]N1_MEUXBG\"=M4"<# 'CUK'HE/Z1^?EUEBOBC=&Y2SU<':M/SM'4IR M3;W^7UYGW&N%@-K3.V]_[_V-OKW9J^?--V7SS7H[A53#QVJ/%86R*BV#M5*:UG#J,:HQER-4:T6J+8U5WN;/@

4QYVU)>][S-E%<*Y;W='#PN MJ^^[&_TP)AB><]%*%U%LA%8LJJ"_QI%9ISSY=AK$Q&Z\$Z:6=GF=B)A:F%J. MG%HZY272,[4PM1P]M?!(R8K-FAJY&/82Y?+<"=5@I/4:'ZCR[RT#:4[0\=#G M4??Q6S@R._78J;<];8VX^PW3%M,6RRVF+::MQM#6X+Q3?3#J6&CKU,--F?EE M^7YB>0:\U@7"=8RY"(T(VQ4 MP+R >0'S N8%S N8%S O8%[ O."T>$%%;0AW;QSX0DO"A^4&A]]%%([5]W+B\'-J#OL M'5V#PK$!AS*SP@5&N &7SM2HM^]WOQN6@J*1P,M#ZB;XS;-\8Q+(#RL(M\L" M?(! *0\R9@%UHU'OB9%/2*8 MY'^3IOOR*('JE\UN!N[.,\"F1%1'.ODN9I;K VCSY?X/S_AA MX;CZD6O7DEZD)'DS&C3$V*HO[511L[<**T6!Y$9; M(;]:$^J405/E2D57_/ =X+Y QB5#2;&M;#5%) V17WWU\2PD?/C.V9_6'V' MU;K@3-6^\AJ17NTD0^G2H/;85EH2WZMHU01.TS\?,:-A1G-H[WY] /<2M>V> M&W#\<*L=PC6O++PYZ'4L#+TA'O0J0?BSG)E^2)6Q-LI0VQQT2].&ZG+ 52L] M+&IJ0Q'UM94:Q04&Y_W2_%-U.4GF LWC B=DR##ZU+>3<.V0Y5AX*L>1-L/V M[Q1#JJ6?I#:*RH?^'N-HC>S=75H.4XVHKG:"BT-(IQY"NN!FE,QH.(342&6Z M1G"K'<)Q"(D9.H>07@7A;1!.A%NFN59!S5)MU*4/_=)F]FT+I].VW5B0<8#J MN )4K?-.EYVIS 4.S05.R$QB].$ U?:KHC>,L^C?7/;&G8Z-_W!L-=O#2Y&%[WK[L7ML-,:C-N#JX/, M\R@))^CC2FN8NWR:AP9$(X>BD8+Q1;0YS);>(@C>N,*JAJC(CWCY)S>&5]H; MSN72BEQRM7P+102+('+A(RAMR?=382 GLOR%,;4B8QZ*.7 HAP;56(#]]!/B M?^);B8-Q?V0?%'FV\,/$]2W?=BT/W@Q?X"BCR'!]NC=TX"=A/+OQE#XK2IJ' M+MPQ]X!)/ I?A);G+?!W=*8Y!G4E% 9R//ATAP\E!!C/8!.V97SX5S6BJM/Z M_/OYW;G66'H\_I;]V/[\D0;NN-A4RIUIZW3]"8X\040R+-^1R\-7NC[PW,2F M24M&'!BW<%G^]';K[+_H^C%*04\4?FFU<8G?Q6/BR0??G?U_Y\0]0E0"O(6) M;U@83F#X00QOLKW$ 0!['MXG7UY-&MA=$":"]$8H_$APP::+Y(H 9SU\<7P#N!,5N/=)WYTEFO/=Y03#QAQ[1\RT$\I>]- MXWGJVM-L=X$/YRK'R\ M=A*&^.S"#;ZP110AXP5XSR6)&Q/+#>'..$?-]%3; MP\_1RR=ZOCK!B)G#>YC#SCP D3@4'ET . ]H'$V#Q ,D%O"]180.3_E'XA/% MY62X[LRW? ,P,-1M+ !Z3E;]W8+&V7QVNT#WLSK)Q3."*R0Y?FR:6\9QV(='ZM-!_3@"> ZHKT MCW/- KKY!&#)/&6O.M]5QEM8URN;G6^CNTGIG2H%"7Y99!3$>3$*&B4/D>NX M5@C&/?:B?%1E$J"$Z7Q -G9*;A10,Z"*'Y)(D_4&>E$AY,P MX7HW-+S UAYXCE*8YI*2O5"X)9Y:<4:19*JM75( ST6I;2E[#)_CX%S&T 0] M*Q**M#W7>G ]-\8G@^$H'RQU,GB-?%ILA*D5)_ZTX8F/ G_$QSY8'MF(T52( MV$"VA'P$F(B@IXL_T4<&UA%PIW7/)R8E9Z-D\,E>(5^:ZAYS.)3 :,LMS] MD8D2CW2<21C,Z++T^9IZM)9-;G%0 ;S2DCP/;)9 !Z'<"ZP46:V3O]T!#2TD MGJC>[PNR%E-XX%U@2F%B@Z.L[&262'#( T/^&XHI0,U]$NI6.# C0KL>KJ,+ M A\/!1X?H7-Q"FQ A)&V!P,-SGC!3'BO3/AW0'0XDQM8S0Q1EZ%?*M^5KJV, MLC8YKD -06\"SF\FDS1WN"@W3*3Y3M (FED_@)330Y-DFH_LENS6FDS088(D M'I*AA.QKENE6Z_FI=,SDCB"\$LU;X%?XZDU,6+X&6>E+#,R4BMF&!87B2?B) MVHUBPI'A).3!R6\BZY#X:H3>KC@A3P_R5#3$T=AWW G:BHK!!9$&J5*Y2Z78 MTRR$WY;=?!>V!SA$H8ZR+:UJCV.7@%Z=-G E0O11H2,K(\R;_S$+'\$5GUKU;X0\B![7?H<2>1 ML#,P])2&;(Q\DT_WT!O2HVWH[G!1[Z8PRA06Z2U D,,)HV:/R>92)0%2!WLF M$BI098&^$>/!+J1T#X4 R]&/IT3#GHA6- #+AF=&+M*\B?K*@Y"D+G)D.M<1 M)\H01ZY16J43]T\R.<@4T=>W9E6/H8!W9\:CMD3$46FG;-XP*4PVW*D"!0!4 M#0BPR0A(PT@B5#[@)EBS"]:C RO +4B6&!77B&:3QDTM^.;);O 0B?")7N'Z\R1^ MAT@Y-,T>'1/2Y ;Q 47D&/L'Q3Q$:"0LL3I[ET1:P, A\' M>^5V]U4H'#.F]4C60;UV[3'PC*BAG?R1PAC$J:[.9 M" F.:R%:?#XF4J'UA9[:1Y]D/WZMI#WY0C3@$I^+$GN:Q\R4HP5O4BX/+DH> M_D&NPJ!P5(0T5'B:X@@@EW"EBI4FP< ]+LGQP$G@$:C5DH3^&>3C!#AR*=D0 M>%^4S#L%ZI?(4#SEG#$KX^#F]R*'>';!RI1 8\R44]D/8FW>!S:R$=[B)4D4!@A6FXC!BL4TA1$&CV MD$,>OY6D] P6%MA6N&L,15K D!&M%EX<,K<07=% M;56R=D6J,XI.F)\E_*=TY3VHLKZY(30F9[FGCI- M69!J$G,52F;&26;=1QC6 6?C2!!$A>931*Q> ROAH954U M1:TRCW=*%Z,KG+2,)+!!P:)HAF7, ]>G7#4T]^5K2"G,\0/]T2XZ&Q^2.(#; M@@=R2F*^1!AX)R<9)(O7\FZE_Q[I15.:LXB C.ZD(:DT$+#9^YIJS01>>$&4 M>G0S08+2&I7L+"\&.=L3"")BJH4WI0=.Z7U3-T3]/XQ)@FDYQ%@V&Z<>)!?1 M6P9SUC^SL!:,]\ G1]9V:?DM::B,L"K+>2'68%KS]\(-GX"F47EI+,Z_Q8845 M*2,0\*H>%0\&2-$-#&L."(:G-4?N@R1$66H.>0T0?^9SCRK6QG=78,:#@F , M6H-4_&C<(\5%]'M8,^ N\.*4I:E(K,(*_3HIMB(7=F*%B ]X VP'8&-'*ZZ( MS#D+CXORI3]3@ARBO4)D1$+@9:C)2)S>N E:$D#??7(=A?:T9D[<85WMC2F MHMCEX!H0U0OF,DQT9OR^P$:77VJVT.7P)"L\ZD=&?_^.YW@M]9:VAD M&E7GL_'%-_XS\07])MV-MYE+5CN=NQAXBQ4ZD7$9P'^,#WBE9E7>CN\N"Q7P M((JC!(YM[3-^GU.*D&Z6POH*]ZNUFN]VDJ]BI(H.YTU0SJC3B:%_97R0;&_8 M'GW\9'R9 >=\2E,, N,K<(W9W L60AC45^7LDO39;\I5G&^Z'-UH"5 I< IV MO-13+'B_(]<)8BF5!Z#-SBDC*]N46=BMAA#K0"&59)4B@1%8GWPZE$&!Q=4( M *G0*U^Y]-DK"$4?2?JIXKZU5RMI],/Z+T"G2UP MUUWR$!-,^ZW^6;]E4J)DO- *K\H(DB*1&O-U(P1E#>+B504WL#020)F MK&V@XD 18OQ>*V>.8-&/KN]3V':"R6]I4;+1[IN*KNGAJGM!&M!52H;,C=&[<2"<2*FH]QE1KI2^ISOBID+-J!I&EI8"; 1O](P(A#Q]F$+DBU(M#IGRF"DJD[ MA@L/MJETG'P#KU:H9M52Z%Z*Q["!-N, M: (69&4F'O-=52;J5%7C78K'H%U]STS-JT+RIKI4"3\0-ZO347:!R:>JMK9< M24)I7BHK\-[ZT[@A;JH(=ZR5+/Y&KO6UFR]EQ^LE=J?H>?]&51@@"@I8L%+V ME19+S82%F45IL,7!7ACT*VQT4TF6]#]A#08E9"L/ C%,N,NSGDFTRGI5F:&= MY?E0:F1>!"J3AP(4L@DBCE[.@;P<+X_<.,GJ3I5O3:[=4[7V]"A\M5 G0]%^ M++'=NJ;4>$96'H0N2+W4".NN5 ME9IH*47%(549<(.^>$:)3H:(MO[_M'SBTK)[RZB *FDF7/JF8E9&H5K*HA1[ MO*$4+O(OW5'7;+56.V;N9$5DAYR6B6<5]WKI>=XE:QN2Q+P3(AKM.F!,KNW& MJ5:V.6%ZXRR#^CHX&VOX#\]:%\N&_Z_6(M\07K-1/\&[]V**OV*)ZD;Y76K4 M_AHXN0*@^1NJ$N0(C*(@IW9EN>4-B*]#'7T'+IB^CZE+"RTB%0K#=2KS6OKV MT\"&RC;S*3;FN*K*9;+.M#6L9_*J*!$"-TDV3*WMR)5KS'00:<9RH@LJVEUY/J5>EZ9C/AH';C830!!^J[?R0JD$>G*\\^B229R.V3 M9,95F/HU;E30JE0.J.Q!#,X4?4*5+FFM.T M%+CTX]Q\\WM!_YD6_Z$K%[EJ&*U;8$3<@EQ46E6!08W[4D.B\,L:!%W_IO MM?6V;63AY^VO$(S%;@W(MF1)OJ3= (XOJ($T21UWBS[*$F43D46!I'S)K]]S MFYDS0U*28S*IMWG9;F1>AG,YU^]\1U@Z/!/2.!:,29X%XAIE&0GXMF>%FGFV M[_*?\L5!KN^V5Q.V5[>0=.%ML;[]U6W,_GJ#%PKYV0"L$K F;6O0HDF$D*M'4 MLR\9B&?(=KENSY/"DIMPHRQ*XB=(U+6%MF7^"<;K>'[1[$4U![9W-NV7RG<]'T7I+B-J6D1S: 6#R+HM:&$C;O$C!Y>DB2 M9,D8LNV-OTD:??>P&8F^M_7\ZJJOF85XA]EKC+#@V,NUS+MDVWQ98YK&I2 P M3H]UGV?(^F/S#;V_?K[!8[YI++M/^VM9B ';$KA+RUU_R_4O#$\.Z\Y,W%<, M4$T#5@:&O/J_Z?)<2M%65^\21!I#\B"UIL9@\,2MB%I*O\_&ZI<\R=$3,&1P M =>(+?QFIJ@5,U+45:*6"OQQ*R/3^VM$IGV=5QU^MC$@IUIIN$LBT>>$)9]% M 5E]E9+QH]-&#WKO3J/<4XL<@.)@M[![$AM+2F4\\4Q-.P>1%;]H;:'N[G:W M!5=-RTK:ONA8+=\_-F0T0S-)2(*8&;X0C]Y_ID_T/:>_4IONA?[1^U&>>$9B MM>:2)[3KJR"MD/Z2(+X%/>$LZ&KSWT1%LR44]9V"2J!.5LHG9DP%8CKDH@T8!?:^Z5 MKY6_42):4SC']G-M\8R[A0IM"J+J:34]1)9R=0CG!VT6ZR&@OL%E*$,R!=B4A2,S%#(CS2;HJ!3'T57NL3Z=%F>,3&C# M[VAY[[%DS*VKPP-+SBPD960O2+84K('ZDX]'2K!PUCE*IQO453:HB 31X8W&%H?=WH%6LBLRV"*3Y;9*02XA0' MH0=/@<;(8J *IR'8W_H,47C2V1I5$^A8A>S9V$*'!;,B'CO1"L"7&S.]6(AG M2O8GG\GRC6@'LWJ_\6FT473KK<6&GK+D#?Z9]Q)=SJH0+,TD3N$S*@#.!4O M87!*[R/SP=D!+@A967S[I-9KNH_@8D[((BLL@_R7D7-T*DKV/_++JDW$9\_M M@A))Y8LF"D,DI25+K"$5T8SU&&_QT#_K5-J'XYEHG^5.DB M]IN$,*U5S5!3M- 646R:ZO5I@B@B8D-6[@U_/9?-#>ADLGD);L1T.!)+05>Z M3&W3' =!UI@E2FUSM0O%[G0/K3%\9/KH9+2YCUT4!%VZVFMG1MK$B/5)K8_E MN:2JZ'L,U!Z\PPOQNNF@,"["+DJ1PDL7(*5V?FU.K\>ZT6-WUO7 >O] MQE"9=&. R0]]=ME,S2MU=%29P"0@8=D&;8,7R\@%&-",[:;B'GUA14&&-A M7%TN]2MGAPOFM^H%A8BP2Y JV\9T%KB/,QX(FDZKA@YJ!]F!$G"A<0#I8AH9 MY\@T:H?7_Y+<(Q%-FTJG,-X^&F:&=50-RR9WRP$?;(G(2+" R,67E7N]O-\> M7A'D-Z7!#^Y SR?M=5KCX6,F<6ZBW*(XN4?==,9LV-B7/L[@.O4P]#;G"04A M$IOF:?6-&?%^IO)ONP-M&]%,1M0(6L6>AN.[F.P?< 8=G8^E,B9JU9C*GW(Q M"VPC,;M@.EO^I#FC;X65:'4[6[^I9M/:VPY3 PZGCM.INZ7A_ 1\X9DJN^?H MA1F^6"8"CM:@4YH%,F36+FSV_'/;>DWL7/J]D+V.XV3_I3B9CL ;N.9N9_-5/8YF\]KF M+ 4I=Y^DG[:._>(7=KK !=Q(UM*N7*@2 M&(HSS1XP.=$!H.:5GS0MU>*+T=Y_;^@@O:WNKOEVG?MHHEN@TX37'M' M,HBEXB_1^!IWH='#72R;N!RFUQ0S"PFDCOP"7W\B7BVV,F;(*B0GQ/ #>@[X%"Z"0FFAYL>2:=T:>I,\\X^BQ]. M#8?N? M;Z6"^7=7PF0^G 8Z) \,E"JM"F15E(; [AM-,>E$;MS@W^SX.]GW& M0076LZ3Q1L&TJ^ER+A[Z(PA%9>V!9=-9+@; U2(%*>3N'RJ"+[>*ANM?SI; OH(5+]IN:]%=% !AS^6]T/Z^T_@"X=7/;"]AR/A**O6[ M$OT&2K2(-EM,UZ\[[#:'-SLU%#4?,$Z'O :V$&2OL_D3>H$H!Q8QB&O8C!I! M1GE6@?;(/?T#NF<=M?SCAV&JC(CSS5 ?&PJI4D0<9UI/D(_Y FX:M\XB[$"+ M B)\,#SY@K.M)N6%\WP^DTI *J2,4@R4X5M_Q7.5)]0QXR(:1]$M.4OE@U!$ M5^^2FBY ^=(SKF-(Z3F0=MWEQ_1\)'VS_ MH9J/!7H'F8%.%(\V2 M>92F'U*K"-=)GE7(RB4BF2";,QZI[=8?"++S64:X$G3YG#A_U.]:K.$W&C1I M[P0M5C*7B"M"= *\=XY$2408*C<'M &$"G2J1Q6N!O0#*#$?!)!5:HKB*"AT MN^UV47@PEV\JI,6.1[! M*EFPSMJ(P&CLJ*FO:9TPAC,:(B-9XUU]H ! &MSL"J$%2*/9G9CD$@NI= ]5A0!_[*T_$^R8,B06W78"JCX+[1RU%HL MB4X48F!K6SZ>AF?=Z$YJI9+VQ+P4P-$?0J^'^8KB3E M;8B&#>$D:M@?+6MPK]O9VNULMEL?P$F)%[>MHUMTCC^+4P3'T[:?/X9C08\\ M0U&B7)8S5J^M M0LXGJBA.1<.S"H>:D7J&+U%;3X(JM'"YO(QS0J<*N(.-X527?Q45W-+4 76* MJX D@'9-L:]D#7"'[8$'*9H'\>POT;Y]+&<3_09'!HO42M_CS*LIZ;[SR8X MZG^- E[85=@2!32U230WGMORF":U M<#^(UP=A5(1Q$5L 0?2WC;.M9=MBF#-R):-[:=16?Y@95]]."ZW*1/90 M;0OA((JF=N4=(H$1I<1H+*((2LU4ZI*A"6%T3%)@,2,<3W[#9WV8IC3_C-BF MY*5Z$_8_NHX\L6M+KPP@1;#>5X\*RQT\EDJ,HW$F(78]%,^Q=*/^J75CL%MX M#['@JG?+@%!?\Z,9KZ[H+?3R4!72R!7047A #R*H;REAT6:6:!"Q^..8^\VA M"6-?(6&$\,,-\,B??A4$$#P\#(W\<]Y@9A7+%A^G@EMPOM1MD#M MP0"*9:JK'TOWQ+#U.4H3W(&SZ)H3 .$GP13*QH.K*0>4\X6J A$./(TQII*^ MJ>A;?3'NX;9^EAP5F;#J@Z(H2G/67%E0YV>>B+]6C(^F()P DH87J]X8N[' ME_$#2H[@+,(^L,/TT5^#"M-A'MH+4KW!H1PJL$>S8IA)B1_MJ+):J3ELD5$\ MG^JC:0&* ES XHU8D!'E1N2CF$'(Q$T5*0@ G,33*+7TKP15T%^&PXHIUT-@ M#=E*QI*J6C8N0/RBP,;A4MN3QU/ D%2/P\E,HD!EJM Q'10>2$&M=LO8*%^B MI56K8?5BN2+WD%H_,*5,#Y&UR5 :;";R%A.QCAVRO[O99#E_ %70+JFH_>1!_Y(QJ4 #U51848Y< M+6?#P#]84GH;KF'[:J;1>4Y'&X((6EX+/+C'\O&KQ[8*F@@*X2Q@6&;_:X(5$CP#/8Z;2=SEJG\, Q;2$*E)$3A]IW6H&R8&^1[ MYOC5LDJNML-VB)QGC@036+39NT+CV(IH%>>+3'-9TMA\G5\^;\,TI+0IP60/ M?F#U!DFW@$"(+/-P]+FIM/4V@HNOXFY:8GP@O)N_A2%=0U5G,(?U$J],1;XB MTR?9DXNN+I4]21<[U1U=,.\93R-O>KZ2+>37[ZII=&7,18%.^QUM#OS0A17_ MR^TJ\_]_WEED6]?#X?S51P>T=LG"#S!<;%!_"5;+&W P/[W^X1\_VSM4:0MG M*I$GUN'N[4V7FRT8K'\ -,WU;_L+_WYGCOH-_M M'@_VND>'W=[@M'_0Z1_USWJ[G<'&Z\#6TF+M,KZ%>7@':WB1W YGE2;5<^H8 M:Z[E+%1N?JRH$Y)>D,^M;LR3^:LU*AM?3KGF-_B@"C6-19EPP+G5#![&/\AV M*U'+-7[CRW)T:B?Q>*^:(G8'I>0'LUF"U1L&GFO1+L,9V['W*>K*F<6[U,9" M"CJ\-^BW#WK/;H3#64GJUB--[DASW2:"30'[I[YPMS"H#K8'-;4*FT?21+>M MB+A YU^G&.D$VY'CI?7U.>MTMCNUTK^:)GQDOE O)3&_[ 8B#^0ZC4A]^QOP M&F6 ;#][/=*'P 8TQF_T$*6C.&,*+C"+:QEUKZ;U4Q6ZQ> !A@[DT"6MN0 , M6HNY(*J4 U#+8';;AYU>>W=W4/>14BL6T%2Y8V9*SK'J6%8,8]G, $?!3OSJ M6D9V<#"HKU??T[Y24 EF*1E'6!\SM1[ MH+'D=OWFHU-OS1LI=0\>8TAPC*8B*&O9-/T!B,%NOYX->"^&*A-D.-$VK"D5 M_<_][<-GM[@(#CUS/BFQ56);$$-[ P9&S0+@;\J)7/X_5*+.HM5_B!GC: M3E-Q,&G9'3%AJ7HL"0>5W7UAJ+.P)H*C7[09D= ]G2>.[LTV/:# TH)JY4W3 MS2S'+5;-P:G W>_9]'[R:FTLLS6B,X=#/K@79WN#_;Z!X/CD^[! M4>_-R?'^F_WCLY/NZ9N];QZ=^P94:[]S/8:=QK]O&KMVB7[)8&>0C#: 7TJN MP+3EF$'%M!$Y9(YUU*9)54%Y+C7&D=W[4L^[N)VK_G?2.\^AFE!-F(Y"$R^] MZN+P;0N+%OH6(:<$RX02)Z4WF0R69G J3PR8>NNR 0DK96931V3[CQW(JJ3K MP]$HYWX05*$.(T4L#-8L(>\W.R:8%;4S]53!Y,L8E#Y8W?9JDB3Y#"346_A' MZX%^2A/<&S=Y/G^ULW-_?[_]<)5.MY/T>F>WT^GMX)]W\,(-N3Y_G,/U5/8$ M7M(&/GJG\.S7/_R\@\^)7^'_OOX?4$L#!!0 ( #QW94T1553&1@X (B/ M 1 9F]L9"TR,#$X,#DS,"YX-SDF[@0BSN$W9]*+Q==3LC2ZOKQN_?OKIX[^:S=_[#S=H MP"W?)4RA2T&P(C9ZHFJ&OME$?D<3P5WTC8OO=(Z;S0 )F0_/TCZ7UHRX&&&E M!!W[BEQQX0[(!/N.NFCX[$\?.W1"B0TL.$0/L0*0N*VPF!)UAUTB/6R1B\9, M*>^\U7IZ>CK!+K5\J69$8(_XBEKRQ.)NJ]ON?&B?G8)X(#"3YQ/NV%7P',J^ MK^ ]CX5SPL44(-NG+7U[C"6)P!EGS'>S$6PE6FKAD18 -0&*"&HM\;8CK2)H M %LM<9)Z@KL>%0FS-D!,LQP93"F5,T&QWFJ>=!@I4U]J=KKUN(A30CDN(KQ=<''6PL+2I@:S6:I) MGCT',ZRX6%S!]V*<.4*L4/D<$]$LGFD6.^]JL&@H,S+51:4X2TFLG?)10BT1 M1NWQLTM"$3:2F';')G1KKI>;D/2'*ME]A1AYMF;E M65ABF4^UF:!L3J1I-$[+&"6!%GYNQB2J<<(P=*NEO2/&"C[6]@M)+4VN4X:) M"$=_:,;(%1E0GBCO%DLL\RG'+3!C7!E*^E)TT?,HF_#@"ES35?L\*MT/9(), M?WP>%L[\+KKE">X1H2@T4XF)A"$P$V1RT="SEF8T)?G#PLX)]-T1R-H JTV% M*5* 8OF.$>(F9C*BH-/V14."MAT22O[#A;+)I*Q0@$(9W6.9'#PN*Q.@$&=/ MQ?$$*2L.H$B8T%=R/$W@$0 0AC+1;4.<#HC!U:JH^(I)G@3?MMV_:G3P+H)]#.O\Y)%M(293L M,?N&XC%UJ [:6X*U>NR>NL)4_(8=GU2P3T'"N5$#_V5$C:&,,+-1@C:*B".L MD":/#/VC*=,:KQYQY>CG!F.G\Z;=K6788[1N-L$-F1/G]($[SH2+)RSLE[;Y MQ@&W.L%I/2=H(C,T.D6)P8^NL=E2CWCLD)=SA)!\GME/.YW3C$)<+O:#<0[) MOGT,4UK0_X ZOB+V'5$W7,HA$9?<=3D;S;"H4*4+4B@OT)ED\N?KIQG/M5;I'&:&!,&Y0VV]D:^/';T!'AEJEN\5J M;TT\%;0:^GF%]J%&V%);\GZBJ^^5PY]J1EHVR7S;O=D2<3%-Q"=!FV#('JTV MN>0N"#8C3-(YT0N .[3>&NE\*YZ6LV*2NEFZ/%IS7>4[S*PEQMEBYRV9=IN= MC[EWS1[W'JG1_6^EF6_/;JFXCD-T&9*S*6\9@Y2_T?\B8C6FT ],M^-M< M;SV%F;_^6GDBED,K?XGK0\82E\8.8B&B%UPZQ&F9%KSJ(E0"-W]!Z4/&@E*@ M\<-;$QH0:0GJ:6KWD[XO*2-5>KML,ODY*6OW9H*.+@(1I4,W2(U$E4,M/U5U M,A:.-ICG,%-5>#)!C]F?F:)JD7A@6<%0>=1R#-5>KB,M3TI(?-0+WP&YY./4 M S+2-=14IKB@50I*$CD_E;W/2&4)[,-4>.6DE4$C/U6]S^BJ$D0.,CTEY*_: M4*V3R.^KWF?T52MF.+SVRFR-ZV/ UNL3A,F*Y6$#G?Q'<.V,K!3LU=,OQ-DH M2>K@;?+Y67\D(]]UL5A4SEUEB.<_N&N_:;\K:CVX%0Z!PC$.,N=E*_\."[V2 M-*^^>[H@W:WV?%O"GDOJ1TLNU?(@?;V'9#@6\.%E(C5OB*WV?5/"O@^CK\'& ME&'??#S&;=H4(\6M[_=FLMFS(!)@%K-C8^>,L-76:]M?2OHIQES5<21/Z- M C(';8?PM2Y]'?J4;[I+9*I&^)4<('\AYBQCS3C+@N9Q5_#NF"F-N@^*1CK, M> NZO_O)B$X9G5 +--&SS)ENE$V'W*%6I27,@G3SXS+K'=ZH7>43E""-8MHH M(GZT8DK;5UQ N6&7X0EYC^#U$ELUJ^BN1LZ/[ZR7?XM[ @"''*"(!93DX1CY M&RWWTAF@4";HMN'/>GXO;O^?HT__4 -_;*4.Z0LOK!SE9P[R"X\<1W@LE0#W MOV@HH<]1TAZACS_[(U;?2$%UQ,*67SV]3\JZ8B(8YHU ?F54,F.IM M__KXM& PZPKRC"S@/E++O7^^U"F(I!5 M! JN0.\!N48LTA*-@^W;( X94U56SLWFU >8)(X3ZSW36-+L>\5DL]6Y35V] MZY$;ZZQ*J5]Y8M/Z5DMQJ+?M43O&"?31+EP+^@!2T8X05-.# 1L4GD MY=U7B[F-@EQBQZ&V+_N4>S E=O$ULU;S22[$ZR>12^Q1A9T; E/Y^[%#I\$^ M46#2-UG"9S:Q^XLD6)\+P9\@%F0L8STB>^>X"?6LO8P)$[G>'#HKS?&$"XF# M/8OQ*Y*Q5BKAOD8>#L[-5SM7!113W]5= [&!=RF_,D&P0_^"K^"\?8U$'O%S M'8T5'^)5O.S':U9OUW]AS::'^">Y;'RZXK(QKZ/$;')[IK#-Y0T@&'E.5;34 MQ3VLR@Z=3'XC4G?Q*=ZS[NQ!%8Y?(IZ3WE00@$E]X4+NI?RACBA7FM M8TC$-=RU0MJA=+7)[%N.W&SB%5'U:N?48/1"A&R59,)5E[G>E"!'MN6J,;1, MGC[>P7' BA,:;CI-^71A\#V,5&ZFVH&7QO.:Z&#*!<0KTR^OH^Y :,WD/CRO5L-?,\]4643/ JX>]32SJ M8B=/M&HI;?G2TH@PRL4=5T1VVYUW Y]TV]W3-:,6!']](^J>Z!I4(LQ6^J%! MIU98A(:01"WJ80>N6WIM9DP]D/^9O\3-U???.UQS=3^+S0LWN+OE%;R$A]B/_RJ"- M>A+ B)"QP)5P:R1T0W?G"3W=& X%'X==\?UDV0_WK!DE^&I!2_UH'[[T"2,3 M&F?TXN#[ELQBB:-@]#S!Y\2^A9)HZ9>*H4Y?X;%8#*@DYA?"0I&+PU>7F4(> MF!)1<;*T)IMN?\/DDDPMP/'0%]9,/X":!"DH+64IS-=KK]]VBVHRP@ MNTP%=M=$RP;9&YMEL =:[V.E"-O@DL50]ES".^(+[O IM6Y& SG0/Y_#O?C) M?E7D%Y6ZE&L&X7(MI4]LLY)L!:50'U:UDG,+Z-]"U ?B+7-_5K.>(7(!E#T6'<*,^JX<8FIK M\V4^+HBE+@J]=P)O['&'@L[UXR\'6P8R*OW+AV6KG6YQ\/UKYQ-3D>B5'/T, M6F]N# X,U\=QIL4M@_+Z+?X#5$7FDP=B\6FPQS3Q!$/-N!UGXGL6EM!D)JN! MOV\/2JOI9.2/72KU?D>]D<%, Q)/@60E/6VG^??57;CJH<\'T%D_JOC0L=R1 M9W7%??$_@D5QO16GM[\F%I_NMU#:CU3Q>&'K_JE;B\0A4 M7=8#:#M82-7[T+KM]OO@K3>8,@ =Z#HU5$KZ6B3V3R6/?>!YJ/T]G!ZNBKOY M]OZ)HG=>92^+PU]F-K@J6PGX'R=L\"**M&;$Q9]^^C]02P,$% @ /'=E M35N=+Z0\'0 R3"?F:<(2[Y;"[M^>M J=4VQ2IK:)L:W_])GC(DD61)585 M2#FFHTV+<@&5^/ !F0DD$G__Y]>+R;//L6GKV?3GY^0G_/Q9G/I9J*=G/S__ M_1,Z^?3JW;OG__S'7_[^7PC]^^7']\]>S_S519S.G[UJHIW'\.Q+/3]_]D>( M[9_/4C.[>/;'K/FS_FP16A9ZMOAA4D___%O^<+:-S[ZV]=]:?QXO[/N9M_/% MN\_G\\N_O7CQY+?[UYM*TW/0C5DA?__N7]IT4[43UM MYW;JX_-__.79LR4^_8G/[MX MD1]]<>+_]ZINZPQ;"T(LZCIO8OKY>9I- K2?:&P8SJW_ZZ9GY]>7\>?G;7UQ M.8'VOAA6H-=Q;NO)H^3ZKLCPXK5MG+P$MC^TNT[543P\G\K:V; M_[:3J[A3Y,=5Q\]QPC[.)I,T:[[8)@S;REW5'ZK9OUDW MB4,U\FYE@S?II6UK#T*\KB=7H!9^C?/WL[;]$)M7LXN+V?33N6UV#K''U'&0 M!G2DW1Y5':0YW?CU^)H&;\PKVY[G/V] :WRV$S _VE]L\R= "*_]%/U5LV ] M"/DQMO.F]B!G?GY7T_K6>S0-/0EAH4SMY-T4YK"+A5'5D:UCOO-H !H9BR-O M]BL[\73DMM]YQ]$ T&V*&Z;VX1L-%HEUL\9VLO4W/SVR4%W'U;9"(X@X;6>3 M.F3_]*6=9+_KTWD$(VFWF#L*EA/U VC5*92!Q^UD;[DWUC)J(S[-X3,O$+2G M*0^1MY/9ET?AOK6"!ZG;?TY9GMG[R8\5-'AFK(WM1Y?:[%&GE[& MSM-DUQH&%_YU=/-=XMU^9A0!H/V?8S.O07/EKQTG\-TE1Q&VF_J^_^0(PK2^ MJ2\S/T[3RZNVGL;=<\+60F5$[-R]N\L.+_!J*1G,JC?3>3V_ON5'[!2X0]G! M!7X'_)_.9TV]FY(;'AU3G([=_'"),87K-H@?+#"X:(L5BY>V!1L>E!AHL$Z, MVUZJD)!OON8?XZ>KBPO;7'?L]3VJ*M2<7VV3=>[GK@MKCZNE4",^ME?9,_S@ M&OAAB)[I4&&AIGV:S_R?IPNU<.(!89AG>[5L=WV%&M9M2NI2MI# ?\3Z[!PL MUA.PP.Q9/&G;JXO+QWC@/:L=OIF9"N<@9FS:O.PRO][9@@=+%!!NM=:=?P]# M\X\\XX#7T!7[_:H;OEG+N>0T?:K/IG4"1PT,*.]G5V!!3<\^@%?D.Y@VCZOE M0(UX.VN VM-75PUXI?[Z-\"WM?Y1 V;@]QP(B&%[M7/O>COQ5Y/%'/,>OJ\> MSW+WBG-8OB]^G<=IB&',-V[LO=%>O$]LP8&%V0Y0EF@MTV3F[Y!O)<-/[9K(%7_?P1++-:)Z'B_6Y7-8VG@4F!T"4FAP$;J]AO:"9KMKQ&=+,@?+A9-LMIPM%U!O M6K-4A7EAYM?9U"^_;*'@0&^HO**9"VQ_6M*G M3LO#P?R-JG]_L4E%'4)W=0OX.K""W>1GCB72XR.O#BE)T=[:-_QI+'F&B5DZ M-NFZ!Q,5-#$W-.8[J;]OQJTGM^B\7O56Q$?NM(DH64&1(B"W<-$B22F1VG(A MC#V<@;H2_SNA3^:O;--<@Q5TQY%Y )N=Y2M&$R?1&H2%ER@JPA"7W"&AI16* M!.)).G8CM" +9F4P+F65WH.I^]#;5;22)$@I60!(@T><"(.\P0X988C&PBCC MC]Z./!RS1H"WJ/TX:/QG)TUU?R4N_V93%\)+3S[#6[(HH");NPS#^";5!MKO M75?%N#,N*85\H."3,DG ,94>&2X,]Y8JWVT$^^O+G*'Q_"O!FRRWZ=- MM)/Z_^"KK:CA"='-%AX"Y% MNQO$WLZ:3_:VE[#3.G]L%96PCF&1+")&6"2,3\CC *K B0"_]R9$_L,IY*%) M-R+:A^+<=S;%Q:R99Q/BU:R=Y^7KQW!O5U55PBY1R@DB/&DD8R(HP@A$25$> M!+7!^ /NC^]HSMX>XZ#U5R)0EJR*2"4ED118(:= GS--DR9.Z\AZC..1W<,R MS-DQ:$OA?B0C>F\?<=#ZJXB383#Y02LB103F0"0$J&(%/4=D-_T6+BSUV;J"#US)*;)J,[&3MB&\D:>E$<\ M+J&/H9.>A*8M&O6U);E+F7<6#;KKF(BE8"S8,FASV]RV>* R,@2%<^ $YQ$% MJC#B$0:B5 9^X9DA@A[.#%D*^6IG5/:=YZJ@3/">P/3!P#[&T8.%Z() "G02 MC&MOG#GZD/]]NN?[B;$G*(?="/E/"-Y#I-BK1W^PD+K54;_V8_01I ?%]FN< M=Y@GMA2K#-662'B=34(BA8U%)I]3#]D=..(V6QCTPQ1;C;O]_Y$^OWGM"4ZN@/3;RT=5@E MBP$-=YH-]JYF9(?2E8\&$VX]PM9S< X#,%VPA"R.P6,N@W0]]L+$$Z/%.(B5 M8\OL,C;SZP\3NTS-!:;093Y5N'V:V%:L2DS9@#7.QQPMBLD+Y V3B&GCB+3. M"*&D8].KI'GB4ZM5;DU*G0]X;GZ]"<#@0S1&E6"!J"4;"X7SN)%$/ M^I H&Y^&0="KOX<"IYSM-[?3LYP%="5TG+_YZB=7^=*@#L.]2_'*)DPH50Q% M'2.20G@4@/!(2V$:!*?4TC()>U!@)JU),N76^'336P_F[MB=IV5BTDDP3 M%3A&20D#HP*<92ZL0-K!?PR,(N$[G4T8O>7=&EEA*276P8*OQPGB-LE51*-@ M@CO)<20]-K**IU49H--F0X)U ,KO=H_N/US1X)T+D2)#N 2+'A2_2M*#84<< MUR1BS9\2#1[74P_W^/[PE%Y _6"O\V).WL/UOKF*X5&,>$0M%5?1>RLQPL%K M1(6C2%(#;B;%8#A2 ,/W,)>+4V6O+GY@C74<^(HG78(_]2(<8&$B/HI(G>NH M/,!,HLSGNZU"VH"E(IPT"#.6# 8C!?=1/,43)PU!HS'!*T6B/?*0[6;5_I56 M/!"<1'>VYX:+(,CU4I M?BPV2_,YB:74MV_-V<")#4]7G&OI\Q%2JQ5&S((;:E(^$(0U84E;GTR/1#]E M5A^'XL$P^!RQ:=-)Y_2JMR*>\B1M7H8#(\!02E",H)RY5-IQ*[UU/8+DRBQ9 M#L6GTDB6-F[>3?WL(A_-NJU6MVYQ[BA9!>8LPU@B$Q(X$D1+1".XI,$+;+B0 MU*<>>R'R2;%G>*R*[HL]UM3=8I\Y!Z9]% DI'37*TS&\U.;$T-!!@A F? ]; M13TI5@P*4SDS]N*BGE^L3G7,7LV<=LCFU"3$F1@.A(>VF0BPXL=4(D"L)80:UP M-/6(M2WNU0Q/BT$P*SEMK*X'VAFL_]VCE07MR8#H")[E2#C-D+&2HV"5"CJ" M11^.-C'14)VU84KHB5&Q;:2;/-@?; T6T"M[6<_MY%8+MNT>[2Q2 MV'1-U:KWPO]LTU-"./ N8CH_##>3W&H/!CWE8Y363N3^03]#71#E 6(1_PLLX+K6U*/4+8 MRRPE'H;"(\-COMT^N8:E]O6QW: M7;BRP@#_;42268P\?$&,)K!38%(WB<$GE<>^=C@P4T9!K6Q2BHK/\ZUH'Z'!;U**?MLP+2M(911G08#;&E)FL(T&P5!A,$ B8R0D,.@Z M+0R/TROY8#.T\$,S^UP##UY>_][FU?S3R\6FS_1L=??W]D70[I54Q 7L H^( M6YF0R\'VF!J?C]XY[ 7%5!Q]T.PQ$VA6L&<*'E5,]>(JMRT<_/90I:V5VB>' M:-YT,A;,BT!B0#P!8$P+Q_LD,RC#L;$Z[OY1Q?U1*^9U+O-8+6 [36_K*6A8 M@"!GM6H7M_VURU#B;:YDQRH 3)9O: !+)M <:V4L2MY$Y)T2S@<=9+><0(=< M="O$G1$Q+11 MHRY9S;U)I$=849FUI4+,& S!8CHH'^I\=W%IZR9[5*] _K/M%T5L+%!Q 1YR M@LDO6*T1U3K'2D6.B**>>&]42$E9*OPR%8"F.W-Q^ 0"]!C/_,Z#Q>7D< M^"9V;GUY].GT8UX_;0"N16;.5PNK_]WT;CK\'3;O."^L@C,&)P[SLZ,*89L( M L4-, <3800Z+F(/#7=KD6K,*P\*D?1HNJ!8EI"5B*=3,/ N9VV]-/^6A][) M%K)N+U@%HQ,-P>658)GO"H(W.^60-3'/_LD*W>/0D?JA2#,)PB[K4U1A/K18]S M3OI'TO/'VR6[A\4#5S!\M]W_$41>J( L^7KP[KPN]%&55"=OWKXB+^DKK/0K M<_*2@*>GA8I(F.21#Y"ZSWU)BBN< Q]KEXK=/?:P1@V"**'X],ZZ^KVK<>M MY2K&>"*!,:2\S3?)!8I,T PYQ[1*GJ9^ =;T!V=0/R@/1YW%%/H-GL23 7'2$6X91 #.\(4L&O[Y0R%NOO;WY_%&E^ MB&V&D0'=FR+W2?SM^.Q-V[=/.7O54WE)B'*.(LZ40E1RA0(VZN8B,AI5C]A4 M4B8XM01I"B [('O6W/X8ZPMWU;3+Y;/NK-E-( @<"E*>2V""?%%VU MR2O"6!^VE#GP?ABV#(9H*5OH 9BR>]#V#1+=4$E%M10B,HXXN*C(*0>8")Z0 M"!$;@P/VLL>U,V6"L)Y^D.@P/5,P2-3'&-JWT!/Y>!+ ^XN=YQ-*UZ?IX;-+ MVR-*]ZFQ\MQ:K$#(1)Q"FFN"--,442*3X9$3KSNENS["\-/>E+@??EH(XF(T MM->+V?RWV8F'\=S$39=&;2-=E_)5C"PY!0H"_&>-*'Q%28,#$[&RAAH-BFF8 M+(H'6(D8G&,C(7HP1CUXO= ]PS%)-!28>Z_>KV;#!Z-9'UJUWU6NBEHYRYQ%E&J!'%,>*4[9>@="!F)Z MY"P6/X1*&@O)OFS(R"V\)CP1)TC/8R7@^X)CJEW!L#QL';+ZE**'5=[["Q;66DQ-F"@ M4244XIX!JLXH%"U.,8'SR%@/-7704S-E[)9^8)8BT7)5ZS3=7NDZG?9:4]M" MNQ'>5BG"+<,!AJ72"1%N7N M)'*[G9WS]OGP\@G=[N<)[9#4=4NIRB>)16#YN$N>MO(51E:"Q:2 ,I)K M-9 MI^E_M'V2;]E0MV^%?'NNL@1F6DLX OWMH$HJL2R%$IX- MU6?WMR9Z(55*7VU+B[L&XD-.A@1],X?IQETMMI=_FRT30&[A2L^:*V$D%Q9K MY"/ 93#.H?-2@ 7A4L@1JYKV,)@*14J-Q*[RV!Z:CYNRC%N_:. T;,TY/BQ[ M1Y$#G"*GL(H<%+8,B"L74-ZZ1XKDY=S$*?37L<^D13G9<3P<2V\=>O3XQCI##]<]Q MNAQ'E-=Z%:I_*_"CN!]T6+]@M-./ZYM+8(0N]T*NP*__!O0M"(ON%D+ M;5<*>8*9QBY0'(X^\70/!MT_*7E$2!?3_.MS/9W&ZX:G*^&UP4)A) SF2!FE M$9,!/H0S,O@$JJ>'ABW#HJ/I^^^U[R!X%\N#UV1%N$B?O85#MYZJ0H(A*358 M)LHNKE7ER'AGD>9['KA4R[Z]'.<7L7U<&G ._JC MGI^_ F,%0&AN5KUS4@/X/VQ? =VCMBI?E9P\9@@ 2[LW=?WXDU+X%>*6SG:,<<.+-JT==W\UG.55<82 =YU)"HB[KQ&)A' MCQB88SD.KD^VS$(AID,1HB\TQ&P_>K9 H MY QQ,[](B[G59^I1:R6=E%)YBY0(,-ZBQ$AZE5"$25&#\\QXKQ1^92V2_1AP M3[>41+,4\S[%A97^KS@%K"8Y"4ZXJ*=U.V\6V:I7S=M"LFX55-(PSU4(*,ID M8?[6 OP *9!RUE*9E'3BZ'>CAN73:,"5HLY-?O-?OF5*S=;6[].9:V.S2"OX M;GIYM4@S"#YA/5E>]W$WT_E-%MYUDM6ED99'T/K:ORWL*R9#9;44DFF.4A[' M24:#E ;WU7KBC$I"8G+\9U^'9? Q@U]J$#R-RS_*1(T-RZXG=\?'\=T85289 MV[#=_D0NAEJF"\C$7+HKG;8P-A>I1/+!8A&1<#@@E2A&A) 'R)$4/XQNAXI M^Z$8ML\ 11)QE*B7+$!$Z,>46$ MZY'VN(S-=*PT'+B8F<1Y\$C+:0 Y\LXY&D,R6O/A.HTQ8[E M:#L@=#MOKA8+ [9IKO/*^^*VKZV.]\/%*JV=3B0DF,)D0L('":I6P$_Y")C" M'ER#HS^+LW\7WO/!!T6JW +,,GGR:8*_.V1IVOA\E76:I '<00? 12\ULE8( MQ"P#<]\R$=+Q3_D#4F$8C,IQX#9U?Y_:Y4WT\>;.^<.4ZIRJJG( M4#[' ' ZGE,V).Z$QS0>OX,]TC0Q#%X'6F39H1PW/%VYY$1D,2"C.+S!2H,8 M5PX9ZX6 41.)[90'L%C[ONU1+_MIUT)UURHJ+0V5+-\5Q@$)J0+,!C%?:4 T M)=0FXIPZ=MW9NX>WKQ8-"5ZQK:U;8B[3-Z[']8<>^3*I#(?J_?$P*^YD_Y:W_!]R=0=WM5O? MU)?+L;*^*/J K][NYP\MPGC2K#A#LYB+SST MDLI:E.M?XZX-W_5CE90YVYNQR!+/P+SF 3D-IK"RV$>FF"+=,O^.W**W.03M M/(9_S69A>:@VQSTVGW?<7[BS=.5I"%ASC$+$"C'-''(A)_IQE!K!*#>XSV6% MA6;\?3MTPZ[T\("5C'U82/_'K/GS)M#UT61YN'2%J7=:2H^P(QX)D@32,3#$ MJ*(+MU3)8=9@GA19!@6L.%D^VB^_6+"8:CMY/%<>+%Q9HXR/UB$&;426!X%, M( %Y:S -(FK1)XE2*4MR:*H,B5=1*_*6EB]I3'XZMTU\:=L88/ M!T/F'W_Y?U!+ P04 " \=V5-]![CVB1$ !%?0, %0 &9O;&0M,C Q M.# Y,S!?9&5F+GAM;.U]6W/;2)+N^_Z*/KW//:[[96)[-^HZQQ%NRR&[IW>? M$# )23Q-$1J E*W]]:= $;0D\P+B3K4?ID>64$#5EU]59F5E9OW'?WV]G?]T MGV3Y+%W\^C/\&_CYIV0Q2:>SQ?6O/__^\1?UT;Q]^_-__>>__67_]:7 M[WZRZ61UFRR6/YDLB9?)]*Y\H_O5+^=@OQ:]^@>@7#/_V-9_^_%,8X2)??[O"1\K' MB[].E]L&3Q^F;Q[_N'WTNU=_P>MGH93RS?JOVT?SV:X'PTOAF__^[=W'-22_ MS!;Y,EY,DI__\]]^^ND1N2R=)Y?)U4_%__]^^?;92^+;V625+V^2++Y+5LO9 M)/_;)+U]4SSZ1DW^M9KELP+A/'1B_:Z;++GZ]>>K=#X-4$$!) 8%4/^^Z]GE MPUWRZ\_Y[/9N'J!YTVZ';+*,9_.3^O6B2?O=R_-DF:O%]-TL_CR;AX\F^6]) MG*^R9*J6/IYE_XSGJ^1HET][S5##J"J 6F\;:E#ODOMDCB_3^?PJS;[$V;3= M41Y[_5##_A1_GB=M#?+YRUH?DH[SV21TPL[FJZ!!WB?+=VF>?T@RD][>IHN/ M-W%V=(J=\HY!!E"1=C5>-U/A@3YS?%_US0&O?Q/%@J^6]Q]F> M,'SV8S)996O6ATY>)ODRFTU"/XOGCPVMZ7M',U UG:Z5:3Q_NPAKV.W:_JK( MUBZ_.1J .L9BK,.N-L/;>7O[@PX*.?Z<9G$E4W?WTQUWJBJM#C7JH(N+/)W/ MIL5.3L?S8MOQ\28)-L+Q;AYIV%]7/P2EL@AMPN/QO':_=[ZETT%\7(;_%EOI M_.*JF")^GGXY"?>#+^BOZ^GM79;<)(M\=I\4ZK[V$/:]:+BAU*;6Z6_M;9 7 M=TGE9;+J&UKOO$T^+X]U[^DSG70@C/\^R9:SH+F*?U9$@XWZZ6)E\1YOVWZ'-T[78%:YQ7*V?'AB1A_M M<(6VK7?X;>#_8IEFL^.4W/%HE]VI*.;]+;KL7+5)O+=!ZUU;;]C#IC[8\$&) M!0U6B7&'6_742?>U^#'YN+J]C;.'BE*O\:J>AO,^S@J=>U_5KW3:6WH:Q&6^ M*G:&'SYGX8,RG?QYL58+:A(0#NMLHY$=?U]/ ZNV)%5IVU.' M_TAFUS?!8E7! HNO$Y7GJ]N[4W;@#5_;_C +*MR$;B997KA=E@]'1["W10^= MV[AZB]^'J?E'L>*$74-5[.N]KOUA/:XE%U+V578J 4#:C))5\&"6EQ_ M"+NB2073YK2W##0(GV:!V@NSRL*N=/+P*>";QY.3)DS+WQD(B':E6EFZ<38I MQ[7Y\>G0MI$'L\7RS71V^V;SS)MX_L(AL2>VH0Q7*.(BZ+K_3UJVW:GP<^'F M2!>_3).K>#5?UNSBWO=TV.'T-IXMFO?WV6M:[^[Z[;_<)K>?DZQN7W>]H^V. MWH3W99/5Y^27+30UNWO@37L['4@S6ZP/G-Z%?VZ>+OK5*'#F\7/)UV6RF";3 M#C^X3K9A>H:T:LX_[R&=97_Q-,E_FY6_6R]HO M &Y"I?Y]\^NH]&H\Z5,85O)VF=QN.S6//R?S7W\.'8BJ-(L,II(0Z;B"RFCF M*,7*$4V%01Y1XIX/=EZ$A:79!N-N1UM$74U7\^2;-^>I+/3#DW^M[=D#")SZ MJL@!; 4) %CH/23"4,\WJ!@!'*F"RC?NJ6SR4YH%T^G7GV'9T4K#"S\8KV:_'TR3X,Y_^O/RVP==;7Y9;I8AEGEYFN_=EA(DNOBAR.D M^]X>*'X3K2-KGO18?9WMFBM[GXV841I3;3"4#DMMB<-T,SB+* 4]4N' DOL] M-;J38MHN9&L^M"%:^TS%'Q/NX].1(Y!S:H4"8;2",* Y*/O*N#?13D.G4S'O M-;*^";D%[ ])L1$VXY;G,')\-I*QB;$E\9EDGBR2K[\]LU]?2NW90Y$&T"./ M 8<4,@JET%9L>N8L([Y/8>VROH](ZE1\TY: ."ZB8K1Y.=P\F?SM.KU_,TUF MC]97^.&ET15^%;U+KN/YXU'4'BVYXZF(4DV@QA@23SA@G@#@RJXC)6!M&:(S MUX_-P>I(SH_]V;NZOGPD/Y8>UXM&$$I7'0,:+#;LX) M[8)Z*!.TB,$*O7J,MUK[S*^2+"O<3]7,U7WM(T>- M],0[R;Q@E"GNU+?QH'YGZ6$)=^*$Z!*LVL*_3.Z3Q2JY3";I]2.NO\WF2;Y, M%\EOR?(FG88.%F<,R6)YL;!%)E)Z]^BRV$V&NN^+@(02J; "8F."A6B9P_9Q MO!CXP/T>C:W!R-$3>/V0Y>/J\^TL+S2A6DS5W5V6WH>5K7Q^KZ>JS6]$U!,: M%DT2MBN8($B!,O@;+D;5)A5^I:1J%]#NB/9;_'5VN[HMPJ2*=(\/\4,Q#R[N MD^Q]\G7ITU7V/TF##ORHDD67W? M.ST+XG0!TC="_,>;%_B$CO[9ZM%IG6S[KHYQ&^3*]WC"N^W(H?Y>+"Z+?+XL MJ*/PP/MTD97_+-)\\W<5CH1;_4Z$*%<>6,0IX(0 !24O]N62,<"THI4,B/'B M>>QPN;5O1!HH12'P..Q;(9: "D[7.(;-,J:XS\W]P5/G@=B3C@/WCLZO6R:\ M?MC^^']G844,ZN-A72-CCVO_M!=$2# HG<1*4P(M5PZMK9 ",NV#$,=Z*CX M:?;1MDV ^S+SMCW>0+5.//Q^&'M]TK7>$X6EP2AI!%>"(!+^:X788&$"0F2< M!Q!="7P?GSJ$\J]-KU&=BYPEJP9FT]O%W6J9KT%!>P]@*K2*PLX*6,FP19AP M1 P#B&S&:2D ?'R^^8[DN(\MC3$;DANX%CWB! VEAA!L":$6JFP MM[8<'X&N_GK1<6S,"*SD5A#MBS'ED62!U,LC.DX3_9PY.@PW MBZ3BH*9"CS_$05^]3Y=O%Y/Y:II,_Y@MU_7MPMA?EKD[9K75?VGDJ3$$/)G,OU62_$H\0ZTBKPQ*(Q5 M6"D59881Z4DY3A<&.K[MPBB8U1ZD_2UIV5U1-7)=<.P$\AQL%P$" H[, J< MI508@9TNQZH\$>.+V1D%?=H$M2\"_98NDH?'6JY^M9@>9\[N!E$1'T =18A0 M:+UQSFI3CLY;4#^PM+,HG%%0IA4T>[/MP]"XV/E\9#'GW%E@ MB7:0 D(D5)NQ08),_92>TQ>7,W-;M(%G;S;-MU[FCTC$WW[SM K,<3OGM#=% MQ$.$=< 7$VTU@@YZ7^(AJ>3C=CTTE/%+@Z87['YP:I0>@G%3J:4PY4\: ?"A MJ-CV(4NOL_CV< [4GL0?<<,<;1LQ)+F$UC!L+86:*^1+$]2,EV]IX>:04(4XZ00QUGFFD MJ"J5-C8,CJC46P?230>&LZ_5I]#TCR EDYO%[%^K8X;/[@:15PQA*AVQQ!BH ME(<(;49'1!AA;;*PUV[MM +H<'0YJJ/V-8D$1= !RR4(@&E@<$"N'"'DP([; MH&DJMJ,L:(32:^3#*$V5L="@);/D0Y9^WFBU\I8>.\O7%W(\7CY<7(QZV/@X MX141U@J$<02+S1$)%!:>@G)4&K,1!FLV%U#:"U:]A3I]2T1:9PM5<)WL:Q(Q M!Q"T'A4U(Q5'1$A3EA4@'MOZX4[\M=L0+4$Z)&F.ZHW]C:*PAFD(7+&PHF!< M*R>$VDX-2=2X+8GFPJO AD9(O59>C-*B&!,=QDB5>QLO]IYO5&T>,!.!, MH4P)Y=8+IFRIJBF05H[/ZFA#A$=8T1BGVC;GRYX\,8HNKK9N%#6YF27WZZ<. MVY\U7Q=!Z3EG#GM*-.604Z;+Z44YQ_5#63I+[VB1%3TBU]'.4P&1"F-R7);C8XC4+_(E7KM=V@ZB0S*F^#%+CELA1]M&A=\7&2R5 M8TIZR G;GH%3"M3(W5V-)5F!&6W@]=?@RB@-U_%1I*VSNG@^GTU7N9ZE=S=Q M=AN_74R.',#M;1$AC @0P5ZW%A@ML("B/(%B2/#SN"R@KAS2+C#J-:/X6[6= MPF">IX4.59_S919/=MT=4+EM)#45(AC;89,G4)@M0&^-;29P@XK;W1>J&K2F M:-O(#LZF.BR*K#!,2.P]5=H[Z84V90X^,TK4W[QTEVK1GMRJ,N)$E/IBPI-9 M4V]QJ?:"B'$LK!:$>(2!1E(S7Z[2'%DYYG)G@ZXPG<#;MYUJTMO/LT6\N9KG M8#A+!4$LTU0"4>*BX1AO1VI;X'OLVNY [(M<-GF\U,D4 MR6R+?-WGC\&62S['>3)]FDSW+58J3,TB:W(]4R>/_SA N):^$#DN.#;$T: X M),2V6 A*_(SF(US[.B;A,,".0Z765J611) P: GSSMBP=<7"E08$=[+7,@OC MH%&K>/48<7V?9,O9Y_FZJ,R.CA_)_#C6.F+(<1T,#(:]"I:KPWCK$1=,L/JI M[9WQ9!RF5OO8MAV@_?*,Y,00[)?-(^F54%!QB@BC #IEG=F.)FQ]:C.ELQ(_ MPS*E0W"_464L]RP]5EZ^3.?SJS3[$F?3PY<=#7+_TOJ :+CKESXNX^5:XN\J MW*'T_<,1=$()P[FTG "LPR( -ZY&I@ACE9*@.Q[9L=N,GC\8 2X5M@09S@BR M5ADA\&9$ FC9IROHX)5$3821MHA /.;+@=H[Q(:$!! Y-]YRR@5587'=@"*9 MI_73CSN^_J>N;"N>1)\&R^LX751!Z5(#D6/:66,,D\J78T8 C3QG8-?HT,<_#ZP1[7\L(L0[;3&0TG"LE6*,ZM+.$Y+V&MY2C7DM&JN# MXWE.+/T^W:I?XA[]?F0,$M(#XC4%4C (N14E]EXU< EW=K(P,BZW#7%?]/XX MN4FFJWER<;5#+>7ZXH_- 5\OSL,J'1GZ MYG85I#PM^C>[3[Y=+."^/EY[X@,9B\/1U7(M_(LK%V>+P(IB$.ON5W$XMO6) M2!0LDQQ@I+$%@G-H'@O?44NEJ98:V_4RV'"P1]VQ?. 7 ?M7.V(1Y!Y^Q\P1$';X=?C8"C6#"A+-(, M4:F*W40I'.],G_483G,2#\31EY&GHQ%-;U',.SO\/KX][GL\UC327CD* / , M6*B^))T@:H#EA>G,:02UASM3/Z>K,-]@Z/;J!JB]J_+&^ M_F5_P8F=ST608B8PDE2YL-42F"D-R[$@)NIO+3OSLW4F]B; ]"7DRR1?9K/) M,IFNEZS? ^SYY2Z:ZNA/_D^2J9'K8(JK:/M$,4(6,=DP$P:S1D9$MR".K/_M/K M_@]J$W0$6%^KPONDN $[O4T*QW6%),R=ST<6 L.I ,%FIAY0XBTHR4VQIB.Z MK&4T_L8V@!R$)%7)$05>$X"M=! *CSGSFK)R+$+:$>X:&LKDD(1/1*,WRV]3 MCE4%JS6^3MZO"H NKM8'45T6 (4= 6',#!#HLBTZH M%XV.,1X#ZYZ,XL7I:DWN[7]AA'7 Q!GEC%&"$:*@M!MT M& =C7*&Z(\ )3&L-T6$]JI7GK;HM*D9V=U;U^/Y(!#6#O+!0 @EIT#/"X1([ M L$(LVX'7P^' 'YD<2X'$]/:C78I*K47_W/_6LWNXWF1-?];G/V9+(LN//&K M+YYLAXKG1]TY-9VNOQO/WRZNTNQV394^$Q#K=GSHN*(GA]'WH2-%;WV:?8R? M=OI=E6S%4]X3>2LAYY1H RC%T"I/'A4,Q\0BY(:+$'KN[WTYEF-A/Q5:1Q(C M!#QQ$#-)8;%$;:H7< PA)*.)Y>E(HM^5]F@;L5%'X?C9(EY,9L4R%5:!5?'= M(Q$T>UI$4C@B@ B:C6B"L1;0E8 CZWHMS7A2]$NK G\9X=T*5GW9LY^R>)%? M)5FA%#XFV?UL$JR:BZL=@\B+8MGY[C\=C29H\S,1E)QA0:3'%#@% %46E$@Z M2D=^KV=C?J2C@_8'6>LC.LHPF;/F:$O'7Q]OTFSY*!RG%*J$59T&P6S MVH.T+^K\EBZ2AT<_DU\MIL=9L[M!1*&R0EFF $68>1/F!2Q')X+5,;[XGU$0 MIA4T>U-_143CU2R(KD##)G=I/CL>+'B@5>08,L(@+I"7 'K"D);E."T"]:\F MZRQX:!2L:0_2WJBS4ZFJI8FS["$@N,ZJ/T2B*NTC997V5%-(-8.($\(\*EV( MR/ 1GN/VXR+M KW>;)N]N#S?.!PR="J^(M*,"2B"AG88>\JH)E*7"&BJ1W@G M7C_\Z0C 81>?TRIE5WY')*SDTFMAG(8*X; IX*7NIESH^I4'NRL[,> BU!S! MH1:B%\<0MVG0R?];5)C/E^M"+R%6F"H)146HHIU@8!H,NEF2*F1QA= M/\S"U#*0(Z'69+*Z7^++(GGQ;C^$22ADZNTB/[X6I]OU=X? M6:$Y!EP83[RBRH.RNCW'3#)37SMV9JR/@H2=H#MV9A;Q25TR\]G[HR =Y1B7 M5E!@&((42E)BYQ6LG\W,_IK,;()N[2.;'?%/P5S8#B'T)O]N"/L.<.J\*P)4 M.A\&:8"%01T8*'"I&UC82=*TVK^5#:?'TDC'5"$(PT\?JJ4-\]N4^>WJFXN4-QSY_71VKQ9#V$=Q42 M!=K\3.2X$@IH3PDW)MBK5)%-4J^A@,-*1E?7>14M#+AZM=&V/A:0M0PI1)QU MVCM8+%^;;"J#.;'U[R!M.4MA&#KMK3HZ$/ZCSGDH3M*#\OPVVB,9#SN?CY"E M2 ;-AA25FCO*"5F7&G.#24\4L79"_8_>#4*#,1QDVEH6+(=R_2 M%>+$#S6,F")"(,6-4)#8,&P-6#E:9'#]4+KN2B]U)<_OPKU;!*XOFGQ*">^^-]!; LIJ9(4!7NTNAI:"F) :2"\,,!OIX?W$(S;F&DLN>-,:(33Z^3$*(V1\5!A M%!0X:F_L?#XBWA@5S+?B9@AAF(-&^-+!P0WJ\\J,JM[WYG(Z+/E:R-0^IOD0 M/ZQUGT^S?7IQWQ%,A::15\XS)8U71'IDL32XQ(0J9T880C^H_ZXC7.L?XCW[ M_G66K+]NTD59W$A=AU]>Q\ND[/2')'L;_CI9'R'L/;QK]MH((J"I-5H!ZX43 MR@"T*0=GF':FOB^XL\#ZX5G5+^9]'N4%;-+Y;%H;)%GV=62V MY^L?XBR >).$Q^-Y[UW97OV8A_U.G-_X>?JE?T">]2*]OBZ%/F(L^?$NC?%?AL'A/BP@)0 PS2&G)'=/$ M>+NYT]3[H(XKNG$OGHZ*_"M!C=?>L")VR%"VN17>(X)]GS;\@=\_' %,D OF!H+6>:R%E(B64'#? M($6_AWIOM<7ZTA?<%);>C@F>=?2HKV;7XQ%AQ#I-8%')5G@8;#Y6SB-D#27C M=MTU$=5!J3="YS7)?Y1NNJ'%/HRX"^47C-QUAX]ZYKY_./)28Z$!8D);Q9W4 MD)008:;U"$N1-1-.VC(B?B]Q'J;&'%/= VCI=3-/%V[ 5S#['BS\OKJZ2H'J*;K][JR\N MCROP*NTC0)4@!/"@K*A"R$"UJ=<:QJZ]K)\/V)E.;R+ EQJ] XAZI,=UZ/=M MH?@J!.[L>CPBED!'M5'!^/6HN#Z'N"UNEM2WW4^O(C.8LF\!F*%$?G3QW]T@ MLL'RU8@$Q+A0#! 84-N,CC%!T+@5?S.!'9%^(X1>&P]&:0B,0?Q#!?4^.R8Y M]2;ULG0C$HH#89!D6%.GK91R,S8N'.I5Z-44?E,A';XUO18L?8G\N:([HN*_ M?SC"UD%/B(%8(8,#0!"6HQ*<^/K6W>DEO093\(UA&4;8WZZ*KBSR)[=+.RW6 M06(8&N2+N[^=+,%2./QKW"J^B<@.2K\Q0J^1"Z-4\V.@0&OA3/"LDX.]M$"!"FF78"!;+XNI<''U),SS>!K%T<:152T*+BT&YCZHD([M4TXY!A(PTCXKQ-.!:.[ MM)R">#]N6Z.AC!M6 ME*B'W0].C=(<&3>56G)P?,AF]T6&V#R>K'OR895-;N+\6S[980='Q>91V,(# M+I$PRDI-A D_ELK:."UZC5OIIOA(97FEG<-7+HPD2G4MO[XQ^\41$ M)>": 2>)1LI8:&H]*\_8JN/Y']%N"[7=T> M%-JS9R+.79'YS8AP@'#C(6:E-K$2T1'IR]JHI^V,O3>/79G0:^9QGE=T\N]K M$QD()'%2(J-ID?5OK0";,3JI/Y5M\]'$'G M/:(>J6 8&J:1(*8,=')>8#%.==JBM%X&\[0%T6LAP*AT\:CD/E30WNUMNECW MLT+ WHMG(XB]TUH09K7CR'AG0>DH<)JI7BVOBAEW#03S7:!>,SCZ$O&.N[>/ MZ/0]+2(M#/<.<\6E8UI)XGV)E'?!>*TM[M-OO1E,H[>#36\'*UE[-[4?.H]I M\3.14,;+=J4UT02$@NI MU%([2PG$-,"^1H(#H*0:?6SMN\9EKSJ$:YB8^O55[1_OLB2>7BR>YA3# Z2I M^HK(6L<5I3@L\H9"RPE5I$2 ABUN;<)T5HNTVSIIK4$U#%D^)=EM95H4#Z\7 M9J$)<( P BQ%F)ER5$:1^E>IG)Y:/0H"U "EMNGQ_,L?DFR63F>330';#]DL MZ-*[>!Y^/PG_CJ_WWB9ZZGLBQZ3'S"DB96'9.8#T=MWS2M2_'N7T=+N>A=X' M7GU-_0]9.DF2:>X#6F_S?%54[[VX>EH1=<<2L+]1%.PF[8S2#"(2N"]5^'FK M#:FJ[[(]/1ECH*6@-7#ZSK!_D2ML5EE1#WA3G7OSC\\!IWARB!LUWA9I0EQ MFS&%M54800KP!A=(.:\?^7)ZK.U0%F?GJ UC2P3K.5&WZ6KG%0K'FD1,,VLT MA<8CK*@V7&PND@HCM+9!?;;.T_<[D>-!FZ,V;$-HFJ+K[Y/EQ56Y0)HT7QXZ M1#C>. JK:=C %ZDN&(E@2G.,4#EJ8EW]&LV=[4+Z)$OK #8(H$UN9ZO;_$,\ MFQ;W>^QTRNSBP@FM(^NU]AC-7VL-Q1%P*V_[)"2[5 ^^(E#70202L=PP0";F%KL2 M 5K?FNEL2S0R+M7"<7 N?0I?R6_"$OS-<;2)+UJ/YU,VN[X^&%;5\,V108B3 M8 <[^KGIRR>SA;7-G[8:VJ? M]I9(0<8DTY(:HJE2% )CR[$1I>JG+)X>H3TBYG2/Y'C6K.(ZKV2R*F[7>S*< M6OKPV#LCA*FF&#%$G>66<8@W];$"1L"#^FP[/7IP1&SK&]?^CQYZ;!G?Q@M= MJTY0;.PZ*(C[CRQ>+)/I[XN ]I=L%@ I[HXMLX/+C>PQWT'U-T6 6:ZH-4H: MJYA0'*MRGF NFU26/6O?=#]PUJ;,)HBG[*":EC>_/G9CT]E/Z=/N[B--G7=% M&GC#/-52*EO\C# IM[;8F@8G7?"LO=1] =J?K;2N4U!M6>[&_CZIXO*\V1Y*E->-HJ$ MD1!Q+04U)DP'8R@7FU$2 &R#5>:L7=NM(]=;TE6:);/KQ2,8DXGU7@H=:!4A22F0R'/-.836&NS*>$="&6F0K/LJ7-;M03>H M$6/J63";9I'6COLPL "9)1AR#\!VI$")!B1Y)?[EUK#KBR47Q57WCWKT.#>^ M?S@RD'-#L"(>6*2=9@B!+?=A@U-X>-9^X]80&\8]G%>(%-W3(O < *\Q 9A@B_+^+;-$R48/W863XYB0T[VD9><^N=QU1Z M!@FGF-(R6BW\ /J\R7D4E&B.47^\N$K"PCA=WT=:Y%4>B03>^7QDD7 **(^\ MY<9+Z 0K#]89P*;^W5\]9:"U(?_FN/29A^RI7]4)-_K69Y.;['1/<#<^]0LT@5]3&Y(CB8 M$P()RX#;U+]A$&%4R=O?48CIY":9KHI+U'8,(-[ZF-N_?9B",M ME0-8,NE]>#MBFP(287 "@/J7V9Y.A9.JXG8GQ;1=R.J;IB^^O;.SG":MI^(<6^T!!8T\N93BJZ[]_."H" MY0472 GC+6?,BS)L/FA)@T983+:9< [<:5$+D;[D_/3"A"/J_>6C$;<20",E MUUZRHG0E@Z(\@X"H0<#/Z6>\XU3N#1$;@@-'%_;O'XY$F!=4(X.PM5I["##R MY:@48W3<:KV^D Y(NQ$RKT7NHU3G0XI[(%6>+J;I8AV*\CE>_+D.64^F1;?? MO=47E\>U>Y7VD>8X;(@-"NH1<1TVLAK#G"ZD&GNEXN4P6%6=UA5=$'@M/D7582T#" M"@AP&93*$%(-;D;M+'2W5ZDWQ*LC%KQ/5@&Q]'HV>??1YC:Y3^;IW<[Z(O5? M%DG -20RK%]8*6B01027(^7*]+GE&RDSVD&N+]OP,@D,SB8W:C'==+6(QMN$ M*Q^P"0^VBQ0!QI-@Z1!+H=<>L;*D+GM^0?MH2O-W$FO9)DA#^/WZN@+76V84 M , 9@; WD@M?3@U,PY):FRZ=E3+JA"X=8M9?>GE_]^ ";)40Q34Y7E(,PN;= MEOMVK!6M'T7066VC3EC3$5[#,.;TRW =XH H:K7#QCE.K2EO+V'8>51?U716 MSZ@'%M1 IB]YMWT#JB64&V"H=8P)!XWE9?5KAJ$E]2NT=E:]J!/YMX90G_EF MZ63-UF >N<4R*+6WBZMT,MR??.YQMUMEG>TSO M6Y==#.HHF9KTMK!X^Y/K[D]O[.Z/J]O;.'L8.MUO=Q]5EL6+ZW5JE'[X]LCF MGFOU)!\ZP(7B]6#<:E$;22.[\CY+:GMT>' MF>\;9_6Q MK0S\L)PE'Y?!=%_?>5T08W^&8X56D:862:XM5@(CA1R2&R?E&AS>6 :$)*T?/E:M_K-1=KMEPF[!.,.W1F;B[V^_C['%B_'#W'*:-4LX: M*@$EA H'L&*EE2.$!K#28=H/=T\2<0^Q45@8XBU%&GFN-CI;H");]!6Y>RI3 MIC-WSVE@C]K=\SBJXS4XGCT780F-QTX%4P*CHKR\M7@# !;*]^8.*%UY(&E7#HC Y[>0BH=$YNQ$ #4"+.;AQ5IVC7$M>GR6YS]F2P_ M)-DZ]&0Q>1S_99(OL]FDV X7/?L]R.D(<4Y]3^2U(0I2+[C63'A!Q>8.]C ^ M#QI<+=V91VL\%.H8[![=[=]U^/+C[U4<[?O;1098CPW7S@5@K>9,8UZ.55)6 M/RZVL^2=41"K"W!["ZK<#/W(YO'I8Y&TDAK"@10T[-P%I-2 %NR,I_8MT4'U.WZW*%0-<61"P* NW^MUA'0D[!&S>Z3XJG#!F># M5T9 >*2QYT%],<^]8(1OM9CQ#;(X.]N^U!5;.@AB?4W_3[-EH0C?+J:S^]ET M%<^/& [GX^L" .@15A*I8599Q:DI+7&JL)7C-BH:RO@88SK! M[@>G1FG C)M*PU#(?4TFJT+97EQ=S29)=M3YL;M!)*S"D'%#-$9APP^80:8< M'0"TSYM\*IHTGE'JE$^>VI"!#@$0^SQU'N"@>?4Z5E MQA!H4%&\MR*40UDO]5'LF0W':Q,^?2ZB&H9A,T"$EU(PP(.I7H[%>$7&;6_4 MDLINR3;"X[QE/$K]W[]H6W)?F/GLZFKSY2-70'WW9%2$@R$!D%/2 ("E4+Z, M$V/MAG+:)0U_3SZ2+HH]!HX2?\ED =JU]]$.%8+2C;2-I.#!0 M$0&M)$0"ZX'>8@=)?=?"Z86@SDPYMXWMP'RJ=&/0T;:1,E)1#+@W1"!AA*1" ME6/&%HU="DZ6)_"F*3UT4^C(XBHP632AGJ@SK>Y&()KK0>84YBBQ),>P>PYIJ29\LG MZTGXU\NU)/PJNBRT\AZKY=G?(R^Y851))XGV5'GA-W>PACXC*.J?@)Y><_!, M+),F^'4N\[TKPXLG(DLM8!PA;Q352EEO73EJCHD;:81#3>Q?2JX1!NK8VZFD[8^_M M\&43BOTQR>YGDV1/#FVZN _J/GD,MLP_I<$95O'BY!0X?'P;@39F6,4R=E/AP]) M-DNG/LTVORJ>.U0#N=^.1-)[*;&GCC%#!44>LM)^%P*P^A[:X5(1SG""M"&; MT>3W[<._C+ K*Q7G%T4YAT\W\6*S-/PCO&*9OUT\HG%@CO35A4@K6%3?+2JU M.*N]P-"7RE]RBNK/CN'R*3I,[A^G5$8_+];_V9P7/8[PD'YH\S,1,H) 3"B6 M5!-A#&2HC#^2C$A>F]^=7>ERCOQNCGRO'/Y\?(B?#PWQ];D40HJ#JD@<7, JV0X/.<0H-++;SGWK_7/L/!MT(/^]")+1R$+NB/BF13 &I87FF M+!W0NO;$Z>RJI5Q=J=_>]-CH)3J#G#8J79= MY[8R93JK:6H[ \RS!XL;'\)<&"])E ,E"H7F4" M'*I4=!J,8Z]@XX%G@$!I)6> 6RA@F0TKB](<;)QQ?,T$<[B433U$SEW.HXKU M&U*\+<7DCZQ2D4+:0(BA\I1Y 4E8_C99ZK*X'W>$=WC4%5M;E8I.0ZROZ5^O MOKWCX6T6>AJFD%'0>:M%.19 Q%^@1F%=S=\$Q]'X3L^@2#AV EN4"$=[3QA MG)?3FT(_]H3$FBSIHUIX/6!_4+<]A$=I69TQ8X=A:C517Y2C>G3P!W-DE?[0&OKR[],YW.?9D6C0BV3J)$$SW\.C2\\S5/IN!)<48HYU(()4#H^.=/Z->5IO98YU$B"YS^' M@F"NDMG0T^B[7D3:4JR%,MQ Z17@14 A-)!A5>Z-A7"HUUI3H]&%W7!_A'/X1/&?_\1]C0E_6E(TV:\R\SA;OEP/G/X^<[ZW'.XQ/[&&$)2-C&**.+PB_& M*U-F@$II!:BOBL_9P7/F\[A;#IS_/-[LZU=9DH]S$I_2P<@209V62CK'/2L$ MZ&@I/85X_;/"-3L6-V,K4II/.?1!>K9;Z,%]/9XOK% M"G.9%!P)OR]N+BBP6<7S3TG631)Q%_V,J"YV)!@#;2U!3$A,RWV)X@R/\'*L MT;.^MUG:O;Q'7_+ON$ROK[/D.M@ ;P,0LT4^FZP-@:WQIP5IZ#< >O\O$D%U!-EK/[XD+@'T4^#AMT$EF+ M"!!*F[!;,D+K3K-*M@S^*?"21)DY@"24A3%$&,#=HL]E4 G'89_)M MYT4^JE*FLR(?IX$]ZB(?]9)],;(:8 MPF>0['M6C#V5J7NJL92U$$,'["Q+)D$H^=.+E X77JG6.H+.:L4\=&$\%"I( M +7E6+CV]2^ .*]DWLHB3;N&>#0+VY'ZZ$\<8!W'U![\8 2Q"6L#YQP2K:R4 MCL)R92@*>K[."]YJ[UC&((,S9'CGESU\]ZT(9"Z8WLA7GU-L]7R=2NLNUU6NO1/;.]-M>W'#YD.OEE$0]R@5X[88HC M/(F)D)L8%J4UE_7]5..+D>B(JEUC?B[+[I/0J2XS0/=_+?)(DN6+U@]O&=R7@.,G>7"CG0O;'L':UF(8A)T6=MT]I\:L^MY-5NQ!)113C MV#J -0F4L,Z@[7*#:'WWW_A,[^&])QU)Y5SFQ;"79UH@%2B\K])QBC7D7):* MU82?ZE]@-C[+?7BF-X7_7"B]/PJTW+Y\R&:3=1+'59\.\HJ=B8@@0>M; RUV MPBO%F"R- 2,LJ^]Y&=\68/A)T;E\7MFL&7ZJ1%@P8"6Q1$(5T-<.:%SBS[%\ MW4[XUDDZS'PZ48BCF41[C[&K9,&W-I':ZT6$H)"!*@X5CF3KL46 ;^6 ;*7( MW#/9:XQP,@TFR+.94.4@!Y]3)W4DPDA*@C ES@.%E&9T:\X8R>AK2ML\PVG5 MI2S/9F;M<'0/-;=.[$J$D%$"6^P)XJ(XA9)\<\N(LL1+\XIV2&%TUTE=B:BP%#AJF'&64\DQE65PI!4>U7= G\.YS.CG5[?2',W\:NRW M'\B-T:QCD6; &VD8Q1!0#B!@BI32XKC!AFQ\ZT95*O9@%2)60*ZI M(<08237>+D"0-XA'YS\F0*>B&'T=F=H5=="QR=!O;R+N+>'!^H5$ @V@#2M0 M*1?G*7U-J4CM\K2M^C"]R>Y8@35Z$P5*&< #LQ#3AGA"' 2E7(R& MZO4=.XUSJG4ONW/9-SU979Z7?^LGD.CY-Z, ,#4"(ZN4@(67UHCRJ,$AK>H; M@Z,]..IP?HQ 0NNT R],997GJ]M'&?RHKWO8)>XP90J$G3<7$,+ M-5U>?QM^--)662LZ0NZ\ZNLJ S"GB@&E-+ "";4Y6M 2:=/GW9)=U]>M3)GN MZNN>!/8KK*_+)!;8">, 5TZ&07,B2P :G!\?3[U=:M2X&!]W=-P'(TU>P9% M2E'8@(>U 5D: )6&&HI8B:R46)Y3?=W*+.FC6FD]8']0MSV$AZ'L2?5USXJQ MIS)UR/JZ##!AH*;.6FH,04KC4NTHZ_@YQ@1T*M(:]75/@W@T"]L^%+<7)C[9 ME);^@'^F\_":^6SYQE1B>0LYP(E[/\3Y\EA?LKR9)\V>/1TY2QU78^!@*#49"4USN M?S2SXG460CJ5T:.51Y_G6<7^XR8 D63YXW64_9QB???9@/[MYH+(L#_Z(\[6 M]3N&/KTRZ3Q,X+3(&;U/GNX90Q_?IXO)GC]_"C_E\63-B2KG6&U^)L(0&4HM M9T!#K;%"5&[.3BT@5%;RC7=]HM7"@*L?;;7UL0@ZPZS4P#DM">=(4KF)L#)& M %P_KJ#E,ZYAZ+3WM&L@_$=][/5Q&["GW3QZ3/#]PQ%6V$$NN1,@ MF$<<8H!*G*RD>.3W/[8@K;0CB%X+ 49YRC,*N0\D[V\&\MZ3G+W/1J[P'TEL MF: ,>!?V'&4E$V,5-/736SIS;C<1S$L9-X2C-[]:R>[MEN@N7:R58$7#8%>[ MR 6"^R/2BJT=5Q,[G(^<4@5!# M1P470H:Y0C:E^XV3#)Z+F=!,;FEW2+TN-HS;9A@!"<[1=&!%=29$ 43:&4&) MM&610>,H\VQ\ID-#V1RU'DY#I#?K8?4YGTUGQK$^QIRBGG MBGL$$>:.&8'+,1KI*\7%MW0F=K960TO@]D:@;[TL0ITNKIY <3P2\6CCB DB M6!@BEL1@8H"V9>J<\5(I.W);HKDT7_*C*\C^*H09I[DQ1IX,PX^+^R13\WFZ M+-;5QR#'H_;'WC:1#R-!A ODN8>"RK B@W*,CO ^3U^JGFFW*+BT&YAZ]E9N MSG4OLLLB7_&(<;*W3:2(T9!*#Z"2$"K*-"S=-UYQUN=5K^=JG+0%[J $JNKW MWM4J D0;!A$,UC^WLJCNS$PY3NC\R%T;+$V) W(["L#K)Z%WEBLQ#H[417#@ M-68=[-M@B7G>/K(ZF.LZ3 )$J(:2&>I5.?;B8H0>':QGQ9X.P*V=2?!X&?3% ME8T?'B\<3*:_+X(0OF2S99(5USE]6&63FS@O"S[LHDW--T66$,RG]&EW]Y&I MSKNBXAH6)4BP&272%GAF]": RB+J2'WW6F>E"8>G4P] ]Z7T/F3I)$FFN0\P M%XMHO)BLW53;L\\#"N]HV\AK@RP76D&OH &:8U@J>L29J7\M6F<5^4:A[-H& M=E"'S+.[;K9_S#=_S0_E?M9Z7\2\PV&9A1Q(:IS2S&QWL$@"57]%Z^R*EU&0 MK@^PAUC5-GW>WF!;<4%[V:PXQK/,>.(1H%HI*!7=KM] LOIVEWC5M&H1TP'B MIC[$V46VCB1[W&H<2/,]H77$L$#48DJ*RS )@\"[[:RA#-4_R)*OFDOM0SL MI1YM1+5:WJ39['^+%-LJ5'K9*K(*6Z^]P!QSX0D%!F^\O19;@QKD?H&_"H<: M8MIGNO;J]C;.'L+F=':]F%W-)F$559-)NEHL"U=(.I]-9GT5(J[4E;"C3L+? MS2K+DL7DX:D(A\[M?I]\>=+?+%V$'R>//+S(S$W!NK>+IT_,%I/9W3QY5R&A MN_&[(TJE$9)Z3XAW!'!C-BYR3@S!JE(]W7'A=BQAN]%[(V>DI4@Y;XWA#FE/ M'-_@)8AT]7>8+>=F]\B,=#A\SR/WNM4T*\0$$M9"JXN-$"9%3-\&(,D0J%]R MI>,<[)YH<5)&U6E8GE<.C35 0*6($I1Z:*61R)9CXXS!<8<=M22W2LDT]9!Z M76P89:#1F$@PC/##>KBZ7?:I)T_5HV:_K]@+1? '(T_JO:"B!H+)8!2 M$ZX!Y11(2#>C5\#3/NO<-\J]JBS%E]7JNX"I-Y)LNUEL@P[HV6-7'YSRGLA* M;S!T2$G &$= (H4W6&CF<)]1*6=@AW2);5\\*TI4%X>/:;4,BUV/1RPLV-H( M#@A53C@,H"HW%1IBJL9ME70DQ;0SX%X3-49IHHR8$2T%C'P;T,?BRL(XF^:_ MWTV#IEP_B@Y7^Z_4.!+6^6#-*4V4YDI[[TRI5C7PUHW/^F@FD+1CA'JT3O?V MG4%1Q3@]WKY(72.>"2:HE@X1)+4M)XUAQ-6OE]]9^&LK[.@2I%XC7'=6?=T7 MSOKLX0@B"Y$40'DLE7 ,6%":\\'Z KTFYE83_7!NU\;P]46*R^(\9I%,79P5 MMZSG3_9>-LAJ,EL>(,GQQA$G5@H-+<#,"X:Y]+)<*PT%#0K.=;9>#$>:UN'L MBT3ODZ6)\YL 5E$!>ZH??L^3Z=O%1=@(Q@5&:K*<>*^2 H*A$P=D&QFEG4?1#'@!U!.OH#L K'(1O>EK\I[BIX#__[?\#4$L# M!!0 ( #QW94TFEQEUP*\ /L;"0 5 9F]L9"TR,#$X,#DS,%]L86(N M>&ULY+UI<^0XEB7Z?7X%7G6]KDPS127WI;I[Q@"0J FSR%181&15CY4]$^M$ ? Q07NO_ZO[_<'\#4M MJZS(_^T/YI^-/X TWQ:[++_]MS_\^OD=_(S?O__#__J?_^-?_Y]W[_X=??H MHF)[O$_S&N R3>IT![YE]1WX^RZM?@/[LK@'?R_*W[*OR;MW[1^!YHM#EO_V M%_:OFZ1*P?IA7C6T.(_W'O[_X_#>[^;09 MAN%/S6^'CU;9:Q^DCS5_^O>?/WQN_'R7Y56=Y-OT#__S?P#0TE$6A_13N@?L MO[]^>G\17?@3^\1/>7K+^/Z8EEFQ^UPG9?TAN4D/%$;SM+LRW;_^B$-9/GD" M8RAD#)D>8^B?WGAP_?B0_ML?JNS^X4#I^6D"?@G ]4NPNM U)/PB W*,U>B>K9@]/O=9KOTETCFD\>#;+=O_V!?K4Y5N]ND^1A$Z4W M=915VT-1'O/YV< M>$);L7WM/6B0[)/JIH'3^4MAF<%/Z:&N^I^\8S]Y9YC=J/I/X\0\9[+8JF*R M)>; 9@U%V;UQ3UX,6&Y!4>[2DLYF^C]*RNT;+=!]XJ=M08?HA_K=D\9@LQJU M3A1*WZZ6$^K":WR\VE'>T\E(V!KI+&P*MCL>4E#L0=-Q3OBJB]U%'7G\$J.3-S%] M.:?L0Y'?OJ.TW[\@#_RCP;F YCQCZ@W!D>5U/6HC[<$K4C.-#5Z=HX:RDCCDQ?-?(FIBR!56E3D)2$C(C*!O75HR!0'"F5OTA0%B8K[),LWCN=$ M,7),UR%!0,P8TQ_TIB+L.O(:PFE@;A5I84W2$5[J9)1$ VL3M>0MPF90DQ8" MMYX([UN#/Z?W-VFY(2&R V187H BZ, MOFP/H5A$4R0>KUE1&"(VC6\QB>F(#%E\*J*9)S$->4H1^$<+:&8)>\+0-:/0]AV(<&P0V\9>9\:!$)HB MPB'\<,VRT>,!#)#48D:<+C[IT,J4F' (D:1%-9Z3,:(9TKRM0S'DX1>*WA]Y MM>AF-# .+1Q:T+2)8SMQ0!=*@R'L$4-6+S@?/Z]B2"U<9$@35PT-?$W2C466 M+"\)X=0.0?;6IQZB#HSHAQ07W$N5(M\5^?N<]L6;)/_M>K]/Z22'F?WP'EU_ MZN8ZA@L#QS%\.JUQH65A$\91;QN1T!=:O2BQJ'M!PZ (KF/4,,FYM)F=1,'5 M3H,/# !!A[ 5HQ\:D#\NM0CBX6YL7:24^W5(EV*?GJ^>-# F('"W;&.1[4I] MH7_9S,:0(17BE#.B6KR?;J5> X9):7\FQQZUA M>HD3EBQASG3ITPM>QN5(GL;5J,\$%UZ*S50^9+6EFZE%KD.0Y81AX ?0,QP3 M$]09\[S L::H"Z>)1?1%:C4FRZ&YT; :41)'.=6B/JQ!MJ M(\4)]VYUD7]-RSJC"T-FKYLWQ58 ?2/ 5NC9R(U1%(9A9\L/8DM(;N0LZ-ZO M/H$"OQ1U*IA0)\D:YTZU=L($MZK/N&I2Z9998[U*R]AF]20:UZ$L$WUXOEVM M@!&Y?-UFPF1'L4DT.![Q"AB(_$XS4KRK,D4ZFED0QI?)JB MF2\Q01&D:H9LW#?60Q/86X>.3'%@-!57@@LY!?DEN>\G0C$*PC@RL&UBB]C4 M4ASVB;_0IM_)ZXB D7G5Y HP:)++(7DB9;1%$X>3%(:7OAF4YD0/M]Y(,+I& MU9%Q8U1[I'EY2X'VQ6%W/EGZG.9943;+!-K&7G1,+<.RN^E3%/DFCGW#B6#@ M!IYO.['9FS8#/C52:G#&E5.+LUU 8;T"E"L@('EDRBU3(_+U6(DRZ^VSOEE M&$$'\NT5F$:6=]U-"LT%".MC^PD\;M8_4IA42++\%M0%J.]28/_9^'_!,:_2 M[9%M,EY\[7?="P]^8'_UAQ>!A1__S#O<,,J:0<0(;:,90D1(?&4XT=(&RPXM M>EPJ-+ZS8I/>S\>;*MME2?GX.3FDU_O/=;']K9ED6X;C(0_%@>U'MN/;R/'L MSAZ*HT!H?U'>BN;!A<%A&!'H?H=$U2=DQ4VJ;[>?RF3O$JV; CM=Q^@$2$W@) @*R9^Z")L]88# M8@KM""@P-Z\.22V[59#**4GS\CE)FQ99@K]-T)A,J6-W)7JET*'GPJ6:*UX% MNZ9S-G@X%#6;^E\_,'O=/,V&,(A,&QLH](D;6684]:$!%#D6$1$N>2N:]8H! M>Y?TR$ +34RN)C#(IU+SD"K6C3K5>)&]&H:T>O0JHD^ M%"I?/3&-.K-2P7Q'WZ:SE^G\7>J4,C 10501XSB.X@"Z0>#WQY$Q,8B0>JFV MK5G7SN%R=#VI!:+RYN 3NR5;0DP&%3>"%@449'-$&W6URSI44YMWQ3QOM\#. M\<3+-OP0RO , J1$V#Z9;\2QC$* MN(Y5*S6H65,[F&# "7J@8$ JL*&IC&:.;>,E&!;32AYR9;:-E;$LL&V\!-MR MV\:?T@?ZVV9\RO)]4=XW?P[*]-#4&*@+\-"UR\/0+@]]NR2].]74+6).PBYM M$:OF>P5;Q,I=*C2^GWQC2U76FT]L)&M6"*[K^V80.*:'78.:, *G/PT2T>4" MY!D\Q)ZH>71H@ B%!@0)&9=Y?5R(Z3@7#3PS6>K0V2R6?O=\!OO$XU>D08Z1 M9?N^).9BRCL@V'L[;7!#PT>>$8<.LB".0NP,IRXBS[604/_E?.8\/5AH+2Q, M"V>96-@T0B<.0PLCE[B.'T6! MT=F+0VC;0@E1TE8T=_X&S\2$3'D&^>+9\Y G)A5BO.G)>;I$RUBJTV0JUQ%L M5N#'\\0F1., MGL5N<'E&QYAB2%.W$L&0Q__BUI9I3/#*!'9[0XHP#Z);1_Z8>PA M&#J$].)$X@ +W?XM:T.S= RPIE[@(LTAGY[,09^8JL@PIT5;+E SHC!3R5R' MSDSVHE#[B@EF3;.$G#WML##??4[+K]DVRV^O]Z^ J%BB9/7ZK[I95 Q"3&" M1A11D!$TB=O+(C%BX@DE6\\); %UD\U9G+?!^%1QM6TU74J7RFI42>F(!"_2 M7R3]SE8$Y/_%[?3,E"@0;7HS9$#-R,3ZJELKF-N/-F+T6LC95F1J=3>3[X6XUQ,TSX\K13=([T"'58P M@ 7X+>ZU5Y%^B\<1_=/2'.L013VNC=2D5LR?W&0-)556?7XHTV1WG9]7L#0W M413[T'5M!$/LFI'ON-#IS;N!,>$:\ E&-9B=Y,%$^:^5V!EN[/ ]U/ZM\N.1>\3!_WY%!!"ZQ#&-6[-3I]5,:;G"!^ M2(#<=SC,BU; _WAC!TL+ST<3U>L\@UW3 [+T@.].=;%JZ]33>Q%Q+;BZ$3AFR#/S8L-,SI" Q"[IT4Y98UBTZ/$#RT M$*_ PX!-(,2OGG".+95%N9XH60/O'WO>!\#@XSI:0&"W9=&6D-MV4=TB?/LO MHD1=VHC11O@*=F3T^5;,\PM UF%C0;L=12"8> MQ0:7IQ2^/Z,P&J-0R\3X,D$C$V0%K*YCHJS"D4+Y&R>XC].587Y6-14?RY(E MQ39WRVV[;VZH?B;;>H,<)P[H]-V#-HJ@;9FN87=(3-?WN6[ET6E?>U[2TTK! MR(',/:J%R[P*TC6W>:&R$=%\>\WGC(BS!R34PL&[H(^X'A]>:B")KR84P!(YHE$=[>ENEMF M?39ID$T):8J0*!/8U,3?Q%@!0P7@.'DS1#E/Y'#'.B7X7(=B37=C-.XIS8O, MLI*9_B6MK_?]]!$755UMZ'0Q='Q62LNV@L"(?=NR>L-.%$>RRTM)<]H3;VJJ M1-TZ*=G3)]#UY>ZXK5GNQSY-VXNVTZK.[ILK3-/O#VE>I8))@RIH%U^(SL#X ME 4I@W<%6 /0%>FP.FTP+K,\1%W:ME%,\PHV:U1[5.A[*06&DE^. M[%C.]?[S74+?139RI;N/:?D^WY;-;6C7^V?AA4WDQV$0!Y;O>C *3,?W G<8 MS[R8ZUI$3:8U#S!5 [39N:$][H%.K+,>*YOP;<^"=OP[.KI:@6/06;8!Q,:? M%BNXWH,6+6CALOUJ, !FOY:+4.MJ!8&!:=G6F%P=HZ;#5=XV$NT+75=YLX_0 M/TMJ\"VC@]=-VO>LXT.1=Y^L*)H_ RJ)=)F:W#\/9W_.1L64 M_NTC^*-Y91C&JW8?^GWOJ<.D<+-=&C'UM?\*!D^-SA6S]*$I ?$SFWAXJS^Q MGF9N"$%&9#F!:4!LV @2B/W.O@4C4^A*&W56Y\C_/75P=K8A*\ /6=YUZ!^G M1,XGL2T32I^+Z(FQ]3.8_3<-^0W2):/M(_QQA]]5M,$Z@E4:_!H-T*MC3J$X M?BRS;6IN8(3-.+2,B,2>X82F'YEQ;]\S7*' O3JKLZ18-%WS@0%J='%7' Y) MV4ZH&HU4+Y&\G"N32 UT:Y+(!NGJ)++E;YI$"K;![T8B1?T2ET@IYB9+Y!?Z MCE5W=*I[2M?M+IIN\'PIL]O;M-Q@R_(='#J6$3N&'9DF#OI\.)<"K" MHEE.!Y3"QSUF:XR)BKI .ZC4V5,#G?"?KKYO7 "=#RN18#["9819<5.N7*Y5 M>\LKXEI8ECBM5[V&Z4N9[++\-DH>JPTT/2_T4.AB![D0NJ:!HQZ! R&1/*LW MV>YLDEVWH,".HI(^(3:=9HY8^H(,3Q+CZJ(:=W!!M"SWTF?S9FT#V2W>GNRS MD/9#NLWV6?KTY6_CY-OV L6J&1G;Q6%=G ?2VI^]%N\^G;:OP/VQJD'ZG25+ MT.>^G!Z!;UE]1Q>=R1D8^L JW1[K[&LZ 'MHCI(Q"'4KF>=0]FE2'TOZ1M$' M_>EC_G_RG_/H2_Z_Z7\^_PFTA;2OVE!]']C_TT?S_[@_FW;T)U ^W5>@WQ8E MRU7;)]MF&Z'(4_"8)B5] @-$2:GOZ)O,$MLHRI6Y#A4PL@C*/+=T(+]8&$3 M'PN6>%5B4OONPMD4LD^88+GKQYR^E-_*K#DFD-R6:9NS(;TIJZH%^/1X ?+% MQ+>-9G5)2RW$[AZ.JRZCB1T<^-9^8F:IY2-O1%<5L[\.$57MU(MZLQHX$TKY M9/K[US+)Z<+JU[[S4T$A1?F1OL1W297VB30;PXM\Z$88ACB"7@!]&_8B;?NA MQ5]^0X-MS8+YR[ R;];AMRWHDUS2)[:9V1WN4UJ:1.:ARB;A"%HMW!IB"GK* M &5P08<7G -N$@5[R*=RKW4P/L*HC0Z MO7LM^U(;BUS#6W>;=0\&[G89>YV30VNR _:E.(>V00;!'G%1&,*(?6W93I_I M9$>8[UH7?=8U#W']%?&G('0RP.Y3K/MQKRZ>#'T"TJJG73A&N<6;1&R M-2)%F6:W>7N7XO:Q*:.=;-G,[J])EG\HJ@JE>_J9+\GW31#%/@J097DDB V$ M8&CZ P+7$\KP4&E7]T[B'?TN9>E=^R0KP=?D<.PNL^[;2C"I0RGG?#JV%-UB MPM:A!#U,<(83,*#@!P;UQRMPTZ %%.Z\@B? XX@"ZFB-=4BB%L\*_>^RF&B> MU8!N5[_P6-\59?9?Z6YCA:YKA!;QD>^;9A1A.^Y+WSBNYPA=\3_%SHSI%5=] M[#09X(D)XB0^^01P+BK%!.^\4'R?'@'@VRQJT;81BD:T3 6QZ] N)9X4ZE\[ M!<&Q[JKL#4*Q3Z@%.W8BQS9]8AB#20,&0N(TR=#\8;%,=)8VC<@)D3 ='*H( M@^'5Q,"P7 !,E-AUR)(:5WA"7W+\\ K3=7V7ENVJMC>$3=_'C@T=8D06BI%G ML2.(G0*:?#?L37B\9A%J$+4AKNH*2 6X9#CC4Q[-=(GI3\C&B M+A/(6X>F3'&@4/8B33F95)TJ?2##(,@V8F)83F3'END,<3$+65QU/J?:T#Z= M>7J4E:=*CEH.>:L8E57*..O95$M>ZKP"3/-_4_B1TZ!?\^2^ M*&L60(JR:MO8)Z?BN[;K];>GT"\/.K![0$C7&7B5E M5(2FD+@6X9GDPPNQFI-=.MM"53!&Z\>GINXWC/K?0BJ*Q:Z<5P70X2P[2#+#K$9.'&OPWX41%SE MG=59TZR YP#;4R;2$6X%S/)IW[RDBHG>'Q =X;\7$]G I@:1,3]TCJ9MH;IKO^L!N6QK@5(U@ZHW_;[?$*V.0ZC9< MP0TZ*KTI]+SID^,+&^3&./!1; 4F0706[UI./W/WC3@P1/9!9)ZO>3OD"_N3 MR>&!MUF2C@0H)4C%HG_QQ;W8.IZ;OW5,:2=Y\/;J7) -[H7XMID;LQN:BT.V MI2/3$ EUF24?(M\@OA6A(/2"[O9*)_"A[_"N$^4M:)Q1#:! CVJQ"/]E@L86 MA--974>W4>'(\R6@*FYX.]$OZ;Y^>?:'*K#^D7 M-G'3R!Z1Y'D:<1VJ/9.OQ1+=1+06 M3U(W$.+_/&;U(R[N'XJ\.:7T/:LVEA=80129$8IM,[ =NN+KQYO0H\2+E>"9 M8DFS=K>8P D4G4Y16()B/)%,/K&=CTF8J*NZ3+-]$V A,"!T8N"XQHQ"'5M3;\CU/:&]5SL+,:@3^T>(2 ME"-)]OAD2#]QT^3G; MZ DE>''#Y0DL@&=;2(*)'HJHYX[BSIX M&%!ELZQ##E4[]3(\J)XS;L$/;F==MK$9$V<,2W:]1HK(Q(UB<1U*-$T%PJ%+Y5( M4N^@8Y_K)-\EY:[Z]6%'IXU-7IW5&0ZBF%A> )$#D0\1(3'NIXG((%',G]>K MQ)S^96T_"1A0@A8F:-]V2R0/50W#XUJT$+G2^2B7>'U[B:J-8)%IP'&(%WB!B\+89XTIO5,'\ M.B;!BGVZF/2HCC'=^8\?LCQ]7Z?WU<9U0QR$+B$47NP8/L91/WUGEXH+59G3 MCV;M>9#,$]"X,E,RI$!#\BGONMI03)5G:;Y5948.K&O(CA1OT76H_8S^*LJ2 ME&6:/U.RV/YV1R?J5!';'(6-:46F%08&)'8(@]@S(J-/2L!^;$1BZ9'"C]<= MH&4GU-IJ>1VN?_ZGP#+]?P%I@T\T-U*@_D3Z)*27M^TGSLQ M\CE+H]F0TI2N0[ZF./ B[W$B%[P"\RFM$ZIANS@I(?NX9M;[ZFY4W!*SD*#(ITI'-LW/VIQPC2#B3X(3E+ ME=FU."]?A:*-:3YMFIEB,:T:N(T';L_3D**WN-6B4V\S-J);"NE>AXZI=*C0 M]FJ*+K=KG%1W=&KW-=NE._3X:Y7NWN?7#VF9L!D=W-;9U^:6B4WLQ-#S0]OV M?6)#*S:"_CYW!\>1V!ZX0K/:%]#LIN3J#AS951QTG57T&-FE'!U(T96Q.LYY ME\"+T"VZUJT!0PEZF.#F$?SP:TO[CV "^#;O&M:TO*R.+IV5=X4ZU!''8Z] M6(UJXHY7+=&QHBI=5;BXO\GR9I?P=!X\#EW;#$QJ,[*)YV$+(TA-!C%Q7"]P M>,]R3+*AKW?VL, YKL7N.1@C::3S*>%V'=U-C2N%AG=OIT[]V*>]-K8CP\3$\3ULFW9W5M7SB!&)W9HQ MS9+N^4)30ATD^0Y\R)*;[-#>#?ISFC"L@P)W_ESO7^?;XO[%.8[=MZ^3._2O,J^IMU/>PTE M,70(CCV;G2"U'8("H]50/W0H/MY;PE2;U;F)VR%EIVV>0 0MQL6F$((W=#$R_B&QB=)/W H/RXBER3)^R,;TQ(L+@.A9'$_G)[ M09H!7G6XKN_2\A518B:I_>O]E^3[1W;Q>Y&?OSQ?BO;5&;3+]BVZE")!C$GL MVY'O12[NT7E!$(HEG\R%2GN&2N,(V#Z9)?QP:/KB;9+E?Q%3J]D:BT_GUMA* M8@K9-L^KD[A6,:\ $U$ZT:.N7('.F8OW["PT[U/4#B-:/'=+KT/%9_>Z6+9_ MJ1DYN@NJ^ONIFFN(6&8*!9F_?BD1AR^;,,!&Z!.3F! C8HYL>NZ0MZ.Q^G 9/:WL5W MU,=WS,FS0GQJAN39VGS:(+S&QE8^[,*7S7WR\W<]SBIJ/HF1=>X79]UCZ>QL M<(Z>R[323&'4#0H=*[10$#BAA2-H62;NE^AN;,>Q2#U+W5B$%JSBM2]?"YEF MG0HVP]ZL,=.W6V:66*G21EDP1KJ.L8:3='T!4>[F7/=8H=Q;M0%0099YM?X5 M0#V8C4]78#9"9@0C&QO(MTGH]1:)9T,1'9]B1[-&/U4#\6WW213R">Y<[(F) M*;>,KD$^1R@BK9/ G9LS7H.G1^ M ;\O)7K/S+SP&((>AR__=Y:6]._O'C^D7VE#-74> \\,X]"&R'7,R(>Q9>'. M."*.(70CAR*3\ZG_ *Y5#/@WJ=(]JI@6E/#Y2);69V%^]>KP*&,\(JN&\I4I MJ"*G+LFC2LZ$M>]\@O 21E>*TO)=#$,<^#!P+(?^.PJ"#@.FR!PI"51B>5$E ME*K>HYAY04F@8W"A2@\C//'(UP1V5R964SRY)$V3V9DB1'9GD2#//[M-QFR>%C\I"6OQ3L>.?AN$MW?\_J.W:3)#L@3O_#;A+_FAS8I*T' MY&+LV+[C!/1?'D269[5A/<\P3!C9(CJE$89F&3LA!P\,NO"FLS;ZN?>DU\"\ M\)9U3WJ#^@I0W* '#KY1Y.TUN6SQV7QQAGXAO90G>GQC6W?KK4-MYW#TY;;X M/-QRUSQD&S$HV?Z6[DZ9IKU%C"UJ-8C"$+H>]IR0.+W%F)H4JG0XP8YFM6V@ MO;MIL$D?*IC$(Y^JSD6AF&P^8>\L1W^AFH67.1I1/!7,KD/2E'CRO"JA,G;X M)Y#E0U$F=1JE-_4+FX9C&%84!*X11ZX;X,".46\3$D?H:I]IEK1/ SMP8$?1 M24O31#9YIWQS$2DZJ^LY9,"6%ZA1GD8G92KX78=(*?+EQ=1*'4.\0O5SD:>/ M/R?E;VE-COFN-X81--W8M2S'-2."XSA"N#=&(D/PU*>D$9$^)758L\$%[AM@ M8,^0B>F2+'E\@C0#:V)*U-+5(@(-I(4DZ'5F1K1G(I7K$)VI3A1*7R\^F=D7 MA]WF"Z+N?BSN']*/97%;)O?])D(8.#XRW3 @1FS'3@ =LS-E0C_BNBEFD@'- MLY\O@.$"#3#0(>,3F&FTCG?A^:-WX,Z^,,Q8: M<39"VVBD>8R75X19"8W+RK(:%PJ%KQ6?)%=EO?DY^9[='_OG&W&,/8(1<7 8 M(M.$=N1US[<0,2P>'19_JF;Q[<#P*8<$)^,BJY<.P6E;BT/-7(TZ=C9/H]\] MGZ.]\/R5WB_/SK)=?@+N8NI[(1I_:JJJTX& ?E5ENZ;,79&CQR_T,4T*KF>% M?FA&V+.CR#61#RW2BXIMVC81BT%-M:8]#M4#!$\0LCJ1#*/4 0 %'/-&IN:D M5S0Z-8U932&J-P@;#5.I(GL=JT:%_KP(5ZEE:J*V,:M=FJQ-0B-R'<_SHC"P M?,<*C,&N1T*A*TBG6UM*V]KN)Y7/KX#B2=*FB5U%TL9'[)S*=N)+7-DDN%ZU MLLGXPZ=LTDQQ1?LD%9UD0^[!! Z M3AS&@8/=F'C(@B[LIY,V]DRN:=V,<);2QL$-T/O1)$6=/ $G5P2"3S.U(4> M;WW-ITA\7VDY>*GE9.*',S6A0+1Q?4TY.39Y.2ZY/>^.Y:E1MZ?W8?OD?;@? M')T:O53"\Z58Y[R-N(+(Z,P.%XMU&+'%"\MC;R<3Z?8NS_[SV*Z4"/0LVPUC M)W(P-B$DIF5UQIR &A19L4B:T#P4#Z@ ?'@HBV3;IB$/&*5",+)L\BU.9B!2 M;%"U>G.U9+N3CF]"MVGH0/;(]KMJ3JS@!+8]S\7@"JQUE7+.$918BFXQ7>-F6B:\H)1R M@2#"4M1K#!5\'<:?>AARBCW+91J:[UO??+M3\VU9\^VIMU/C!0*47HH*Z&B5 M%:S]M;A5:'Z;!?/F3]?U-*?23WN>L6&9$;%1[YY\RP4BHTON8*T]WXWDZO1I> MINA/-SFGHQ0RC9C%!RPW)C . C@(7N@(W>TZPI_"IKP.:2!2C1(M MLFZ_S)"@&@G2NEX]$G6$0Y&DN)'5I'Y*]BFITVXRYCE4_#";CSFN'Y' @U$? M.'"-, JG:).$.[X>-8KB]R]*OS:(ZR/5-W_50 M/]5S?=]&W'%)70!FC%$6^U,B#CA#*A KT]8,'*'*-;3 9*D\;X_K"^TA$\34 MUC " QF/&]%IO2HV.5Y6E5P>U_ M'K,J:^HWLJ"&X2(WFF"6'0[8[5B@K'NZ2\CYYGV^[V9ME6XX1$#N*(@.C MP [,H#]/YEF!S[5K/-6&9AWKD8$!&KN:6N1DS@3Z.%;\,S$G)E&ODR9UKFD" M>R*'E>9A46-:T4O*66V)[>3311>)N;2R5D#E"A;/*KPHU+Y@DD5I)E1\_4 ' MF_=U>E]M+->'Q(@LWS5\QS&@&?K],MU#T)4KO#H+,LW# \GR)&]J%R2--TTN M^>'D#ZB.-_^1;FO61?>L[,O7IJ+>_5G9M/FK= NT*]]T>;U-*C9NG1?F@:?V M/'.FK^*] U2!1VIX-RZ!?S"G0./5[["<]] B(W/W95I^'?/\A7S74-I;M@6$ MBEV/#31LAWJ!#84BL].M:1XT M6H!_D2AT,8U#/C&?ESXQ@6ZQ78&SXK0G?. ?/<(EBE^,,38BH.K87H$-J$N!"1."0!PGUE( _#@"MQ8KH5W3/S7$7* M]3:!$Q5+*7<*E6HE\B0C2]R4KER.^/W@E2%!9GCEYVPV-Z9]GF\'$0H:0/_/I6% H5FE5D4K,PG:$4G$JIHI1/G19@4TRJS@"N;6;%Q]V(CBDF M?QVBIMJI0NL+*[>-CHO[FRQO(MUO78RT":(@M/S(M#T2.)&'W- (>B3(M(0. M+^JPKWN+ZM(E8P_)8W)S$$SAU]( 8KON2W$ON0]_!O<*7+H!\.IT!> R._," MI'+LU>MHHG6(JU8/+^SGZV.35W:C=)^69;K#K(Y'7C4V/]\E97J35.D.EB5] M\]OMBM-]=$?Z!WG=QA.W[3>;V ]\&SNQ2]?;H6E'+)C8H\/(%YJ&SH5)LSSW M;E!Q/OD!'NAGAHVBRY*P;&/QR?8:VTE,RH&H4N %GB]8GF6R/?U1A1YB4P;]ZBQ_2;@LRW1R^=1M;E[%).Z< MTJBA]%4QNSQNZ"K.\A9G(Y*FDO%UZ)I2CUZ6:%',UI0B+<\/;6Y" @-H0M^U M',\US!A&,1Y,A[$QM0R+L$'=2_/^4HZ2^Z83M7R.J]IB5 K+VH60YXLSXTMP M/+UFB5:NY1<6^EIL9#VR@M=D' _,?D ML0G&#QDRAF=;T/9]8KIA&)(PCF/4CM$H) %W6H1F%!JWU4X)9,7^Z=Y:AQTT MX*^>;+7U#BR6=#:-[[%=M'D:SS_?,YN285T<^;^_2W?% (36F$3-] M#NY\*P\]GC[3P8/?DG+WA>G=!D%LV+X+/0-"9$2!117FL,#$4=0CNPXP#'A@_CD#[7=\+>AF%Y0C$8 ML2=K'@':_BU=SD60)3X!UD>0F(CR MB4JKU E=OOM(7[!?DOO^TC$KB#P3(RMB-5]#[&+7\GJH86@+E4=8!*!F=8K_ M\\BN2.XF(5(W'R[3;IPSS;4WF9A>BK66GCFC!D;'IH]+-N Z%'Q9"IY/*I=O M#ZZTDOC^X5 \ILQ8E)7IEC9@];DNMK]=/S# 55_JPO ";"(WCB(78\>"R.YG MMC"*??ZZMXKL:5;[#@S;=7F@'[FC;<2.?MS3I6K%P KD0*@BF"/-9 %N!66Y M P@H0C! ! U&T',N<<.D*HX%TDP6X%HNRP3F(#FI#OAVEY;IS2-(D\G7I)>29!2_$"O(D5'M4:&O^RA>0%T: MFC\,=ZS%MNM!PS4#/S!-.B1#9)$>&,*AT#WP,\#1';SGB.N^$=;]P''+XF*- MJ6@--6\["H;IYVG"999:;Q(_96&EKE5_)\LHA0Z++II4@J\#Q)D&$97MJWF46:AI9QZ&GIS'.O/T"@POS,G9\>JXZQJK^)M/ MQV"FX>7YG8]V.AA1-1QJ:ZU%QLM/6?4;H6O\]SD=)M*JJ<"[L1%!L1-#WW!C M,[ (-OT^%(HU]_[\/A:V\TU.$YZ;_X;#HW3^- Y,"IH*:%A\>9MW#Q[Q7 G&O1>,CV349JT6TZ_?"8)F7UH\2(N%!S M"@R%ZV_)U8R!P_O!?%Q@Y-/25&\->PZ M?*SL9+OG#G[(YHV+5)Q,=<_K=X9'E G5Y/L57^CCVJW;V_2=JE@Y+4]-W9FFM M2]D_ZWI55I \M#)"BM5V:\$( NW:#<;K/4ZJ.W(HOIT./KNA[Q+;]2,/NH[A M&"BRVFOE?3_$DW4_V2ULS4Q[)@?7B''G^E'?]]?OW07-R5W\)M37LWN\UV $)GP'#20#-K'0F0[*^=1M8;;%-(^";:6N MA\LF\#\PQ"#+?P2G=CBA7DP/Q8D=44F-K;0.[=3I8#';&R^FLQ3!/JO9G6@; MP_(-8N(@LH/0=T(O=#RW,X"@'PEM5P@\5K,NLN[*[O,3TT(16O@T3A,CXMKU M[!X\^NWAN&-Z=>F..U;QHLAK:N[ /M;OR_J)>6WS96&S5G(MIA!M8E]UR=N[!,#N3&!)" 6[,Q'GA4)'3!49E3W '2& MDP7Y6,D:L.OK.["#Q+N^R-^^=T)PI%%&/^?HL03S@B/",])931/POJJ.%&K: MWNW:4#]@G5G:.1DX]J>WYLP \O8?$W+FX*_*JW HT6ZWCD*[AYXCD:TB*P(17R2I8T;,5GB M(D53)=:3Y1%5D>)I'=(MH8"#H!,BWDTRF9XX8>\HS.6&SX MMH*[%]XTH7DBU-R$T66NGE><5G%@YVWZ.'>)]3,GD?_T2EKP&@ZP")\ZX>9Q M'8HRU0FN\QV"G' OR:J*KA3O'Y*L9$M(3&W?LA)^H8EC+W9=W_<#B_BVW5T] M0XVYKHW%9AR21K3//=C:&-")?S9 $UQ029+'N7S2SYK@8HD! B=$H(,T\YKH M55K&5D#3>%R'QDQUXOGJ1@4GO!KSUR3+65>[SNFJZ:&HLG9-U6"HS T*+#IQ MHGKF$]L*G,"T8+^ BDVV[9>GMRPADT]K)AKCZCUAVWO.<7%W(H:/:#$I&94E+4L-B%ZBF99^@8GRV^>65IG*H1>5+$\3ID2I4S MA9;W4$RVAH377](Z2LOL*YV'?4T;FWV)]\>NJN7N.O^4LHJ'67Y+9VY9104U MOTW?Y[_F99H5SL6IZ8W"T$4KM,MMC8 M%NNI:'L;%>]]%,PS6:HU^81VS[JR:E6G:EX]W[]V%?\W8&F MKEKG&VB;S^]E[F/">[7*P2G2O_LG@KKF!INTX1H0LPS5,"'UH!%&/ M'EJ>+Q8R6 MJ[3&(7XK\79-2M&VP#_= /QWVMJ=JZ=MS3\!#\LBR!\7&PK60 MRSDXK@6NOM&R]Q"%87^1*$U4P*&L!_S4;JGG_J2?-_8ENEY+K4> MQ+%IL4.3$'< ",+(X5L6:C"L?:G7UX??]O7ARW/ X(=;"OG'GP2.%NA@?WRD M6HIVN:59QWKZTN@(M7D !+T>]P)T%RS6!W-T#BIN"[ZH (9)>&5 U M,KV"H_N:'"NTOZ4"(Q-=<["$X*C+)Z564I;3=LT*U=!O4)JG^ZRN-I;MNBX) M(^@1%T'/[%#QT1PR[:VCR(7>/Q-/7_*Q8%?T>W'0. 2I$S3,>TC(K=E,OJN&D\=*XH[H55C#B*'>IT/C6 MBL4>W^?;DHYM:92V_ST[=(*3AZQ.#L.)D\@/C-B$KDDLRT6.[\-A#X\XIBET M/E&A63(>68-*4$I/: T4]IJ[^IOB^AQIF9=50%Z4J=7"@^-/;%,\D M?R]I$Q*^":RO5?*FN/2FV$WF2U[FWN=?Z<*D*.ED9^,BUX&&A9#I4&&-32-" M_9D:0J*8,QRNQI9V83L#,U70A#B453+EY*F4,!XR9Y*N,RA"FB7#[UK%2LJ7 M-U5*GB%Y>?I8INSFWWXIS>X^S:NT7TRWN:B;,/:#D+BFB2/D$.(;9I]!'Q@$ MF?94W5("0KN@=2A!VL([#RVUNWQUM\B=*G=JVD16!^=K#)4"V3=.![=IFS8: MNT3>O!RK0G*JM)G6JK-JG7Q3@#5P.B&HR&R>KK-IC;,$#NS:/@E,%&(/1UYD M]\9=0O!4)98RJEUYVX[CM$.)VSZ>'!CVTN,!5A^I/R2*7CM'NPP0$R N2Z)K2AXP:N8755 MCR@8PPNX]O(U0]"\U])A[%.FFWE/TJ(<)JJJXHG3FF)JA'&V5E ;<_QXUC = M<'"&?&EAY6%7*C2II+G6*KQJG>0.7RKDE"NEZB42=IES.P4;QH5S##X.,8Q\ M&,0FBMT@M@+?Z3'$@<=UCX\>RW,D675STP-'[YZ#ZW'!79[FZ3K[/@5;].;#D]K9L M%H(@&4[WY*>6/.M!].-)39]3'0\U8-)\=B=U^[O;-&?TI&>Y)EES2>S4I"[1 M)KF4W:6M:5>0YJ7/MV*.SC%I+.S#1)_2[/[F2(>,YI3.)D(0.:Y)QUX7$2>T M713!WK;GN^Z$,5#2HN:Q;\B#+<]A31)>66JEAKP96%4RU T\/P6Z"-&31K89 M")]_1!O&L=VKW:%2/QJ]3B/_*#2Q&58Y^DSU:7S44<*8^A)VF]C"Q,:Q02SH M66&(':,K3,EB:%EX7Y#T8P'**>A:;:CZ$PV;6N>LW7+?5+^EK95&ZL!JW#9 M2SV-PB?':V@/,4WN$;>1S:%A>M1#\9X3V"LP./)N7Y3OJF3NPPR2+(\(M.YV M6X=*:_?R947/&5CEUNODL:OF!K?_>,?WY7<(2BA6IL!JJ.35W/H[E%+;#QVI?=@C!">*9L,XL MHCRTC4FF4MI7(I!J?7HNAQH8DQ8_JLT/:5D_?J3O:DV%.:8_?6 ?V3BA'1(/ M!:X?^%X4^HY)3@ "T2.P"@UKE\'^C'J3M;;+Z$@U6?@FT"RI?IKY52:!/IW98[Q;3"+'B>JJBE5:MJTH>[B9NKL2SB>V: ?!)"?S@+9YG0$[K>;[HUS2KZ=*\BZR"V=3P82% Q ME%<@3YLTN.$#6U9<7GX?29)Y\1TC_:1/V1MZ?\9WBP\T )?;^WF5+\Y=GFE< MKT,2%?HSLG.C@JEI@M=$1],=VX?<&+[C.K%')[$AA):'$72BWJYA>%66[*<,N%T[+>W HDERCX DQ/T7P=)&N2O Z?,U>^!H$[XPO8<&3 MX7K-@B?E#Y?@R3/%*WB?TH-.Y'5?!&4F=LBL-KB_7 M=9R538$3C;.R*G^2L=DP+([U_E!\8Q>F%=N,O?3@6U;?M;5/WGZASX_B3SW! M^!9MKPPA:NE>P8E%=;X4.EY(\;&A(D5)!ZDNA?%Z_RFMZC+;TO>LB53\FK,Z M+"0T#2^F& @TO3BT,7;Z?3 +$CL0'R:4F)TMLY/U,+8[V!P*[H&V\5)PS,6J M1"GEG7\(F8_P:3E.%"8XX62CRPEI&S$%OR[)N/@P,SOSBD:]+EF[W^ MVI\?K%=3B$N LS>&&Z6TKV?D4>O6*X.0!MZDSH0Q8]?-X:8J_IZ6VZQ*=QN' MN(%O86A'&-NA[Z(@)IU=&]F^+WWZ2\K:K/'KM(/%QJ*V"Q8/XQ$%71R+1ZKU MTSLE4MV.*AT\,.!;\%36:W1Q!JJG4;V.N(Q"?\;.5"E@2O0 P?5^2(/ ;)=I M8SG$<7P[\EW7"UW#0J'9!WWL&,>^W'$!83-SQEZ&^W7V0SK1/I4]*B!.**=Z M:65RVA29M> M^:A),XZA85DA)%X4F]1.U-^G8H?(YKKW3HFAQ:95WUJD$V94XJ2*3Z:T\CEE M'M4!&V90<\O2"$>1'?8+\)K AH8M1QXVPY1M12(PA M<]1&G@45'">2,2LD81..$SV!;GC5@4)#ZXR,*$N^"^L8>A9EH%A/ MSQ0;S"9A^MAL0[Z\^GE[..[H2'SN?M9^W0UVB?^M%O91QS#HPK0ZUOS%0T,%Z!UFGP2C&%*S"X M_FQ@;KV?=U"=MV5'QMN5OF+K&(K72D[QNY")&0?P#8EB:!#?B"F8,$:V3]'T MF-P@Q)LVT^ASG93U#*/RFWA$I/0Y="%5Y1Y/05*#F_0VRW.FD'3UTIJ=<9A] MNQ%GAMMPB@^#O:"#3-2YQ-^)_@V&&WU>5HX8@P_,, K$5(N@&D0<];!/7 ML2Q[&)AN+X!(*4_?EOZ_W\D)+R-^-]!2+A]52HD M8@SS"LGGX\/#H:G4E1R817(HOKW/]T5YWR2X#Y<(D<"S?-=$!K2#$!J^':(^ M9<;UD"E4AD>53B8M?NMF>]J0XTB?S9";C8%% 9\WR3O25( M%YO6/>&[462&$9R!7.PZ-$[R1M15-?WKT%'E7A5Z7UHQ;7R?4]6@>OPQR7:_ MI/7&(I%! M\R7=LDQ U=;/7W"KET7F>*:*#HLS5K7=/='BB6EX>. *6;JEP+ M5TSBA GDDS*=W(E)5H\$,"A7+%S:!4Z[:PBR_TI9C+7]T-59#?:EDEF>43.\V06!YL>%$H1W'ONM1M?/[$JJN83A" M-RE.M:5=B%[6.;@"QYQIDVB(;2*IO$&T^?@4#9-=N"4'].#F7KB.,C6Z-%7# M\3JT29DW+Y:7*EGBNN;@#9/DF#<)>^&#?0&:IL$]N%1,XEZ^Y:<;%<66MHEHWKT +'J#' M9W>1G1Q83U,)7*JPGB:3NV9!<]/QW;(PB<171L$96V8%-S',Y&@Q^ULOF'.> ME&Q_F64=?+Y+RO1TF[L%+2.(;3^";A3[H1<8[2CNQH8=.KQ7W4H_7V,^< >) MY2:!!M1B\;Y+[(SEXTXE=!V3T^EN/,^,5<.+;+_YDGZOT8'="DYGN$80FFX4 MF"3T+&@0+QCL>80(G;B0MJ)Y,HF2*MLVFY91=CBR'4N61OJAJ"H6S1ONQF>8 M!4]%R/,J)TAZ*)VN2 P7:( MK$D#00*B)$[J.E5)PH\W9$F6&?Z]A&UQGWZF M\]EF.^,#(Y3M8'S/J@UR(ROT463#P*:BR#9ZV_N>Z!0B#.Q8;%]!WHYF;6JA M@0$;Z,'189["N]R=U!/*N\\P#Y>B>PZ2-&K:4+C(T>CFPG1FUZ%,2CQYL>F@ MBIV)ZA05]TF6;Y!A$6(A8I,H1M@*PC T>YNFZ0N=59UF:3F%:@&JT2A>6B>I ME 9&E>G46V3.J50M%G&M$N1WU6HEZ@N?7DDQQ%^93L+FY%=.Q)[2>X0,=0/"/%N+,Z&]O_YKF:9DXX1! MC'L,7HB%0EQJ+>M.U6W!7H';%F[35Y,G@.544#'_?'JX'/5BRCBP_M, G MIYJJ>.:3RP4H%M/) 6"[A_#NAD$$YQA[F9Q7'/F(&U%%Q)A'+D. M[S%+P:=JS%UH)W.+95 ]X6$L14&.L'7T#UGPSY,1IG# /?9O[]+=\9"R.H@' M^HNB77A!=NGX;1.XK^BJ[!?J^(5??Z%?5>SVZR*OOB0WAW1CQMB+0F3$,0I9 M_F/HAD$/-#!LH8W!!>#IGE-T'K%)Q1.?P+E33="$NO5N>^DCX-PS.D0RWP0W M(I=H>\XIR[J;77!ZLTB+ZYD/*6^7L;G3DJJZ MWG=5,Z[+3]GM7=WDR$ '(],-B6'"D!5\]Y 9=?8(]#VN71I@3&CZ MPC"LM"L#)Y5--X%,/IV?AT'1)REV>!6J,]5ML-I>0" ,/CZ6%CK/3ZMCT'U51Z%A,E01;Y M9$@?@6+"T^O-,KD:3U@8$18YMM8A)9+8"Q7OB^"$9OKJ[T.6I^_K]+[:V*:% M73?R/0.9"-G0AH!NBW3UA7!B=*L3<4YLUIK*PE. MQ=1%\9@[H/%G[NF;PJ88F^\MT>+K4/5E7'\^HUR.?^XM*#;?>E]5QW07-==, MMC4UFDR8ZI?T6_.K:N-"Y$2FY40AG?PBRZ??.9UQ$P8FW-"IW$W!O;&DQJB( MQISC$Y":TYP49 W>MO(SNWZD_%9F3:I$TH\1,V\'<)$X%N)7VPKKZ/>JG7H> MBM?!&7=?958^EMDVW2!B0,?&;AC9@4.0Z\1&.!@P?+&[O_D?JWGNU8!H;L6H MFIL=V*W>KW3!'[(<[)AVEM7IPS\*;K\*<,DWO=)$H]CDJ+T1HT$QLQH-WH\I MCCA%*U$5">#/E4/6]XDC^=^2PS$]*5.$'+H@I=)D.2XR0P^[!/:V0^RY0L*A MQ*)F3?EKV=RT4Q;;--U5[?#=Z,@+=;E)]P7M/+MT=]PV _N349Y5&V#I<.TJ M@_TA?0J;H0GJCII6XI2DV1M(4*T:WEN H$7854&\ @W(*T!AMA^8^59N+NK$ M)U>2U*]$!=7ZQ#>UFL08KW9^[.2!4)^9H83RP;(MF#HTN#8$82OR P1- DUL M(-\V>\VV? _[8@N@Z?:TKWW8)65/59/5'\@ZL,_%<][.^29](QU3'?7KZ)0* M_2ETO:0*]NWC[VFYS:IV!C7\LNI^6YD;C\2V&1BF;X0NCB'R\!!RMT(#"B6^ MZD&@>:+3 P)I!Y1V7[:<4K%:TM0DG''KQ5M#,$!]*5> 52/IFJ9=Z9X^4PT? MFKL&I@RYHBD&RAIK'9*KV4>>M 3%C/+O0 [B_S$IK\OF@J%VBM;?VKCQ[,!R M(]MU(FQ&CF<:)!XLNYXEENJIP)[V_<+3+.@*/"0E^,K@J9%=%73S;@[.R[3H MGE][26Y+,@7(Y+*%V"X43]?!SKV1]R9MH_MSZDA?B32J].C%;IIJMOA#:]T] M:M=[DN5T'IPEAX]%E3TI>.<1TZ>38 ?["$>1[]NVW\;\?40,E[LC*K&E,V33 MWQU()R\#0- C7*X<) =MH^$:A:ROHRNJ=>E%L$8Y7]PWQE156E>#$>P12 U M GTW0M P7)?T1F(#"U6 %'RTYIE%BT;PFA=!5R3D$C[\*J> M3&.$O_IKQ6X69?]A%T'0%7V3M5?CI"P?L_RV671LG- V[=@T(XA,(T9N$'IA M9]O$?N"+U8!585&W[+"2U,WV-_LB/>$4+0.KA%W.P,;LQ J&-GI.FR_.(%Z! MI 8]RC;*,7=Q6 [FQJ(;2IE?AZ0I]NE%N5CUC/%*WL])^5M:L\L!/J?;8]D4 M0N_$=A-BTS-#$CB&B6)(3 O;06_1"[%0MN$4.YKE[7W^-:WJ]BA!EH/[ 2FH M!JAB2C>)5#Y]FXM/,54[H0(G6,,L;%X=&V%H1+U4\+H.S5+B2:'^K1-Y-^%%BQ&48.C (#QW'@6;TD6BZR Z$%WQ1#ND-"'390 M#N $UWZ36.1< LY%H.!*L.?NA(NE%]8+J=(82V/K0A7DKD.7U+CR?)6HCA_^ M2EU?Z<.+\I%:HNM1^C@4&*[C.1&*/=\F7F^"W1@@5IA+X,$SS(T8%N$ID!@[ M? JCC1@Q11E@-#HR=^FL$P4CA% M"1$GLKRGE:-*^VH*;:;R;:-QDK4,\)+&/;9H),B!P>.HA+>O'CP=6 M-"#?L=!U4XV/S;EP8 6N$82Q9< 08A@$5J]!MDD($CXW)6]*I#-('9GJT37C M<=I#NP*'M*)3H.WV>'\\-"FKN_2A3+=96V>HV(,_FNZ5$]C-W_W1M*YI(#==6B>&E=>'F-3Q0]_1*BF+QJ[V;#5 M7VHI_KX]'-D-B'\MBMVW['#8Q#8Q(L_V"/3"T'1-TW/,WC0)#*'K'I48U!Y! M>M><)ZU8]+JKW_O/R?W#OYP71A:-+:G@F3?F-#/%HK&H'MZP!F0G>'\8,((> MY.4S*)H"56_S-AK 4DC[.E1.K4LO E[*^>)5O>'QQ$^)Q0#YWZH9O7J<8@)%#\E?"*DA0TQH7F3""TJPJ$4PMRL0PW$81<3WPFQ M7GT65V)7%G8KR0"[D6\&KD4B%)@D]*#E]+9P#(4"VG(6-/?W-IR:L\M$)X2 M),GC$P/]O(DIP],(] G2O$KQ*BLCLC&-Q75HR$0?"I7OE4PP>>,C@Y4 (1'& M<4 @"B*S3QFR(].$XE'D-Q\Y2_A8_@C7VY2(Q(N5LB$3*%XB/OQF8)B;E77T MT[XH#):1Z5DC3#_S0)[&+61%M,T!^ MY+J]>1<'0LBYR8^)H\L&YIJ(?U)>4QW+Y%L;-OU;!*%!#I>[$,[-$RK1^ '1.AR:)5V M-4O5<#+@H<5ZQ3;K&=0A@?'JE0S&,V&3.X.AI$4X5X$+-8;@4K%OAPYF0WH' M%+PFB\NAJE^Y0^?X?I/UE3R:>)E[UB M/X+(CEP[B+#G8(QL9)$^V\I!Q!6ZA42=5A^?<4T$1VK+$^K"A?W-UG> MI#7B(F=E,ZA-^E6548J;'_>0'GM Q"<(.73*:V'D$H(#JMB#2(=B\4"-,'0O ME@>8K"SN"6<_(Q633YW-P:>G*VD),8'M08,SU%1.3TWS!/C5H+J/"VFN/,DC M(CQ#RZU#E>=PM)B]5TP-4FX^';JVZ^+>D-6$ /AW8B4>/\NN M[.05O QOLA%)I91-CT0N'7X4"CMR<[<.29KBP)MA1D$NU"V'SW)(('*A9830 M#$.*P7&P9\ .@@L)%+I'2JGA_QZ+8A&F5:V+-9&L9VF\5$Z:"(V3%L@2K;$. MZ=/CFO R69H__@(J^=>TK%E^_H_%'7:QS,W$8FC )FVX4/;-2W' M-V"_/J?RC83R:J?:TK_F[>&!G.$2K8TRD4D^!9R31#'1.^>O@=1OFRRGAYHI\^9%!125+'%7/V$W_*6[WF*4WM0;PS 0"F&(+9>XCF-[!K)[ M2Q[]N5 988GG:]:FSVF>%65[[2>=5M GW(-#D>2"M7YEB..3)=V/*_L,ID-C;L&9_,SW\*6%]!9&G)]8OA& M'$%OP(0CH9F27B3_W?<.1!I%V_:!IO:8;0=A*:F<1+7:?02))ER'_,[DZ_3= M!&F&1:.![_-M<9]^2;Z?KZW3>H,M[@BB-X-Y7E=4B>,F\N MA.C4L"1TQOWU,&#HF!ZQ8! &=@0Q75_[87]EM!>:@2=\T%W.C&:Q>GG:77IO M= J7?'HU$XUB4K6BW0:IO04%I*Y#F50X\MJ!>!7<2.1E;"S+,RV"D0FA9UAV M&(9VOVWK!59()!,RWGSN+)D8*C(PWF9(./5"*3G2.1>+I5KPY5APD[0.79!" M?CFK0M![_OW!^_NL+4'%"H'UZ[DML^A;GF5\BPA4#-(5^*/Q9\,$#TD)OC)X5\ UC"NC_:>9!UCNZ?OJCO8V.CTX MUG=%F?U7NKL"9A!>6:YS93MF\W'3\ZY"^C,_'#Z>514[C=TN*_TV.TRMJ^7'#XFV>Y]CI.'K$X.9]8W,8$^"0S7"PS?BCVZ,AUN>/8C MBPA=P:S G.;)V0DA8$61WF4YV+8@!6_F4$ LG^#,S*F8!)W1R="Q6M@=/I;, M<)*GF:_?>).R$852R/+W_DGP?YI*8!#&)H(N191''M,P(]5=:^A;Q'<%KB[1@T*V 9]6% MNFN*SH&# \4LN%#5UAJ<"KF"AA"4S;,V:+<#GV#NDQA^8+!_;,MS%/LFIV&I M!:\DQV,ZJ[G55B*^NKU\>>O1#*PJEFE2E&EVF[?'3[>/7\HDKPY-/AK<_<>Q MJKL23 WB#30BY, .Z81>\1$!%FG 26.!,O$+8%0^U*_0]N=7M\^@OJ$%R0# M8"TBK[8ME0X BS6BUL&A;^S>+7#F%S@Y=CZ*K'+H$&F=Z<.*EG?A=S7DZ&% M;CC2V!J*ARKX-@@&L>G'V K-YCZ6'JF- M75?+4*44H?:AZM>\3),#BRF#VR3+ 1N@>@?>[8OR745=:$_7R=V?.G^C*AVS M%FM-K6,6.RH&3JY< ?BBS:^>C%W)GJYT5SMTB332]*%+RROQNQJZ]# @-W1I M; W>H>OO24D'S";!XU-V>U=7UZ?MMDT4$!1BWPQL,\*>:3BA-2SL3#<4BGA- M,J0YK-5C$QL@IE''I_2SL28FV3VL9NNU!0;.D,TKM&,D\+MW%29E3*]69C$;I/MMF]09#& <6#AW#]RW+1(&!^WQ8/W#% M;H108&[&>/NNA31OWWJ;HI$>II#?=?0SE0X5VM[%J2F7&^@&EH,,TT:1Z5FV MX_MAGTX0Q"3T1J$_)'@FI+B9:+IT,*)0$R$WF.CK0% ?>3/H3Y$)5 MS<$-,3PK,&S/=B)B.4%(HMCHS2([%&I?,=$% MZ=C.MBH817X8=K7FQV> 3SM\0IXM,2 MK>R(B4@/93'Q>,[%Z)I;DK9UR(4\_!?KZ4D\" H$H8ZP\Y',TM^S^@X?Z?KR M/BVI6AV.+&#&JJ+3_^]8()^0F& 3VJP"L!^P:NBAV2/Q*$0)#5%J7[/,L%22 MA[+8';GQ1B"H^\=/'D9BL]>1T2.8^K'A&PH@( MR9&U#GF1Q/[BC*(\ [R2\->RJ*J/9;'/ZHU-2, N&D6^%?D1MK$=H]Z"A5E% M"_X@K,AS-<=;&RALNK0?V?F;3@Z?!.CB14P 6DH^CE.BI?>?^3_2]V586D?/ MET)>3']'!&_1?&CN&\YOX^\/:5Z=+?%<,[9]S[0]T[,-(XQ\*R:]O=@RA.I^ MR5O1O'P:@(&T0R88L)G 'Y],S$.=F&B<6.M!+1;,N4C/_VWOVY8;Q[$MW^+_,PXD +ZC)F*K,C,RLZCA1#PI:HFU.R:2;I)SI_OH!0%*B;$D& M2 "$W:B#3T'WCZ8]A.+3^YZZ@]86Q%*YI]?2F706V$SI>X'IVFKA>;";X_P.B M)'(Y]R[)PR%]GKF#3MB+,T7RW:>'["JQ],7,D2IVV2\8V^*?WOZ2ESAD;#$N MN+DORH*$"U(DJH>V\N+4L^(@M>W$2 S7#^%P@2VT;!.Z?'>."6E2LB#W**_ M;8>3*D-VA)3W1C(Q3+/)\ (D\RGNGM]?1OP>@QS$5_4%9BS,7=J0*)9Z/=12 MM%$O;CZ3P!FK!J*LJ&G-L-_RK-G5= \%F=#_O:RNF[Q^)(>1/I0/N[;YDA.Z MBFU!C])^(2>3:@P[RIJBV=_T\TM6E.0@4[<.0&1\V+^\2@SDIS"-$M-Q8I?D MX4FZG_(S+'=5YK=D=S.;D.J#FTDFPDXFQB:R3W#?X>]("<02W&"KNQJ+9,9[ M+?0&-GT8991Y?0#+BQ3$QJ$8X\C,;M5V;"CH+ 7'IEZ!O;& 6GMT]QNQN#]% M"P:K22\;[%8;>Y2Y\T+XTJ]+Z1$!->2ETET,."M&-$W>?KA_P&80Z%CS:ZSY M*R,)4>18>/#CP=2)0S>!_:Y?B(=$H<%58FY:$Y+'&H1E4JBAV ,CH2TC6!4+ MT&E^+JC%3$+U>+7G&O'\H+L(3MBO?7RH\W7W(J_2T RM, GBP"0U7.(T1?LF M(CLV^>YXY'BPY!=DC$7UI8.'EB^\!I/(TJ/S3X/^XN[ R?9/7N)N90OF:NXZY M\.(ESZ(E,V]ZJ,4,_*\M4G(RP:T;AQ(SJ\#S33].P\@* ]>'8>P>6G(LWYRD M'!S/EZP=-)^D6YQ[_:C*J;K!0QJGWM\7VY+U*F,7)$HU=+K6OU08@G GZQ5?&3@!,URHL2.S2 ,C02:0VD"QW!BR+<2SOMTZ>O5 M>X7)7]G"(H8L5F61P-)$0>GI662'SS,>+HK'-,9TT8R)Z%](Q1P6F.=IR'CB M;#JTBIPX2@,KC5T?19X-PP -I0J< *5<-[#/;$K)P&H_HIJ4I,PEDW$J1QV/ MG+,ZE,*+XRK%,SP7F;HTV2.&8CT$290QSZ> 1'+$5S6,WK71UP$HRAUN^]-^ MQC7*;ZJZ+VS^+?N1-^D//*+#)!=E5C]]://[!H,F&]@PAUL*NT_!HM (4^C: M;F1'(1[C!1 E ^(X0@;/]/22.%5,2V<:.-@V.+C_?6K>%3@V9['1J#3'7,Q)E^\.>H03+9@X68I/!^_P!3*, MI(^745[FY*"Z!QTKMI";)+[G(B]Q4F_(\ETC]5+>$?JT5A2,U(? @96&8IH2 M0";0QR/^DGB;(]SD[M3]X<@>E>*D^@PWKVKG=#9UTKT95IS4K+FL,"^CYNUH MJ=8W8.R93NBX:8 B:)NI,>P5A';GX&6=O6Q?6NI2<4 MVHI<#DUN<1_7VE>\L#>FZ=(BWB0Z]7A%)F)_OC@W@P'6UV'84_\YK[_>975. M]N"OR?G@8KO#P6QEFXF70-P@\I"//,<)T;#\YYI)XO',>\UM2_+$%\\K QZZ M>];IY\06\!.X)N9T!10Z@\#?BA)LLB<,&LJ.9V1\]J]G%RIE6_@(QXKW>8? M=_?7>?WIAB(8W;/U' Q9L#3L)$'(">*47 !HN7LP.&_ANI!/#@3)PCF@_BGK M8!\)8P.J _"S*MG]*J*H&GZL>>C M- AAUZ(9&:D9M'IXAW$AO3K+&8ML MS2=<,_428- Y$1/%%;>6_:.J_]H7M3MNV8D,&QFVA<4T3:W8Q9TE&5J.H3M- MS&:T)WO$AI']5)0_/738)NK9'#XY!4T1E9,5C> ;%>341=/.T\8B:@)(UTS5 M1%AT3M:$L<6M:XB4JKO+-[^0NTF.6T:V&Z3)/$#H8F3.3&?#M1.1XL>76^JZY2](B*Q=XD M3 7+*\/#F&;O!A?T]5==$\@ M_X23A7LP KW8_"<_KQ?>0(E.TN,]E6G@\]O/9',I_IW_EO]H(TS77ZO8]GPO MA8@LD6":8]]VX@&)G_#E\3+:EYS7GWO_?\OJO_)NG\Y74D6T:'$LI:J LY2V M+M9DN9/\&>=EC3(\)%J6Y3A'OBX3W( "UU:9]]0*D69^1[TU;9Y@X61QGLHF M\XTD:SS:V6WS3S>O[$+Z1F3G@"9R_,A, ]^*0A-A'&'L=;'"3>+ "KDNDI*% M0;)*#[#)%$%]5.*9?-+>Y:#3.HG !JF#%7WKX /(4!XZ%J<7@OLNU^V^C-T<9['#^R%GS/ZQSDO:'= ML5T25]8'NE_-\"-_&JC"088$%O(';4WO*'CJGWV?MW<5YXWN2_06 MW@BC94>9'GS&YHP'?.E1AQB9=#IB:12>1#F(*7(I[PVZ!37U!)R-=POY@OU: MA^OV .M+GFV+?^6;X4J651H'KA_#. Q,-W&,,$[<_FBFY<:!PU5I=F93LO?] M]7C +;VI:4O+16!AV6#4H-G#Y@L=<]EE"P,*B>63= )L)-_DAJR>Y-%U6*KO MV;C$U05U%42R'DHIRI@7MW,(Y&B:@L''K-B2H(^J^FNVS7\OZQX&@?"Y:@IZ M=0@*H!6DJ>5X*/429)C(\WHHGA>Z7/?,2@$@>__,T>6&V8#YIYNJ_JG!J)_+ M'IFQV>TMZ2=G>EMF::(H?TU1R@5<-5,_X0M'78$#:D +50VXE]15-F:9U5:P MHW348-$F7E1F*7RRZO5AP8ZL \!R\VPY8&6G41)9,'"#"!I^ZMF)$PS-QB;D MVJ(]NS'I6>=^]7+-O7HYGTDVU51*(I]"/EO]I7/3SUBAM6P?/,Y>R*=''[/ZLU7LFSQZ8&.L\B=RW2:$#;- M[K[[[-EZF1M%#K("Z'JN:QA>'"=V=[#.BPTK\:QIRU!*H"E<@CK<]$Z^ZTV8 MNBBDQF^\"T+:N6SZ8A UY:=K8@OHC0'4FBM [1D<> 7V)H&131HM HEP"M," MD%+OZQ%2EC+^[,+/ CZ8$W3(*E1>-A3/&"1_\Z"+:0=,CRH*^X8PBH\@Q!OTB< S(M8P5 M?'1SQ@=)OM0W)L@RF"$.2.5ZHO9?/P=V& !1B$=#(OK)[V71GH/L.3#!8 T[ M]9S$#6W?]>P]9)/O4L=%@2J,%Q^K\J<_,'*L45^^_GZ0HEV)WPXZ[?$9_^VL M^*'8R9,BB[[^%3-R.8X_HWGK+A0].\K4?4@MU#8X"?48>]A:IJ-H&= 6HN)R MJ%O2/Q/._MP_;*NG//^:UX_%.C\=K.&6.IYNT/N2KZO;DJR5?L[KHL*_UXS/ M*D';=2S/CO%8#1J);4//\@:\-D(3]X&K1JDP_)$I5JQM8T.&^SXF3\DI=RIO MQ-/9G]/#W6 5Z,VZ$/\.MG5E9@;K0&<>H/9I%/ $.XSM_-%"G42W4+<8#^?/ M,"WJ&?X@%Y'S,'F#8RP6VW[37O0T^HZ^9ZO4L)/ 09:;F B93A"[R,6<%6@J/K^GN3;7=KY.VH(?BC:%98UB/;C6+;#%,[C!(G MM=V^G<1R78-%6*<_7;)R4DS'[R.!Q2B,,TB[K'QJ^.*3ML6HVE3K'5F"I.G( MPI0=89%'W3/1)[91*3="VZ!"?M;:$TH]GYEEI5@ _DI4'YDAIDEUGQ7E*G5, MWW>3 !I8K@/',R+?&%KR?+8YECG/5R^H'; Y.L%*W011E<#:;%E51]@,:95 MW#1Q'>@"-U4-%"EMUR2KUG)2I:':\EIP26\GL<&DN'&^SJX9!E$2] VDB<=V^GO"8R7K:P^&0QLX66'04'F$\$EGCP/\V2'A M$4Q.4CAT4AXYT^21F20V)3PR[YP 3N- ]V;"+R:[7\VE=ODQ>K7_#;;IF5; MM$\TKH'F)(XNBYYL M>OA4CX>9$Y.'S3![V.3KGV^KQ__$UG43A_B+Y_.%)RP_\<[/X6?9EWX6\FI^ M[V!_[;N'#[E3FMI1D%B1'5M^X"+\1'MXO)U:3)?YQKL:F9OX!BS?*39W/=BD\=WQ793YV7S M?ZKFH6BS;9]"F&&^5T\JG]=":E["ZYQ-*%G21"R-5CUX@8 M4RH)G6_& F9'_E1_6X&,0"?UO(D=C!O !5,]80E4"MJ)YCA76-=3:K&B2YXFVZM XKB#&F4/(E?\S+ M7=[O)"<-_E9L\Z:MROPW>JD!!D.NT\$]]E.9X%_>5@^D^ZZ,T PM:-NF'<=) MD"9>:B<=%MM .!MG#BW2$$@.-2,HX'Y S!-:Y%'/$&JT8)TO]/20P0CS%=BC M!AULJHL]ZNHQV^Y_OUFYR''3Q'=B*[$=RW0-&-L'?#&4$Q;G MHI(<*@_P:$&"K >H(&S.=I?H4*K24PK"Z\BSV!XP&'3X.WT]*RL2J_2PPN@\ MP],2@O8K) L)Y*(<^=:"NS"[)P=\LLSK MC_F/%N%W[;_SK&Y646+:%HQ-T[)"-T!!C*QXP!:%D'U3@#)$DH-_#Q/D/<[] MM&R%D8*2%&&XP7\+G@A8D=%"F,=$Y !+.$M*_!_<.5BRKYU+; '$&$"L ?^M MK3M%!OXEW"HUZ(MQKZ"(S\CNY&@OVGMO(=(+MYDKRLMAG...(/ST-2G(/YI3 MZ,M"K6S3\CT4FG$$32\-@]1/K7U6$7I,Q^G%M"0Y(@_@Z&!\,YK&SCM\W-<% MS2&5;7N'.CYY@^:(RO&*0/H*E;(N"3K/TH7]'6+8U6.#AR!;7MX-)(PA_D)+ M)VX8P4"^WE5U^RVO[S^4CUAC":#G==Z-R/#, )J^88:^!:,$CY9H!2C?,6-H M3RRG+@V.[&G(40F@]7!=T(E+*J=>RZO"86QRJ9FO^#25P+UZ<=T:==8(KD95 M_*9R?$&1%3I0#]E6:?#9^DZ*N.8/ *]=33?X238U4G)E7 M)MD6[R7==%J"A6>%61:;K$I,;G:C%[O]6F37Q9;FAK_E6;.K\\VG\@O)%^NB MO(VRIFA^+ZOK)J\?2;_^4#[L6C(;4J[Q7]$)NSC;KG?;KH)YM=VBJB;W-ZW< MT$I\(W9,WT8XBI@H#+H;F=S427R?ZXJ+Y=%*5OG#17M78&0C&(PDDK,W$U [ MR87F!TL!-14+D4\"'(O N/>M.ZQ"X4Z MD>YA"6^+= ?-0MHR')P+8PMZA&D?V;"B?7/8SW9TG&OE!I'A!,BT0R?U'=N$ M7FP.;48Q2E=E?IOA@>XWQFUBLQMD4J&P4Z$7V)@5:=A&0I9>#OM*UT=G&(N2 MSL_-W%7R&B'G=HL((U*#72#B;*ED=#4UJ>"95_^7K"A_K9KF0[G>[C;YYD.9 M9C7);IH5#&)L@H_BQ+"CT A[J1]X->]Y?(>_PZ-L_"[?D"3D MD=@.-CN:2QQRQRO\"YT%Y#>;%KM"PC],/00Z%G8\CID&!Y)K*=?KR=EILE1]NOH>0?;0\& M\8^U\W+#.,K62@3U&FFQ.O1MBYL@#I2,M/@\PBI:<+W>W9,IR7R3Y ]UONZ@ MX*^W>=N?'KJOZK;X%_W\XI^1!<3N5#$, M]U+1-Y. 5"3IBD M?MBM&L+835.F.DG*04E>9!O9 38C0X@\/?2@Z9I^/B#FFQ!4YSRV.4 M_<8W M[3=VV=B&*["W@GIL;,<5&"S!7Q%;KNBOI*\Z54K\$>6$"R%'N9_UB#+JS:X6 M?K_X8DETWG. MN6U(5OH.%AZ%8UQ7H*'(0$&A\4GZ9 [9%%H%?9Q;E3OFOG;,=:"NP(?+U$D1 MSC/<7-#!N6SJ(6NSK:C$]K&9HO,)Y]4MCK\XC5X%T/,<,TG"T$H1Q%_%IM\W MB;#Z,=T?(Z2A)>2G.N";J4%79I"KJ;B-,F4 MUQ1J.C_\!Q%@V1:;8KMKB\?\Z_Z85/JCFZ5$F $,[V'7G4W_=#-,6G[.:XJU MNQ\[,%P[C,P@L)T0!EYHA;V6NHD1.R'705O%T!0>7QC; PX&@<$B0/H;&-E$ M_FBP"F"S.@5X]1I[+3S.IKL:.YM/J9?PL^3C$R(\PG2R0JGK]8@C2QE_]CS& M CY@GA.>!RUZ.OT >GFYD0YL\+R&+XT4:R!7_6(/UHP\7PZ60=, B+3Q^P^ M[R\QC!!,7<,PD&'EOLK^FSD M0A0ZR+'"V(A\QXM@?S0L<;PTYEP[F]>6]$GL/3Q05BUOZ:#93+).7*LCD7?N M^L ?@7:4UREJ^OHB5Q=GL,6PK(=H";/FQ3RV2)8X2D#VE23H#/KO9=$V M7[[^WK<9V"[TH]"RTLCQC< *;3LTD'-,J65E[D1HD<.\!D=L MQ=M4R>RK2A?1?MU??AW@"!B$OF%;D9T8@>^;L=_#<\,XX3M8H0J4RJG/J;6& MU7E(R2*8'.>(6?'BWHA!C '4&BUF6OF=(&]1C-_/>HPFU)LM=KEK*N^L >-C MWGXHU]5]3@XMPVLR)=;%(LGRD^7<5X0 <(_(U ^CN +4YKKG%G);.].(W]C'LH MSG7_', JELV3A%W0P'D$ZR%H,VVH1':Y&5*SPFFN8]A)F)IF@&S?0Y'K#6T$ M89*L'O/ZNIHD,J\^F^>5&G.V& G(GKTPZ]&1B3L\7LC9[^*2\,JPOBK, MA&KXBK!CO_1J<#+ ^DK\(R]N[_ H$>)>EMWF."KAH>&GFQ?' _9OIN%9J6,@ MF.)V(SQV3 ,XC!I=PPJX K/PQB7'["0OJ_NBG!"UQ=/,%M 799@OU@]008\5 M=&#)2*F#.SZ.= 42DM&2*<2%(C\OLQ>43IJ3]!!#>>95BCJ[TADP>%_MRG85 MX 3(0D%BAD9HNC@#"E*[Q^8YIL%UA%,-HF7FOD!^-,>R/IYCV?0JD0]S+0]8 M4>@Y4? W4CV.=HV_*YT_8_6ODLDS":Y=9.;L"G26O*E)LPZRO!DS3N?J$2T4 MVRQVKFP2XZQQY7BK$QPN'T15_37;]@>C0MNR#.2DINV%KDD:1?T=-K9IF@[7 M^5@1[4E/R(^V^V$5>'DEXZ1#K$*X9E-PU33SZ;,(AJ5H+P-M%Y15).EZZ*90 MBRIY791C ]/^]L2XJA^J.FM/[_8T'=MVD(-2$TMKY%IQX@1]R[9AQ2GS]B5! M[4G?+MZ# QOR;C:C=Y-4422SX0^D%E95+PW M>.AZUQ1EWN#7X#HK_^HN_:W:.SQ"P&BZ1]$[3#)2@O*^:/J+/A^ZRO1S]SFQ M,7UNEY-@/VFPQTFT196\7LV7A?]6E?G3;UG]5]ZB7;D9&G--F 0P\:#A6K:' MXMCN[R_ C06!P34M/K$)R7&'H@+W%);:5.\T'Q>RNYD$ZI'0S36B$MJI.$_W MD=,Y-P4F,&\^W23Y0]44;=]BZEEQ$%M^8*'0,)'C65$XM)A81LAULF]&.[+3 MM!$T.A/9@>,\VS>'1[;AIRH*^7*PY^SUN)8ZSW>>HPLJ)()9/:1(B"7/S_ ) M8V="*;IG(]A#ZO#K?K,;2D+3]UTGB@W7M5@I8+DA_R$EUA]QXV7;P#;.ZOJI*&^[^SM@ B/D1J[I M1IYI^8[C(6MHVXI]SFUV8MJ4OOV.X*-Z26XEI-=<]$@5)RXL;%U*882RK(/$V"N'T06UW24L%85C/' =7=Q M('Y/#W>^%\YJ9FB,\V=G1W:.6;N&I:>A7C*G(L,PS=,'%MUXYBS&HT)*JNY45H MU59MMIV6*EQ M/(:_ 'C$@D)=- M*5_CDB.U%.86/=14GGFOI)J">12DK83;AA_$R$'0A<@(4K?'YH5>/&MH+@>1Y%258@.[/3APB]&IE&51CA.B MU0OX3(: CRZ;[?Q[, 3\0OU[36T!V!BM])V-_^FB+]B_;R(2B+:9+SQ(85QV MS" 'PD?8+ NFGA\F@6O$GF6Z9N@,V! TX:K,;\E#OLD/'7S F&0H[&3HA0W3 M(PBIBZ!%!.%TH]P((L%U"T607ZE_WUH$.>)?0@29YM^W'4$FVBPH@LQAG.F M#)E'>K[26&[V<''+S0NX*\,-4X1!Q$9BX@%/; ;V,/KQ#!-9+%,Z\EI7,J=S M-/U-YVH%! .)'KDL_'HX@W^2_.K%##G D$]M>'H6$A;W!\<)G,7],NT\#O5, M4=)CSTU_KFS]!*H2W-'7I0'?\^V6_'>3WY-/^NW-_1F;[@0..:93E/@E*S+L MEK)IBW9'4#0_@P\MR+9-=6BB.ZGS5U%NZ'[?;+TF)ZD;T-YE+6[S,:?EC&_S M,J_QP]9W&2G@D=<%.0_4[Z\^QE&4W=^2/UOOFK:ZQ\^_SYZ&WP#99E,0-/AQ M-V1_(\"_G)5/H"WN/;IY^[GIZ/UX*ZLA6D&'-!MFB!]39KFN*FR"F[]X=MEN,#?CU= MH-D?E[H"=\7M'4:X+?#3-^ #O9WA/M]S1TI=7&-V 8Y*FP+_XGIT74I;@;_* MZGL)LON.;DSDFKZ:A #LGS+/:D)A0;AK"8ZG/:U/8*@T?5^4Q3WF$;OC+_H( MW$EN<^J#1[K:=9VOLUUWXFKTLZ+$%F"T@!SAP9WBE\Z[VZXO0M!_=5V=[13K?-<3[XSQT.PC=/.._'N4F'>9/C[DA] M_C. 1[VO,Y\\Z] F04AWB-"^@,G%IH^.I9&-R[<8$$DXR[R@W1<[[B[?;GYJ MJY_V;)484%MGQ--SSYA-T9(3B:1\7=+@_)E<^RI5"B\Y&62=_0B3R'9AXGF1 M#+ 'V8_0L,/?.8CUDN"7&:B6J]<4YC#):6D2_A:8>;*-/4=O3YQH5EG MD)P/+]$IIJ?-BW<.>U2W:Z51H- MDAW.SK!8LB.O4^B7[#!WCB62G==6ZK3Q_;M+=B;2("_9F>,7:'9JV,/J8P3M6.ZJWQ1 DA<"Z5$,.CFM6]8RR7N2,A39CE.8C7 > MOEG0EY(3#-D^G7EM:4-7[/H*EMWJ3CZ\G*"YR_,69$V3=S^F+_"&+,7=[-]G M4BF0_ VM^O<$OM_E=&VFV:WOAG6>HAF6KKK5M@R_W0\9K2*XSAZZANON!P_T M?BG\C&*=;<%F3]G/ .[7#\F"57N''YIO<[IR1%8+KW.P:_#C"U*CL"S)2B)^ M+%W&(NA&> \/;4!-%IKJ[L_HKU556U;M\2^U5?>S_=IJ@\FF+3<_@V_$]-,X MZ#+@"3K)LNG^\4/+37:/_]E=WQ=-0U?,OA$+R5HE*9HX^&I]KLX!_?#D*N82 MJV!LY]L6>:7>:(XVR^2Y^=A\OIEK1@UO5E?DV/!#:">D1(/G6$D"XR#H"KM[ M7F!$(=?I#,Y'2UZ]VJ.95B^=EZ?+^8H"BO@R#W9VY)1=.N+APM[0B83IL?$D;6!_O#I]^)6A M^I@PTCB%0@Y?D\6"A2JYBO$K2S6VZ>QIIAP3##BG'E.Y8%60?0X#\6B&YCR_ M%MEUL>TK6&YT0 T"-V$1X$6@"=;P7;W>#SR1'>74IOH$&5[L(J,=OX?'J>1 M\=5H>';?&7M_L7J;-BYFTTO-O_C4TV,#^C0.$/B XE>L MS^(=<$'?%_2V'O%A20(J;=X\]?&)_#V=!OR6K^_*XI^[_#GV.+:"$!D.BEPC M##S3])-@P(Y@S'7+I1Z(94>QONXK"6--<5O2$MHXU=R5U763UX]4UHKR88?C MVS#O1Z;S'@?#ABE5_.JTV&J2IN(OFP*_@MW/'[(G\A#UH4Y ;U$7_=1V%!$! M$7SH>@6)A7OTX #_7<3$5]TB.4R*ZQ;O)W(*Y$1",!7M,?[;"*+^XBJX_N>N M:.B:4A,]C;Z+]U(=CY7Z@! '?P,BRT5NFB2V'09&Z@P(DS2!T^XJD(]+8:P< M'3L3&_F4^I%Q-DQ3%W).HXV\-]@!QH:0A=[1]U?@8 PXLF;QR";0(9>F\19P MNQY1:A'+SU[(H)I]MGUDU19_32[+*QYS6-=$#4E6"*^;EARE7KFQ9=I19+N> M'P2F&=N!T>U=7;YJ*1UXE[@ M.?0R[OMXA86S&SI$L:?#3@UAME0R^A=GC?8SS?:7@'G0"0(+^G$ 32>!N'W# MZQMUK-CFNR=P7E.2\]2S+P]G-?:9?+(EEPJI%*;PRUP:>)&H"WF<((;U2,U$ M&?.\D+I(CIB'[+OK)O_G#C>3/I+])?B/X8^B6:6!&3K0#WR$4!RBQ,!B.;1F M1(G'-?R>V(;TQ=,!%J"X &&8SN&QKL)9"J)C&-?!?QQCF.G4"=G&'J:FTM# MRIELZJ%!LZUX/M03PLH,U4FJ^ZPH5Y'O!#%*H6_ R A0$!MHKW((F<9,W6%L M91GEZ<#-UQY6*B>KCP06A>C/:P2J4J .!Y\&<7*JK0KQVO&Z#DUB9J(2];F6 M@^(86F&:&#%NU$O-.$!]6ZX?6_8,%6)L0;$"S=(<5M(FZ8T$OF9JS3)#KY.T ML$L,)XU:R@NO#9>E91(C3//2G[,GNEL/5?6Y,=T*P11Y,(P1=$)D)788VX.: MN3"-F?:U"FM,LM@,$,%-58/UT91&QCLQ)(Y@AKE_U=SR"=.>5@P/S)QO$T-GF1\K;.:4MQ50XGK>$M M_I"4JQH ?L[K#_BGZ^X-,BTCRW%^,$' M+=TU>0U[6;<)6>(6[;XIB^#<-+*MD47K;YH*68G14(1ROU M!YS@S\5V:W*0.&$5?XXK])AIDF(9X_K^?/:8!B*_T<)%6(-OJOJ>E$J*LB;? M?,F;MB[6;;[YVN*&?R^+MNEGQE 4.]!T4>!'D1>@P U@V.W8#!QD0(MYY"&\ M9$%(\" (@8'R(!B!A0T1_8JW@<,HXM%Z>=344[F7Y^*5^$"CA'#HJZ8 M-D3X>I?1 FH8(OUK\/VN6-^1395JEX+_@&#Y]QS_^8W7<[7\(D=&/'-\+ A5X4F*X;&T,3:> P3;Q->K#L MU1C\'2!@)FUUXZ.(+<.7Q@[G>@HK,5(R]#$)%U+P25SID6-/@UX)Z"O35*#? M=P)]&[D.-)/$MX=&W-CFFB7@?+0Z)9BT]8R7*#XUD,#19#U89&/9 M,1$,FL#)F%ZJP O^C"Y,XH!I_$QSD$^TDC)I#.)D>-/E**2&/C;=3^F%FA^P MV249XI/?ZM,5(T!69"/?]R(/^2CP'-\?X,0H=IF'TC)!R-YR1L<''79 WZT> M/1C@ X(?= : O07T=SD&>%+]Q## ME&ZH3$;-?0'UN+I_R,JG_VCV_B.U<1C>L+F#Z1E$GAM7J_"-!D-L)696BOL\ M7\K]K6A)E0&R.OA8;';9EJ;W28 ?Z$(_L7%/L\W L??IO9L:$5/4G->"Y)!( M09&IL0.L28/RB?2QY>/RF>.+5!-(DY*>G^3E0I8^CT<]DO69-E0B>]9,A?E' MT=Y]R;$5FJE9-W-2V "?3>.!A303KA.ZHMN6[(J MC9&1M*+#-G&.0#CO$T5+(>5\>I)0I M2?\,QT"6C[._U/53LKZ;PF& Z5E&F/*H"L]S)4M)#V72\(Z+'C;QD,4,GV(P MDB)%)48,7)"&*3SIH0>3D%?S>\FD-W](7R(S-H3A)XE( "?Q,U(!%!CQ'++RN YQL::4$O-A/:\$D!M@.2FZ+ MFYN^E:'D61!$%JG+",,8&QX&$%E#*WX:,TW"3'VV9$6@B$ /B>?\VP26&!8M M)1/$)PE'W$Q97)Q"$L^Y/[EDS=BG^U.W679=W3_D9=,5"L^^9S6Y#/GF)B?7 M/A=T'?#Z"61@37E^['F^R;.67 (]]S3?"W+.+>_-H%LYZ"LQG8GK%/K) M\MS#U1)/&$5);@/_K=AB*%69#_MLW0"Z5AP%7@AA["(,H+\G,/!A%#&-QJ0" MD"W3Y\KO[X&# 3G80^E"\*.F._NXJDJ/-*NO!44/(.G.!R?U@WNSC'A,)/1N^)/M'AQ@GV\1* M87_G7/.X?]A63WG^-:\?BW5.LRMZ*"4>Y58?R0FH!N=3D.18S;>JS;;CG\=5 MTWZLVO_.VR_YNKHMBW_U1UFZS3?-*DACVXE1Y*>!9:9IX'K[2!^$)N2J,Z@' M8MD[9@A@L"/W7?7HCI/=-<;/>:1=#]Y8%WVT "MQ#:FW#_0&@O&P9FS#%=A; M"3HSKXY^CG_<@J>\!0<3K\!XD^OY7B)G44J%XRZM<6G5QWKGX7DF.:KBM @?,I?!/XEZ5*0H>CK\2E_/C9HRG!09 MRH,TG]J[O/YVEY5]AO$+?D3;?"@[:U81-#W?,VV4I&D2H< V$>KAA[YK<85J M;4!+#M)]59Q1"91>D>M#59RN^LJ.5L6Y)>CQ9R1(-X0 WBBM#;&L5P;H@E=> M9#X7B(]*S5T_'07LWM(N0%\=COWMK0747%*2IQQ&Q5>@,YE<*MT9K?B: T6N MO!"4M>M->H1C_6AY?K^#=@#5A&#Z3[^"W"$T5U8<.*;MN';H1DX0QZ9G#8>H M0L\)?25A=@HPR:&40MIO>>@'MU,'LVH])CD4RG:6\G#7N7K81?2F8MD)7\B( M5W-<_L9CTBS31<6=^?QSQ9;KUR%>7X+XI;B]HT6\256 [#9?V5[DV6Y@.V'@ MQHGE>RC=QT$7V4P%8I=%J#3:U!3=A!"CWG$J1N;PCZS^/G+U]^Q0(V@@:P=QD5Y MN<0R'#IG&-DC)EF=P*-HM0R]HL:/0GR MA&XK9/_(2;3--Q +.HZU](=)UN8H*^H_LNTN7_EVFOBF&QM!C/P$0B?H+RG$ M]D6QPU60^.U8)7N-C4;"8>GL"GSO 8.L0PSRKI_EX*$F&R-(7-R0"UWJ[NY! M&B,U7683T*7T6H=3VYO>RD+=%1AX 3TQW:\ 0@T@W !*SAN)ZJ+[A 8K?N+Z M[1O/(I;C;:$U0]&>7SYK^8-N9]JOB0813$T[#4S3=T(/&F%DP@%^:D21HJ&V M:-C21^ TZ^@W4I)*S655_M1_VVWFR7\\Y'2'3UO1W]-Q5P]O7U@ZFY#8"71- M%CJ3W]^NGF-7+A+C)_:F]Q["I]*B+$+/\MOB)V$.3^K^Z+EUJ]2 MI,Z?H3, M.+#"T$!HN"(M3!+.\IS:6K'H^1A-SK[,[PH+'X-1V@N6.A%S\D#JZ&'='YT( MWN_D;,QK3E[D\*JHCJ=','\#/"D[Y"K6LZSA_G"7]Z>;,41:LYM8U;3-BW2E M.=S[;<>&$7D^-!S/CZ(D"5VCGP6(/<\-N;94R<8B.?12:."ET/(%7>D.80N= M.OF"+P >D),[5XXB6@^>GO5LKDX-4AOP)[$!4",4E_:<2?F%<*3*F7H$%676 M5LN\,IP"GU^W!V2'UE 8PSBP8S\-H($;)7?2TM9\TPD9:\5R%A+#"JBY8RHKFTPU< MKZL=K8;VN=H6ZZ?NWT/CJ0<3%*6.$T$+)JZ)0KO;X>*[ANM"KBQ14).2M8>B M) G(YZZRX(1,4!2W;-JT *U\4K5G] #Q"G3PP)_]?Q=3+S;V+HB98/KUT#;1 M1E52NRR?\I&:C[BA#7VQGS?I1[@=*TE0X,:6Z;AVU!^XQ4TFH<%5-&)60Y)5 M[@@;G[K-XX]-TY11QZ=D1[#TT;!+;%U0+B$DZZ%78DRI)'1"/FU"59T7MV6\ MJ^N\Q,W5&1Z*KNDT(BPW]-O^1K[G>"S/"FR8QH89&A[&%IB1U>,QD\2&/,(E M#X5D5>N!@P$Y&$/G4SF)GF"30#V/%_FGFX[&N+71S\E47Q!7^>[30WD5 MV%FI?C'X-/OW)O]TDS9M<9^U>;-RO= .4&+",/(AA''BF.[0B ]3DT>(.1\M M>X="0R?F]WCX!)67)C:5E,@0G_0])T>?[/"8H@N2-9%+/71H*OA*2'_B'(%F MS1V6*O(?LG7L,=N2]80O^Q)[IW_>]:-5Z#@>@@[^GQNE 5U0WHN8D\*$:X0J M$XCL$2P&=07(OV"$[0H,HV)=W,4Y M:A[,D,H<6W3B(.:<@)[\ MW.6C&N'/!]B>GSJI$8:ND9"]C48(TVAH%UF(:_5D?FN2!:P'"%CN%I#%)YMZ MJ:623\-.L*B/;KU*W 7U$D>Z'AHFT)Y*5O?DT[./^??1"G1=E?C+-3WHU9Q> MCS;"-+ 2'*]..K23R?=]T(IB$8>J:<;?5&I)#-ES7F"X$4;)0BRS4-[(0 M_$EL!+V1C#=<+]T9V,+"&^@'?,%CX2Z@5UV'BTZZ$(\6[A5Z1*VE21!F\,L M@#TZ4!W@7>'QRII>XPYL\PI@E?&7JS@\P;7*0YD$?VH1Q=YFQ>$7CE$3N3@[ MP;L+6KSVRXM7DSRA*E0=5R#\I:Z:9A4YT K#T+#3" :A$<#$]P:DL9L8*D=J M4_!)'J8=UU9=Y K-.QIF([-=)$L<*;2<( MW1Y(%/EAL"KS6U+9@3'ZB ? )%)A)U)CK/SA98]I1H"1X #&^+$0\XN'A\&> MY2Y'YF;^DO++Z+9M+56,&5-4W>='N,.Q]851DA;[I>BF,0]PO M71O%43H@17[L<.KV @BE"WL/*C^HQ7(CATDN5#-RD.:[Q4/#R+(W5V/[O',D MCAOF= 5-PLN2# @>-\SWAKI+'A^*;G?M :D;DE, CADCT[03,S63U!R0^M S MAP#U3=W<(S%0S>D* M[R-0S6) ^&V/<[VQW$8!WR53<(YAVF'LP10E!@P&G :"PT:!M%0TDN)'R+]- M8#!FWB:!K[B7][L$#+I+(&"*6EJJU[)KQJP>?A_*-<-^Z6O&?)Y0I5K=G3BP MW*3]M6/?*O+12_@A=*#GVTEJV)'CFTZ2QM9^=&"YOLJ%9&&@5:TN_W&X[VTW MW!GR_)ZWR:JG>;]0D\ OTB66R^I''2H=]:,_:#]Z\]NL6)TI,9(*[T_O(\"* MIT5PW)7D-W6S7<\OMR?'+ T3FDZ8X@PB,GT_'&;E8OQ5I#+N\J-3%6!'R$#6 MOJOQPPO2I8YXD%9CV>77D]K'Q_KHMU3LYYW/3G/)S M@=!.8C.QTP!!Z'GA<,XC#A)/Z994"?#?YL'"*S#8#WH"]KM? *4 _ FOF[;. MUNURIPZ%]3 U8Y*%.]=RHQ/1_4K+N,SO7343?Z*[VON([#()DC=U*,>7FN4& M*SOPC"1T$BI49D#^A].USV0.4LY J/6;*71.V%V@7[V1T+L$,[SA=S'O*0O!^P.$3$;85A@ZENTZ*3*@!2//CN NH1BP?Y7%(V7<_V" ?G$6=_W%I.Y_"HS+,OI8.\D,DLB1W1P MENE#9?'YQ#&XRVF&%/"D?4+\X#7C3# M#1+72-W8B]/$=T/?=L-D,"- EMAC*ZK!JQM5'TZ.+QZOA?< 9:/JY9R_Z+CZ MQ/GS]Q:O.7TK=VPMIYN]DW@MC1[QXVN9?M1M"QBT[0BE:60&EA\F@1E[T!C0 M1[%M+'A4?A9N90?HF<[/<\3N_]G(HZ1?O!%55&_/LJ:\B>/\2V_"E=V=U.S-U:@G+;=EE[T*P-L: M;DGU_:)% X1TRO>1-*@B2WF! 8$^7J#LP$7TH>U9MAMX9@1A"EWD0SL:T,>^ M9RU4C& 69KU*%"R='0CK"6K2@"4ZP7+Q?F3M.POIC'Y44_I"2$]Z'T%:."OR MRF0(])JJL LWFX)\D6V3HEEOJX:LS@['X5<)M)PD,/W(C1TGCD,WLO>I@NG' MH'O191*CK)BN\CYB MJR N!$=4D1[BBJ/7KV.^YI[?_Y+?9T6)/X^KDEJPR[;?\OK>6ODHUN:.K9O@EQ]S]Z"/K1Q_U@!2L#U#!MKC!0Y6*K<;WA-"J M&>D\ 5U-Y;#T;F V+_ M%9K7]?B]F:]C:-(KFN#)V*[[IB51KU MN6?BSQEHKIS4,_W$M6T4V":*(]_QANF!U#4#I#(94&B6CCG"X\2U=;7)@\J^ MIR:GT+3;O2AXCK$Q+3DP4Z[OO(6I8@3G RLYCO5>4XY]2O+>ZK34^D=!LU>VE4 8 MF*2X=QP,Y[)3*X+\ZQ:+H)0:)7XUGM9D M76%O(: FOJV5_;.>4G,J;F+OT"A6+LN#O)-OLSRCSUFWO;0_LP>Y:13'R'33 MP$969%NNOQ^_>Y'%/X6OI17+Q4V%\_):,J_-N3857>3';[H M.;:YG?!]Q'L%/"D_O2;&LPOG"Z.)@'/V^+:%(M.S7<2YFQ7+Y@HP9<2TI7C8Q4-Q'-$T,CJ;.WW=B\+K#U2<& COANTX,1/*D)C$0 M[EG6Q.!3?9N5Q;^H%3'&5VV+36=2N?F,)0?#I]]^ND%%F97K(MM^Q9]TI=7V MQQ4BQW/

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end